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Abstract 
Progressive Multiple Sclerosis (MS) is a degenerative neurological disease with no 
known cure. The overall aim of the research within this thesis was to investigate 
physiotherapy, an important part of the care, for people with progressive MS. 
This was done in three studies. A systematic review of the current literature for 
the effectiveness of physiotherapy for the rehabilitation of people with 
progressive MS; an online survey of people with progressive MS assessing levels of 
access to, and use of, clinical services across the United Kingdom; and a 
feasibility study of  High Intensity Interval Training (HIIT) for people with 
progressive MS.  
The systematic search returned 15 studies, 482 participants in total, which 
investigated eight different interventions: exercise therapy, multi-disciplinary 
rehabilitation, functional electrical stimulation, botulinum toxin type A 
injections and manual stretches, inspiratory muscle training, therapeutic 
standing, acupuncture and body weight supported treadmill training. All studies, 
apart from one, produced a positive result, however, only one study was 
adequately powered. In conclusion, the review found that the evidence was 
positive for using physiotherapy for rehabilitation in people with progressive MS, 
but further adequately powered research, is required to strengthen this. 
In total 1298 people with progressive MS from across the United Kingdom 
completed the online survey in August to October 2015. Participants were asked 
regarding access and use of clinical services, delivery and opinion of 
physiotherapy, and use of complementary and alternative therapies. Access to 
MS Specialists was high (95%), as was access to a physiotherapist (87%). Seventy 
seven percent of physiotherapy was delivered by the National Health Service and 
32% were currently receiving physiotherapy for their MS. Physiotherapy was very 
well perceived by people with progressive MS and the most common 
interventions received were independent (83%) and supervised exercise (71%). 
Five percent of respondents were currently using disease modifying therapies 
and 23% had previously taken them. Almost three quarters (74%) received a 
regular review but 37% received this review less than annually. It was 
recommended that service providers make steps to address this gap in service 
provision. 
viii 
 
Finally, eight weeks of twice weekly HIIT sessions were compared to twice 
weekly sessions of continuous moderate intensity training. Ten out of twelve 
participants completed the trial. The HIIT intervention was well tolerated with 
93% adherence, 100% compliance with protocol and no adverse events. There 
were three adverse events in the continuous training group and compliance was 
79%. In addition, those who received HIIT improved their maximal heart rate and 
mental processing speed while no changes were found in the continuous training 
group. A larger, fully powered trial is required to confirm these results. 
Overall the studies within this thesis demonstrate that physiotherapy has the 
potential to be beneficial in the rehabilitation of people with progressive MS, 
that people with progressive MS are engaging with physiotherapy, and that 
interventions such as HIIT may provide new avenues for eliciting health benefits 
from this patient group. However, despite these positive findings, more work is 
required to strengthen the evidence base and gaps in service provision should be 
addressed. 
 
(Word count – 66,596) 
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Chapter 1 Introduction 
Multiple Sclerosis (MS) is a chronic and progressive neurological disease with no 
known cure (Compston and Coles, 2008). Disease Modifying Therapies (DMTs) are 
available for people with relapsing remitting MS, but until recently there were 
no DMTs for people with forms of progressive MS. In November 2017 Ocrelizumab 
was approved by the European Medicines Agency for use in the early stages of 
Primary Progressive MS (European Medicines Agency, 2017), however it is not yet 
available via the National Health Service in the United Kingdom. Due to this and 
the lack of other available pharmacological treatments, physiotherapy 
rehabilitation is an important part of the care for people with progressive MS. 
Access to physiotherapy services is part of the current National Institute for 
Health Care and Excellence guideline for the management of multiple sclerosis 
in primary and secondary care (Clinical guideline 186) (NICE, 2014b), and the 
Healthcare Improvement Scotland Neurological Health Services clinical standards 
(Healthcare Improvement Scotland, 2009). In addition, the International 
Progressive MS Alliance, called for more investigation both into the efficacy of 
physiotherapy in the rehabilitation in people with progressive MS and for more 
proof of concept studies (Fox et al., 2012).  
 
1.1 Overall aim and investigations central to this thesis 
The overall aim of this research was to investigate the use of physiotherapy for 
people with progressive MS by evaluating the current literature, surveying the 
patient population in regard to their use of services, and assessing the feasibility 
of High Intensity Interval Training (HIIT) not previously investigated in this 
patient group.  
 
1.2 Original contribution of work to knowledge 
Each of the studies in this body of work has contributed original knowledge to 
the current literature of physiotherapy for people with progressive MS. The 
systematic review was the first to evaluate the evidence for physiotherapy 
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rehabilitation interventions for people with progressive MS. The online survey 
also addressed a gap in the literature, as it was the first national exploration of 
levels of access and use of clinical services by people with progressive MS. 
Lastly, the exercise trial was the first to explore HIIT in a sample purely of 
people with progressive MS and an Expanded Disability Status Scale range of 4.0-
6.0.  
 
1.3 Organisation of thesis 
This thesis comprised three studies. The three studies form a coherent 
programme of work and complement each other. However, individually the 
three studies may be of interest to specific audiences including health 
professionals, academics, service providers and users, third sector organisations 
and exercise scientists. To help facilitate this two of the studies have already 
been published, however, this thesis will offer greater detail than presented in 
the published work.  
First, a systematic review was conducted to assess the efficacy of physiotherapy 
in the rehabilitation of people with progressive MS (Chapter 3). Second, an 
online survey of people with progressive MS in the United Kingdom (UK) was 
conducted to investigate the level of access to, delivery of, barriers to access, 
and opinion of physiotherapy services by people with progressive MS in the UK. 
Furthermore, the level of access to MS Specialists, a regular review, and use of 
clinical services was also investigated. Lastly, the use of complementary and 
alternative therapies was explored (Chapters 4-6). The third study, which was 
based upon the outcome of the systematic review and the online survey, 
explored the feasibility of High Intensity Interval Training (HIIT) in people with 
progressive MS. Furthermore, this study also explored the effects of HIIT, 
compared to continuous moderate intensity training, on physiological and MS 
clinical outcomes in people with progressive MS (Chapters 7-8). Overall 
conclusions and recommendations for each study and the collective body of work 
are presented in Chapter 9. 
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Chapter 2 Literature review 
This chapter will present the epidemiology of Multiple Sclerosis (MS) and the risk 
factors for developing MS and progressive MS.  It will then outline the different 
classifications of the disease and the pathophysiology of each, the process of 
diagnosis and the diagnostic criteria. Different methods of measuring disability 
in MS will be presented before outlining the clinical signs and symptoms of MS 
and pharmacological treatments available to people with progressive MS. The 
effect of MS on employment and the economy will be presented before 
summarising the effect of MS on mortality and the progression of disability 
amongst those who have a progressive form of the disease. Multidisciplinary care 
will then be discussed before outlining research priorities for the field of MS 
research. Lastly, physiotherapy will be discussed in relation to progressive MS 
and then the aims and objectives of this thesis will be outlined. An individual 
justification for each of the three studies undertaken in this PhD will be at the 
start of chapters 3, 4, and 7. 
 
2.1 Multiple Sclerosis; epidemiology and risk factors for 
developing MS 
Multiple Sclerosis (MS) is a chronic auto-immune inflammatory demyelinating 
disease with no known cure (Fox et al., 2012). It is the most common cause of 
neurological disability in young adults and is the predominant member of the 
group of demyelinating diseases (Compston and Coles, 2008).   
It is estimated that approximately 2,300,000 people worldwide have MS with a 
global prevalence of 33 per 100,000 however incidence, and thus prevalence, 
varies depending on geographical location (Browne et al., 2014). In the UK there 
are an estimated 130,000 people with MS and current prevalence is 
258.8/100,000 in women and 113.1/100,000 in men, with peak incidence 
between 40 and 50 years old and peak prevalence between 55 and 60 years old 
(Mackenzie et al., 2014).   
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There are many risk factors for developing MS. These include, but are not 
limited to: gender, age, location, ethnicity, environmental factors and genetics 
(Compston and Coles, 2008). Incidence is generally higher in women than in men 
(2:1), apart from cases of primary progressive MS (PPMS) where incidence is 
relatively equal between genders (Mackenzie et al., 2014). Age at diagnosis is 
usually between 20 and 40 years (Tullman, 2013).   
In general, the prevalence of MS rises with a rise in latitude (Kurtzke, 2005). For 
example prevalence and incidence rates are the highest in North America with a 
prevalence rate of 140 per 100,000 compared to the lowest in Sub-Saharan 
Africa with a rate of 2.1 per 100,000 (Browne et al., 2014).  
Historically, the prevalence and incidence of MS in Scotland has been higher 
than other parts of the UK. This has been documented as far back as the 1950s 
(Sutherland, 1956) and has been monitored relatively closely (Forbes and 
Swingler, 1999, Forbes et al., 1999, Grant et al., 1998, Murray et al., 2004, 
Poskanzer et al., 1980, Rothwell and Charlton, 1998, Shepherd and Downie, 
1978, Shepherd and Downie, 1980). Prevalence, especially, has remained high 
and this has been attributed to an ageing population (Cook et al., 1985, Cook et 
al., 1988). After the addition of Magnetic Resonance Imaging (MRI) to the 
diagnostic criteria for MS, the incidence dropped due to the removal of 
misdiagnosis in some, but not all parts of Scotland, as previously diagnosis was 
made on clinical presentation alone (Visser et al., 2012).  
Even though latitude is a risk factor for developing MS, ethnicity may also be a 
factor. This is demonstrated in the high incidence and prevalence rate in White 
Europeans in northern European countries and North America (Browne et al., 
2014) in contrast with a low prevalence rate of MS in the Inuit populations of 
Greenland (Gillie, 2006). In addition to ethnicity, environmental factors also 
have an influence on risk of developing MS. An increase in prevalence is often 
seen in first generation migrants if they move to the country in early life (less 
than ten years old) and in second generation migrants if they move when older  
(Gale and Martyn, 1995).  
Recent opinion to explain disparities in the latitude model propose the concept 
of the MS ‘genetic burden’ which is a count of all known MS risk alleles that an 
  
 
5 
 
individual may carry (Isobe et al., 2013). Furthermore, hereditary factors also 
increase the risk of developing MS. The risk of developing MS is highest if a 
person is a monozygotic twin of someone with MS (Hawkes and Macgregor, 2009) 
and if a child is born of conjugal MS parents (Dyment et al., 2004).   
In summary, there is a large body of evidence seeking out the possible cause of 
MS, however no single locus, environmental factor or infective agent has been 
identified. Causation is likely cumulative in nature including susceptibility of 
genes, environmental and hereditary risk factors (Milo and Kahana, 2010).   
 
2.2 Classification of Multiple Sclerosis 
There are three main forms of MS: Relapsing Remitting MS (RRMS), Secondary 
Progressive MS (SPMS), Primary Progressive MS (PPMS) and a rarer form of 
Progressive Relapsing MS (PRMS) (Lublin and Reingold, 1996). Relapsing remitting 
MS is characterised by distinct attacks, or relapses, of symptoms with either 
complete recovery or some neurological deficit. Primary progressive MS is a 
progression of disability from onset with either continuous progression or with 
some plateaus and small temporary recovery. Secondary progressive MS is a 
progressive form of the disease which can follow on from RRMS. Progressive 
relapsing MS is defined as a steady progression of disability from onset but with 
distinct relapses with or without complete recovery (Lublin and Reingold, 1996).   
It is estimated that, at time of diagnosis, 15% of all cases are PPMS, 5% are PRMS 
and 80% are RRMS. However, 65% of those who have RRMS will go on to develop 
SPMS (Mackenzie et al., 2014). Thus 72% of all those who develop MS will enter 
into a progressive phase of the disease at some point in their life. 
In addition to these classifications of MS there is a subcategory of MS called a 
Clinically Isolated Syndrome (CIS). A CIS is a singular event of demyelination in 
the central nervous system with symptoms lasting more than 24 hours either at a 
singular site (mono-focal) or multiple sites (multi-focal) (Miller et al., 2012). 
Common sites include the spinal cord (transverse myelitis), the optic nerve 
(optic neuritis) and the brainstem (brainstem syndrome) (Miller et al., 2005). 
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Many people with a CIS will go on to develop MS with documented development 
rates varying from 30-75% within 30 years (Miller et al., 2005, Nilsson et al., 
2005). The more time that elapses from a CIS the risk of developing MS 
decreases (Novakova et al., 2014). Indicators for developing MS from a CIS, 
include a younger age of onset of CIS; oligoclonal bands in the cerebrospinal 
fluid; a multi-focal attack and a greater number of T2 lesions visible on MRI 
(Ignacio et al., 2010, Kuhle et al., 2015). 
 
2.3 Pathophysiology 
2.3.1 Relapsing remitting Multiple Sclerosis 
Relapsing remitting MS is an auto-immune inflammatory demyelinating form of 
the disease exhibiting remyelination at times, but also over time, axonal loss 
and the formation of sclerotic plaques from which the disease takes its name 
(Compston and Coles, 2002). Stages of sclerotic plaque formation include 
inflammation, demyelination, remyelination, depleted oligodendrocyte numbers 
and astrocytosis (Compston and Coles, 2008). 
An attack, or relapse, is an event of lymphocyte driven inflammation. This 
follows a leak in the blood brain barrier and the lymphocytes incorrectly target 
and attack myelin as a foreign body. This results in either total destruction or 
partial damage of myelin sheaths, this damages the Nodes of Ranvier causing a 
decrease in insulation of the axon which affects the speed of the conduction of 
action potentials as saltatory conduction is reduced (Goodkin et al., 1998). 
Remyelination can occur through repair by oligodendrocytes, which can 
potentially produce improvements in signs and symptoms. The new myelin 
sheath, however, may not be as thick as the original, decreasing electrical 
insulation resulting in less effective saltatory conduction (De Souza and Bates, 
2004). Prolonged inflammation from repeated demyelination and incomplete 
remyelination can cause reactive astrocytosis and a decrease in new 
oligodendrocytes being formed (Guthrie and Nelson, 1995). The astrocytes 
produce a scar around the axon which is the typical sclerotic plaque of MS 
(Bjartmar et al., 2001). 
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Repeated relapses can also cause permanent changes in the brain via axonal 
loss, which can be multi-focal and a prominent determinant of progressive 
neurological disability (Bjartmar et al., 2003). Higher level of disability is 
associated with greater axonal loss but location of lesion is also a factor 
(Bjartmar et al., 2000). Damage to axonal tissue can start in the early stages of 
MS and can often be clinically silent (Ferguson et al., 1997, Kornek et al., 2000). 
This damage is caused either by a lack of trophic support from the myelin to the 
axon or from axonal transection (Coles et al., 1999). Axonal transection happens 
when the centre of an active inflammatory lesion transects an axon or axons, 
the subsequent distal axon then degenerates (Trapp et al., 1998), and, as there 
has been no demyelination of the distal axon, a hollow myelin sheath or ovoid 
remains (Evangelou et al., 2000). These redundant ovoids, which are visible on 
MRI, can then also degenerate (Bjartmar et al., 2001).  
 
2.3.2 Secondary progressive Multiple Sclerosis 
Secondary progressive MS is defined as a period of worsening disability of six or 
more months independent of relapses. There is currently no known physiological 
trigger for the onset of SPMS (Fitzner and Simons, 2010). It remains unclear if 
the development of SPMS is linked to the inflammatory phase of RRMS, if 
progression begins at onset or, if the development of SPMS and RRMS are 
independent of each other (Fitzner and Simons, 2010).   
Whilst there are no known biomarkers, or clinical signs to discriminate between 
SPMS and RRMS, neurodegeneration is responsible for the irreversible deficits 
and progression of disability (Stadelmann et al., 2008, Trapp and Nave, 2008, 
Weiner, 2009). This neurodegeneration is independent of the inflammatory load 
experienced during the relapsing remitting phase, and accumulates when active 
lesions are less frequent (Fitzner and Simons, 2010). Hypointense lesion 
accumulation (black holes) indicate disease progression in SPMS (Truyen et al., 
1996). Furthermore, an increase in the number and volume of lesions that are 
visible by MRI correlate with an increase in disability in the early stages of SPMS 
but not in later stages (Brex et al., 2002). This may be related to an overlapping 
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of the end of the relapsing remitting and the onset of the secondary progressive 
phase (Fitzner and Simons, 2010). 
 
2.3.3 Primary progressive Multiple Sclerosis 
Primary progressive MS is characterised by less inflammation than RRMS and 
SPMS (Smith and McDonald, 1999) as it is antibody driven, as opposed to 
lymphocyte driven. While hypointense lesions indicate disease progression in 
SPMS, they do not in PPMS (Truyen et al., 1996). There is an indication that 
axonal loss is more diffuse in PPMS, with white matter lesion load being lower in 
PPMS compared to SPMS. Remyelination occurs less frequently in PPMS compared 
to SPMS and RRMS (Lucchinetti et al., 1999) and demyelination without 
remyelination is a suggested mechanism for disease progression (Pender, 2004).  
Clinically PPMS produces fewer MRI focal brain lesions compared to SPMS (Kidd 
et al., 1993, Thompson et al., 1990, Thompson et al., 1991), but the focal lesion 
load and rate in the spinal cord is equal between those with PPMS and SPMS 
(Kidd et al., 1996, Kidd et al., 1993). Therefore, generally a higher proportion of 
MRI lesion load in PPMS is in the spinal cord (Kidd et al., 1993), and axonal loss is 
also more diffuse compared to SPMS (Nijeholt et al., 1998, Thompson et al., 
1990). This increased likelihood of axonal loss in the spinal cord is the probable 
cause of lower limb paraparesis being the most common onset symptom in PPMS 
(Thompson et al., 1997). 
Despite fewer white matter lesions, PPMS often causes cerebral cortical atrophy 
(De Stefano et al., 2003). Cerebral cortical lesions are characterised by: 
demyelination, axonal transection, dendritic transection, neuronal apoptosis and 
cause less inflammation when compared to white matter lesions (Peterson et al., 
2001). It is however unclear, the extent to which cerebral cortical damage 
contributes to disease progression in PPMS, but it could be linked to the 
proposed antibody mechanism instead of inflammation (Pender, 2004, Yim et 
al., 1994). 
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Spinal cord atrophy is found in all cases of MS (Kidd et al., 1993) but both brain 
and spinal cord atrophy are considered surrogate markers of progression in SPMS 
and PPMS as they strongly correlate with disability (Kalkers et al., 2001, Simon 
et al., 1999). 
 
2.4 Diagnosis and history of diagnostic criteria 
Diagnostic criteria for MS have changed over time, mainly due to advances in 
technology. There have been five sets of criteria with each newer set replacing 
the previous: the Schumacher criteria (Schumacker et al., 1965), the Poser 
criteria (Poser et al., 1983) and the McDonald criteria (McDonald et al., 2001). 
The latter were subsequently revised in 2005 (Polman et al., 2005), and again in 
2010 (Polman et al., 2011). 
The Schumacher criteria categorised diagnosis as clinically definite, probable 
and possible cases of MS. The criteria for a clinical definite diagnosis were all of 
the following: two or more areas of central nervous system involvement with 
clinical signs; white matter lesions; either two relapses of greater than 24 hours 
in length separated by a month or a steady progression of disability; aged 
between 10 and 50 years old and no other possible diagnosis (Schumacker et al., 
1965).  
The Poser criteria further defined an MS attack or relapse and introduced the 
criterion of laboratory evidence in the form of oligoclonal bands in cerebral 
spinal fluid. The Poser criteria had five categories of MS diagnosis: clinically 
definite, laboratory supported clinically definite, clinically probable, laboratory 
supported clinically probable and no MS (Poser et al., 1983).  
The McDonald criteria introduced the criteria of dissemination in space and time 
as evidence by MRI and thus increased sensitivity of diagnosis. The McDonald 
criteria had three categories of MS diagnosis: definite, possible and not MS 
(McDonald et al., 2001). The McDonald criteria also created a new category for a 
CIS. A revision of the McDonald criteria further defined an MS attack (Polman et 
al., 2005), and the most recent revision from 2010 is considered to be the 
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current gold standard in diagnosis of MS (Polman et al., 2011). The 2010 revised 
McDonald criteria allow for diagnosis of MS in the absence of MRI evidence when 
there are two distinct MS attacks, and it further allows diagnosis with just one 
attack if there is definitive dissemination in both space and time upon MRI. 
However, it is not possible to diagnose MS in the absence of an attack (Table 
2-1). Despite the changes in diagnostic criteria, the diagnosis of MS has always 
been dependent on exclusion of any other condition by differential diagnosis and 
a need for dissemination in time and space of lesions of white matter, signs and 
symptoms.  
Table 2-1 Revised McDonald Criteria for the diagnosis of MS. Adapted from 
Polman et al (2011) 
Clinical presentation Additional data needed for MS Diagnosis 
> 2 attacks with clinical 
evidence of > 2 lesions or 
objective clinical evidence of 
1 lesion with historical 
evidence of a prior attack 
None 
> 2 attacks with objective 
clinical evidence of 1 lesion 
Dissemination in space, demonstrated by: 
MRI evidence of at least one inactive lesion in at 
least 2 of the following areas of CNS: 
periventricular, juxtacortical, infratentorial, 
spinal cord. 
Or await a further attack implicating a different 
CNS site  
1 attack with objective 
clinical evidence of > 2  
lesions 
Dissemination in time, demonstrated by: 
Simultaneous presence of asymptomatic active 
and non-active lesions on MRI or a new inactive 
or active lesion on follow up MRI.  
Or await a second clinical attack. 
1 attack with objective 
clinical evidence of 1 lesion 
(clinically isolated syndrome) 
Dissemination in space and dissemination in time 
as described above 
Insidious neurological 
progression suggestive of MS 
(PPMS) 
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the 
following criteria: 
1. MRI evidence of dissemination in space in the 
brain in at least one of the following areas: 
periventricular, juxtacortical, infratentorial. 
2. MRI evidence of dissemination in space of at 
least two lesions in the spinal cord  
3. Positive CSF (isoelectric focusing evidence of 
oligoclonal bands and/or elevated IgG index) 
Abbreviations: MRI: magnetic resonance imaging; CNS: central nervous system; CSF: cerebral 
spinal fluid 
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2.5 Prognosis and onset of secondary progressive 
Multiple Sclerosis and progression of disease 
An individual with RRMS will typically have mild to moderate disability (Bejaoui 
and Rolak, 2010, Scalfari et al., 2010). However, if a person with RRMS goes on 
to develop SPMS, or has PPMS their disability will steadily worsen over time 
(Lublin and Reingold, 1996).   
The risk of developing SPMS from RRMS rises by 9% every five years and 
quadruples after 20 years (Eriksson et al., 2003). Other risk factors for 
developing SPMS are the age of onset (>30 years old), a higher level of disability, 
being male, high early relapse rate (more than two relapses in first two years) 
(Pokryszko-Dragan et al., 2008), and early signs of cerebellar or brainstem 
lesions (Scalfari et al., 2010). A high early relapse rate and brainstem lesions are 
also strong predictors of long term disability (Scalfari et al., 2010, Scalfari et al., 
2014).  
The average time for developing SPMS from RRMS is 15.2 years since diagnosis 
(Scalfari et al., 2013). The transition from RRMS to SPMS is not always clear as it 
can be difficult to distinguish between progression of symptoms and the 
symptoms of relapses. Some people may experience a complete cessation of 
relapses and a steady progression of disability whilst others may continue to 
experience relapses with some transient recovery along with the steady 
progression (Lublin and Reingold, 1996). A diagnosis of SPMS is made on signs and 
symptoms as opposed to imaging: this lack of official clinical markers in 
established SPMS means that there is no clear pathophysiological line between 
RRMS and SPMS and a mixed presentation often leads to a blurred transition 
between the two (Fitzner and Simons, 2010).  As the transition from RRMS to 
SPMS often has an overlap with no clear distinction between the two forms of 
MS, this could potentially lead to people with SPMS still being classed as RRMS, 
or people with RRMS being classed as SPMS earlier than they should be. This 
potential misclassification of people with MS may lead to people being included 
in, or excluded from, research projects that have a specific type of MS as an 
inclusion criterion. 
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2.6  Measurement of disability in Multiple Sclerosis 
Disability measurement in MS has developed over the years. The Extended 
Disability Status Scale (EDSS) is the most commonly used measurement but has 
come under criticism for being reliant on mobility in higher scores (Hobart et al., 
2000). Other outcome measures have been developed including the Patient 
Determined Disease Steps (PDDS) and the Multiple Sclerosis Impact Scale (MSIS-
29) the latter of which measures the impact of MS on the individual. Both of 
these are self-report measures, which increase the ease of application, and 
while the PDDS is also reliant on mobility, the MSIS-29 includes questions related 
to function and the psychological impact. 
 
2.6.1 Extended Disability Status Scale 
The EDSS is most commonly used measurement of disability in people with MS. It 
is a 20 point ordinal scale ranging from 0 – 10 with 0.5 increments. It categorises 
impairment in the following domains: pyramidal, cerebellar, brainstem, sensory, 
bladder and bowel, cerebral, visual and other (Kurtzke, 1983). Despite 
measuring disability in different domains, after a score of 4.0, rises in score are 
dependent on mobility. Scores of 0-4.5 are fully ambulatory, 5.0-8.0 are of 
worsening ambulation, 8.5–9.5 are restrained to bed or chair with worsening 
independence and 10.0 is death due to MS. The EDSS requires a clinician to be 
NeurostatusTM trained to carry out the assessment.   
The EDSS is reliable with an inter-rater interclass correlation of 0.78 but the 
intra-rater interclass correlation has been found to vary between 0.62 and 0.94 
(Hobart et al., 2000). Furthermore it is not sensitive to change and, as it is 
focused on mobility as scores increase, it may not reflect any improvements in 
function (Hobart et al., 2000). Due to this lack of sensitivity to change patients 
often cluster around bands of 3.0-4.0 and  5.0-6.0 (Sharrack et al., 1999). 
Despite these criticisms and limitations, the EDSS is still widely used in MS 
literature as a measure of disability both for screening and as an outcome 
measure. 
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2.6.2 Patient Determined Disease Steps 
The PDDS is a self-administered measure that provides an ordinal score from 0-9, 
in 1 point increments, and is focussed entirely on mobility (Marrie and Goldman, 
2007). It was developed from the Disease Steps (Hohol et al., 1995), by the 
North American Research Committee on Multiple Sclerosis Registry to use as part 
of their online data collection. The PDSS correlates moderately with EDSS  (EDSS 
below 4.5 (rho = 0.641) and above 4.5 (rho = 0.688)) (Learmonth et al., 2013). 
The main advantage of the PDDS is that it does not require a physician to 
administer, unlike the original Disease Steps measure. However, like the EDSS it 
is heavily reliant on mobility and may not reflect function. 
 
2.6.3 The Multiple Sclerosis Impact Scale - 29  
The MSIS-29 is a 29 item self-report measure of disease impact. It is divided into 
two sections: the first 20 questions concern the physical impact of MS and the 
final 9 questions the psychological impact of MS. A higher score indicates a 
greater impact of disease. Each question is answered using a 5-point Likert scale 
and responses are given in relation to the previous two weeks (Hobart et al., 
2001). The original version of the MSIS-29 was updated in 2009. Version 2 of the 
MSIS-29 is similar to version 1 but is answered using a 4-point Likert scale (scored 
1-4), these are ‘not at all’, ‘a little’, ‘moderately’ and ‘extremely’. This gives 
the physical and psychological impact sub-scales scores of 20-80 and 9-36 
respectively (Hobart and Cano, 2009).   
The physical sub-scale of the MSIS-29 version 1 was found to correlate 
moderately with EDSS (Spearman’s rank coefficient 0.63) with correlation 
increasing with higher scores (higher physical impact) (Gray et al., 2009). The 
MSIS-29 version 1 is sensitive to change when compared to the EDSS with larger 
changes producing exponentially larger changes in MSIS-29 scores. For example a 
0.5 change in EDSS approximately equates to 5 points in MSIS-29 but a change of 
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2 or more equates to a change of approximately 40 points in the MSIS-29 
(McGuigan and Hutchinson, 2004).   
In terms of the physical subscale of MSIS-29 version 1 the Minimal Clinical 
Important Difference (MCID) has been reported as a decrease of 7 points for 
those with an EDSS of 0.0 – 5.0 and a decrease in 8 for those with an EDSS of 5.5 
- 8.0 (Costelloe et al., 2007a). In the psychological sub-scale of version 1, a 
decrease of 6 or more is deemed to be clinically significant (Widener and Allen, 
2014). There is no available MCID for the sub-scales used in MSIS-29 version 2. 
The primary advantages of the MSIS-29 over the EDSS is that it does not require 
training to administer and can be administered in 10-15 minutes as opposed to a 
30-45 minute assessment for the EDSS. 
 
2.7 Clinical features, symptoms and treatment of Multiple 
Sclerosis  
Clinical features and symptoms of MS include, but are not restricted to, mobility 
and motor problems, sensory disturbance, pain, spasticity and spasms, fatigue, 
visual disturbances, bladder and bowel problems, cognitive and emotional 
problems, sexual dysfunction and trouble swallowing (McDonald et al., 2001). 
 
2.7.1 Mobility and motor problems 
Mobility is defined as any bodily movement that creates a change in bodily 
position (World Health Organisation, 2009) and mobility problems are often the 
most visible sign of MS (Sutliff, 2010) with approximately 25% of the MS 
population being non-ambulatory (Einarsson et al., 2003). Initially mobility 
impairment usually presents as a reduction in gait speed and quality (Freeman, 
2001). Motor problems can arise from muscle weakness, spasticity, tremors or 
ataxia due to cerebellar lesions and which impact on mobility (Koch et al., 
2007). Ataxia can arise from decreased input into the cerebellum from afferent 
sensory input from spinal cord lesions as well as decreased output from 
demyelinated efferent cerebellum nerves (Schmahmann, 2004).  
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Difficulty in walking has been shown to reduce physical activity in people with 
MS (Motl et al., 2005), be directly correlated with disability levels (Kobelt et al., 
2006), and is the largest prognostic factor in disability (Damasceno et al., 2013). 
The earlier an individual requires a walking aid the earlier they will be confined 
to a wheelchair (Tremlett et al., 2005). While the prevalence of mobility 
problems is similar between PPMS and SPMS, in PPMS lower limb weakness is 
more often one of the initial presenting symptoms (Thompson et al., 1997). This 
is due to the previously mentioned predominance of spinal cord lesions in PPMS 
compared to SPMS (section 2.3.3).  
 
2.7.2 Sensory disturbance  
Sensory symptoms are often one of the initial symptoms of MS (Murray, 2006) 
especially in cases of PPMS (Thompson et al., 1997). These can present as 
decreased sensation or complete numbness or paraesthesia (“pins and needles”, 
tingling or burning) (Gaby, 2013). Sensory symptoms may arise from damage to 
both afferent and efferent pathways which can cause secondary issues with 
sensory feedback and proprioception; leading to sensory based ataxia 
(Schmahmann, 2004). 
 
2.7.3 Pain 
Evidence suggests that MS pain affects up to 86% of all people with MS (O'Connor 
et al., 2008) and may be the most pharmacologically treated symptom 
accounting for up to 30% of all drug use (Brichetto et al., 2003). Approximately 
69% of people with MS are affected by chronic pain (Kalia and O'Connor, 2005, 
Khan and Pallant, 2007), but despite the high prevalence of MS-related pain it is 
rarely the initial symptom at onset (Hadjimichael et al., 2007, O'Connor et al., 
2008). 
MS pain is usually considered within four categories: continuous central 
neurogenic pain, intermittent neurogenic pain (including trigeminal neuralgia, 
Lhermitte’s sign, and glossopharyngeal neuralgia), musculoskeletal pain (pain 
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arising from tonic spasms or spasticity, or contractures) and a mixture of both 
non-neurogenic and neurogenic pain (O'Connor et al., 2008).   
Central pain is the most common type of pain experienced (Osterberg et al., 
2005) and a commonly held opinion is that all primary MS pain syndromes arise 
from the central nervous system and that neurogenic pain, from the peripheral 
nervous system, is less frequent (O'Connor et al., 2008).   
Pain phenomena unique to MS include the MS ‘hug’ or ‘girdle’, Lhermitte’s sign, 
and trigeminal neuralgia. The MS ‘hug’ is a tightness and compression feeling in 
the chest (O'Connor et al., 2008). Lhermitte’s sign is the spontaneous discharge 
of mechanically sensitive axons causing electric shock like sensations in the 
upper limbs or flashing lights (Brola et al., 2014). Trigeminal neuralgia is 
characterised by severe pain in the face or head arising from the trigeminal 
nerve, which can last from seconds to hours, while optic neuritis will often 
present as pain with eye movement as one of its symptoms (Foley et al., 2013).  
A definite physiological mechanism of central pain has not been found (Brola et 
al., 2014) but demyelination and diffuse axonal damage can lead to central 
hyper-excitability of central nociceptor pathways (Solaro et al., 2013, Truini et 
al., 2012). Pain is a complex symptom, as many other symptoms in MS,  and can 
be multifactorial in nature which requires an holistic treatment approach (Solaro 
et al., 2013). 
 
2.7.4 Spasticity and Spasms 
A European working group for spasticity defined spasticity as a “disordered 
sensorimotor control resulting from an upper motor neuron lesson, presenting as 
intermittent or sustained involuntary activation of muscles.” (Pandyan et al., 
2005). Spasticity is highly prevalent in people with MS (Barnes et al., 2003, 
Berger, 2013, Collongues and Vermersch, 2013, Oreja-Guevara et al., 2013, 
Rizzo et al., 2004) with some literature reporting prevalence rates as high as 80% 
(Rizzo et al., 2004) although a recent worldwide estimate stated prevalence at 
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around 40% of all people with MS (Collongues and Vermersch, 2013) with 40% of 
spasticity being moderate and 25% severe (Collongues and Vermersch 2013). 
Although the pathophysiology of spasticity in MS is complex and not fully 
understood, (Amatya et al., 2013, Kheder and Nair, 2012, Pappalardo et al., 
2006) the definition of intermittent or sustained activation of muscles is related 
to the hyper-excitability of afferent and efferent neural pathways which affect 
the activation of the muscle (Meca-Lallana et al., 2015). Diffuse axonal loss is 
correlated with an increase in excitability of the tendon stretch reflex and the 
severity of spasticity (Barnes et al., 2003). Worsening of spasticity is associated 
with disease and disability progression (Shakespeare et al., 2003).   
Progression in disability due to spasticity, can impact negatively on quality of 
life and function through impact on mobility and function (Arroyo et al., 2013, 
Fernandez et al., 2011, Hemmett et al., 2004, Zettl et al., 2014). This decrease 
in independence is cited as one of the most worrying symptoms of people with 
progressive MS (Strupp et al., 2012). Despite the negative impact on mobility 
spasticity can, on occasion, provide physical support in cases of lower limb 
weakness and actually reduce disability in mild cases (Pappalardo et al., 2006). 
However, these cases are in the minority and in general, spasticity impacts 
negatively on quality of life and disability. 
 
2.7.5 Fatigue 
Fatigue is defined as abnormal tiredness or absence of energy, disproportionate 
to the task or normal effort required and impacts on routine or intellectual 
functions (Weinshenker et al., 1992). It is deemed clinically significant when it 
impairs activities of daily life or quality of life (Bakshi, 2003). Fatigue can, in 
MS, be the only symptom of a relapse (Flachenecker and Meissner, 2008) and is 
one of the most common symptoms affecting up to 75-95% of all people with MS 
with 50-60% citing fatigue as their most disabling symptom (Bakshi, 2003, Kos et 
al., 2008). However, fatigue is usually only cited as the most disabling symptom 
during low to moderate disability. When a person enters a progressive phase and 
becomes more disabled, mobility then becomes their most disabling symptom 
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(Strupp et al., 2012). Fatigue in MS can be classified as primary or secondary. 
Primary fatigue is a result of MS and secondary fatigue is usually a side effect of 
medications or physical deconditioning (Bakshi, 2003). 
Fatigue can impact negatively on cognitive ability and quality of life (Krupp and 
Elkins, 2000). It can lead to a transition from full to part-time employment and 
increase the risk of unemployment (Simmons et al., 2010). MS-related fatigue 
has been linked to low mood and disability (Bakshi, 2003). It can be difficult to 
distinguish between primary and secondary fatigue as fatigue may be caused by 
other concomitant conditions such as depression (Bakshi et al., 2000), which may 
independently impact on quality of life (Janardhan and Bakshi, 2002), or as a 
side effect from disease modifying pharmacological treatments (Mohr et al., 
2003). Fatigue is inversely correlated with cardiovascular fitness and related to 
deconditioning (Valet et al., 2016). In MS, when fatigue is caused by 
deconditioning, it is regarded as secondary fatigue (Khan et al., 2014, Kos et al., 
2008, MacAllister and Krupp, 2005). 
Current evidence of non-pharmacological treatments in treating fatigue in MS is 
limited mainly by methodological weaknesses (Amato and Portaccio, 2012). The 
pathophysiology of MS-related fatigue is not fully understood but is likely 
multifactorial with links to both the central and peripheral nervous systems, 
immunological and neuroendocrine factors (Amato and Portaccio, 2012, 
Gottschalk et al., 2005, Roelcke et al., 1997). There have been links made 
between fatigue and lesions in the central nervous systems including diffuse 
axonal damage (Tartaglia et al., 2004), lesions in the basal ganglia and the 
hypothalamus (Comi et al., 2001, Filippi et al., 2002, Roelcke et al., 1997), and 
cortical atrophy (Pellicano et al., 2010).   
The multifactorial nature of fatigue in MS, and the lack of definitive 
physiological mechanisms create many different possible routes of intervention: 
pharmacological, behavioural therapy and exercise interventions. However, MS 
related fatigue is difficult to treat and the source of the fatigue and 
physiological impact of the intervention may limit efficacy of interventions 
(Amato and Portaccio, 2012). Nonetheless, exercise has been recommended as 
part of a multi-factorial approach in the management of secondary fatigue that 
has been caused by deconditioning (Asano and Finlayson, 2014), with evidence 
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suggesting that aerobic exercise can improve general fatigue symptoms 
(Latimer-Cheung et al., 2013). This improvement comes from the impact that 
exercise, and fitness, can have on function, and quality of life by decreasing the 
physical burden of tasks  (Andreasen et al., 2011). 
 
2.7.6 Visual disturbances 
Optic neuritis, inflammation of the optic nerve, affects approximately 40% of 
people with MS at some point in their lifetime (Roodhooft, 2009). Symptoms can 
include diplopia, blurred or “smeary” vision, spotted vision or posterior eye pain 
(Optic Neuritis Study, 2008). Optic neuritis is often the very first presentation of 
MS and is used in early diagnosis of the disease (Halilovic et al., 2014).   
 
2.7.7 Bladder and bowel problems 
Bladder problems affect approximately 75% of people with MS with symptoms 
including increased urgency, increased frequency, hesitancy, retention and 
incontinence (Browne et al., 2015). Incontinence may be perpetuated, and in 
some cases created, by mobility issues if a person is in a progressive phase of MS 
with worsening disability (Andrews and Husmann, 1997). The most common 
bowel problem is constipation, which has two main causes: directly due to 
decreased peristalsis of the bowel due to demyelination or as a secondary issue 
from medication or an intentional decrease in fluid intake to limit urinary 
incontinence (Preziosi et al., 2014). 
 
2.7.8 Cognition and emotional impairment 
Cognitive impairment is a phenomenon only recognised in people in MS in the 
past 30 years (Amato et al., 2006). Cognitive symptoms can present in all 
subtypes of MS at any stage (Haase et al., 2003) and remission is rare (Amato et 
al., 2006). Cognitive impairments can have a large detrimental effect on an 
individual’s quality of life by impacting on activities of daily life, independence 
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(for example driving), and making and maintaining social relationships (Amato et 
al., 2001b).   
Whereas dementia and language deficits are rare, common cognitive issues 
include deficits in learning, memory, attention and processing speed, 
visuospatial abilities, and executive function (Bobholz and Rao, 2003, 
Chiaravalloti and DeLuca, 2008, Rogers and Panegyres, 2007). It is estimated 
that between 50% and 65% of all people with MS have some sort of cognitive 
impairment (Amato et al., 2006). People with PPMS, in particular, are affected 
by issues with memory, attention and processing and executive function (Camp 
et al., 2005). Cognitive impairment is associated with worsening physical 
disability (Lynch et al., 2005), time since diagnosis (Amato et al., 2001b), and 
progressive forms of MS (Achiron et al., 2005) and it has been proposed that 
cognitive impairment symptoms are signs of disease activity in the brain (Patti, 
2009).  
In people with SPMS there is a weak relationship between cognitive problems 
and both white matter lesions and brain atrophy (Benedict et al., 2006, Benedict 
et al., 2004). In people with PPMS memory problems and attention deficits 
correlate with diffuse brain T1 and T2 lesion load but not with whole brain 
atrophy (Ukkonen et al., 2009). In addition, in those with PPMS brain atrophy 
and diffuse white matter damage correlate with deficits in complex reasoning, 
which is part of executive function, (Camp et al., 2005, Camp et al., 1999, 
Ukkonen et al., 2009) and grey matter lesion load correlates with general 
cognitive dysfunction (Tur et al., 2011). 
A study of all subtypes of people with MS, but predominantly RRMS, found that 
all participants displayed signs of cognitive reserve as measured by vocabulary 
(Sumowski et al., 2009) . In a follow up study, people with SPMS who had had 
what the authors described as ‘life intellectual enrichment’ showed cognitive 
reserve (Sumowski et al., 2012). This attenuated the negative effects of MS on 
their cognitive efficiency compared to similar patients with less cognitive 
reserve and improved their memory more than similarly matched healthy 
subjects with less cognitive reserve. 
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Depression in MS, like fatigue, can impact negatively on quality of life and can 
be separated into secondary and primary depression (Amato et al., 2001a). 
Primary depression is caused as a direct result of an MS lesion whilst secondary 
depression is caused as a result of an MS symptom, a situation, or as a side 
effect of medication (Holden and Isaac, 2011). People with MS may also 
experience emotional lability, or the pseudobulbar effect, and display amplified, 
non-appropriate or incongruent emotional responses (Cummings et al., 2006). 
 
2.7.9 Sexual dysfunction 
Sexual dysfunction is higher in people with MS compared to the general 
population (Schmidt et al., 2005), and is a recognised problem in people with MS 
(Fletcher et al., 2009). It may arise directly from impotence or decreased 
sensation and sensitivity or as a secondary symptom from other issues such as 
pain, spasticity, tremor, incontinence, weakness or depression (Previnaire et al., 
2014). The most common primary symptom of sexual dysfunction is impotence in 
men (Guo et al., 2012) and delayed orgasm in women (Merghati-Khoei et al., 
2013). Sexual dysfunction also has the potential to cause secondary issues with 
mood and depression (Fletcher et al., 2009). 
 
2.7.10 Dysphagia 
Dysphagia is a disorder of the swallowing reflex and can result in aspiration of 
food or liquid into the lungs (Brady, 2008). Prevalence of dysphagia amongst 
people with MS rises significantly with disability level and the onset of 
progressive MS, with approximately 5% of those with an EDSS of 2-3 and 65% of 
those with an EDSS of 8.0-9.0 experiencing the symptom (De Pauw et al., 2002). 
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2.8 Pharmacological treatments for multiple sclerosis  
There are three main categories of pharmacological treatments available for MS: 
disease modifying drugs, corticosteroids and drugs for symptomatic control. 
Until recently, disease modifying drugs were only effective in those with RRMS 
and not in those with a progressive form of the disease. In March 2017 however, 
Ocrelizumab, which has been shown to reduce progression of disease in people 
with PPMS by up to 25% (Montalban et al., 2015), was approved by the Food & 
Drug Administration in the United States of America for use in people  with RRMS 
and PPMS (U.S. Food & Drug Administration, 2017) and in November 2017 was 
approved by the European Medicines Agency for use in early PPMS (European 
Medicines Agency, 2017). It is however, not yet available on the National Health 
Service in the UK. The purpose of disease modifying drugs is to decrease 
inflammation via immunosuppression, which in turn decreases the autoimmune 
attack on myelin, the relapse rate and the severity of any relapse experienced. 
A decreased relapse rate can extend the latency period of subsequent 
development of SPMS, thus slowing disease progression (Martinelli Boneschi et 
al., 2013), but not necessarily long-term disability (Brownlee and Miller, 2014). 
Use of disease modifying drugs in cases of CIS may delay development of MS but 
may, in some cases, result in patients being treated for MS when the disease is 
not present (Brownlee and Miller, 2014). A list of common disease modifying 
therapies and their brand names can be seen in Table 2-2.  
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Table 2-2 List of disease modifying therapies, their common brand names, 
sub-types of MS for which they are suitable and their availability in the UK 
Name of DMTs Brand names MS sub type Available in UK 
Beta-interferon   Rebif, Avonex, Betaferon RRMS Yes 
Glatiramer acetate Copaxone RRMS Yes 
Dimethyl fumarate Tecfidera RRMS Yes 
Teriflunomide Aubagio RRMS Yes 
Natalizumab Tysabri, Antigren RRMS Yes 
Fingolimod Gilenya, Novartis RRMS Yes 
Mitoxantrone Novantrone RRMS Yes 
Alemtuzumab Lemtrada RRMS Yes 
Olecrilizumab Ocrevus RRMS, PPMS No 
Abbreviations: RRMS: relapsing remitting multiple sclerosis; PPMS: primary progressive multiple 
sclerosis 
 
Side effects of disease modifying drugs vary depending on the individual.  Some 
non-serious possible side effects include depression, fatigue, malaise and flu-like 
symptoms shortly after initially beginning treatment. However, over time the 
severity of the side effects can often wane and become more manageable 
(Scolding et al., 2015). On occasion however these side effects can out-weigh 
the benefits. Additionally some disease modifying drugs such as Fingolimod, 
Teriflunomide and Alemtuzumab have more serious potential side effects such as 
bradycardia, blood clotting, changes in liver function and an increased risk of 
leukaemia and progressive multifocal leukoencephalopathy (Cohen et al., 2010, 
Cohen et al., 2012, Vermersch et al., 2014, Baldwin and Hogg, 2013, Goodin et 
al., 2003).   
Corticosteroids can increase the speed of recovery from a relapse but will not 
affect the magnitude of recovery, decrease residual deficit, slow down the 
progression of the disease or affect long term disability level (Brusaferri and 
Candelise, 2000). The pathological mechanism of aiding recovery is not fully 
known but it is theorised that corticosteroids either suppress the immune system 
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or decrease inflammation around the damaged nerve tissue (Myhr and Mellgren, 
2009).  
While there is now a pharmacological treatment for people with PPMS which is 
available in the United States of America, this is not yet available in the UK. 
Furthermore there are no pharmacological treatments, to slow disease 
progression, for people with SPMS (Fox et al., 2012). Thus pharmacological 
treatment in cases of progressive MS usually focuses around symptom 
management (Scolding et al., 2015).   
Pharmacological treatments for symptoms include Fampridine, which can 
improve mobility. A recent review found short term improvements in the timed 
25 foot walk test and improvements in the 12 item MS Walking Scale (Kim, 
2017).  Several drugs are available for treating fatigue: these include 
Amantadine and Modafinil. Amantadine has been shown to be effective in small 
doses (NICE, 2014b).  Modafinil is often prescribed off-label for the treatment of 
MS fatigue.  Research has however, shown inconsistent results and a meta-
analysis called for larger and methodologically stronger trials to confirm or deny 
its efficacy in treating MS fatigue (Sheng et al., 2013). Neuropathic MS pain can 
be treated with anticonvulsants such as Gabapentin and tricyclic antidepressants 
such as Amitriptyline and analgesic painkillers can be used for musculoskeletal 
pain (NICE, 2017). Muscle relaxants such as Baclofen or Diazepam and 
anticonvulsants such as Gabapentin are used in the treatment of spasticity 
(NICE, 2014b).  
 
2.9 Employment in Multiple Sclerosis 
Unemployment is common in people with MS which can have a detrimental 
effect on quality of life (Boe Lunde et al., 2014). In addition there is a strong 
inverse correlation with physical disability and working ability (Krause et al., 
2013, Moore et al., 2013). Generally those with MS have a lower level of 
employment compared to the general population: 41.9% compared to 76.9% 
(Ford et al., 2012). However, there are similar percentages of people with MS 
registered as permanently sick as the general population: 29.8% compared to 
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24.5% (Ford et al., 2012). It is common however, for people with MS to move 
initially from full-time employment to part-time employment (Jennum et al., 
2013). Busche et al. (2003) reported that 66% of their sample who were 
employed had RRMS, and 78% of those who were unemployed had a progressive 
form of MS. They found that predictors of becoming unemployed included a rise 
in disability; having a progressive form of MS with SPMS having a higher risk than 
PPMS; being older and with longer disease duration. Overall the people most 
likely to be made unemployed because of their MS were those who were older 
than 39 years old, had moderate disability or SPMS (Busche et al., 2003).   
Both Busche et al. (2003) and Ford et al. (2012) agreed that as disability, 
particularly physical disability, increased the less likely the person with MS was 
of being employed. This likelihood is perpetuated if an individual has progressive 
MS, and in particular SPMS.   
 
2.10 Economic impact of Multiple Sclerosis 
Multiple Sclerosis can be an economic burden to the individual and their 
families, the health service and society. This burden includes direct medical 
costs such as visits to outpatient clinics, hospital admissions, assistive devices, 
pharmaceutical prescriptions and long-term care (Naci et al., 2010). 
Furthermore indirect medical costs can be incurred including modifications to 
home or car, transport, and informal care. There is also a cost to the economy in 
lower employment, moving from full time to part time, loss of earnings, 
decreased tax receipt to the economy and through receipt of disability benefits 
(Jennum et al., 2013). A rise in disability level also carries an economic cost 
both in care and in loss to the economy, which doubles as EDSS moves from 2.0 
to 4.0 and triples from 4.0 to 6.5 (Trisolini et al., 2010). 
A review of the literature of medical costs of MS in the US from 1999-2008 found 
that cost per MS patient per year ranged from $8,528-54,244.  Of these costs 
approximately 77% were direct medical costs and 23% were indirect medical 
costs. This direct costing placed MS second only to congestive heart failure in 
being the most costly chronic condition in the United States of America 
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(Adelman et al., 2013). Another study in the US found that cost of a relapse 
increased with severity of relapse and a higher relapse rate was associated with 
higher costs both directly and indirectly (Parise et al., 2013).   
The cost of MS is rising over time; mainly attributed to the rise in cost of disease 
modifying therapies. An expert editorial reported that the cost of disease 
modifying drugs in the US have, over the past 20 years, risen at rates that are 
five to seven times greater than that of prescription drug inflation (Hartung et 
al., 2015). They also noted that newer disease modifying drugs entered the 
market at 25-60% more expensive than ‘first generation’ disease modifying 
drugs. This however, would not impact on the cost of progressive MS who should 
not be taking disease modifying drugs (Scolding et al., 2015).  
There is very little information regarding the cost of progressive forms of MS but 
a report published by the Multiple Sclerosis International Federation (MSIF) on 
the global impact of MS noted that caregivers of people with progressive MS had 
four times the absence from work of their counterparts who cared for those with 
RRMS (Trisolini et al., 2010).  
 
2.11  Multiple Sclerosis and mortality 
It was previously thought that people with MS had a life expectancy comparable 
to that of the general population, however a review of cohort studies found life 
expectancy to be five to ten years shorter if an individual has MS (Ragonese et 
al., 2008). Furthermore a Danish study found that over half of those with MS 
died as a result of their MS (Bronnum-Hansen et al., 2004).  
The literature of survival times from diagnosis is conflicting. A review in 2008 
found that survival times from diagnosis was the same regardless of age at 
diagnosis (Ragonese et al., 2008) but a more recent study found that a younger 
age at diagnosis correlated with a longer survival time but overall a younger 
mortality age (Rodriguez-Antiguedad Zarranz et al., 2014). The converse was 
also true that an individual diagnosed later on in life would have a shorter 
survival time from diagnosis but overall die at an older age.   
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2.12 Multidisciplinary care 
Multidisciplinary care has been shown to be effective in neurological conditions 
such as stroke (Greener and Langhorne, 2002, Langhorne et al., 2002) and 
traumatic brain injury (Turner-Stokes et al., 2005). A Cochrane review concluded 
that the holistic approach of multidisciplinary care in MS did not affect 
impairment but it did produce a positive increase in activity and participation 
and thus improved quality of life. The authors also noted that this had a positive 
effect on the general health and social engagement of carers of people with MS 
(Khan et al., 2007). Multidisciplinary care has also been recommended 
specifically for both SPMS (Giovannoni, 2004) and PPMS (Khan et al., 2011). Both 
position papers addressed the management of these progressive subtypes and 
recommended that management and interventions focussed on symptoms, 
addressed mental health aspects, and quality of life. 
Multidisciplinary care can vary in its setting, interventions and intensity.  What is 
common is the holistic and cross-disciplinary approach with the involvement of 
the patient and patient centred goals. This is vital in MS, due to the variation in 
clinical presentation and needs of the patient. Since there is no available 
effective treatment for slowing the progression of progressive MS (Compston and 
Coles, 2008), treatment often focuses on symptom management. Such treatment 
can be pharmacological or non-pharmacological. Non-pharmacological symptom 
management often takes the form of rehabilitation (Dix and Green, 2013).  
Access to MS specialist services including physiotherapy is part of the current 
National Institute for Health and Care Excellence (NICE) guidelines (NICE, 2014b) 
and the Health Care Improvement clinical standards for neurological conditions 
in Scotland (Healthcare Improvement Scotland, 2009). These guidelines and 
standards state a person with MS should receive a regular review of their MS at 
least once a year. Under the NICE guidelines, published in 2014, this review can 
be undertaken by any health professional including general practitioners, and 
not necessarily a specialist in MS. However, the level of access to a regular 
review by people with progressive MS was unknown before the research 
described by this thesis was conducted. 
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2.13 Physiotherapy for Multiple Sclerosis 
According to the Chartered Society of Physiotherapy, “Physiotherapy helps 
restore movement and function when someone is affected by injury, illness or 
disability.” and that “Physiotherapists help people affected by injury, illness or 
disability through movement and exercise, manual therapy, education and 
advice.” (Chartered Society of Physiotherapy, 2013). There is evidence 
indicating positive benefits of using physiotherapy in the rehabilitation of people 
with RRMS. Several review papers concluded exercise therapy to be generally 
beneficial for people with MS who are not suffering a relapse, (Dalgas et al., 
2008, Latimer-Cheung et al., 2013, Rietberg et al., 2005), as well as having 
positive effects on fatigue (Andreasen et al., 2011, Pilutti et al., 2013), health 
related quality of life (Motl and Gosney, 2008) and muscle strength (Kjolhede et 
al., 2012), in those with a mild to moderate disability. Further reviews have 
found physiotherapy to have a positive effect on balance and mobility (Hogan 
and Coote, 2009, Paltamaa et al., 2012, Toomey and Coote, 2012). Although the 
evidence for physiotherapy for people with MS is strong for those with mild to 
moderate disability it is less compelling for people with moderate to severe 
disability due to methodological weaknesses in the studies (Hogan and Coote, 
2009, Toomey and Coote, 2012).  
Whilst some of these reviews considered their results in terms of disability 
levels, none have made a distinction between RRMS and progressive MS. This is a 
large gap in the literature, in relation to the efficacy of physiotherapy, 
especially as the physiology of RRMS and progressive MS and between SPMS and 
PPMS, is notably different. At the time of this thesis, there were no published 
reviews examining the evidence for physiotherapy for the rehabilitation of 
people with progressive MS. Furthermore, rehabilitation of people with 
progressive MS has been identified as one of the research priorities of the 
International Progressive MS Alliance (section 2.14), who have called for more 
intervention trials in this patient group and specifically for those with a higher 
level of disability (Fox et al., 2012). 
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To summarise, the main gaps in the literature when the work within this thesis 
started were: 
 There was no review of evidence of  physiotherapy for the rehabilitation 
in people progressive MS 
 Limited knowledge of access and use of clinical services, access to 
physiotherapists and regular reviews by people with progressive MS 
 In people with progressive MS with a higher disability, there was a lack of 
rehabilitation intervention trials. 
 
2.14  Research priorities in progressive Multiple 
Sclerosis 
In 2012 two groups, the International Progressive MS Alliance and the MS Society 
with the James Lind Alliance, set out to broaden and deepen the research of MS 
in general and specifically progressive MS.   
The International Progressive MS Alliance was established in 2012 as a 
collaboration between the Multiple Sclerosis International Federation and the MS 
Societies of five western countries with high incidences of MS: Canada, Italy, the 
Netherlands, the UK, and the United States of America.  Its goals are: 
1. To raise the profile and accelerate progress of research in progressive MS 
2. Secure resources and globalise research funding 
3. Inspire, galvanize and engage awareness in progressive MS research 
4. Deliver operational excellence 
In 2012 the International Progressive MS Alliance then set out its five key 
research priorities which can also be seen in Table 2-3. 
The James Lind Alliance conducted a Priority Setting Partnership in the UK 
involving representatives of patients, carers, health professionals, and 
researchers (MS Society, 2014). The purpose of the Partnership was to establish 
the 10 most pertinent research questions regarding MS. A steering group oversaw 
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and conducted a survey completed by 507 individuals culminating in 1084 
research questions. A year after collation the top 30 questions were discussed, 
face to face with key stakeholders, and then a steering group identified the 10 
most important research questions (Table 2-3).  
There is an overlap between the 10 most important research questions identified 
by the James Lind Alliance and the research priorities of the International 
Progressive MS Alliance. Of relevance to the research reported in this thesis, 
there is notably overlap between the research priorities of proof of concept 
clinical trial strategies, symptom management, and rehabilitation and the 
questions relating to mobility, cognition, physiotherapy, and fatigue. Other 
areas of overlap include the research priority of repurposing opportunities, 
identification and validation of targets and the questions of treatments to slow 
disability, the use of Vitamin D, the treatment of pain fatigue, cognition and 
mobility. 
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Table 2-3 10 most pertinent research questions from the James Lind Alliance 
and the top 5 key research priorities from the International Progressive MS 
Alliance 
James Lind Alliance’s top 10 research 
questions 
International Progressive MS 
Alliance’s key research 
priorities 
1. Which treatments are effective to slow, 
stop or reverse the accumulation of disability 
associated with MS? 
1. Identification and 
validation of targets and 
repurposing opportunities  
2. How can MS be prevented? 2. Experimental models 
3. Which treatments are effective 
for fatigue in people with MS? 
3. Proof-of-concept clinical 
trial strategies 
4. How can people with MS be best supported 
to self-manage their condition? 
4. Clinical outcome measures 
5. Does early treatment with aggressive 
disease modifying drugs improve the 
prognosis for people with MS? 
5. Symptom management and 
rehabilitation  
6. Is Vitamin D supplementation an effective 
disease modifying treatment for MS?  
7. Which treatments are effective to improve 
mobility for people with MS?  
8. Which treatments are effective to 
improve cognition in people with MS?  
9. Which treatments are effective for pain in 
people with MS?  
10. Is physiotherapy effective in reducing 
disability in people with MS?  
 
 
2.15  Aims and objectives of the thesis 
The overall aim of this thesis was to investigate the use of physiotherapy in the 
rehabilitation of people with progressive MS. 
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The objectives were: 
Objective 1: to systematically review the available evidence to assess the 
efficacy of physiotherapy in the rehabilitation of people with progressive MS. 
Objective 2: to investigate the views of people with progressive MS with regards 
to physiotherapy; more specifically access, use, perceived efficacy and 
preferred delivery of physiotherapy; and access and use of other MS specialists 
and clinical services.  
Objective 3: to conduct a feasibility trial of High Intensity Interval Training in 
people with progressive MS, to assess the effect that this has on both clinical 
and physiological outcomes, and compare this to traditional continuous 
moderate intensity training. 
To achieve these objectives three studies were undertaken 
Study 1: a systematic review of the available literature pertaining to 
physiotherapy and progressive MS. 
Study 2: a nationwide online survey of people with progressive MS exploring 
access, delivery and opinion of physiotherapy and access to other MS clinical 
services and the use of Complementary and Alternative Therapies. 
Study 3: a randomised controlled trial comparing high intensity interval training 
against continuous moderate intensity training in people with progressive MS. 
The rationale and research questions for each study are discussed in chapters 3, 
4, and 7. 
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Chapter 3 Physiotherapy rehabilitation for 
people with progressive Multiple Sclerosis: a 
systematic review. 
As was stated at the end of the last chapter there had not been a systematic 
review of the literature examining the evidence for using physiotherapy in the 
rehabilitation of people with progressive Multiple Sclerosis (MS). This chapter 
will present the need for such a systematic review. The methods, results and 
discussion of the results will then be presented. This review has been published 
(Campbell et al. 2015. Physiotherapy rehabilitation for people with progressive 
Multiple Sclerosis: a systematic review. Archives of Physical Medicine and 
Rehabilitation, 97, 141-151.e3. (Appendix 1)) and presented in Sections 3.1 to 
3.6. Since publication, there have been a number of new articles published 
assessing physiotherapy for people with progressive MS. The final section of this 
chapter will present the results from an updated search of the literature and 
discuss the impact of these newer articles on the conclusions drawn from the 
original systematic review. 
 
3.1 Abstract 
Objective: To assess the efficacy of physiotherapy interventions, including 
exercise therapy, for the rehabilitation of people with progressive Multiple 
Sclerosis. 
Data Sources: Five databases (Cochrane Library, Physiotherapy Evidence 
Database (PEDro), Web of Science Core Collections, Medline, EMBASE) and 
reference lists of relevant articles were searched.   
Study Selection: Randomised experimental trials which included participants 
with progressive multiple sclerosis and investigated a physiotherapy intervention 
or an intervention containing a physiotherapy element were included. 
Data Extraction: Data were independently extracted using a standardised form 
and methodological quality was assessed using the PEDro scale. 
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Data Synthesis: Thirteen studies (described by 15 articles) were identified; 
scoring between 5 and 9 out of 10 on the PEDro scale. Eight interventions were 
assessed: exercise therapy, multi-disciplinary rehabilitation, functional 
electrical stimulation, botulinum toxin type A injections and manual stretches, 
inspiratory muscle training, therapeutic standing, acupuncture and body weight 
supported treadmill training. All studies, apart from one, produced positive 
results in at least one outcome measure, however, only one article used a power 
calculation to determine their sample size and due to ‘drop outs’ the results 
were subsequently underpowered. 
Conclusions: This review suggests that physiotherapy may be effective for the 
rehabilitation of people with progressive Multiple Sclerosis. However, further 
appropriately powered studies are required. 
Keywords: Multiple Sclerosis, physical therapy modalities, exercise, 
rehabilitation, review  
 
3.2 Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory autoimmune demyelinating 
disease of the central nervous system resulting in grey matter and axonal loss 
(Compston and Coles, 2008, Noseworthy et al., 2000). Currently, there are an 
estimated 130,000 cases of MS in the UK with an incidence of 11.52 per 100,000 
women and 4.84 per 100,000 men (Mackenzie et al., 2014). Approximately 15% 
of all individuals with MS are diagnosed with Primary Progressive MS (PPMS) and 
80% of those diagnosed with Relapsing Remitting MS (RRMS) go on to develop 
Secondary Progressive MS (SPMS) (Compston and Coles, 2002). There is a strong 
evidence base for interventions for the treatment of people with RRMS but 
whilst studies are currently ongoing there are limited effective treatments for 
people with progressive MS (Fox et al., 2012). The Progressive MS Alliance have 
highlighted this area as a priority, especially for those with a higher level of 
disability (Fox et al., 2012).   
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There is a growing body of literature investigating the benefits of physiotherapy 
(a physical intervention that may be used by a physiotherapist, including 
physical activity and exercise interventions) in the rehabilitation of people with 
MS. In a series of review papers, exercise therapy and physical activity have 
been shown to be generally beneficial to those with MS who are not suffering a 
relapse (Dalgas et al., 2008, Latimer-Cheung et al., 2013, Rietberg et al., 2005), 
as well as having positive effects on fatigue (Andreasen et al., 2011, Pilutti et 
al., 2013), health related quality of life (Motl and Gosney, 2008) and muscle 
strength (Kjolhede et al., 2012) in those with a mild to moderate disability. 
Physiotherapy has also been shown to have a positive effect on balance and 
mobility (Hogan and Coote, 2009, Paltamaa et al., 2012, Toomey and Coote, 
2012). However, when the level of disability increases efficacy of physiotherapy 
is less compelling (Hogan and Coote, 2009, Toomey and Coote, 2012). Whilst 
some studies have considered their results in terms of disability levels, none 
have made a distinction between RRMS and progressive MS. To date, there has 
not been a published review examining the evidence for physiotherapy for the 
rehabilitation of people with progressive MS. Consequently, the aim of this 
systematic review is to assess the efficacy of physiotherapy rehabilitation for 
people with progressive MS. 
 
3.3 Methods  
In December 2014 a search was conducted of the following electronic databases: 
the Cochrane Library, Physiotherapy Evidence Database (PEDro), Web of Science 
Core Collections, Medline and Embase. No restrictions were placed on 
publication date and studies were limited to English language only.  Individual 
search strategies were made up of keywords and Medical Subject Headings 
(MeSH) headings (Table 3-1). Reference lists of relevant articles were also 
searched. 
To be included in the review, articles had to: be published in English, include 
solely participants with progressive forms of MS or where there was a 
combination of types of MS distinct results for the different types of MS were 
presented, evaluate a physiotherapy intervention(s) or an intervention 
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containing a physiotherapy element, have randomised participants, have a 
comparison group and use at least one objective outcome measure. Articles 
were excluded if they were non-human studies, conference abstracts or posters.  
Articles were initially screened by title and abstract. Full articles were then 
read. When there was ambiguity in meeting the inclusion criteria the authors 
were contacted for clarification.  
Quality assessment (external validity, internal validity and the reporting of 
statistics) was assessed using the PEDro scale which has been shown to be 
reliable and valid in rating methodological quality of studies (de Morton, 2009, 
Maher et al., 2003). The 11 point scale was given a score out of ten (no point 
was awarded for the initial item of stating inclusion and exclusion criteria) as 
per the guidelines.  Scoring was carried out by three reviewers (EC, LP and EHC). 
A pilot quality assessment was conducted to ensure consistency where all three 
reviewers read and independently scored one paper, following which, scoring 
was discussed and agreed. Each article was then scored independently by two 
reviewers and scores compared. When there was a discrepancy in score, 
differences were agreed via discussion which included the third reviewer.  
Quality assessment was entirely based on the content of the study in the 
published article. When two articles were from the same study but reported 
different outcome measures they were combined and considered as a single 
study. Data extraction was done independently using a standardised form into 
evidence tables. The following data were extracted: study design, sample size, 
drop-out rate, type of MS of participants, Expanded Disability Status Scale (EDSS) 
range (Kurtzke, 1983), intervention type, length, frequency, setting, time points 
of measurement, control intervention, outcome measures, baseline 
measurements and  main findings. 
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Table 3-1 Search strategies for electronic databases 
Database Search Strategy 
Cochrane 
library 
(Progressive near/2 ("multiple sclerosis" or MS)) AND ((MeSH 
descriptor: [Physical Therapy Modalities] explode all trees) 
OR(MeSH descriptor: [Rehabilitation] explode all trees) OR 
(MeSH descriptor: [Exercise] explode all trees) OR (MeSH 
descriptor: [Resistance Training] explode all trees) OR (MeSH 
descriptor: [Transcutaneous Electric Nerve Stimulation] explode 
all trees) OR (MeSH descriptor: [Electric Stimulation] explode all 
trees) OR(MeSH descriptor: [Acupuncture] explode all trees)) 
 
Web of 
Science Core 
Collections 
((progressive NEAR/2 (MS OR "Multiple Sclerosis")) AND 
((physiotherap* OR "physical therapy") OR (rehabilit*) OR 
(exercise OR training) OR ("electrical stimulation" OR FES OR 
NMES OR TENS OR "neuromuscular stimulation") OR 
(acupuncture)  
 
Embase via 
Ovid 
((progressive adj2 ("multiple sclerosis" or MS)).mp.) AND ((home 
physiotherapy OR physiotherapy) OR (prevention OR 
rehabilitation OR therapy OR rehabilit*.mp. OR rehabilitation 
center OR rehabilitation care OR breathing exercise OR muscle 
exercise OR arm exercise OR treadmill exercise OR aerobic 
exercise OR static exercise OR leg exercise OR isokinetic 
exercise OR closed kinetic chain exercise OR open kinetic chain 
exercise OR exercise.mp. OR exercise tolerance OR isometric 
exercise OR isotonic exercise OR aquatic exercise OR dynamic 
exercise OR stretching exercise OR anaerobic exercise OR 
exercise OR nerve stimulation OR electrostimulation therapy OR 
electroacupuncture OR functional electrical stimulation OR 
neuromuscular electrical stimulation OR transcutaneous nerve 
stimulation OR acupuncture OR acup.mp. electrostimulation OR 
functional electrical stimulation OR muscle OR gait) 
 
MEDLINE via 
OVID 
((progressive adj2 ("multiple sclerosis" or MS)).mp.) AND (exp 
Exercise Therapy  physiotherapy.mp. OR physical therapy.mp. 
OR rehabilitation OR "activities of daily living" OR exercise 
therapy OR motion therapy, continuous passive OR muscle 
stretching exercises OR plyometric exercise OR resistance 
training OR rehabilitation, vocational OR exp Exercise Therapy 
OR exp Plyometric Exercise OR exercise.mp. OR exp Exercise 
Movement Techniques OR exp Exercise OR Electric Stimulation 
OR electric stimulation therapy OR electroacupuncture OR 
spinal cord stimulation OR transcutaneous electric nerve 
stimulation OR Transcutaneous Electric Nerve Stimulation OR 
exp Acupuncture Therapy OR exp Acupuncture Analgesia OR exp 
Acupuncture OR acupuncture.mp.) 
 
Pedro “progressive AND multiple AND sclerosis” 
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3.4 Results 
3.4.1 Outcome of search 
From the electronic search 1027 articles were identified and four articles were 
identified from relevant article’s reference lists (Figure 3-1). Of these, 197 were 
duplicates leaving 834 unique publications for screening by title and abstract. 
After screening 783 articles were excluded. Full texts of 51 articles were read 
and 36 were excluded. From the remaining 15 articles; there were two instances 
of two papers that were from the same study but had used different outcome 
measures and so they were combined (Barrett et al., 2009, Esnouf et al., 2010, 
Patti et al., 2003, Patti et al., 2002). Thus 13 studies (published within 15 
articles) were included within this review (Figure 3-1). 
  
  
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 PRISMA diagram of identification and inclusion process 
Abbreviations: n: number; MS: multiple sclerosis 
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3.4.2 Quality assessment, study design and sample 
characteristics 
PEDro scores ranged from 5-9 out of 10 (Table 3-2). Lower scores were mainly 
due to lack of blinding of patients, therapists or assessors and not conducting 
analyses with intention to treat when appropriate. Only one article (Barrett et 
al., 2009) supplied a power calculation used to determine their sample size but 
due to ‘drop outs’ the results were subsequently underpowered. From the 
remaining studies, six highlighted their lack of power calculation (Baker et al., 
2007, Briken et al., 2014, Miller et al., 2011, Paoloni et al., 2013, Skjerbaek et 
al., 2014, Taylor et al., 2014) and four highlighted their small sample size 
(Donnellan and Shanley, 2008, Giovannelli et al., 2007, Klefbeck and Hamrah 
Nedjad, 2003, Lo and Triche, 2008) as methodological limitations; two studies 
did not mention either a power calculation or comment on their sample size 
(Freeman et al., 1997, Patti et al., 2003, Patti et al., 2002). 
From the studies included in the review there were nine randomised controlled 
trials (described in 11 articles) (Barrett et al., 2009, Briken et al., 2014, 
Donnellan and Shanley, 2008, Esnouf et al., 2010, Freeman et al., 1997, 
Giovannelli et al., 2007, Klefbeck and Hamrah Nedjad, 2003, Miller et al., 2011, 
Patti et al., 2003, Patti et al., 2002, Skjerbaek et al., 2014), two randomised 
trials (Paoloni et al., 2013, Taylor et al., 2014) and two randomised crossover 
trials (Baker et al., 2007, Lo and Triche, 2008). The length of intervention 
ranged from 15 days to 24 weeks and the frequency of intervention ranged from 
twice weekly to daily. Eight studies did not follow up participants after the 
intervention period (Baker et al., 2007, Barrett et al., 2009, Briken et al., 2014, 
Donnellan and Shanley, 2008, Esnouf et al., 2010, Freeman et al., 1997, Lo and 
Triche, 2008, Skjerbaek et al., 2014, Taylor et al., 2014, Patti et al., 2003, Patti 
et al., 2002) and four studies included a follow up assessment at 4 (Klefbeck and 
Hamrah Nedjad, 2003), 8 (Miller et al., 2011), 10 (Giovannelli et al., 2007) and 
18 weeks (Paoloni et al., 2013) after the intervention had ended (Table 3-3).  
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Table 3-2 PEDro scores for included studies 
Author C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 Total  
Freeman et al.  Y Y Y Y N N N Y N Y Y 6 
Patti et al.† Y Y Y Y N N Y Y Y Y Y 8 
Patti et al.† Y Y Y Y N N Y Y Y Y Y 8 
Klefbeck and Hamrah Nedjad Y Y N Y N N N Y N Y Y 5 
Baker et al. Y Y N N N N Y Y Y Y Y 6 
Giovanelli et al.‡ Y Y Y Y N N Y Y N Y Y 7 
Donnellan & Shanley Y Y Y Y Y N Y Y Y Y Y 9 
Lo & Triche Y Y N Y N N N Y Y Y Y 6 
Barrett et al.§ Y Y Y Y N N N N N Y Y 5 
Esnouf et al.§ Y Y Y Y N N Y N N Y Y 6 
Miller et al. Y Y Y Y N N Y Y Y Y Y 8 
Paoloni et al. Y Y Y Y N N Y Y Y Y Y 8 
Taylor et al. Y Y Y Y N N Y N N Y Y 6 
Briken et al. Y Y Y Y N N N Y Y Y Y 7 
Skjerbaek et al.  Y Y Y Y N N Y Y N Y Y 7 
C1: specification of inclusion criteria (no point awarded for this criterion); C2: randomisation of participants; C3: concealment of allocation; C4: groups similar at 
baseline; C5: blinding of subjects; C6: blinding of therapists; C7: blinding of assessors; C8: one key outcome measure taken for at least 85% of sample; C9: 
intention to treat analysis if appropriate; C10: between group statistical analysis; C11: point measures and measures of variability 
EC assessed all articles,(Baker et al., 2007, Barrett et al., 2009, Briken et al., 2014, Donnellan and Shanley, 2008, Esnouf et al., 2010, Freeman et al., 1997, 
Giovannelli et al., 2007, Klefbeck and Hamrah Nedjad, 2003, Lo and Triche, 2008, Miller et al., 2011, Paoloni et al., 2013, Patti et al., 2003, Patti et al., 2002, 
Skjerbaek et al., 2014, Taylor et al., 2014) LP assessed 8 articles(Baker et al., 2007, Barrett et al., 2009, Briken et al., 2014, Donnellan and Shanley, 2008, Esnouf 
et al., 2010, Freeman et al., 1997, Giovannelli et al., 2007, Lo and Triche, 2008) and EHC assessed 8 articles.(Giovannelli et al., 2007, Klefbeck and Hamrah 
Nedjad, 2003, Miller et al., 2011, Paoloni et al., 2013, Patti et al., 2003, Patti et al., 2002, Skjerbaek et al., 2014, Taylor et al., 2014) 
†Patti et al. 2002 and Patti et al. 2003 described the same study. 
‡All three reviewers rated this paper initially and discussed results to ensure consistency. 
§ Barrett et al. 2009 and Esnouf et al. 2010 described the same study.
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Table 3-3 Evidence table 
Author, 
date and 
design 
Sample size 
PPMS 
SPMS 
EDSS range 
Drop outs 
Intervention, duration, 
length of session, frequency 
Comparison/ 
control 
Time 
Points 
(weeks) 
Outcome measures* Main findings* 
Freeman 
et al.1997 
RCT 
n=66 
PPMS (n=6) 
SPMS (n=60) 
EDSS 5.0-9.5  
Drop out: 4 
(6%) 
6 weeks, MDT in-patient 
rehabilitation, 45 min, 
2/week (n=32) 
 
Wait list 
control (n=34) 
0, 6 Pri: EDSS, FIM, LHS Between group:  
FIM (p<0.001), LHS (p<0.01) 
Patti et al. 
2002 
RCT 
n= 111 
PPMS (n=23) 
SPMS (n=88) 
EDSS 4-8 
Drop out: 13 
(12%) 
12 weeks: 6 week MDT out-
patient rehabilitation, 50-
60 min, 6/week, followed 
by 6 week HEP, 60 min, 
5/week (n=58) 
 
HEP for 12 
weeks  (n=33) 
0, 6, 12 Pri: EDSS, SF-36  
Sec: BDI, SET, FIS 
Between group:  
SF-36: RE subscale (p<0.005) all 
other subscales (p<0.001), 
BDI(p<0.001), SET (p<0.001), FIS 
(p<0.001) 
Patti et al. 
2003 
RCT 
As above As above 
 
As above 
 
As 
above 
Pri: FIM  
Sec: EDSS 
Between group: 
FIM (p<0.001) 
 
Klefbeck 
and 
Hamrah 
Nedjad 
2003 
RCT 
n=15 
progressive 
MS 
EDSS 6.5-9.5  
Drop out: 1 
(7%) 
10 weeks: Inspiratory 
muscle trainer, 3 sets of 10 
repetitions, twice every 
second day (n=7) 
 
Normal 
treatment 
which had deep 
breath 
exercises, 
regular phone 
calls (n=8) 
0, 10, 
14 
Pri: VC, FVC, FVC%, 
FEV FEV%, Max insp 
pressure, Max exp 
pressure, FSS, Borg 
scale 
Between group: 
Max insp pressure (p<0.01) 
Within group: 
I: max exp pressure (p<0.02) 
Baker et 
al. 2007 
Randomise
d 
n= 6 
progressive 
MS 
EDSS > 7  
3 weeks: Standing frame,30 
min/day (n=3) 
 
I+C swapped after 3 weeks 
HEP of 
abdominal 
crunches, 
bridging, pelvic 
0, 3, 6 Pri: Ashworth Scale, 
Spasm frequency, 
Resting ROM in 
supine 
Between group: 
Resting ROM in supine: L ankle 
(p=0.020), R ankle (p=0.026), L hip 
(p=0.039), R hip (p=0.020) 
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crossover 
design 
Drop out: 0 
(0%)  
(no washout period) and lumbar 
rolls, 5 
repetitions of 8 
exercises (n=3) 
Within group: 
I: Ashworth scale, R ankle (p=0.08), L 
ankle (p=0.08) 
C: spasm frequency, R leg (p=0.06) 
Giovanelli 
et al. 2007 
RCT 
n=38  
All SPMS 
EDSS 3-7.5  
Drop out: 2 
(5%) 
15 days: I: BTX-A injection 
in either upper limb (FDS, 
FCU, FCR) or lower limb 
(tibialis posterior, 
gastrocnemius, soleus) 
followed by 40min/day of 
passive movements to 
prevent muscle 
contractures (n=20) 
BTX-A injection 
only (n=28) 
0, 2, 4, 
12 
Pri: MAS, VAS of 
relief from 
spasticity in 
injected muscle 
Between group: 
MAS (p<0.01), VAS (p<0.01) 
 
Donnellan 
& Shanley 
2008 
RCT 
n=14  
All SPMS 
EDSS 1.5-7.0  
Drop out: 1 
(7%)  
5 weeks: Chinese medical 
acupuncture, 2/week (n=7) 
 
Minimal 
acupuncture† , 
5 weeks, twice 
a week (n=7) 
0, 5 Pri: MSIS-29 phys, 
MSIS-29 psych  
Sec: FSS, GHQ-12 
Between group (C vs I):  
MSIS-29 psych sub-score I (p=0.04) 
 
Lo & 
Triche 
2008 
Randomise
d 
crossover 
design 
n=13  
PPMS (n=5) 
SPMS (n=8) 
EDSS 4.9 SD 
1.2  
Drop out: 0 
(0%) 
12 weeks: BWSTT, 3 weeks, 
2/week, 40 min, followed 
by 6 week washout then 
BWSTT and robot orthotics 
a/a (n=6) ‡  
 
Same as I but 
BWSTT and 
robot orthotics 
first (n=7) 
0, 3, 9, 
12 
 
Pri: EDSS, Timed 25 
foot walk, 6 min 
walk, DST  
Sec: step length 
ratio  
Between group: 
DST: (p=0.06) 
Within group: 
Whole sample: timed 25 foot walk 
(p=0.0002), 6 min walk (p=0.002), 
DST (p=0.0007) and EDSS (p=0.001) 
Barrett et 
al. 2009 
RCT 
n=53 
All SPMS 
EDSS 4-6.5 
Drop out: 7 
(13%)  
18 weeks, Peroneal  FES, 
worn in daily life (n=20) 
 
30 min HEP of 
trunk and 
pelvic stability, 
lower limb 
strength, 
balance, 18 
weeks, 1-2/ 
day, (n=24) 
0, 6, 12, 
18 
Pri: 10 m walk 
speed 
Sec: 3min walk 
distance 
 
 
 
Within group: 
I with FES vs I without: 10 m walk 
speed (p=0.001), 3 min walk distance 
(p=0.004)  
C: 10 m walk speed (p=0.001) 
C: 3 min walk distance (p=0.005) 
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Esnouf et 
al.2010 
RCT 
n= 64 
All SPMS 
EDSS 4-6.5  
Drop out: 11 
(17%) 
As above (n=32) As above (n=32) 0, 18 Pri: COPM 
performance and 
satisfaction scores, 
Number of falls  
Between group: 
COPM performance (p=0.0038), 
satisfaction (p=0.007) 
Falls (p=0.036) 
Miller et 
al. 2011 
RCT 
n= 30  
PPMS (n=11) 
SPMS (n=19) 
EDSS 6.5-8  
Drop out: 2 
(7%) 
8 weeks, Domiciliary 
physiotherapy, 60 min, 
2/week (n=15) 
 
Wait list 
control (n=15) 
0, 8, 16 Pri: MSIS-29 
Sec: EDSS, FIM, 
MSQoL, MS-RS, BPI, 
HADA, HADD, 
Dynamometry, 10 m 
walk, timed sit to 
stand 
Between group: 
R knee extensor strength(p=0.018), L 
knee flexor strength (p=0.006), R 
knee flexor strength (p=0.001), HADA 
(p=0.014) 
Paolini et 
al. 2013 
RT (3 
armed 
trial) 
n= 42 
All SPMS  
EDSS 2-6  
Drop out: 0 
(0%) 
4 weeks: 3/week 
G1:  60 min passive 
movements to prevent 
contractures + 30 min SMV 
(n=14) 
G2: BTX-A injection 2 
weeks before study then 
same as G1 (n=14)  
G3: BTX-A injection 2 
weeks before study and 60 
min passive movements 
same as G1 (n=14) § 
- 0, 10, 
22 
Pri: MAS, FSS, 
Barthel index 
Within group: 
G1: Knee MAS (p<0.001), ankle MAS 
(p<0.001), FSS (p=0.004) 
G2: Knee MAS (p<0.001), ankle MAS 
(p<0.001), FSS (p=0.05) 
G3: Knee MAS (p<0.001), ankle MAS 
(p<0.001), Both knee and ankle MAS 
higher at 22 weeks than 10 weeks 
(p<0.05), FSS (p=0.02), Barthel index 
(p=0.004) 
 
Taylor et 
al. 2013 
RT 
n= 25 
All SPMS  
EDSS 4-6.5 
Drop out: 5 
(20%) 
24 weeks: Weeks 1-6: 
peroneal FES worn in daily 
life,  
Weeks 7-12: addition of 
gluteal FES  
weeks 13-18: eight sessions 
of core stability 
physiotherapy and HEP of 
core stability exercises, 
Same as I but 
with 
physiotherapy 
and HEP first 
followed by FES 
(n=14) 
-4, 0, 6, 
12, 18, 
24 
Pri: ROGA, 10 m 
walk speed, MSIS-
29, Falls frequency  
Between group: 
ROGA: Without FES week 24 
(p=0.044), with FES week 18 
(p=0.028) 
Within group: 
I: MSIS-29 psych week 18 (p<0.05), 
MSIS-29 phys week 24 (p<0.05), 10 m 
walk speed with peroneal FES 
(p=0.06) and gluteal FES (p=0.06), 
  
 
45 
 
weeks 19-24 continue with 
HEP, FES wear continued 
for second 12 weeks (n=11) 
falls frequency (p<0.05) 
C: 10 m walk speed with FES vs no 
FES (p<0.05), MSIS-29 phys week 24 
(p<0.05), falls frequency (p<0.05) 
 
Briken et 
al. 2014 
RCT (4 
armed 
trial) 
n= 47  
PPMS (n=11) 
SPMS (n=31) 
|| 
EDSS 4-6  
Drop out: 5 
(11%) 
10 weeks, 15-45 min (mean 
Borg 4.6), 2-3/week 
Three groups: Arm 
ergometry (n=12), Rowing 
(n=12) and Cycling (n=12) § 
 
 
Wait list 
control n=11 
0, 10 
 
Pri: VO2 peak, 6 Min 
walk, VLMT, IDS, FIS 
Between group (all vs C): 
Cycle group: VO2 peak (p=0.003), 6 
Min walk test (p=0.005), VLMT 
(p=0.009), depression (p=0.035). 
Arm group: 6 Min walk test 
(p=0.003), VLMT (p=0.007), fatigue 
(p=0.013), IDS (p=0.001). 
Rowing group: VLMT (p=0.001) 
 
Skjerbaek 
et al. 2014 
RCT 
n=11 
PPMS (n=3) 
SPMS (n=8) 
EDSS 6.5-8.0  
Drop out: 1 
(9%) 
4 weeks: 10 sessions, 
Endurance training: 
predominantly UL exercises 
(6 x 3 min at target work 
rate 65-75% VO2max with 30 
– 60 sec sprints each 
interval) and standard in-
patient rehabilitation (n=6) 
Standard in-
patient 
rehabilitation 
(n=5) 
0, 4 Pri: VO2 peak, MDI, 
MSIS-29, 9HPT, 
HGT, BBT, 6minWCT 
Between group: 
VO2 peak (p=0.06) 
 
Abbreviations: 6minWCT: 6 minute wheelchair test, 9HPGT: 9 hole peg test, BBT: box and block test, BDI: beck depression inventory, Borg: the borg scale of 
perceived exertion, BPI: brief pain inventory, C: control group, COPM: Canadian occupational performance measure, DST: double-limb support time,  
FCR: flexor carpi radialis, FCU: flexor carpi ulnaris, FDS: flexor digitorum superficialis, FEV: Forced expiratory volume, FEV%:  forced expiratory volume in 
percentage of FVC, FIM: functional independence measure, FIS: fatigue impact scale, FSS: fatigue severity scale, FVC: forced vital capacity, FVC%: forced vital 
capacity percentage predicted, GHQ-12: general health questionnaire 12, HADA: hospital anxiety and depression scale anxiety sub-scale, HADD: hospital anxiety 
and depression scale depression sub-scale, HEP: home exercise plan, HGT: hand grip test, HRmax: heart rate max, I: intervention group, IDS: inventory of 
depressive symptoms, L: left, LHS: London handicap scale, m: metre, MAS: modified ashworth scale, max exp: maximal expiratory, max insp: maximal inspiratory, 
MDI: major depression inventory, MDT: multi-disciplinary team, min: minutes, MSIS-29: multiple sclerosis impact scale, MSIS-29 phys: multiple sclerosis impact 
scale physical subscale, MSIS-29 psych: multiple sclerosis impact scale psychological subscale, MSQoL: Leeds multiple sclerosis quality of life scale, n: sample size, 
Pri: primary outcome measures, R: right, RCT: randomised controlled trial, RE: role functioning emotional sub-scale, ROGA: Rivermead observational gait analysis, 
ROM: range of motion, RT: randomised trial, Sec: secondary outcome measures, SET: Tempelaar social experience checklist, SF-36: short form 36 health survey, 
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SMV: segmental muscle vibration, UL: upper limb, VAS: visual analogue scale, VC: vital capacity, VLMT: verbal learning memory test, VO2 peak: peak oxygen 
uptake. 
*Baseline values of all outcome measures and final values/magnitude of changes can be found in table 3-4. 
† Minimal acupuncture: a form of sham acupuncture where needles are inserted to a shallower depth and not at true acupuncture points (MacPherson et al., 2002).   
‡ Groups did not return to baseline after 6 week washout period so analysis conducted after end of first trial.   
§ Intervention group referred to as “I” throughout apart from studies by Paolini et al. and Briken et al where the three experimental arms are referred to as “G1”, 
“G2” and “G3” and “Arm ergometry”, “Rowing” and “Cycling” respectively. 
|| Characteristic data of drop outs not supplied. 
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Six studies investigated physiotherapy as part of a multi-dimensional 
intervention (Freeman et al., 1997, Giovannelli et al., 2007, Paoloni et al., 2013, 
Patti et al., 2003, Patti et al., 2002, Skjerbaek et al., 2014, Taylor et al., 2014) 
and seven studies investigated the use of only a physiotherapy intervention 
(Baker et al., 2007, Barrett et al., 2009, Briken et al., 2014, Donnellan and 
Shanley, 2008, Esnouf et al., 2010, Klefbeck and Hamrah Nedjad, 2003, Lo and 
Triche, 2008, Miller et al., 2011). Study sample sizes ranged from 6-111 
participants, EDSS scores ranged from 1.5-9.5. Eight studies included 
participants with both SPMS and PPMS (Baker et al., 2007, Briken et al., 2014, 
Freeman et al., 1997, Klefbeck and Hamrah Nedjad, 2003, Lo and Triche, 2008, 
Patti et al., 2003, Patti et al., 2002, Skjerbaek et al., 2014) and five studies 
included only participants with SPMS (Barrett et al., 2009, Donnellan and 
Shanley, 2008, Giovannelli et al., 2007, Paoloni et al., 2013, Taylor et al., 2014). 
There were no studies that included only participants with PPMS (Table 3-3). 
There were 45 outcome measures used across the 15 articles with few instances 
of commonality despite often measuring the same symptom or functional status. 
Baseline measurements of all outcome measures and final values or change 
values for the main findings of each study can be found in Table 3-4. 
  
 
 
48 
 
Table 3-4 Primary and secondary outcome measures with baseline values and main findings from each trial   
Author, date and design Outcome measures and baseline values  Main findings [Intervention, Control]  
 
Freeman et al. 1997 
RCT 
Pri: EDSS*: I: 6.5(5.0-9.0), C: 6.5(6.0-8.5) 
FIM*:  I: 67(13-87), C:  69.5(18-84) 
LHS†: I:  61.5(13), C:  66.2(8.74) 
Between group (Change values): 
FIM*: motor domain: 4.0(-10,19), 2.5(-16,5) (p<0.001), Self-care 
domain: 1.5(-5,9), -1.0(-9,3) (p<0.0001) 
LHS†: 2.9 (8.9), -2.7 (8.6)(p<0.01) 
 
Patti et al. 
2002 
RCT 
Pri: EDSS†: I: 6.2(1.2), C: 6.1(1.2)  
SF-36 subscales:  
RE†: I: 56.1(40.4), C: 42.1(43.4),  
PF†: I: 39.3(23.0), C: 31.2(23.1),  
RP†: I: 36.9(36.2), C: 26.4(36.8),  
BP†: I: 58.2(26.0), C: 65.4(27.1),  
GH†: I: 49.9(21.1), C: 45.0(20.6),  
VT†: I: 47.8(17.5), C: 42.7(18.4),  
SF†: I: 59.8(21.5), C: 57.6(27.1),  
MH†: I: 54.2 (22.8), C: 53.4 (23.7) 
Sec: BDI†: I: 11.0(7.5), C: 12.5(7.6) 
SET†: I: 28.9(6.0), C: 29.3(5.9) 
FIS†: I: 116.8(40.9), C: 127.0(36.0) 
 
Between group (Change values): 
SF-36 subscales:  
RE†: 6.2(23.7), -0.1(0.3) (p<0.005),  
PF†: 6.91(18.1), -0.1(0.3) (p<0.001),  
RP†: 14(24.3), -0.2(0.5) (p<0.001),  
BP†: 14.9(20.0), -0.1(0.6) (p<0.001),  
GH†: 5.8(10.5), -0.2(0.5) (p<0.001), 
VT†: 7.4(12.5), -0.1(0.5) (p<0.001),  
SF†: 11.5(14.6), -0.1(0.3) (p<0.001), 
MH†: 7.7(15.8), -0.1(0.5) (p<0.001) 
BDI†: -2.2(3.4), 0.1(1.0) (p<0.001), 
SET†: -2.6(6.0), -0.3(0.8)(p<0.001),  
FIS†: -18.8(14.3), 0.6(0.9) (p<0.001) 
Patti et al. 
2003 
RCT 
 
Pri: FIM†: I: 92.9(11.0), C: 93.7(16.4)  
Sec: EDSS†: I: 6.2(1.2), C: 6.1(1.2) 
Between group (Change values): 
FIM†: 10.2(11.8): 0.0(0.7) (p<0.001) 
 
Klefbeck and Hamrah 
Nedjad 2003 
RCT 
Pri: VC (L)*: I: 2.4(0.5-3.4), C: 2.1(0.5-6.2) 
FVC (L)*: I: 2.7(1.0-3,4), C: 2.6(1.3-6.7) 
FVC%*: I: 78(36-93), C: 69(38-127) 
FEV (L)*: I: 2.2(1.0-3.3), C: 2.3(1.3-5.0) 
FEV%*: I: 83(82-100), C: 88(81-100) 
Max insp pressure (cmH20)*: I: 42(28-74), C: 
52(15-120) 
Between group (Final values): 
Max insp pressure*: 67(55-100),C: 54(10-126) (p<0.01) 
Within group (Final values): 
I: max exp pressure*: 63(44-80) (p<0.02) 
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Max exp pressure (cmH20)*: I: 46(36-58), C: 
51(20-147) 
FSS*: I: 4.2(2.8-6.0), C: 5.1(2.0-6.7) 
Borg scale*: I: 14(9-17), C: 14(10-17) 
 
Baker et al. 
2007 
Randomised crossover 
design 
Pri: Ashworth Scale*: whole sample: R hip flex: 
1.5(1-3), L hip flex: 2.0(1-2), R hip abd: 1.0(1-
3), L hip abd: 2.0(1-2), R knee: 1.5(2-3), L knee: 
2.0(2-3), R ankle: 2.0(2-3),  
L ankle: 2.0(2-3)  
Spasm frequency*: whole sample: R: I: 2.0(0-4), 
L: I: 2.0(0-4) 
Resting ROM in supine*: whole sample: R ankle: 
10(10-12), L ankle: 13.5(10-15), R knee: 2.5(0-
5), L knee: 2.0(0-2), R hip: 10(0-10), L hip: 20(5-
20) 
Between group (Final values): 
Resting ROM in supine*:  
R ankle: 5.0(-5-7), 10(7-12) (p=0.020),  
L ankle: 2.5(0-7), 10(10-15) (p=0.026),  
R hip: 0.0(0-5), 10(5-15) (p=0.020),  
L hip: 5.0(0-10), 10(5-10) (p=0.039) 
Within group (Final values): 
I: Ashworth scale*:  
R ankle: 2.0(1-3) (p=0.08),  
L ankle: 1.5(1-3) (p=0.08) 
C: spasm frequency R leg*:  
1.0(0-4) (p=0.06) 
 
Giovanelli et al. 2007 
RCT 
Pri: MAS†: I: 3.63(0.49), C: 3.61(0.50) 
VAS of relief from spasticity in injected muscle, 
week 2: I: 5.18 (1.10), C: 5.50(1.38) 
Between group (Change values): 
MAS†: -0.95(0.78), -0.28(0.46) (p<0.01)  
VAS of relief from spasticity in injected muscle†: 2.68(1.08), 
1.06(1.16) (p<0.01) 
 
Donnellan & Shanley 2008 
RCT 
Pri: MSIS-29 phys†: I: 55.2(23.6), C: 57.7(23.8)  
MSIS-29 psych†: I: 34.3(23.7), C: 48.4(30.0) 
Sec: FSS†: I: 4.6(2.4), C: 2.8(1.9) 
GHQ-12†: I: 15.8(9.9), C: 17.7(9.5) 
 
Between group (Change values, C vs I): 
MSIS-29 psych†: 23(21.0), 6.0(13.9) (p=0.04) 
 
Lo & Triche 2008 
Randomised crossover 
design 
Pri: EDSS†: whole sample: 4.9(1.2)  
25 foot walk (s)†: whole sample: 9.9(4.2) 
6 min walk (m)†: whole sample: 220.3(96.5) 
DST(%): whole sample: 33.2(8.0) 
Sec: step length ratio†: whole sample: 0.9(0.1) 
Between group (Change values): 
DST†: -7.1(3.9), -1.7(3.9) (p=0.06) 
Within group (Change values): 
25 foot walk†: 3.1(2.4) (p=0.0002)  
6 min walk†: 83.4(78.0) (p=0.002)  
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DST†: -5.5(4.1) (p=0.0007)  
EDSS†: -1.0(0.7) (p=0.001) 
 
Barrett et al. 2009 
RCT 
Pri: 10 m walk (ms-1)†: I: 0.79(0.35), C: 
0.68(0.28) 
Sec: 3 min walk (m)†: I: 99(44), C: 97(44) 
 
 
Within group (Final values): 
I with FES vs I without:  
10 m walk†: 0.80(0.35) (p=0.001) 
3 min walk†: 125 (55) (p=0.004)  
C: 10 m walk†: 0.77(0.29) (p=0.001) 
C: 3 min walk†: 113 (46)  (p=0.005) 
 
Esnouf et al. 
2010 
RCT 
Pri: COPM performance*: I: 3.5(1.75-5.0), C: 
3.4(2.2-5.6) 
COPM satisfaction*: I: 2.2(1.0-5.0), C: 2.6(1.0-
4.6) 
Number of falls: n/a 
 
Between group (Change values): 
COPM performance*: 1.1(0.1-2.0), 0.0(0.0-0.9) (p=0.0038)  
COPM satisfaction*: 1.7(0.3-2.7), 0.0(0.0-1.0) (p=0.007) 
Number of falls (final values)*: 5, 18 (p=0.036) 
Miller et al. 
2011 
RCT 
Pri: MSIS-29†: I: 89.9(22.8), C: 82.8(17.3) 
Sec: EDSS†: I: 7(0.5), C: 7.1(8.1) 
FIM†: I: 68.9(12.9), C: 72.2(14.2) 
MSQoL†: I: 11.9(5.3), C: 8.3(5.3) 
MS-RS†: I: 32.7(13.9), C: 27.9(9.4) 
BPI†: I: 26.7(27.7), C: 25.6(17.7) 
HADA†: I: 6.0(5.7), C: 3.1(2.1) 
HADD†: I: 5.8(3.3), C: 6.3(3.6) 
Dynamometry (kg)†: R knee ext: I: 10.0(5.9), C: 
9.3(6.0), R knee flex: I: 9.7(5.1), C: 5.5(4.3), L 
knee ext: I: 7.2(5.1), C: 8.4(6.7), L knee flex: I: 
7.7(6.0), C: 7.5(6.8) 
10 m walk (s): I: 41.2(32.9), C: 43.4(27.7) 
timed sit to stand (s): I: 6.2(2.3), C: 5.8(3.4) 
 
Between group (Change values): 
R knee ext strength†: 11.1(6.1), 8.4(6.7) (p=0.018)  
L knee flexor strength†: 6.9(5.3), 5.0(5.6) (p=0.006)  
R knee flexor strength†: 8.7(5.7), 4.8(4.2) (p=0.001) 
HADA†: 6.2(5.0), 3.8(4.0) (p=0.014) 
Paolini et al. 
2013 
Pri: Knee MAS ‡: G1: 3(3-4), G2: 4(3-4), G3: 4(3-
4)  
Within group (Final values): 
G1: Knee MAS‡: 3(2-3) (p<0.001)  
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RT (3 armed trial) Ankle MAS‡: G1: 4(3-4), G2: 4(4-4), G3: 4(4-4) 
FSS§: G1: 53.6(2.31), G2: 43.4(3.10), G3: 
48.5(2.77) 
Barthel index§: G1: 79.8(1.63), G2: 76.4(2.95), 
G3: 77.5(1.50) 
Ankle MAS‡: 3(2-3) (p<0.001)  
FSS§: 46.7(2.75) (p=0.004) 
G2: Knee MAS‡:  3(2-3) (p<0.001)  
Ankle MAS‡:3(3-4) (p<0.001)  
FSS§: 39.7(2.97) (p=0.05) 
G3: Knee MAS‡: 3(2-4) (p<0.001)  
Ankle MAS‡: 4(3-4) (p<0.001)  
Knee and ankle MAS higher at 22 weeks than 10 weeks: week 10 
values: Knee MAS: 3(2-3) (p<0.05), Ankle MAS: 3(3-4) (p<0.05) 
FSS§: 42.5(2.17)(p=0.02)  
Barthel index§:  77.8(1.47)  (p=0.004) 
 
Taylor et al. 
2013 
RT 
Pri: ROGA without FES‡: I: 13.0(8.5-21), C: 
15(11.5-17.5) 
10 m walk (ms-1)‡: I: 0.72(047-1.31), C: 
0.82(0.51-1.01)  
MSIS-29 phys‡: I: 48.8(30.6-55.0), C: 46.3(16.3-
56.3) 
MSIS-29 psych‡: I: 38.8(23.6-54.2), C: 27.2(11.1-
50.0) 
Falls frequency‡: I: 23.3(8.3-67.1), C: 9.75(1.1-
50.0) 
Between group (Final values): 
ROGA‡: Without FES week 24: 11(6-14.3), 17(14.5-20) (p=0.044), with 
FES week 18: 10(5.3-13), 12(10-16) (p=0.028) 
Within group (Final values): 
I: MSIS-29 phys‡: 26.3(16.2-38.1) (p<0.05), MSIS-29 psych‡: week 18: 
19.4(9.7-27.3) (p<0.05)  
10 m walk‡: with peroneal FES: 1.2(0.72-1.27) (p=0.06), with 
peroneal and gluteal FES‡: 1.04(0.76-1.27)(p=0.06) 
Falls frequency‡: 4(3.-7.75) (p<0.05) 
C: 10 m walk with peroneal and gluteal FES vs no FES‡: 0.89(0.64-
1.09) (p<0.05),  
MSIS-29 phys‡: 35.0(21.3-51.3) (p<0.05)  
Falls frequency‡: 0.5(0.0-3.075) (p<0.05) 
 
Briken et al. 
2014 
RCT (4 armed trial) 
Pri:VO2 peak (ml O2.min
-1)†:  
Cycling: 1490.18(528.20), Arm ergometry: 
1352.30(431.26), Rowing: 1306.00(421.79), C: 
1377.40(325.19) 
Sec: 6 Min walk (m)†:  
Cycling: 288.65(99.3), Arm ergometry: 
296.79(123.79), Rowing: 306.61(103.69),  
Between group (Final values): 
Cycling vs C:  
VO2 peak†: 1253.70(297.33) (p=0.003)  
6 Min walk†: 344.97(118.30), 319.49(109.49) (p=0.005),  
VLMT†: 62. (7.18), 51.50(8.20)  (p=0.009) 
IDS: 14.73 (9.49), 18.40(10.36)  (p=0.035) 
Arm ergometry vs C: 
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C: 325.92(117.35) 
VLMT†: Cycling: 52.18(6.03), Arm ergometry: 
46.80(10.22),  Rowing: 51.09(10.42), C: 
47.50(5.91) 
IDS†: Cycling: 18.36(12.27), Arm ergometry: 
21.10(10.24), Rowing: 13.91(7.82), C: 14.10 
(7.94),  
FIS†: Cycling: 35.00(18.07), Arm ergometry: 
45.00(14.73), Rowing: 35.27(13.86), C: 
38.00(15.15) 
 
6 Min walk†: 360.03(154.64), 319.49 (109.49) (p=0.003)  
VLMT†: 58.10(8.48), 51.50(8.20) (p=0.007), 
FIS†: 31.80(11.09), 39.30(17.49)  (p=0.013),  
IDS†: 12.30(6.57), 18.40(10.36) (p=0.001). 
Rowing vs C:  
VLMT†:  63.09(9.94), 51.50(8.20) (p=0.001)  
Skjerbaek et al. 2014 
RCT 
Pri: VO2 peak (ml O2.min
-1)†: I: 642(209), C: 
872(386)  
MDI†: I: 10.6(1.7), C: 14.6(7.3) 
MSIS-29†: I: 86(11.9), C: 76(20.5) 
9HPGT (s)†: I: 36.8(13.6), C: 66.9(61.7) 
HGT (N)†: I: 20.3(8.7), C: 19.9(10.3) 
BBT (blocks.min-1)†: I: 23.6(8.5), C: 27.0(8.4) 
6minWCT (m)†: I: 205(136), C: 313(71) 
Between group (Change values): 
VO2 peak†: 308(312), 2(29) (p=0.06) 
 
Abbreviations: 6minWCT: 6 minute wheelchair test, 9HPGT: 9 hole peg test, abd: abduction, BBT: box and block test, BDI: beck depression inventory, Borg: Borg 
rating of perceived exertion, BP: bodily pain, BPI: brief pain inventory, C: control group, COPM: Canadian occupational performance measure, DST: double-limb 
support time, ext: extensor, FEV: Forced expiratory volume, FEV%:  forced expiratory volume in percentage of FVC, FIM: functional independence measure, FIS: 
fatigue impact scale, flex: flexion, FSS: fatigue severity scale, FVC: forced vital capacity, FVC%: forced vital capacity percentage predicted, GH: general health, 
GHQ-12: general health questionnaire 12, HADA: hospital anxiety and depression scale anxiety sub-scale, HADD: hospital anxiety and depression scale depression 
sub-scale, HGT: hand grip test, I: intervention group, IDS: inventory of depressive symptoms, L: left, LHS: London handicap scale, m: metres, MAS: modified 
ashworth scale, max exp: maximal expiratory, max insp: maximal inspiratory, MDI: major depression inventory, MH: mental health, min: minutes, MSIS-29: multiple 
sclerosis impact scale, MSIS-29 phys: multiple sclerosis impact scale physical subscale, MSIS-29 psych: multiple sclerosis impact scale psychological subscale, 
MSQoL: Leeds multiple sclerosis quality of life scale, PF: physical functioning, Pri: primary outcome measure, R: right, RCT: randomised controlled trial, RE: role 
functioning emotional, ROGA: Rivermead observational gait analysis, ROM: range of motion, RP: role physical, RT: randomised trial, s: seconds, Sec: secondary 
outcome measures, SET: Tempelaar social experience checklist, SF: social functioning, SF-36: short form 36 health survey, VAS: visual analogue scale, VC: vital 
capacity, VLMT: verbal learning memory test, VO2 peak: peak oxygen uptake, VT: vitality. 
*Values are median(range). 
†Values are mean(SD). 
‡Values are median(interquartile range). 
§Values are mean(SE). 
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3.4.3 Interventions 
There were four instances when the same type of intervention was 
implemented: physiotherapy as part of a multi-disciplinary rehabilitation 
intervention was investigated by two studies (Freeman et al., 1997, Patti et al., 
2003, Patti et al., 2002), Functional Electrical Stimulation (FES) was investigated 
by two studies (Barrett et al., 2009, Esnouf et al., 2010, Taylor et al., 2014), 
exercise therapy was investigated by three studies (Briken et al., 2014, Miller et 
al., 2011, Skjerbaek et al., 2014), and a combination of botulinum toxin type A 
(BTX-A) injections and manual stretches was investigated by two studies 
(Giovannelli et al., 2007, Paoloni et al., 2013). The following interventions were 
investigated by one study each: acupuncture (Donnellan and Shanley, 2008); 
inspiratory muscle training (Klefbeck and Hamrah Nedjad, 2003); Body Weight 
Supported Treadmill Training (BWSTT) and robotic orthotics (Lo and Triche, 
2008) and therapeutic standing using a standing frame (Baker et al., 2007). 
 
3.4.4 Physiotherapy as part of a multi-disciplinary rehabilitation 
programme 
The evidence is positive regarding the efficacy of a six week multi-disciplinary 
rehabilitation programme for the rehabilitation of people with progressive MS. 
The two studies (described in three articles) which used multi-disciplinary 
rehabilitation programmes found improvements in disability when measured 
using the Functional Independence Measure, however the EDSS level remained 
unchanged (Freeman et al., 1997, Patti et al., 2003, Patti et al., 2002). 
Improvements were also found in depression, social experience, quality of life 
and fatigue and these were maintained at six weeks post intervention (Patti et 
al., 2003, Patti et al., 2002) (Table 3-3). The multi-disciplinary rehabilitation 
programmes differed both in delivery setting and the control group 
interventions, however both had positive effects.  
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3.4.5 Functional Electrical Stimulation 
The evidence is conflicting regarding the efficacy of using FES as an intervention 
for the rehabilitation of people with progressive MS. The two studies which used 
FES (described in three articles) found positive results for an orthotic effect and 
decrease in falls with FES in comparison to a home exercise plan aimed at 
improving core stability (Barrett et al., 2009, Esnouf et al., 2010, Taylor et al., 
2014). However, Taylor et al. (2014) found their FES intervention produced a 
therapeutic effect in gait quality, while Barret et al. (2009) found only their 
home exercise plan produced a therapeutic effect on walking speed and 
endurance. These conflicting results may be due to differences in duration of 
the interventions, the control group interventions and the use of gluteal 
stimulation in addition to peroneal FES by Taylor et al (Table 3-3). 
 
3.4.6 Exercise therapy 
The evidence is inconclusive regarding the efficacy of using exercise therapy for 
the rehabilitation of people with progressive MS. Two of the three studies which 
used exercise therapy investigated endurance training in a clinical environment 
(Briken et al., 2014, Skjerbaek et al., 2014) and the third investigated resistance 
training and functional exercises in a home environment (Miller et al., 2011). 
The two endurance studies measured fitness and found improvements but only 
Briken et al. reported a significant improvement (Briken et al., 2014, Skjerbaek 
et al., 2014). Briken et al. (2014) also reported significant improvements in 
mobility, depression, fatigue and cognitive function and Miller et al. reported 
significant improvements in muscle strength and anxiety. There was no 
significant improvement in any of the other outcomes of these studies (Table 3-
3). Differences in results between these studies may be due to differences in 
inclusion criteria and the intervention protocol. Skjerbaek et al. (2014) and 
Miller et al. (2011) included participants with a higher level of disability (EDSS 
6.5-8.0) while Briken et al. (2014) included participants with a moderate 
disability (EDSS 4.0-6.0). Skjerbaek et al. (2014) and Briken et al. (2014) 
conducted their final assessments at four and six weeks respectively without a 
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follow up assessment while Miller et al. did a follow up assessment eight weeks 
after their eight week intervention (Table 3-3).  
 
3.4.7 Botulinum toxin type A injections and manual stretches  
The evidence in this review is positive regarding the efficacy of using a 
combination of BTX-A injections and manual stretches for the rehabilitation of 
people with progressive MS. However, it is unclear which combination is the 
most effective. The two studies which used BTX-A injections and manual 
stretches differed as Giovannelli et al. (2007) compared BTX-A injections to BTX-
A injections and manual stretches whilst Paoloni et al. (2013) conducted a three 
arm randomised trial investigating different combinations of BTX-A injections, 
manual stretches and segmental muscle vibration (Table 3-3). Each group 
experienced improvements in spasticity, with those who only received BTX-A 
injections experiencing the least improvement (Giovannelli et al., 2007). 
Significant improvements were also found in subjective relief of symptoms 
(Giovannelli et al., 2007), fatigue and activities of daily living (Paoloni et al., 
2013) in those who received a combination of BTX-A injections and manual 
stretches, however improvements in spasticity were not maintained at 18 weeks 
post intervention compared to six weeks post intervention (Paoloni et al., 2013). 
In contrast, interventions incorporating segmental muscle vibration also 
produced significant improvements in spasticity however these improvements 
were maintained at follow up assessments (Paoloni et al., 2013) (Table 3-3). 
 
3.4.8 Acupuncture 
The evidence is inconclusive regarding the efficacy of acupuncture for the 
rehabilitation of people with progressive MS. There was only one study that 
investigated Chinese Medical acupuncture in comparison to minimal acupuncture 
(Donnellan and Shanley, 2008) (a form of sham acupuncture where needles are 
inserted to a shallower depth and not at true acupuncture points (MacPherson et 
al., 2002)). Minimal acupuncture produced significant improvements in the 
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psychological sub-score of the Multiple Sclerosis Impact Scale compared to 
Chinese Medical acupuncture. No changes were seen in any other outcomes 
(Table 3-3).   
 
3.4.9 Inspiratory muscle training 
The evidence in this review is positive regarding the efficacy of using inspiratory 
muscle training for the rehabilitation of people with progressive MS, although 
only one study was found which investigated this technique. The study 
investigated the use of an inspiratory muscle trainer in comparison to deep 
breathing exercises (Klefbeck and Hamrah Nedjad, 2003). A significant 
improvement was found in maximal inspiratory pressure and maximal expiratory 
pressure in those using the inspiratory muscle trainer. No changes were seen in 
any other outcomes (Table 3-3).  
 
3.4.10 Body Weight Supported Treadmill Training and robotic 
orthotics 
The evidence in this review is inconclusive regarding the efficacy of BWSTT and 
robotic orthotics for the rehabilitation of people with progressive MS. Only one 
study investigated BWSTT compared to BWSTT and robotic orthotics in a 
randomised crossover trial (Lo and Triche, 2008). There was a trend towards 
improvement in double-limb support time in those receiving BWSTT compared to 
those receiving BWSTT and robotic orthotics. At the end of the study, all 
participants showed significant improvements in walking speed, endurance, 
double limb support time and disability but not in step length ratio (Table 3-3). 
However, after the washout period, values had not returned to baseline. 
Therefore between group analyses were performed after the initial three week 
intervention period. 
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3.4.11 Therapeutic standing 
Similar to other physiotherapeutic interventions only one study investigated the 
efficacy of therapeutic standing for the rehabilitation of people with progressive 
MS. The use of a standing frame was compared to a daily home exercise 
programme consisting of abdominal crunches, hip rolls, lumbar rolls and bridging 
(Baker et al., 2007). Therapeutic standing produced significant improvements in 
passive hip and ankle range of motion and a trend towards improvement in ankle 
spasticity; while the home exercise programme resulted in trends towards 
improvement in frequency of leg spasms (Table 3-3).  
 
3.4.12 Overall outcome of studies 
Generally the articles presented a positive effect of physiotherapy for the 
rehabilitation of people with progressive MS. Thirteen studies (described in 15 
articles) found that the intervention group improved more than the comparison 
or control group in at least one outcome measure (Baker et al., 2007, Barrett et 
al., 2009, Briken et al., 2014, Esnouf et al., 2010, Freeman et al., 1997, 
Giovannelli et al., 2007, Klefbeck and Hamrah Nedjad, 2003, Miller et al., 2011, 
Patti et al., 2003, Patti et al., 2002, Skjerbaek et al., 2014). One study only 
found statistically significant improvements in within group analysis (Paoloni et 
al., 2013), one study reported that neither group made an improvement large 
enough for statistical significance (Skjerbaek et al., 2014) and one study found 
that participants who received the control treatment improved more than those 
who received the intervention (Donnellan and Shanley, 2008). It is important to 
note that only one study used a power calculation to determine the required 
sample size however due to ‘drop outs’ the results were subsequently 
underpowered.  
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3.4.13 Clinical significance of improvements 
From the papers included in this review, where a statistically significant change 
in the outcome measure was reported data detailing minimal clinically important 
differences (MCID) in people with MS was sought. Only four outcome measures 
had MCID data available; the timed 25 foot walk test (improvement of 17.2%) 
(Coleman et al., 2012), the six minute walk test (improvement of 21.6 m) (Baert 
et al., 2014), the fatigue impact scale (improvement of 10-20 points) (Rendas-
Baum et al., 2010) and the physical sub-score of the multiple sclerosis impact 
scale (improvement of 8 points) (Costelloe et al., 2007b). Four studies had 
statistically significant results that used at least one of these outcome measures 
(Table 3-5) (Briken et al., 2014, Lo and Triche, 2008, Patti et al., 2002, Taylor et 
al., 2014). All of these results were above the level of MCID for people with MS 
indicating a positive perspective for using physiotherapy in the rehabilitation of 
people with progressive MS. The four trials used four different interventions; 
multidisciplinary rehabilitation (Patti et al., 2002), FES (Taylor et al., 2014),  
exercise therapy (Briken et al., 2014) and BWSTT and robotic orthotics (Lo and 
Triche, 2008). Three trials included participants who were moderately affected 
by MS (EDSS levels 4-6.5) (Briken et al., 2014, Lo and Triche, 2008, Taylor et al., 
2014) and one had a wider range and included those more severely affected 
(EDSS levels 4-8) (Patti et al., 2002) (Table 3-5). Two of the studies used the 
fatigue impact scale (Briken et al., 2014, Patti et al., 2002), both produced 
similar levels of change despite Patti et al. (2002) including participants with a 
wider EDSS range and higher levels of fatigue at baseline. Similarly, two studies 
used the six minute walk test (Briken et al., 2014, Lo and Triche, 2008), both 
produced similar improvements despite differences in distance walked at 
baseline.  
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Table 3-5 Statistically significant results of outcome measures with available 
data of MCID for people with MS 
 
Abbreviations: 6minWT: six minute walk test, Arm: arm ergometry group, C: control group, FIS: 
fatigue impact scale (maximum score: 160), I: intervention group, MCID: minimal clinically 
importance difference, MDT: multi-disciplinary, MSIS-29: multiple sclerosis impact scale 
(maximal physical sub-score: 80), T25fWT: timed 25 foot walk test 
All baseline and change/final values are mean (SD) 
*Change values 
† Between group analysis 
‡ Final values   
§ Within group analysis 
||17.2% improvement is a change in speed.35 Lo & Triche presented results in seconds.32 Means 
of baseline and change in speed calculated from raw time data equated to a 40% improvement in 
speed.  
 
Author 
EDSS 
Intervention Outcome 
Measure  
(MCID) 
Baseline values Change values/ Final 
values 
Patti et 
al. 
4-8 
MDT out-
patient 
rehabilitation 
FIS (10-
20 
points) 
 
I: 116.8 (40.9)  
C: 127.0 (36.0) 
I: -18.8 (14.3)*  
C: 0.6 (0.9)* 
(p<0.001)† 
Taylor 
et al. 
4-6.5 
FES MSIS-29 
physical 
sub-score 
(8 points) 
 
I: 48.8(30.6-55.0)  
C: 46.3(16.3-56.3) 
I: 26.3(16.2-38.1)‡ 
(p<0.05)§ 
C: 35.0(21.3-51.3)‡ 
(p<0.05) § 
Briken 
et al. 
4-6 
Exercise 
therapy 
6minWT 
(21.6 m) 
 
 
 
FIS (10-
20 
points) 
Cycling: 288.65 m 
(99.3) 
Arm: 296.79 m 
(123.79) 
Rowing: 306.61 m 
(103.69)  
C: 325.92 m 
(117.35) 
Cycling: 
35.00(18.07)  
Arm: 45.00(14.73)  
Rowing: 
35.27(13.86) 
C: 38.00(15.15) 
 
Cycling: 
344.97(118.30)‡ 
C: 319.49(109.49)‡ 
(p=0.005)† 
Arm: 360.03(154.64)‡ 
C: 319.49 (109.49)‡ 
(p=0.003)†  
Arm: 31.80(11.09)‡ 
C: 39.30(17.49)‡ 
(p=0.013)† 
Lo & 
Triche 
Mean 
4.9 (SD 
1.2) 
BWSTT and 
robot 
orthotics 
T25fWT 
(17.2%)|| 
6minWT 
(21.6 m) 
whole sample: 9.9 
s (4.2) 
whole sample: 
220.3 m (96.5) 
whole sample: -
3.1(2.4)* (p=0.0002)§ 
whole sample: 
83.4(78.0)* (p=0.002)§  
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3.5 Discussion 
Overall the evidence presented in this review is positive regarding the efficacy 
of physiotherapy for the rehabilitation of people with progressive MS although it 
should be noted that the evidence is generally weak due to the variation in 
interventions and a lack of power within studies.   
The Progressive MS Alliance, and previous reviews, have highlighted that 
research regarding progressive MS and higher levels of disability is an area 
requiring further work (Fox et al., 2012, Hogan and Coote, 2009, Toomey and 
Coote, 2012). Only four studies within the review included participants with a 
high level of disability (EDSS > 6.5) (n=62), five studies did not make a 
distinction in the level of disability of their participants (n=242) and four studies 
included only participants with a mild to moderate level of disability (EDSS < 
6.0) (n=178). Exercise therapy was the only intervention where the effects were 
compared across disability levels (Giovannelli et al., 2007, Miller et al., 2011, 
Paoloni et al., 2013). The results of these studies agreed with those of previously 
published reviews which found exercise therapy produced improvements in 
fatigue in those with a mild to moderate disability (Andreasen et al., 2011), 
while no significant results were found in those with a higher level of disability 
(Dalgas et al., 2008). 
The results of this review were consistent with those found in systematic reviews 
of the other interventions for either MS or similar patient groups. Previously 
published reviews investigating the efficacy of physiotherapy interventions for 
people with MS found that multi-disciplinary rehabilitation programmes 
increased participation (as a result of a decrease in disability) and quality of life 
(Khan et al., 2007); were unable to draw a conclusion as to the effectiveness of 
acupuncture (Karpatkin et al., 2014); found respiratory muscle trainers 
increased maximal inspiratory and expiratory pressure (Martin-Valero et al., 
2014) and that BWSTT and BWSTT with robotic orthotics both improved walking 
speed, double-limb support time, endurance and step length ratio (Swinnen et 
al., 2012). However there was no improvement in step length ratio in the study 
presented in this review. Two reviews assessing the efficacy of FES in chronic 
stroke found it had a good orthotic effect (Kottink et al., 2004) but were unable 
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to conclude on the efficacy of a therapeutic effect (Pereira et al., 2012). 
Reviews assessing interventions for neurological impairments were unable to 
ascertain the most effective adjunct therapy to BTX-A injections in the 
treatment of spasticity (Kinnear et al., 2014) and that therapeutic standing 
produced improvements in ankle range of motion (Newman and Barker, 2012). 
However, the similarity between the results of this review and other reviews for 
the same interventions in similar patient groups such as RRMS should be 
approached with caution due to the previously mentioned methodological 
weaknesses in the body of evidence presented. 
Symptom management and rehabilitation is one of the five key research 
priorities identified by the Progressive MS Alliance (Fox et al., 2012). However, 
impact on quality of life and participation should also be a consideration. Thus, 
identifying the patient groups who would experience the greatest improvement 
in clinical outcomes to particular interventions, with the greatest impact upon 
quality of life and participation, would help establish the full effectiveness of 
interventions. 
 
3.5.1 Study limitations 
This review was limited to only include articles in published in English. It was 
further limited by the broad spectrum of physiotherapy as a discipline which led 
to variation in duration, dose, intensity and the type of interventions included. 
 
3.5.2 Future Work 
Future work should be carried out to investigate physiotherapy interventions for 
people with progressive MS using adequately powered randomised trials with an 
appropriate control, long term follow up and adequate reporting (Hoffmann et 
al., 2014). Studies should, where possible, aim to use a core set of outcome 
measures (Paul et al., 2014) and use outcome measures for which there is 
available data of MCID for people with MS. Future research should also consider 
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participants with PPMS and SPMS separately to investigate whether this has an 
effect on clinical outcomes. Further investigation is recommended to ascertain 
which patient groups would experience largest improvements in quality of life 
from improvements in clinical outcomes. 
 
3.6 Conclusion 
In conclusion, the evidence within this review demonstrates that physiotherapy 
may be effective in the rehabilitation of people with progressive MS. This review 
which focussed on people with progressive MS had similar findings to reviews in 
similar patient groups. Further investigation, with appropriately powered studies 
and consistency in outcome measures between studies is required to strengthen 
this evidence base and conduct meta-analyses of the evidence.    
 
3.7 Articles published since systematic search was 
carried out 
A second search carried out in November 2017 found four more articles which 
met the inclusion criteria. Two (Briken et al., 2016, Geertz et al., 2015) were 
sub-analyses of an RCT already included in the review (Briken et al., 2014), and 
two were new RCTs (Pilutti et al., 2016, Straudi et al., 2016). 
Both of the sub-analyses of Briken et al. (2014) combined data from all three 
exercise groups (arm ergometry, rowing and cycling) and compared this against 
the waitlist control group. When examining the effect on participation in 
physical activity, Geertz et al. (2015) found that the exercising group progressed 
positively along the trans-theoretical change model (p=0.016) and improved self-
efficacy (p=0.014) while the control group regressed and decreased respectively 
(Table 3-6). Briken et al. (2016), found that while nine weeks of training 
produced an increase in the amount of brain derived neurotrophic factor in 
serum after exercise, there was no effect on resting levels (Table 3-6). The 
limitations of the original RCT were discussed earlier. There may also be an 
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additional limitation involved in combining the exercise groups because, in the 
original RCT, the individual groups displayed different changes in both 
physiological outcomes, such as VO2max, and psychological outcomes, such as 
depression (Table 3-3). Despite this potential for sample bias, there was no 
justification in either of the sub-analyses for combining the groups. In summary, 
while these sub-analyses produce positive results and strengthen the case for 
using exercise for the rehabilitation for people with progressive MS, the 
evidence overall remains inconclusive. The limitations of the evidence were 
discussed in section 3.4.6.  
Both Pilutti et al. (2016) and Straudi et al. (2016) conducted RCTs that involved 
BWSTT. Pilutti et al. (2016) compare an intervention of recumbent stepping to 
BWSTT and Straudi et al. (2016) compared BWSTT with robotic orthotics to 
conventional gait training. Straudi et al. (2016) provided a power calculation 
while Pilutti et al. (2016) did not, and both trials included participants with a 
higher EDSS score (Table 3-6). 
As their primary outcome measure, Pilutti et al. (2016) found that both their 
groups enjoyed the intervention, be it BWSTT or recumbent stepping, but the 
recumbent stepping group had a larger effect size. They also found that both 
groups improved their fatigue scores in the physical and psychosocial dimensions 
of the Modified Fatigue Impact Scale (Table 3-6).  
Straudi et al. (2016) found that the BWSTT with robotic orthotics group 
increased their walking endurance, measured by the Six Minute Walk Test, by a 
non-clinically significant amount at three weeks (16.94m SD 18.96, p<0.05) and 
by a clinically significant amount at six weeks (23.22m SD 32.33, p<0.01). An 
improvement was also reported in gait speed at three weeks (0.05 m/s SD 0.13 
p<0.05), but this was not maintained post intervention. The BWSTT with robotic 
orthotics group also displayed a greater improvement in the Mental Health 
component of the SF-36 at three weeks, but this was not maintained at six or 12 
weeks. The BWSTT with robotic orthotics group improved their balance at both 
three and six weeks, and in quality of life in relation to vitality at six weeks, 
social function at three and six weeks, mental health at six and 12 weeks, health 
perception at six weeks and the mental summary component of the Short form 
36 at six weeks. The conventional gait training group showed improvements in 
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quality of life in relation to pain at three weeks, and mental health at six weeks 
(Table 3-6). 
Both of these trials are linked to the study by Lo and Triche (2008) that 
compared BWSTT to BWSTT with robot orthotics. Lo and Triche (2008) found 
improvements in both groups in disability, walking speed and endurance. These 
are similar to the results by Straudi et al. (2016). Quality of life was not 
measured by Lo and Triche (2008) but was by the two new trials. Straudi et al. 
(2016) reported an improvement in quality of life in within group analyses but 
Pilutti et al. (2016) reported no change in quality of life. In summary these three 
studies indicate positive evidence for the use of BWSTT for the rehabilitation of 
people with progressive MS, for improving gait speed and walking endurance in 
those who are severely affected. The effect of BWSTT on quality of life is 
inconclusive, and further investigation into this is warranted.  
These four publications add to the existing body of work in the systematic 
review in sections 3.1-3.6, however the overall conclusions of the review remain 
the same. This is because even though both of the new RCTs focussed on 
participants with higher levels of disability, and both produced positive results in 
rehabilitation, they shared a methodological weakness with the previous body of 
work that neither had a sample size that was statistically powered. Overall, 
these new studies further strengthen the evidence for the efficacy in using 
physiotherapy for the rehabilitation of people with progressive MS but that 
larger fully powered studies are still required. In particular, these new studies 
strengthen the evidence for the use of BWSTT. It was positive that, per the 
recommendations of the original review, both new trials involved more disabled 
participants and that one RCT was powered. 
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Table 3-6 Evidence table of studies published since original search 
Author, 
date and 
design 
Sample size 
PPMS 
SPMS 
EDSS range 
Drop outs 
Intervention, duration, 
length of session, frequency 
Comparison/ 
control 
Time 
Points 
(weeks) 
Outcome measures Main findings 
Geertz et 
al 2015 
Sub 
analysis of 
Briken et 
al 2014 
 
n=47 
PPMS (n=31)* 
SPMS (n=11) 
EDSS 4.0-6.0 
Drop out: 5 
(11%) 
10 weeks, 15-45 min (mean 
Borg 4.6), 2-3/week: 
training either arm 
ergometry, rowing or 
cycling (n=32) 
 
Wait list 
control (n=10) 
0, 10  PA levels, stage of 
TTM, self-efficacy, 
perceived PA 
barriers, exercise 
specific social 
support 
BG ex vs waitlist: 
TTM: ex progressed and control 
regressed (p=0.016) 
Self-efficacy: increase in ex group 
and decrease in control (p=0.014) 
 
 
Briken et 
al. 2016 
Sub 
analysis of 
Briken et 
al 2014 
 
n=47 
PPMS (n=31)* 
SPMS (n=11) 
EDSS 4.0-6.0 
Drop out: 5 
(11%) 
10 weeks, 15-45 min (mean 
Borg 4.6), 2-3/week: 
training either arm 
ergometry, rowing or 
cycling (n=32) 
 
 
Wait list 
control (n=10) 
0, 10  Resting and post ex 
serum 
concentrations of 
Irisin, BDNF, 
Interleukin-6 
 
Post ex increase in BDNF in ex group 
(p<0.01) 
Pilutti et 
al 2016 
RCT 
n=12 
PPMS (n=4)* 
SPMS (n=6) 
EDSS 6.0 -8.0 
Drop out: 2 
(17%) 
12 weeks 3/week, 30 min 
sessions recumbent 
stepping (n=5) 
  
12 weeks 
3/week, 30 min 
sessions BWSTT 
(n=5) 
 
0, 12 Pri: Participant 
experience of 
training  
Sec: MSFC, MFIS, 
HRQOL 
Both groups enjoyed training, 
recumbent stepping had larger ES in 
post ex feeling, 
Both groups improved physical and 
psychosocial fatigue (p=0.04, 
p=0.01)* 
 
Straudi et 
al 2016 
n=58 
PPMS (n=16)* 
SPMS (n=36) 
EDSS 6.0-7.0 
Drop out: 6 
6 weeks, 2/week, up to  60 
min sessions BWSTT with 
robot orthotics (n=27) 
 
6 weeks, 
2/week, 60 min 
sessions of 
CGT: lower 
limb stretching, 
0, 3, 6, 
12 
10MWT, 6MinWT, 
BBS, TUG, FSS, 
PHQ-9, SF-36 
BG: (BWSTT vs CGT) 
10mWT: 3 wks: 0.05 m/s SD 0.13 
(p<0.05) 
6minWT:3 wks: 16.94m SD 18.96, 
(p<0.05), 6 wks:  23.22m SD 32.33 
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(10%) strengthening, 
balance and 
gait exercises 
(n=25) 
(p<0.01) 
 
WG^(all p<0.05): 
BWSTT: 
BBS: 3 wks, 6 wks 
SF-36 vitality: 6 wks 
SF-46 social function 3, 6 wks 
SF-36 Mental health; 12 wks 
 
CGT: 
SF-36: 3, 6 wks 
Abbreviations: 10mWT: 10 metre walk test, 6minWT: 6 minute walk test; BG: between group differences; BBS: Berg Balance Scale; BWSTT: body weight supported 
treadmill training; CGT: conventional gait training; ES: effect size; FSS: Fatigue Severity Scale; MSQOL: Multiple Sclerosis Quality of Life-54; MSFC: Multiple 
Sclerosis Functional Composite; MFIS: Modified Fatigue Impact Scale; PHQ-9; Patient Health Questionnaire; Pri: primary outcome measure; Sec: secondary outcome 
measures; SF-36: Short Form 36; TTM: transtheoretical model of change; TUG: Timed Up and Go test; WG: within group differences 
*Demographic data not supplied on drop outs 
^Size of change not reported. 
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Chapter 4 Survey of clinical services for people 
with Multiple Sclerosis in the UK – Rationale and 
Methods 
There is a lack of available pharmacological treatments for decreasing disease 
activity in those with progressive forms of MS, and thus treatment often focuses 
on symptomatic management and rehabilitation. Physiotherapy has a positive 
impact on the management of MS, and rehabilitation has been recognised as a 
research priority for progressive MS (Fox et al., 2012). The current National 
Institute for Health and Care Excellence (NICE) guidelines and Healthcare 
Improvement Scotland clinical standards for Neurological Health Services, state 
that everyone with MS in the UK should have access to an MS Specialist, 
physiotherapy, and receive a comprehensive annual review. This review can be 
carried out by any member of the MS team,  does not have to be conducted in a 
clinical environment, and should cover all aspects of care including medication, 
symptom management, disease course, general health, participation and social 
care needs (NICE, 2014b, Healthcare Improvement Scotland, 2009). However, it 
is unknown at this time how often people with progressive MS receive a regular 
review or what the level of access is to clinical services.  
This chapter will outline the rationale and methods for an online survey of 
people with progressive Multiple Sclerosis (MS), in the United Kingdom (UK), 
exploring the access, use and views of MS clinical services. The online survey 
was conducted, between August and September 2015, using the UK MS register, 
a national register which is a longitudinal research database. Due to the lack of 
treatments available for people with progressive forms of MS and a lack of 
distinction between MS types in previous research this study recruited only 
people with primary and secondary progressive MS. This study has been 
published across two articles (Campbell et al. 2017. Access, delivery and 
perceived efficacy of physiotherapy and use of complementary and alternative 
therapies by people with progressive multiple sclerosis in the United Kingdom: 
An online survey. Multiple Sclerosis & Related Disorders, 12, 64-69. (Appendix 2) 
Campbell et al. 2017. Access and Use of Clinical Services and Disease-Modifying 
Therapies by People with Progressive Multiple Sclerosis in the United Kingdom. 
International Journal of MS Care, 19, 275-282. (Appendix 3)) the results of which 
are combined in Chapter 5. 
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4.1 Evidence base of access, use and opinion of Multiple 
Sclerosis clinical services 
4.1.1 Definition of access and use 
Access to services is a multi-faceted concept. In the past, access was simply 
defined as the entry into the care of, or use of, a health care system (Clark, 
1983). However, access is in fact, more complex.  Access can be related to the 
availability of services, the adequate supply of services and the opportunity to 
enter into said services (Levesque et al., 2013). Furthermore there is a 
difference between having access to a service, and gaining access which is 
measured in utilisation (Gulliford et al., 2002). Access can be broken down into 
several dimensions and determinants. These include not just the availability of 
services, but the opportunity to be able to use them, the utilisation of services, 
and organisational barriers which may affect a person’s ability to be able to gain 
access such as waiting times, distance to travel and affordability (Levesque et 
al., 2013).   
This study explored two aspects of access. The first was the opportunity to be 
able to enter into a service regardless of external factors such waiting times and 
transport issues. This was defined as ‘access’. Secondly the utilisation of 
services was explored. This was defined as ‘use’ (Levesque et al., 2013).    
 
4.1.2 Access and use of Multiple Sclerosis clinical services in the 
United Kingdom 
Four studies have previously explored access and use of clinical services by 
people with MS in the UK. Two of these were published after this present survey 
was conducted. These were the ‘Generating Evidence in Multiple Sclerosis 
Services’ (GEMSS) by the MS Trust (Mynors et al., 2015) and the ‘My MS My Needs 
survey’ by the MS Society (MS Society, 2016c) 
The GEMMS study examined the access and use of MS Services, over a four year 
period between 2012 and 2015, among people with MS across 10 sites in England 
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and two in Scotland from MS Nurses’ active caseloads (Mynors et al., 2015). A 
return rate of 47% from 2,648 paper surveys produced a sample of 1,254. The 
researchers found that the most commonly consulted practitioner was the MS 
Specialist Nurse with 77% of respondents reporting that they had consulted a MS 
Nurse recently for their MS. However, this study may have been biased, as 
participants were recruited from MS Specialist Nurse active caseloads. While the 
average MS Nurse’s caseload was described as having 46% of patients with an 
Expanded Disability Status Scores (EDSS) of 5.5 or below, 38% between 6.0 and 
7.5 and 16% of 8.0 or above, the EDSS of the respondents was not described. 
Furthermore there was no distinction made between participants with 
progressive MS and those with Relapsing Remitting MS (RRMS). 
The ‘My MS My Needs survey’ by the MS Society, used a combination of postal 
surveys and the UK MS Register to maximise response rate (MS Society, 2016c). 
They used 30% online and 70% postal surveys, 10,888 people were recruited with 
all types of MS from Scotland, Northern Ireland, England and Wales. As well as 
examining employment, use of social benefits and co-ordination of care, the 
study explored access to Disease Modifying Therapies (DMTs), rehabilitation 
therapies and access and use of services. The study found that 86% of 
respondents had access to an MS Specialist (Neurologist or Nurse). They also 
found that 56% of the cohort were taking DMTs, 17% did not have access to a 
physiotherapist, 32% of physiotherapy was provided from non-NHS sources and 
that the majority (74%) of all MS Services were delivered in a clinical setting (MS 
Society, 2016b). While these results provide a valuable insight into the access 
and use of services across the UK the results were not separated by MS type. 
Thus it remained unknown whether people with progressive MS have a different 
level of access to services and if they attend similar clinical services to those 
with RRMS. 
A study in Northern Ireland investigated access and use of services and 
medications taken via interviews with 149 people with MS (EDSS 0-9.0) (MacLurg 
et al., 2005). The sample consisted of people with RRMS (44%) and progressive 
MS (56%) recruited from a network of 30 General Practitioner (GP) practices that 
were representative of Northern Ireland. The results indicated that irrespective 
of disability, access to physiotherapy services was the most common unmet need 
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and that use of multiple medications was directly linked to level of disability 
(MacLurg et al., 2005).  
Edmonds et al. (2007) used qualitative methods to explore unmet needs in 
relation MS services in people severely affected by MS (EDSS >8.0) in Southeast 
London. The sample comprised 23 people with MS and 17 carers, with seven 
people with MS were too disabled to take part in the semi-structured interviews. 
Overall, both participants with MS and their carers had a poor perception of 
services, citing a lack in continuity of clinicians and being unable to get an 
appointment with clinicians when needed, despite the service existing (Edmonds 
et al. 2007).  
In summary, the two studies which were published after this present survey, had 
the largest cohorts and surveyed the largest geographical areas suggested access 
to clinical services, especially MS Specialists, was quite high (MS Society, 2016c, 
Mynors et al., 2015)). However the two studies with smaller sample sizes, which 
had either more than half of their sample with progressive MS or focused on 
those with a severe disability, found that access to services was either poor or 
cited organisational barriers to using the service (Edmonds et al., 2007, MacLurg 
et al., 2005). As neither of the more recent studies focused on progressive MS 
this left a gap in the literature regarding the level of access to, and use of, 
clinical services by people with progressive MS in the UK. 
 
4.1.3 Access and use of Multiple Sclerosis clinical services 
outside the United Kingdom 
There have been five studies conducted outside the UK examining access and use 
of clinical services by people with MS. Lonergan et al. (2015) asked participants, 
in the Republic of Ireland, to complete a questionnaire either in person or by 
phone. A 51% response rate, from 632 potential participants identified from a 
prevalence study by the same group of researchers (Lonergan et al., 2011), 
generated a sample of 325, 50% of whom had a progressive form of MS (86% EDSS 
< 6.0 or less, 14% EDSS > 6.0 or more). The researchers explored the perceived 
needs of these participants in both rural (Wexford and Donegal) and urban 
(Dublin) regions of Ireland with participants reporting a lack of access to 
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physiotherapy, particularly in those who lived rurally and had progressive MS 
(Lonergan et al., 2015).  
A Europe wide study consisted of interviews with 137 people with MS across five 
countries: Belgium, Estonia, Greece, Italy and the UK (Kersten et al., 2000). The 
researchers did not report type of MS or EDSS score, but reported that 39% were 
wheelchair bound, 36% were significantly handicapped but ambulatory and 21% 
had no significant handicap. The participants reported that the most utilised 
clinicians were GP (75%), physiotherapist (57%), MS Doctor or Nurse (53%) and 
Occupational Therapist (28%). When the data for the UK (n=37) was isolated the 
most consulted clinicians were the same but in a different order: GP (95%), MS 
Doctor or Nurse (84%), Physiotherapist (62%) and Occupational Therapist (62%) 
indicating a higher rate of use of specialist Doctors and Nurses than the other 
countries.  
A group of Swedish researchers carried out a survey of patients of one 
outpatients rehabilitation centre in Stockholm (Ytterberg et al., 2008). They 
received completed questionnaires from 219 people with MS, of whom 42% had 
either Primary Progressive MS (PPMS) or Secondary Progressive MS (SPMS). 
Respondents were predominantly mildly affected by MS with 60% having an EDSS 
score of 3.5 or less, 17% were moderately affected (EDSS score of 4.0-5.5) and 
23.5% were severely affected (EDSS score of 6.0-9.5). The participants did not 
report any unmet needs in access to outpatient clinical services. However, this 
study only examined the service provision of one outpatient clinic and this limits 
the generalisability of the results. The patient perception of services is 
described later with similar studies in section 4.1.5. 
Most recently, two qualitative studies by the same research group examined the 
perceived needs of people severely affected by MS in Germany, from both the 
patient and the health professional’s perspective (Galushko et al., 2014, Golla et 
al., 2012). Fifteen people with MS were recruited (mean EDSS = 7.0), seven of 
which had a progressive form of MS (Galushko et al., 2014). In interviews all 
participants reported difficulty in utilising services, reporting high waiting times, 
lack of home community-based care and poor quality disabled access at clinics 
(Galushko et al., 2014). Clinicians (n=23) were recruited from four clinics, one of 
which was rural, and data was collected using face-to-face interviews and focus 
groups (Golla et al., 2012). Neurologists identified the biggest unmet need as a 
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lack of ability to access services due to disability, even though a service was 
available, while Nurses identified unmet needs mainly relating to maintaining 
participation and social support (Golla et al., 2012). However the results of this 
study should be interpreted with caution due to the small sample size. 
Furthermore, the purposive recruitment of patients may have led to sample 
bias. 
In summary, studies carried out exploring access to clinical services outside the 
UK have been conducted only in Europe. Methodology and sample population 
have varied as have results creating heterogeneity in the literature. In Ireland 
and central Europe access to MS clinical services was poor apart from access to 
GPs. In contrast, access to services in Sweden was high yet this study was heavily 
open to bias as it only surveyed one outpatient clinic. 
 
4.1.4 Perception of Multiple Sclerosis services in the United 
Kingdom 
Only one study has explored patient perception of MS services in the UK. 
Markwick et al. (2014) reported on the service user opinion of MS services. The 
opinions, of 757 people with MS, were obtained from a service audit of MS 
services in England and Wales (Royal College of Physicians and MS Trust, 2008). 
The type of MS was not reported, yet 86% reported that their MS either had a 
“moderate” or “major” impact on their life. Predominantly the views on 
physiotherapy provision were negative. The most common negative comments 
were lack of availability of services, long waiting times, and poor flexibility in 
service delivery.  
 
4.1.5 Perception of Multiple Sclerosis services outside the United 
Kingdom 
As was described in section 4.1.3., Ytterberg et al. (2008) also explored 
participant’s perception of services received at a clinic in Sweden. Participants 
were asked to rate the service on a five point Likert scale which was then 
dichotomised into satisfied (1-2 on scale) and dissatisfied with service (3-5 on 
scale). Results demonstrated that Nurses were held in the highest regard, with 
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96% reporting that they felt their needs were met, and 88% felt satisfied with 
services provided by physiotherapists. While this is a positive result this does 
indicate that 12% were not satisfied with physiotherapy services. 
A similar study carried out by Holmoy et al. (2012) in Norway, asked 339 people 
with MS regarding satisfaction with services after a four week in-patient stay at 
a rehabilitation centre in Hakakdal. A response rate of 82% was achieved 
resulting in a return of 277 questionnaires. The questionnaire consisted of simple 
closed ended questions with categorical yes or no answers. Ninety-two percent 
of respondents reported that they were satisfied with the therapeutic services 
they received. The researchers however, unusually, did not report any 
demographical information on the participants. 
A third Scandinavian study investigated the views of patients following a single 
physiotherapy session in an outpatient clinic in Norway (Normann et al., 2012). 
The study achieved a high response rate of 89% resulting in a sample of 64 
participants. While type of MS of the participants was not reported, 77% were 
reported as fully ambulatory, 11% used a walking aid and 12% were using a 
wheelchair. The researchers reported that the participants only had positive 
comments on the single physiotherapy session received. 
The three Scandinavian studies (Holmoy et al., 2012, Normann et al., 2012, 
Ytterberg et al., 2008), all reported positive patient perception of MS services, 
and specifically physiotherapy. Despite this, all three studies are limited in their 
generalisability as they recruited participants from individual sites leaving their 
results open to sample bias and demographics were not always reported. 
 
4.1.6 Use of complementary and alternative therapies by people 
with Multiple Sclerosis 
As well as medical care, people with MS often utilise Complementary and 
Alternative Therapies (CAT) in their own management of their MS (Bowling and 
Stewart, 2003). There has been some research carried out outside of the UK 
examining the use of CAT in people with MS but not in the UK.  
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Apel et al. (2006) conducted 254 semi-structured interviews, with people with 
MS in Germany, exploring their use of CAT in respect to frequency and therapies 
used. They found that 67% of their sample was currently using a CAT. The most 
commonly used CAT were exercise (73%), vitamins (40%), other supplements 
(34%), herbal medicine (25%), relaxation (25%), and massage (13%). In a follow 
up study exploring CAT use and disease progression, the authors noted that 
people with MS were more likely to use CAT in the early stages of their disease 
as, soon after diagnosis, people with MS are more likely to try as many 
therapeutic avenues as possible (Kochs et al., 2014).  
In the United States of America, Stoll et al. (2012) surveyed 133 people with MS 
about their use of therapies other than DMTs, which included CAT. Their 13 
question survey had closed, single and multiple choice answers. The authors 
reported that 58% of their sample had used a CAT in the prior 30 days. The most 
commonly used CAT were massage (30%), psychotherapy (20%), and acupuncture 
(13%).  
Skovgaard et al. (2012) conducted an online survey of 6,455 members of MS 
Societies of the five Nordic countries exploring CAT use in the past year. The 
authors found that overall use of CAT varied slightly across the five countries 
with 46% of the sample having used CAT in Sweden, 52% in Denmark, 53% in 
Norway, 56% in Finland, and 59% in Iceland. In Denmark the most common used 
CAT were supplements (80%), acupuncture (16%), herbal medicine (12%), 
reflexology (11%), and yoga (11%). In Norway the most commonly used CAT were 
supplements (67%), herbal medicine (19%), acupuncture (15%), yoga (9%), and 
meditation (9%). In Sweden the most commonly used CAT were supplements 
(59%), yoga (15%), acupuncture (12%), herbal medicine (11%), and meditation 
(11%). In Finland the most commonly used CAT were supplements (80%), yoga 
(8%), acupuncture (7%), herbal medicine (6%), and meditation (6%). Lastly, the 
most commonly used CAT in Iceland were supplements (58%), yoga (23%), 
acupuncture (21%), meditation (14%), and herbal medicine (13%). 
A study conducted at an outpatient clinic in Turkey surveyed 101 people with MS 
asking them about knowledge of, and use of CAT (Gedizlioglu et al., 2015). The 
researchers reported that 32% had knowledge of CAT and that 26% had used CAT 
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at some point, but only 6% were currently using CAT. The type of CAT used was 
not reported. 
In summary the use of CAT by people with MS outside of the UK is high across 
western countries. However, in Turkey the use of CAT was significantly lower 
but this could have been linked to a lack of knowledge of CAT due to cultural 
factors. The most commonly used CAT varied from country to country but the 
most common in all of the research was supplements, herbal medicine, exercise, 
acupuncture and massage. However, despite all of this previous research 
exploring the use of CAT in people with MS, there was no sample solely of people 
with progressive MS and the data was not presented by MS type. Furthermore, 
there is no data available on the use of CAT by people with MS in the UK. 
 
4.2 Summary of evidence  
There has been some previous research examining access and use of clinical 
services in the UK but this has not been explored by MS type. Reported results 
have been conflicting; in the larger studies access was reported to be high while 
in the smaller studies, which had a larger proportion of people with progressive 
MS or higher disability, a lack of access was reported. Outwith the UK, access to 
services was poor in central Europe and Ireland yet high in Sweden. However, 
the results from the Swedish study were from one rehabilitation centre.   
Only one study to date has examined perception of services by people with MS in 
the UK, from which perceptions were predominantly negative; while in 
Scandinavia patient perception of services was high. However, both studies 
focussed on single centres. This leaves a gap in the literature regarding access 
to, use of, and opinion of clinical services by people with progressive MS in the 
UK. In addition the current level of CAT use by people with progressive MS also 
remains unknown. 
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4.3 Objectives and study design 
The objectives of this study were to, in relation to people with progressive MS in 
the UK: 
 investigate the levels of access to MS Specialists, a regular review, and 
use of clinical services 
 investigate the levels of access to, delivery of, barriers to access, and 
opinion of physiotherapy services by people with progressive MS in the 
UK 
 investigate the use of CAT in the UK 
A cross-sectional design was chosen as this was an exploratory study seeking to 
describe the current delivery and use of MS clinical services by people with 
progressive MS in the UK. As this was the first study of its kind in the UK there 
were no hypotheses posed. 
 
4.3.1 Research Questions 
In relation to access and use of MS Specialists and clinical services: 
 
 What proportion of respondents have access to an MS Specialist and which 
clinical services are used for their MS? 
 What proportion of respondents receive a regular review for their MS and 
how is this delivered? 
 What proportion of respondents have ever taken and are currently taking 
DMTs? 
Are there associations between: 
 Access to and use of MS specialists and quality of life, impact of MS, type 
of MS, DMTs use? 
 Location and access to MS specialists? 
 If participants had utilised more than one clinician for their MS in the past 
three months and quality of life/impact of MS? 
 Past and present DMTs use and quality of life/impact of MS? 
 Type of MS and quality of life/impact of MS? 
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In relation to access and delivery of physiotherapy:  
 
 What proportion of respondents have access to physiotherapy and how 
many are currently receiving physiotherapy for their MS? 
 Who is the provider of physiotherapy and what is the referral process? 
 How is physiotherapy delivered and what is the expected waiting time for 
an appointment? 
 Which physiotherapy interventions have respondents received in the past 
three months? 
 What is the respondents’ perceived efficacy of physiotherapy and 
interventions received? 
Are there associations between: 
 Access to and use of physiotherapy and quality of life/impact of MS, type 
of MS, perceived efficacy, age, gender? 
 Perceived efficacy of physiotherapy and quality of life/impact of MS, type 
of MS, age, gender?  
 
In relation to preferred delivery of physiotherapy: 
 
 Do respondents want more physiotherapy than they currently receive? 
 What is the preferred delivery of physiotherapy? 
 What are the most common and greatest barriers to receiving 
physiotherapy? 
In relation to use of CAT: 
 What proportion of respondents use CAT? 
 Which CAT are used for respondents’ MS? 
Are there associations between: 
 Complementary and alternative therapy use and quality of life/impact of 
MS, age, gender, type of MS, access to MS services, receiving a regular 
review, use of clinical services for their MS, and DMTs use (past and 
present)? 
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4.4 UK MS Register 
The UK MS Register is a longitudinal research database funded by the MS Society 
since 2011. Adults with MS become members by signing up to the register online 
and then answer, via an online portal, regular self-report outcome measures, 
update demographic information and complete regular and one-off online 
surveys (Jones et al., 2014a). The purpose of the UK MS Register is to increase 
the epidemiological knowledge base of MS by collating and combining data from 
three sources: data collected directly from people with MS, from routine 
administrative data sources and from NHS clinical information systems (Ford et 
al., 2012). At the time of this study the data were not yet linked up with NHS 
clinical data therefore diagnosis of MS was self-reported.   
Previous published research carried out on the register has been predominantly 
conducted by the research group responsible for the inception and management 
of the UK MS Register. Published research has included studies examining anxiety 
and depression (Jones et al., 2012), quality of life (Jones et al., 2013a), the 
impact of MS (Jones et al., 2013b) and the relationship between disability and 
depression (Jones et al., 2014b). 
 
4.5 Definitions of access and use in online survey 
As was discussed in section 4.2.1 access to services is a multi-faceted concept 
(Levesque et al., 2013). The first aspect of access explored by this study was the 
opportunity to be able to enter into a service regardless of external factors, 
defined as ‘access’. The second aspect explored was the utilisation of services, 
defined as ‘use’.    
These terms were not explicitly explained to the respondents, however the 
meaning was implied in the questions asked. For example “Which of the 
following clinicians could you see if you wanted to?” implied the opportunity to 
be able to enter into a service and “Which of the following clinicians have you 
seen in the past three months for your MS?” implied the utilisation of a service. 
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4.6 Ethical approval  
Ethical approval was obtained from the University of Glasgow College of Medical, 
Veterinary and Life Sciences Ethics Committee. The information governance 
panel of the UK MS Register also reviewed the protocol and approved the study.  
The UK MS Register had its own ethical approval from the NHS (South West - 
Central Bristol Research Ethics Committee, Ref: 11/SW/0160).  
 
4.7 Inclusion criteria, identification and recruitment of 
respondents 
Participants were considered eligible for inclusion if they were aged 18 years or 
older, had a progressive form of MS and were a member of the UK MS register.  
Potential participants were identified by the UK MS Register and were emailed 
informing them of the study on the 18th of August 2015. The potential 
participants were sent a reminder follow up email one calendar month later.  
Both emails contained a short description of the survey, the reasons for 
conducting it and a statement informing the respondent that they were under no 
obligation to take part and that they were free to stop completing the survey at 
any point. If, after this, the respondent began the survey then this was regarded 
as informed consent. 
When this study was carried out in 2015 there were 11,041 people on the 
register with 4,384 of those being classed as active members on the register in 
the prior six months.  Of the total 11,041 registrants there were 2,538 who self-
reported as having a progressive form of MS. Awareness was also raised via the 
MS Society’s website, and via a knowledge exchange event. 
 
4.8 The online survey 
An online survey via the UK MS Register was chosen as a data collection method 
as it provided access to a large potential cohort that would not have been 
feasible if data were collected using face to face interviews or survey methods. 
The survey comprised three sections. The first was concerned with access and 
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current delivery of physiotherapy; the respondent’s perceived efficacy of 
physiotherapy and interventions received. In the second section participants 
were asked about their preferred delivery and potential barriers to receiving 
physiotherapy. The third section asked about access and use of MS Specialist and 
clinical services, past and present use of DMTs and use of complementary and 
alternative therapies.   
The survey was made up of a mixture of single answer and multiple response 
options. Closed ended categorical questions were used to make it easier for 
people with cognitive impairment to complete.  The survey was not developed 
from a pre-existing questionnaire. A validated questionnaire was not necessary 
as the survey was not used to accumulate a score and many of the research 
questions had descriptive answers, for example, the level of access to a 
physiotherapist.  The full survey complete with logical progressions can be found 
in Appendix 4. 
 
4.8.1 Survey data collection: access to Multiple Sclerosis 
specialist services and use of clinical services, disease 
modifying therapies and complementary and alternative 
therapies 
The respondents were asked if they had access to an MS Specialist service and 
which clinical services they had used for their MS in the prior three months. An 
MS Specialist service was defined as a clinician with MS Specialist skills. If a 
participant did not have access to an MS Specialist service they were asked what 
clinical services they could access and then which they had used in the previous 
three months for their MS. Respondents were then asked if they received a 
regular review for their MS; how often that review took place; who normally 
undertook the review; and where the review normally took place. Previous and 
current use of DMTs was explored before lastly asking about if participants had 
recently used CAT for their MS and what type of CAT they had used. 
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4.8.2 Survey data collection: physiotherapy access, delivery, and 
perceived efficacy  
Respondents were asked if they were currently receiving physiotherapy, if they 
had access to physiotherapy, what the route of referral was, and who was their 
physiotherapy provider. Respondents were then asked their perceived efficacy of 
physiotherapy as a discipline for their MS, which physiotherapy interventions 
they had received in the prior three months (for their MS) and their perceived 
efficacy of these interventions. Perceived efficacy was rated on a five point 
Likert scale: ‘very harmful’, ‘harmful’, ‘neither harmful nor beneficial’, 
‘beneficial’, and ‘very beneficial’. The Likert scale was used since it gave a 
graded categorical variable and allowed for the level of perceived efficacy to be 
assessed.  
Respondents were then asked about the delivery of their physiotherapy. This was 
in terms of regularity of appointments, expected waiting times, frequency of 
appointments, length of appointments, the number of people usually present 
and where respondents normally received their physiotherapy. 
 
4.8.3 Survey data collection: desired delivery of physiotherapy  
Finally respondents were asked if they were happy with the level of 
physiotherapy they were currently receiving and how they would like their 
physiotherapy to be delivered. They were asked if they wanted more 
physiotherapy, how often they would like to receive physiotherapy, how long 
they would like their sessions to last, where they would like to receive 
treatment, and how many people they would like to be present. In addition the 
respondents were asked what barriers they encountered in receiving 
physiotherapy and of these, which three were the most pertinent barriers.   
 
 82 
 
4.9 Routinely collected data supplied by the UK MS 
Register 
The UK MS Register supplied demographic data, EQ-5D-3L index, Multiple 
Sclerosis Impact Scale-29 (MSIS-29) version 2 psychological and physical sub-scale 
scores and Lower Super Output Area codes or Super Output Area codes 
depending on location. 
The EQ-5D-3L index and MSIS-29 version 2 were included as they were routinely 
collected by the UK MS Register and are valid self-report measures of quality of 
life and disease impact in people with MS. The Lower Super Output Area codes 
and Super Output Area codes were requested as additional information from the 
MS Register as these allowed geographical data to be generated.   
 
 
4.9.1 Demographic data 
For each participant the following demographic data were supplied by UK MS 
Register: age, type of MS (SPMS or PPMS only), time since diagnosis, gender and 
country of residence. 
 
4.9.2 EQ-5D-3L 
The EQ-5D-3L is a self-report measure of quality of life.  There are five 
dimensions: mobility, self-care, usual activities, pain and discomfort, and 
anxiety and depression.  For each dimension the user chooses either: “no 
problem at all”, “some problems”, or “severe problems”. A combination of each 
answer to the dimensions creates a code (for example 13223) and an index is 
generated depending on the relative indexes for the relevant country (EuroQol, 
1990). This index ranges from -1 to 1, a higher index indicating better quality of 
life. Generally as an individual gets older their index will fall.  For example an 
individual in England who is healthy and aged 60 years will have an index of  
approximately 0.8 whilst and individual who is 25 and healthy will have an index 
of 1 (Devlin et al., 2016). 
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4.9.3 Multiple Sclerosis Impact Scale - 29 version 2 
The MSIS-29 version 2 is a 29 item self-report measure of disease impact with 
sub-scales in relation to the physical and psychological impact of MS and was 
discussed in section 2.6.3. A higher score indicates a greater impact of disease. 
Each question has 4 options on a Likert scale and the participant is asked to give 
their responses in relation to the previous two weeks (Hobart et al., 2001). 
These are ‘not at all’, ‘a little’, ‘moderately’ and ‘extremely’ and are scored 1-
4 respectively. The original version of the MSIS-29, which had five options 
instead of four, was updated in 2009. The MSIS-29 is divided into two sections: 
the first 20 questions concern the physical impact of MS and the final 9 questions 
the psychological impact of MS.  Physical and psychological impact sub-scales 
scores can range from 20-80 and 9-36 respectively (Hobart and Cano, 2009).   
The physical sub-scale of the MSIS-29 version 1 was found to correlate 
moderately with EDSS (r= 0.63), with correlation increasing with higher scores 
(higher physical impact) (Gray et al., 2009) and being sensitive to change when 
compared to the EDSS (McGuigan and Hutchinson, 2004). Minimal important 
clinical difference in the physical subscale of MSIS-29 version 1 has been 
reported as a change of 7 points for those with an EDSS of 0.0 – 0.5 and a change 
of 8 for those with an EDSS of 5.5 - 8.0 (Costelloe et al., 2007a). In the 
psychological sub-scale a decrease of 6 or more is deemed to be clinically 
significant (Widener and Allen, 2014). However, there is no available minimal 
important clinical difference data for the physical or psychological sub-scales 
used in MSIS-29 version 2. 
 
4.9.4 Lower Super Output Area codes and Super Output Area 
codes 
Lower Super Output Area codes are geographical codes in England and Wales, 
generated from a post code, which provide a location within a set area and 
population density. Using these codes and other linked codes created by the 
Office for National Statistics, it is possible to convert the Lower Super Output 
Area code into further information such as local authority area, population 
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density, strategic health authority, and NHS health board (Office for National 
Statistics, 2016). The code is not exact enough to identify where a person lives 
in the same way a postcode can, but it does provide information such as the 
neighbourhood. Super Output Area codes are similar codes produced by the 
Scottish Office for National Statistics and these can be used to establish the 
same information in a similar manner (Scottish Office for National Statistics, 
2016). 
Using the Lower Super Output Area codes and Super Output Area codes the 
population density of where the respondent lived was generated. Using the 
definitions supplied by Department for Communities and Local government a 
settlement with a population of more than 10,000 was classified as urban and 
less than 10,000 was classified as rural (Department for Communities and Local 
Govenment, 2006). 
 
4.10 Data collection, access and storage 
The data were anonymised at an individual level using the Secure Anonymised 
Information Linkage system of the MS Register (Ford et al., 2009). The 
anonymised data were then accessed remotely, using a secure RSA SecurIDTM 
token, on a remote desktop with no ability to download data to a local 
computer. Only data specific to this project was on this desktop and it was not 
possible to download the data to the local computer. Data and results from 
analysis could be requested for release, but would only be so, after they were 
assessed for anonymity by the Health and Information Research Unit of the UK 
MS Register. 
 
4.11 Statistical analysis and handling of data 
IBM SPSS Statistics version 22 was used for all statistical analysis.  Percentages of 
total respondents to each question were calculated. Where appropriate, answers 
from different questions on the same subject were combined. This allowed for 
new variables to be created such as separating those who had used only a single 
service for their MS and those who had used multiple services. For example the 
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research question ‘Which clinical services are used for their MS?’ required 
answers from questions 1.1, 3.3a, and 3.3c (see below) to be answered fully.   
1.1 Do you receive physiotherapy at the moment? 
3.3a What other health care professionals have you seen for your MS in 
the past 3 months?   
3.3c What other health care professionals would you be able to see for 
your MS if you wanted to?  
A full list of research questions that required answers from multiple survey 
questions can be seen in Appendix 5.   
Due to website programming some participants were able to answer three follow 
up questions about a regular review despite having said that they were not 
offered one. These answers (n=8) were subsequently removed. Only data 
relating to delivery of reviews was reported and analysed from respondents who 
reported receiving a review. 
Data were tested for normality using Kolmogrov-Smirnov tests. All data were not 
normally distributed therefore Mann-Whitney tests were used to test for 
differences in continuous variables within sub-groups with two options, for 
example: EQ-5D-3L index in those who did and did not have access to 
physiotherapy. Kruskal-Wallis tests were used to test for differences in 
continuous variables in sub-groups with more than two variables, for example 
MSIS-29 version 2 physical subscale in participants who thought physiotherapy 
was ‘very beneficial’, ‘beneficial’, ‘neither beneficial or harmful’, ‘harmful’ or 
‘very harmful’. Chi-square tests were used to test for independence between 
categorical variables. Statistical level of significance was set at p<0.05, and to 
limit the chance of type 1 errors, Bonferroni adjustments were used as 
appropriate.   
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Chapter 5 Survey of clinical services for people 
with Multiple Sclerosis in the UK – Results  
An online survey of people with progressive Multiple Sclerosis (MS) was 
conducted via the UK MS Register in 2015. The main objective was to explore 
access and use of clinical services, in particular MS Specialists and 
physiotherapy, by people with progressive MS in the United Kingdom (UK). This 
chapter will present the results of the survey with regards to access and use of 
MS clinical services, delivery, desired delivery and perceived efficacy of 
physiotherapy and use of Complementary and Alternative Therapies (CAT). 
Finally the associations between access and use of clinical services and routinely 
collected data from the UK MS Register will be explored. 
 
5.1 Demographics and population  
There were 2,538 members of the UK MS Register who self-reported as having a 
progressive form of MS. A response rate of 51% produced a sample of 1,298 
people with progressive MS. Not every participant had complete demographic 
data available, for example country of domicile. The mean age of respondents 
was 59 years (SD 8) with a mean Time Since Diagnosis (TSD) of 16 years (SD 9). 
The majority of participants, 79%, lived in England, 10% lived in Scotland, 8% in 
Wales and 2% in Northern Ireland. The majority of respondents were female with 
a female to male ratio of3:2 ; similarly the majority of respondents were 
diagnosed with Primary Progressive MS (PPMS) (ratio of PPMS to Secondary 
Progressive MS (SPMS) was also 3:2). The EQ-5D-3L index of the whole cohort was 
0.49 (SD 0.2), the mean physical sub-scale score of the Multiple Sclerosis Impact 
Scale-29 (MSIS-29) was 56 (SD 12.6) and the mean psychological sub-scale score 
was 20 (SD 6.1) (Table 5-1). Mean time between survey completion and most 
recent completion of EQ-5D-3L and MSIS-29, which are meant to be completed 
quarterly, was 39 (SD 120) days and 19 (SD 111) days respectively. 
There were statistically significant differences, after Bonferroni adjustment, 
between those with PPMS and SPMS in terms of age, TSD, gender, EQ-5D-3L 
index and MSIS-29 physical and psychological sub-scale scores. Compared to the 
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respondents with SPMS those who had PPMS were older (p<0.001), had a shorter 
TSD (p<0.001), had a higher EQ-5D-3L index (better quality of life) (p=0.001), a 
lower MSIS-29 psychological sub-scale score (p=0.004) and lower physical sub-
scale score (p=0.002) (Table 5-1). More females had SPMS and PPMS (n=578, 
n=246 respectively) compared to males (n=234, n=240 respectively) (p<0.001).  
There were no statistically significant differences in MS type depending on 
country of residence (p=0.343) or urban/rural dwelling (p=0.219) (Table 5-1). 
Table 5-1 Demographics of participants 
  Whole cohort  
PPMS 
(n=486) 
SPMS 
(n=812) 
p 
Age (years) (n=1298) 59 (8) 60 (697.28) 59 (620.9) p<0.001* 
TSD (years) (n=1298) 16 (9) 9 (440.98) 18 (737.15) p<0.001* 
Gender n=(1298)    
  Female  824 (63%) 246 (51%) 578 (71%) p<0.001+ 
  Male  474 (37%) 240 (49%) 234 (29%)  
Country of residence    (n=1285) (n=448) (n=807)  
  Scotland  130 (10%) 57 (12%) 73 (9%) p=0.343 
  England  1030 (79%) 372 (77%) 658 (81%)  
  Wales  104 (8%) 40 (8%) 64 (8%)  
  N. Ireland  21 (2%) 9 (2%) 12 (2%)  
Population density       (n=1250) (n=463) (n=787)  
  Urban living 862 (69) 329 (71%) 533 (68%) p=0.219 
  Rural living 388 (31) 134 (29%) 254 (32%)  
EQ-5D-3L index 
0.490  
(0.20) 
0.566 
(677.51) 
 0.503 
(662.66) 
p<0.001* 
MSIS-29 - psych 20 (6.1) 18 (601.64) 20 (662.66) p=0.004* 
MSIS-29 - phys 56 (12.6) 55 (604.47) 58 (672.45) p=0.002* 
Abbreviations: PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis; TSD: time since diagnosis; MSIS-29 psych: Multiple Sclerosis Impact Scale 29 
psychological sub-scale; MSIS-29 phys: Multiple Sclerosis Impact Scale 29 physical sub-scale 
Figures for age, TSD, EQ-5D-3L index and MSIS-29 sub-scale scores are expressed as mean and 
standard deviation for the whole cohort and as median and mean rank for PPMS and SPMS.   
* Statistically significant from Mann-Whitney testing after Bonferroni adjustment (0.05/5=0.01). 
+ Statistically significant from Chi square testing after Bonferroni adjustment (0.05/3=0.02). 
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5.2 Descriptive results 
5.2.1 Access to Multiple Sclerosis specialists and clinical service 
use 
Due to a programming error responses regarding the health professions 
respondents consulted for their MS, MS Specialist Doctor and MS Specialist Nurse 
were combined and were reported as one variable ‘MS Specialist’. Thus, 95% 
(n=1,184) of respondents reported that they had access to an MS specialist and 
81% of those with access reported that they could access their MS Specialist if 
needed. Overall access to MS Specialists was high and varied slightly throughout 
the Strategic Health Authorities of England and the other three countries of the 
United Kingdom from 92% in East Midlands and Yorkshire & Humber to 98% in 
Wales (Figure 3-1). 
 
 
 
  
  
 
89 
 
 
Figure 5-1  Access to MS specialists by Strategic Health Authority in England, 
and the other three countries of the United Kingdom 
Map generated from the Office of National Statistics open geography portal in April 2016 
(http://geoportal.statistics.gov.uk/) 
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In total 82% (n=1046) of participants had used a clinical service for their MS in 
the prior three months. The most used services were MS Doctor/Nurse (50%), 
General Practitioner (45%) and Physiotherapist (32%) (Figure 5-2). 
 
 
 
Figure 5-2 Clinical services used for MS in the past three months 
Abbreviations: MSDr/NS: MS Doctor or MS Nurse; Physio: Physiotherapist; OT: Occupational 
Therapist; Cont NS: Continence Nurse; NS oth: Nurse other; Dr oth: Doctor other; Orth: 
Orthotist; SW: Social Worker; Oth: other; Psych: Psychologist; SLT: Speech and Language 
Therapist; Diet: Dietician 
 
 
Seventy four percent (n=917) of respondents reported that they received a 
regular review, while 23% (n=287) reported they did not and 3% (n=39) did not 
know if they received a review or not. The most common frequency of the 
review was once a year (55%, n=505) but 37% received their review less than 
once a year. The most common practitioners to carry out the review was the MS 
Doctor (63%, n=569) or Nurse (27%, n=248) and 90% (n=819) reported that the 
setting for their review was in a hospital or clinic (Table 5-2). 
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Table 5-2 Receipt and delivery of annual review for progressive MS 
Variable   n Option n % 
Receives regular review  1243 Yes 917 74 
 
 No  287 23 
 
 Don’t know  39 3 
Frequency of review 912 Twice a year 57 6 
 
 Once a year 505 55 
 
 Less  than once a year 341 37 
  Don’t know  9 1 
Clinician who delivers review 911 MS Specialist Doctor 569 63 
 
 Nurse 248 27 
 
 The person can vary 58 6 
 
 Physiotherapist 12 1 
 
 Occupational therapist 6 1 
 
 GP 8 1 
  Other*  10 1 
Setting of review  911 In a hospital or clinic 819 90 
 
 At home 43 5 
 
 GP surgery 20 2 
 
 Other^  19 2 
  In a community centre 10 1 
Abbreviations: n: number of respondents; MS: multiple sclerosis; GP: general practitioner 
* Answers reported as other for who delivers review: unknown (n=5), support worker (n=1), 
“rehabilitation team” (n=2), “MS worker” (n=1), health administrator (n=1) 
^ Answers reporter as other for setting of review: charity centre (n=12), “NHNN” (definition not 
provided by respondent) (n=1), unknown (n=6) 
 
 
Twenty percent (n=88) of respondents were currently taking DMTs (Table 5-3). 
The most common DMTs participants reported taking was Beta-interferon (39%, 
n=34) (Table 5-4). Previous use of DMTs was reported in 24% of respondents 
(n=303) (Table 5-3), similarly Beta-interferon was the most commonly prescribed 
DMTs (Table 5-4).  
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Table 5-3 Past and present use of disease modifying therapies 
  n % 
Present DMTs use (n=447) Yes 88 20 
No 359 80 
Past DMTs use (n=1241) Yes 303 24 
No 938 76 
Abbreviations: n: number of respondents; DMTs: disease modifying therapies 
  
Table 5-4 Disease modifying therapies taken currently and in the past   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: DMTs: disease modifying therapies; n: number of respondents 
Respondents were able to select more than one option, thus total percentages could add up to 
greater than 100%. 
 
 
 
5.2.2 Physiotherapy, access, delivery and perceived efficacy 
In total, 87% (n=1118) of respondents reported having access to physiotherapy 
and 32% (n=414) were currently receiving physiotherapy for their MS. The most 
common routes of referral for physiotherapy were via the MS nurse (43%), self-
referral (38%) and via the General Practitioner (32%) (Table 5-5). The majority of 
physiotherapy was delivered on a one to one basis (80%) and most participants 
received their physiotherapy regularly (60%) as opposed to varying depending on 
symptoms (40%). When asked to select an expected waiting time for a 
physiotherapy appointment there was not a clearly most common selection. Six 
percent expected to be seen within a week and ten percent expected to wait 
longer than 12 weeks. Respondent selection for the other four options in 
 
Current DMTs 
taken (n=88) 
Past DMTs 
taken (n=303) 
 n % n % 
Beta-interferon  (Rebif, Avonex, 
Betaferon) 34 39 232 77 
Glatiramer acetate (Copaxone) 5 6 73 24 
Dimethyl fumarate (Tecfidera) 17 19 17 6 
Teriflunomide (Aubagio) 0 0 1 <1 
Natalizumab (Tysabri, Antigren) 19 22 34 11 
Fingolimod (Gilenya, Novartis) 11 13 15 5 
Mitoxantrone (Novantrone) 2 2 31 10 
Alemtuzumab (Lemtrada)     2 2 6 2 
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between ranged from 19-22%. The most common frequency of appointments was 
once or more per week (55%) and the typical length of physiotherapy 
appointments was 30-60 minutes (Table 5-6). The three most common providers 
of physiotherapy were the NHS (78%), private practice (20%) and charity (third 
sector) (16%) (Table 5-5). This was reflected in the setting of physiotherapy 
delivery, as the most common settings were in a hospital or clinical environment 
(46%), at home (25%) or in a charity centre (24%) (Table 5-6). 
Table 5-5 Access and provider of physiotherapy 
Variable Total n Options n % 
Access to physiotherapy 
 
1291 Yes 1118 87 
 No 173 13 
Currently receiving 
physiotherapy 
1287 Yes  414 32 
 No 873 68 
Referral route 
1158 MS specialist 
doctor/neurologist 310 27 
  GP 366 32 
  Self-referral 445 38 
  MS specialist nurse 493 43 
  Other  140 12 
  Don’t know  8 1 
Physiotherapy provider 1106 National Health Service 859 78 
  Private (self-funded) 219 20 
  Private (insurance) 21 2 
  Charity 187 16 
  Other* 14 2 
Abbreviations: n: number of respondents; MS: multiple sclerosis; GP: general practitioner. 
For some questions participants were able to select more than one option. 
*Providers named as ‘other’ included: MS registered trainer (n=1), family member or carer (n=3), 
self-treat (n=2), selected other but did not give details (n=8) 
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Table 5-6 Delivery of physiotherapy 
Variable Total n Options n % 
Setting of physiotherapy 461 In a hospital or clinic 210 46 
  At home 116 25 
  In a charity centre 110 24 
  In a community centre 31 7 
 
 
Other*  51 11 
Number of people present 457 1 (individual session) 366 80 
  2-4  42 9 
  5 or more  81 18 
 
 Receive physiotherapy by 
telephone or online 5 1 
Pattern of appointments 451 Regularly 270 60 
 
 Varies depending on 
symptoms 181 40 
Expected waiting time  192 < 1 weeks 12 6 
  > 1 < 2 weeks 42 22 
  > 2 < 4 weeks 36 19 
  > 4 < 6 weeks 41 21 
  > 6 < 12 weeks 41 21 
  > 12 weeks 20 10 
Frequency of appointments 252 Once or more a week 138 55 
  Once a fortnight 46 18 
  Once every 1 to 3 months 53 21 
  Twice a year 10 4 
  Once a year or less  5 2 
Usual length of 
appointments 
462 <30 minutes 120 26 
 30 - 60 minutes 299 65 
  >60 minutes 43 9 
Abbreviations: n: number of respondents. 
*Setting of delivery named as ‘other’ included: private clinic (n=25), leisure centre/gym (n=14), 
hydrotherapy pool (n=5), care home (n=1), at work (n=1), not specified (n=5) 
 
The three most commonly received physiotherapy interventions in the prior 
three months were: a home exercise programme (83%), supervised exercise 
(71%) and advice or education received from a physiotherapist (65%) (Table 5-7). 
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Table 5-7 Physiotherapy interventions received for Multiple Sclerosis in the 
past three months 
Intervention (total n=452) n % 
Home exercise programme 373 83 
Exercises with a physiotherapist 320 71 
Advice or education 293 65 
Functional electrical stimulation 110 24 
Standing frame or tilt table 78 17 
Acupuncture 43 10 
Transcutaneous electrical stimulation 30 7 
Hydrotherapy 8 2 
Manual therapy 5 1 
Walking aid prescription 3 <1 
Whole body vibration 2 <1 
Hand physiotherapy 1 <1 
Women’s health physiotherapy 1 <1 
Joint consultation with orthoptist and physiotherapist 1 <1 
 Abbreviations: n: number of respondents 
 
A total of 70% of participants reported that they thought physiotherapy was 
either ‘beneficial’ or ‘very beneficial’ to them in relation to their MS. Twenty-
seven percent thought that it was ‘neither beneficial nor harmful’ and 3% 
thought that it was either ‘harmful’ or ‘very harmful’ for them (Table 5-8).   
 
Table 5-8 Perceived efficacy of physiotherapy for the participant’s MS 
Perceived efficacy (n=1208) n % 
Very harmful 11 <1 
Harmful 20 2 
Neither harmful nor beneficial 328 27 
Beneficial 523 43 
Very beneficial  326 27 
Abbreviations: n: number of respondents 
 
The perceived efficacy of interventions received by participants for their MS was 
predominantly positive with most respondents feeling that their interventions 
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were either ‘beneficial’ or ‘very beneficial’ for their MS. Only two interventions, 
acupuncture and Transcutaneous Electrical Nerve Stimulation (TENS) had more 
than 5% of participants report a perceived efficacy that was either ‘harmful’ or 
‘very harmful’. However, the overall opinion of the efficacy of these 
interventions was positive (Table 5-9). 
 
Table 5-9 Perceived efficacy of physiotherapy interventions received 
  Perceived efficacy (%) 
Intervention (total n=452) n v harm harm neith ben v ben 
Home exercise programme 373 0 1 12 58 28 
Exercise with physiotherapist 320 <1 <1 6 39 54 
Advice/Education 293 0 <1 8 50 41 
Functional Electrical 
Stimulation 110 0 3 21 29 47 
Standing frame 78 0 3 8 53 37 
Acupuncture 43 2 5 36 31 26 
TENS 30 3 10 34 34 17 
Abbreviations: n: number of respondents; v: very; harm: harmful; neith: neither harmful nor 
beneficial; ben: beneficial; TENS: transcutaneous electrical nerve stimulation 
 
5.2.3 Desired delivery of physiotherapy 
Respondents were asked about their desired delivery of physiotherapy for their 
MS. Just over half (52%) of participants reported that they would like more 
physiotherapy than they were currently receiving, 30% were happy with the 
amount of physiotherapy they were currently receiving and 17% did not know 
whether they would like more physiotherapy or not. When asked about the 
desired pattern of delivery, 65% reported that they would prefer to receive 
physiotherapy sessions regularly and 35% reported they would prefer to receive 
their sessions when required. Almost two thirds of responding participants (65%) 
reported that they would like to receive physiotherapy for their MS at least once 
a week and 69% reported a desired length of physiotherapy session of 30-60 
minutes. The most preferred settings for receiving physiotherapy were at home 
(40%) or in a hospital or clinical setting (35%). A delivery of one to one was 
favoured by 77% of respondents (Table 5-10). 
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Table 5-10 Desired delivery of physiotherapy 
Variable n Options n % 
Wants more 
physiotherapy for 
their MS? 
946 Yes 494 52 
 No 287 30 
 Don’t know  165 17 
Desired pattern of 
sessions 
947 Regular 617 65 
 Vary depending on symptom 330 35 
Preferred 
frequency of 
sessions 
621 Once or more a week 332 54 
 Once a fortnight 185 30 
 Once every 1 to 3 months 91 15 
 
 Twice a year 11 2 
  Once a year or less  2 0 
Preferred length of 
sessions 
941 <30 minutes 238 25 
 30 - 60 minutes 647 69 
   >60 minutes 56 6 
Preferred setting 945 At home 374 40 
 
 In a hospital or clinic 331 35 
 
 In a community centre 69 7 
 
 In a charity centre 94 10 
  Other  77 8 
Preferred number 
of people present 
941 One to one 725 77 
 2-4 people 146 16 
 
 5 or more people 63 7 
  by telephone or online 7 1 
Abbreviations: n: number of respondents 
 
 
5.2.4 Barriers to accessing physiotherapy 
The five most commonly reported barriers to accessing physiotherapy were 
mobility (40%), fatigue (39%), continence issues (21%), transport (21%), and 
needing someone to go with them to the appointment (21%). While 23% of 
respondents reported that they did not have any barriers to receiving 
physiotherapy. From the list of barriers the participants had selected, they were 
then asked to select which three were the most problematic for them. These 
were called the ‘most problematic’, ‘second most problematic’ and ‘third most 
problematic’ barriers.   
The top three ‘most problematic’ barriers reported were mobility (13%), fatigue 
(20%), and transport problems (9%). The top three ‘second most problematic’ 
barriers were mobility (17%), fatigue (15%), transport problems (7%) and pain 
(7%). The top three ‘third most problematic barriers’ were fatigue (16%), 
mobility (14%), and continence issues (10%) (Table 5-11).   
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Table 5-11 Most commonly reported and most problematic barriers to 
accessing physiotherapy 
  Most problematic barriers 
Barrier to accessing 
physiotherapy 
Most common  First Second Third 
n % n % n % n % 
Mobility 372 40 78 13 102 17 73 14 
Fatigue 365 39 122 20 91 15 84 16 
Continence issues 197 21 38 6 38 6 51 10 
Transport problems 197 21 53 9 39 7 29 6 
Needing someone to go with 
them 194 21 41 7 32 5 47 9 
Distance to travel 169 18 33 5 35 6 31 6 
Fear of falling 157 17 15 2 38 6 29 6 
Pain 156 17 35 6 39 7 23 4 
Cost 139 15 5 1 29 5 28 5 
Lack of suitable parking 122 13 13 2 28 5 25 5 
Issues being referred to 
physiotherapy 110 12 46 7 19 3 10 2 
Other  96 10 26 4 13 2 11 2 
Difficulty with wheelchair 
transfers 94 10 15 2 26 4 16 3 
Physiotherapy not available 90 10 46 7 19 3 20 4 
Work commitments  64 7 25 4 14 2 14 3 
Lack of time 55 6 11 2 21 4 13 2 
Depression 50 5 2 <1 4 1 7 1 
Family commitments 44 5 3 <1 1 <1 6 1 
Anxiety/panic attacks 26 3 4 1 5 1 3 1 
Physiotherapy not beneficial  7 1 2 <1 0 0 1 <1 
Personal issues with 
physiotherapist 4 <1 1 <1 0 0 1 <1 
No barriers to receiving 
physiotherapy 215 23 - - - - - - 
Abbreviations: n: number of responses 
Percentages calculated from total number of respondents to question as a whole (n=938), 
participants were able to choose more than one answer. 
 
 
 
5.2.5 Complementary and Alternative Therapies 
When asked regarding use and previous use of CAT, 42% (n=506) of respondents 
reported that they had used CAT in the prior three months for their MS (Table 
5-12). The most commonly used CAT were massage (41%), Reflexology (29%) and 
relaxation or meditation (24%) (Table 5-12). The total number of respondents 
who said that they had not used a CAT was 727, however, 24 of those also 
reported using a CAT that was listed. They were subsequently subtracted from 
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the total of those who did not use CAT, thus the total number of people who did 
not use CAT was 703 (58%). Respondents also reported four types of exercise as a 
CAT: yoga (6%), pilates (6%), exercise in general (3%) and tai chi (2%). 
Table 5-12 Complementary and alternative therapies used in the prior three 
months 
Complementary and alternative therapy (total n=506)  n  % 
Massage 207 41 
Reflexology 146 29 
Relaxation or meditation 123 24 
Hyperbaric oxygen therapy 85 17 
Acupuncture or acupressure 72 14 
Osteopathy or chiropractic 58 11 
Homeopathy or herbal medicine 40 8 
Reiki 33 7 
Aromatherapy 32 6 
Yoga 32 6 
Pilates  32 6 
Dietary supplements 29 2 
Exercise  14 3 
Magnet field therapy 9 2 
Tai chi 8 2 
The Alexander technique 7 1 
Bowen technique 7 1 
Low dose Naltrexone 6 1 
Craniosacral therapy 3 <1 
Diet management 3 <1 
Vibration machine 2 <1 
Action potential stimulation 1 <1 
Bee venom 1 <1 
“Circulation booster” 1 <1 
“muscle activation therapy” 1 <1 
Self-Controlled Neuro-Adaptive Regulator device 1 <1 
Ultrasound on legs 1 <1 
Abbreviations: n: number of respondents 
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5.3  Association between access to a specialist and 
demographics, quality of life, impact of disease, use 
of disease modifying therapies and receiving a review 
After Bonferroni adjustment, age was the only continuous variable which was 
different between those with and without access to an MS Specialist (p=0.001). 
Those who did not have access to an MS Specialist were significantly older than 
those who reported access (p=0.001) (Table 5-13). In addition, receiving an 
annual review was associated with access to an MS Specialist (p<0.001) (Table 
5-14).   
 
Table 5-13 Association between access to specialist and age, time since 
diagnosis, quality of life and impact of Multiple Sclerosis 
 Access to 
Specialist n median 
Mean 
Rank p 
Age yes 1184 59 616.85 0.001* 
 no 64 63 765.95 - 
TSD yes 1146 15 598.12 0.011 
 no 61 19 714.42 - 
EQ-5D-3L index yes 1154 0.566 611.2 0.245 
 no 62 0.503 558.23 - 
MSIS-29 -phys yes 1180 56 621.19 0.581 
 no 64 58 646.65 - 
MSIS-29 -psych yes 1167 19 615 0.832 
 no 63 18 624.73 - 
Abbreviations: TSD: time since diagnosis; MSIS-29: multiple sclerosis impact scale; phys: physical 
sub-scale; psych: psychological sub-scale; n: number of respondents 
*Statistically significant after Bonferroni adjustment (0.05/5=0.01) 
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Table 5-14  Difference between those with and without access to a specialist 
in demographics and use of disease modifying treatments 
  Access to MS specialist   
 n  Yes No p 
PPMS 1248 437 27 0.473 
SPMS  747 37  
Past DMTs use 1227 288 11 0.371 
No past DMTs use  880 48  
Current DMTs use 438 87 1 0.175 
No current DMTs use  332 18  
Urban dwelling 1201 787 43 1.000 
Rural dwelling  352 19  
Annual review 1233 894 15 <0.001* 
No annual review  245 42  
Don’t know  35 2  
Abbreviations: PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis; DMTs: disease modifying therapies; n: number of respondents; MS: multiple 
sclerosis. 
*Statistically significant result with Bonferroni adjustment (0.05/6=0.008) 
 
 
5.3.1 Association between single or multiple service use and 
quality of life, impact of disease and use of disease 
modifying therapies 
There were statistically significant differences, after Bonferroni adjustment, in 
EQ-5D-3L indexes and MSIS-29 physical and psychological sub-scales between 
those who recently received a single service or multiple services for their MS. 
Compared to respondents who had recently used a single service for their MS, 
those who used multiple services had a lower EQ-5D-3L index, higher physical 
and psychological MSIS-29 sub-scale scores indicating a poorer quality of life and 
higher impact of disease (all p<0.001) (Table 5-15). 
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Table 5-15 Differences between those using single and multiple services in 
EQ-5D-3L index and MSIS-29 physical and psychological sub-scale scores 
 Single or multiple 
service use n median 
Mean 
Rank p 
EQ-5D-3L 
index 
single  469 0.566 563.99 <0.001* 
multiple  548 0.503 461.94 
 MSIS-29 - phys single  478 55 476.3 <0.001* 
multiple  563 59 558.95 
 MSIS-29 -
psych 
single  473 18 462.13 <0.001* 
multiple  555 20 559.13 
 *Statistically significant after Bonferroni adjustment (0.05/3= 0.017). 
Abbreviations: MSIS-29: multiple sclerosis impact scale; phys: physical sub-scale; psych: 
psychological sub-scale; n: number of respondents 
 
5.3.2 Association between past and present use of disease 
modifying therapies and quality of life and impact of disease 
After Bonferroni adjustment, respondents who were currently taking DMTs had a 
higher EQ-5D-3L index indicating a better quality of life than those who were not 
taking DMTs (p=0.016) (Table 5-16). There were however, no differences in 
psychological or physical sub-scale scores of the MSIS-29 indicating no difference 
in disease impact between those who were and were not currently taking DMTs.  
Table 5-16 Difference between those currently taking and not taking disease 
modifying therapies in EQ-5D-3L index and MSIS-29 sub-scale scores 
 
Current DMTs use n median 
Mean 
Rank p 
EQ-5D-3L index Yes 87 0.566 245.75 0.016* 
 No 346 0.503 209.77 - 
MSIS-29 -phys Yes 87 57 199.17 0.05 
 No 359 59 229.4 - 
MSIS-29 -psych Yes 85 20 220.88 0.96 
 No 357 20 221.65 - 
Abbreviations: MSIS-29: multiple sclerosis impact scale; phys: physical sub-scale; psych: 
psychological sub-scale; DMTs: disease modifying therapies; n: number of respondents. 
*Statistically significant with Bonferroni adjustment (0.05/3=0.017) 
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The EQ-5D-3L index and the MSIS-29 physical and psychological sub-scales were 
also compared between respondents who had previously taken DMTs and those 
who had never taken DMTs. Following Bonferroni adjustment, a lower EQ-5D-3L 
index (p<0.001) and higher psychological (p=0.006) and physical sub-scale 
(p<0.001) scores were observed in those who had previously taken DMTs 
indicating a poorer quality of life and higher impact of MS compared to those 
who had not previously taken DMTs (Table 5-17). 
Table 5-17 Difference between those who had previously taken and not 
taken disease modifying therapies in EQ-5D-3L index and MSIS-29 sub-scale 
scores 
  Past DMTs use n median mean rank p 
EQ-5D-3L index yes 296 0.503 531.99 <0.001* 
no 912 0.566 628.03 - 
MSIS-29 -phys yes 302 59 698.49 <0.001* 
 no 935 56 593.33 - 
MSIS-29 -psych yes 299 20 661.09 0.006* 
 no 925 19 596.79 - 
Abbreviations: MSIS-29: multiple sclerosis impact scale; phys: physical sub-scale; psych: 
psychological sub-scale; DMTs: disease modifying therapies; n: number of respondents 
* Statistically significant with Bonferroni adjustment (0.05/3=0.017) 
 
5.3.3 Association between access and use of physiotherapy and 
quality of life, impact of disease and demographics 
Participants who were receiving physiotherapy were younger than those who 
were not receiving physiotherapy (p<0.001) and had a shorter TSD (p=0.009) 
(after Bonferroni adjustment) (Table 5-18). There were no differences in EQ-5D-
3L index or MSIS-29 scores between those who did and did not have access to 
physiotherapy and those who were and were not receiving physiotherapy for 
their MS (Table 5-18). Urban or rural dwelling, gender, country of residence or 
MS type were not factors in either having access to or receiving physiotherapy 
(Table 5-19).   
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Table 5-18 Comparison between those with access to physiotherapy and 
those receiving physiotherapy in continuous demographic and clinical 
variables 
  Access to physiotherapy  Receiving physiotherapy  
Variable  n Med 
Mean 
rank p n Med 
Mean 
rank p 
Age Y 1118 59 629.93 <0.001* 704 59 635.07 <0.001* 
(years) N 173 61 749.84 - 166 61 648.23 - 
TSD  Y 1082 14.5 615.54 0.034 680 14.0 631.12 0.009* 
(years) N 165 17.0 679.45 - 158 17.0 617.64 - 
EQ-5D-
3L index 
Y 1089 0.57 638.26 0.048 401 0.57 631.19 0.778 
N 167 0.50 677.21 - 852 0.57 625.03 - 
MSIS-29 
phys 
Y 1113 56 638.26 0.199 411 57 644.72 0.83 
N 173 58 677.21  871 57 639.98 - 
MSIS-29 
psych 
Y 1102 19 633.34 0.435 403 19 599.23 0.019 
N 170 20 656.96 - 865 20 650.93 - 
Abbreviations: TSD: time since diagnosis; MSIS-29: multiple sclerosis impact scale; phys: physical 
sub-scale; psych: psychological sub-scale; Y: yes; N: no; n: number of respondents; Med: median 
*Statistically significant after Bonferroni adjustment (0.05/5=0.01). 
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Table 5-19 Comparison between those with access to physiotherapy and 
those receiving physiotherapy in categorical demographic variables 
  Access to physiotherapy Receiving physiotherapy 
Variable  Yes No p Yes No p 
Urban/ 
rural 
dwelling 
Urban 746 110 0.418 273 581 0.861 
 Rural 330 57 - 125 260 - 
Gender Female  703 115 0.361 259 557 0.666 
 Male  415 58 - 155 316 - 
Country of 
residence 
England 888 139 0.557 328 695 0.803 
Scotland 113 16 - 44 85 - 
 Wales 88 13 - 31 70 - 
 
Northern 
Ireland 
16 5 - 5 16 - 
MS type PPMS 417 67 0.718 156 326 0.907 
 SPMS 701 106 - 258 547 - 
Abbreviations: MS; multiple sclerosis; PPMS: primary progressive multiple sclerosis; SPMS: 
secondary progressive multiple sclerosis 
 
 
5.3.4 Variation in expected waiting time  
Expected waiting time for a physiotherapy appointment varied depending on the 
provider. Most notable was that 27% of participants who received their 
physiotherapy from non-NHS sources expected to receive an appointment in a 
week or less, compared to just 2% of participants who received their 
physiotherapy solely from the NHS. Thirty-nine percent of those who received 
their physiotherapy from the NHS expected to receive their physiotherapy 
appointment in 4 weeks or less compared to 88% of those who received their 
physiotherapy from non-NHS sources (Table 5-20). 
  
  
 
106 
 
Table 5-20 Expected waiting times by source of physiotherapy 
Provider of 
physiotherapy 
 Expected waiting time for appointment (weeks) 
n <1 1 - 2 2- 4 4- 6 6 – 12 >12 
NHS 133 2% 22% 15% 28% 23% 10% 
Non-NHS 26 27% 39% 23% 0% 12% 0% 
Both 27 7% 11% 33% 11% 19% 19% 
Abbreviations: NHS: National Health Service; n: number of responses 
 
5.3.5 Perceived efficacy of physiotherapy 
Due to the small amount of participants who regarded physiotherapy as 
‘harmful’ or ‘very harmful’ to them, it was not possible to conduct statistical 
analysis across the levels of perceived efficacy. However, descriptively, more 
participants who were receiving physiotherapy thought that it was ‘very 
beneficial’ than those who were not receiving it. In addition, more participants 
who were not receiving physiotherapy thought that physiotherapy was ‘neither 
harmful nor beneficial’ for them than those who were receiving physiotherapy 
(Figure 5-3). Although physiotherapy was well thought of there was no 
difference in perceived efficacy of physiotherapy between the participants who 
thought they needed more physiotherapy for their MS, those who did not and 
those who did not know (Table 5-21).  
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Figure 5-3 Perceived efficacy of physiotherapy of whole cohort, those 
currently receiving physiotherapy and those not currently receiving 
physiotherapy 
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Table 5-21 Perceived efficacy in those with access to, receiving, and wanting 
more physiotherapy, gender, country of residence and urban/rural dwelling 
   
Perceived efficacy 
   
v harm harm neith ben v ben 
Variable  
 
n % % % % % 
Access to 
physiotherapy 
Yes 640 1 3 38 44 15 
No 154 <1 1 27 40 31 
Receiving 
physiotherapy  
Yes 408 <1 <1 10 43 45 
No 795 1 2 36 43 18 
Wanting more 
physiotherapy  
Yes 462 <1 <1 3 59 37 
No 268 <1 <1 5 53 41 
 
Don't 
know 150 0 0 9 68 23 
Gender Female 766 1 2 26 40 30 
 
Male 442 1 2 29 48 21 
Country of 
residence 
Scotland 122 2 0 29 42 27 
England 961 1 2 27 43 27 
 
Wales 96 1 0 26 50 23 
 
Northern 
Ireland 20 0 5 15 40 40 
Urban/Rural 
dwelling 
Urban 800 1 2 29 44 25 
rural 366 1 2 25 43 30 
Abbreviations: n: number of respondents; v: very; harm: harmful; neith: neither harmful nor 
beneficial; ben: beneficial 
 
Analysis revealed statistically significant differences in the MSIS-29 physical and 
psychological sub-scales across the levels of perceived efficacy (Table 5-22). 
However, due to the small number of participants who felt that physiotherapy 
would be harmful or very harmful to them post-hoc analysis was not possible.  
There were no differences, after Bonferroni adjustment, in the MSIS-29 physical 
and psychological sub-scales between those who thought that physiotherapy was 
‘very beneficial’, ‘beneficial’, or ‘neither harmful nor beneficial’ to them 
(p=0.025 and p=0.185 respectfully) (Table 5-23). 
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Table 5-22 Differences in EQ-5D-3L index, MSIS-29 sub-scales, age and TSD 
across all levels of perceived efficacy 
Perceived 
efficacy 
 
EQ-5D-3L 
index 
MSIS-29 
phys  
MSIS-29 
psych Age TSD 
 n=1179 n=1203 n=1190 n=1208 n=1170 
Very harmful  % <1 <1 <1 <1 <1 
 
Median 0.357 65 20 58 16 
 
Mean Rank 492.23 779.73 627.91 555.05 580.55 
Harmful % 2 2 2 2 2 
 
Median 0.272 62 25 54 14 
 
Mean Rank 359.05 718.65 856.73 426.65 566.88 
Neither 
harmful nor 
beneficial  
% 27 27 27 27 27 
Median 0.503 58 20 60 15 
Mean Rank 572.25 635.03 620.33 628.48 571.8 
Beneficial % 43 43 43 43 44 
 
Median 0.566 56 19 59 15 
 
Mean Rank 605.33 571.66 580.15 613.02 585.49 
Very beneficial % 27 27 27 27 27 
 
Median 0.566 56 19 58 15 
 
Mean Rank 601.5 601.07 577.49 579.28 600.53 
 
P 0.014 0.013 0.004* 0.061 0.877 
Abbreviations: n: number; MSIS-29: multiple sclerosis impact scale; phys: physical sub-scale; 
psych: psychological sub-scale; TSD: time since diagnosis 
*Statistically significant with Bonferroni adjustment (0.05/5=0.01) 
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Table 5-23 Differences in EQ-5D-3L index, MSIS-29 sub-scale scores, age and 
time since diagnosis by indifferent and positive perceived efficacy 
Perceived 
efficacy 
 EQ-5D-3L 
index 
MSIS-29 
phys 
MSIS-29 
psych Age TSD 
Neither 
harm nor 
beneficial  
% 27 27 27 27 27 
Median 0.503 58 20 60 15 
Mean Rank 572.25 635.03 620.33 628.48 571.8 
Beneficial % 43 43 43 43 44 
 Median 0.566 56 19 59 15 
 Mean Rank 605.33 571.66 580.15 613.02 585.49 
Very 
beneficial 
% 27 27 27 27 27 
Median 0.566 56 19 58 15 
 Mean Rank 601.5 601.07 577.49 579.28 600.53 
 
p* 0.36 0.025 0.185 0.178 0.567 
Abbreviations: med: median; MSIS-29: multiple sclerosis impact scale; phys: physical sub-scale; 
psych: psychological sub-scale; TSD; time since diagnosis 
*Statistical significance after Bonferroni adjustment 0.05/5=0.01. 
 
 
5.3.6 Association between use of complementary and alternative 
therapies and quality of life, impact of disease, 
demographics and receiving a regular review 
There were no statistically significant differences in TSD, EQ-5D-3L and MSIS-29 
physical and psychological sub-scale scores between those who had and had not 
used CAT for their MS in the prior three months (Table 5-24). In addition, there 
was no association between use of CAT and country of residence, urban or rural 
dwelling, MS type or being in receipt of a regular review or not (Table 5-25). 
However, more females had recently used CAT than males (p=0.006) (Table 
5-25).   
  
  
 
111 
 
Table 5-24 Differences between those who had and had not recently used 
complementary and alternative therapies in EQ-5D-3L index, MSIS-29 sub-
scale scores, age and time since diagnosis 
 Used CAT n median Mean Rank p 
Age yes 506 60 600.13 0.68 
 no 703 59 608.51 - 
TSD yes 494 14 578.64 0.471 
 no 679 15 593.08 - 
EQ-5D-3L index yes 491 0.566 599.67 0.408 
 no 688 0.566 583.1 - 
MSIS-29 -phys  yes 503 56 580.78 0.061 
 no 702 57 618.92 - 
MSIS-29 -psych yes 494 19 599.72 0.818 
 no 699 19 595.08 - 
Abbreviations: TSD: time since diagnosis; MSIS-29: multiple sclerosis impact scale; phys: physical 
sub-scale; psych: psychological sub-scale; CAT: complementary and alternative therapies; n: 
number of respondents 
 
Table 5-25 Differences between those who had and had not recently used 
complementary and alternative therapies in demographics and receipt of a 
regular review 
     Used CAT Not used CAT  p 
Gender Female 344 424 0.006* 
  Male 162 279 - 
Country Scotland 51 73 0.638 
 England 404 551 - 
 Wales 35 63 - 
  Northern Ireland 9 11 - 
MS Type PPMS 180 272 0.269 
  SPMS 326 431 - 
Urban/Rural dwelling Urban 319 485 0.06 
  rural 164 196 - 
Receives regular 
review 
yes 372 515 0.843 
no 110 162 - 
  don't know 17 21 - 
Abbreviations: MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; SPMS: 
secondary progressive multiple sclerosis; CAT: complementary and alternative therapies 
*Statistically significant after Bonferroni adjustment (0.05/5=0.01)  
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5.4 Summary 
In summary, the results of this survey indicate that access to MS Specialists was 
high at 95%, but that access to a regular review was lower at 74%, with 36% of 
respondents receiving their review less than annually. The most used clinical 
services for MS were an MS Specialist Doctor or Nurse (50%), General Practitioner 
(45%), and Physiotherapist (40%). Use of DMTs amongst the whole cohort was 
quite low at 5%, but previous use was higher with 24% of respondents reporting 
previously taking DMTs. Present use of DMTs was associated with a better quality 
of life and previous use was associated with a poorer quality of life and higher 
physical and psychological impact of MS. 
Access to physiotherapy was high at 87%, of which 32% were currently receiving 
physiotherapy for their MS. As a discipline, physiotherapy was very well 
perceived with 70% having a positive view of it. The most commonly prescribed 
physiotherapy interventions were exercises with a physiotherapist, exercises to 
be completed independently and advice or education from a physiotherapist. 
These three most commonly prescribed interventions also had the highest level 
of perceived efficacy from the respondents. The most common barriers to 
receiving physiotherapy were mobility, fatigue, continence, transport issues and 
needing the assistance of another person for the appointment. Finally, 42% had 
recently used a CAT for their MS. The most commonly utilised CAT were 
massage, reflexology, and relaxation or meditation.  
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Chapter 6 Survey of clinical services for people 
with Multiple Sclerosis in the UK – Discussion 
This chapter will discuss the results of the online survey. This was, at the time, 
the largest survey solely of people with progressive Multiple Sclerosis (MS) and 
the first to investigate service access and use in people with progressive MS in 
the United Kingdom (UK).  
This chapter will discuss, the access to and use of clinical services, including 
Disease Modifying Therapies (DMTs), by people with progressive MS and 
comparisons to previous research both in and outwith the UK. Secondly, 
physiotherapy access, delivery, desired delivery, interventions received, 
perceived efficacy, the effect on quality of life and disease impact, and barriers 
to receiving physiotherapy and will be discussed. The results regarding the use 
of Complementary and Alternative Therapies (CAT) and the evidence surrounding 
the most common CAT used will then be discussed, and finally the limitations of 
the study and recommendations for future work will be presented. 
 
6.1 Access to Multiple Sclerosis clinical services 
Access to an MS Specialist was high (95% overall) with slight variation depending 
on geographical location in the UK (range 92-98%). This result was higher than 
the results of the ‘My MS My Needs’ study conducted by the MS Society which 
found that 86% of their respondents had access to an MS Specialist (MS Society, 
2016c). This difference may be due to the fact that the present survey focussed 
on people with progressive MS and the survey carried out by the MS Society 
included people with all types of MS who will have different needs and possible 
different awareness of available services.  
The result of this present study was however, in contrast to that of two older 
and smaller studies conducted in the UK. These two studies, which had either 
half of their sample size made up of progressive MS or focused on those severely 
disabled, found that access to services was poor (Edmonds et al., 2007, MacLurg 
et al., 2005). The qualitative study carried out by Edmonds et al. (2007), which 
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examined access to MS clinical services by people severely affected by MS 
(Expanded Disability Status Scale (EDSS) >8.0) in London, reported that a lack of 
ability to gain access to clinical services was the most common theme among the 
32 participants. The results from this present survey indicated that access to an 
MS Specialist in the London area was 94%. Differences between these two results 
may be reflective of changes in service provision over the past decade and from 
differences in sample size as Edmonds et al. (2007) had a sample size of 32 and 
the sample size of this survey was 1,298 with 71 living in the Strategic Health 
Authority of London. Furthermore the mean physical impact of MS, as measured 
by the Multiple Sclerosis Impact Scale - 29 version 2 (MSIS-29), of respondents in 
this current study was 56/80 indicating a moderate level of physical impact 
while participants in Edmonds et al.’s (2007) study were severely disabled 
(EDSS>8.0) which may have impacted upon ability to access services. Lastly, the 
participants in the study by Edmonds et al. (2007) cited organisational barriers 
to accessing services such as a not being able to gain access to a clinician when 
needed, rather than the service not existing. This implies that Edmonds et al. 
(2007), although not explicitly stated, used a different definition of access to 
the one used in this present study, as access was defined as the existence of a 
service regardless of organisational or environmental barriers (section 4.1.1). 
Similarly a difference in definition of access may be the reason for differences 
seen in results between this survey and the research conducted by MacLurg et 
al. (2005). This study conducted in Northern Ireland, examined needs of 149 
people with MS (56% with progressive MS), and reported that access to 
physiotherapy was an unmet need regardless of disability (21%). This is in 
contrast to the results of the present study which found that access to 
physiotherapy and MS specialists to be high in Northern Ireland (95%). The 
researchers did not, however, define the terms ‘access’ or ‘unmet need’. 
Furthermore, 13% of the sample in the study by MacLurg et al. (2005) was 
receiving physiotherapy, which was lower than the 32% receiving physiotherapy 
in this present survey. Lastly, in this present survey Northern Ireland was the 
region which had the lowest number of respondents (n=21) limiting 
comparability of the two samples. 
A survey conducted by Lonergan et al. (2015) in the Republic of Ireland had 
similar results to MacLurg et al. (2005). A sample of 325 people with MS (50% 
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progressive) answered a questionnaire regarding access to MS clinical services. 
The researchers reported that there was a lack of access to physiotherapy 
services, especially among those with progressive MS, and who lived in a rural 
area (Lonergan et al., 2015). This is in contrast with the results found in this 
present study, as 87% had access to physiotherapy services, with no differences 
in access to services between those who lived in rural or urban locations. It 
should be noted however, that not only does the Republic of Ireland have a 
different healthcare system to the UK, the rural/urban spread of the UK and the 
Republic of Ireland is substantially different. The Republic of Ireland has 37% of 
its population living in a rural setting compared to 18% in the UK (World Data 
Bank, 2016). This difference in population spread may indicate different strains 
placed upon services, and may explain why there was no difference between 
rural and urban service delivery in the UK but was in the Republic of Ireland. 
Two separate qualitative research studies in Germany examined patient 
experience of MS clinical services (n=15, mean EDSS=7.0) (Galushko et al., 2014) 
and clinician opinion of MS clinical services (n=23) (Golla et al., 2012). Both 
studies reported that there was an unmet need in of access to services (Galushko 
et al., 2014, Golla et al., 2012) but cited the main reasons for this were long 
waiting times and a lack of home visits (Golla et al., 2012). These results are in 
contrast with the results of the present survey. Again, this difference may be 
due to differences in the definition of access, as the German participants cited 
organisational barriers affecting access to services. In addition, health service 
provision in Germany differs from that of the UK, with reports of a lack of multi-
disciplinary care due to financial constraints incurred by out-patient care 
(Maurice, 2014), which was reflected in the patient and clinician feedback.  
In general, in terms of access to MS services, the results of this survey were 
higher than previous research conducted. However, the difference in definitions 
of access may have led to these discrepancies, especially when other 
researchers were focusing on establishing the organisational and environmental 
barriers to gaining access and not measuring the availability of services. 
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6.2 Access to a clinical review 
Despite the high rate of access to MS Specialists the proportion of those 
receiving annual reviews was lower at 74%. This suggests a 26% shortfall in 
provision in service, according to the current National Institute for Health and 
Care Excellence (NICE) guidelines, and Healthcare Improvement for Scotland 
clinical standards for the management of people with MS (NICE, 2014b, 
Healthcare Improvement Scotland, 2009) which state that all people with MS 
should receive an annual review. In addition to there being a shortfall in overall 
provision, there was also a shortfall in the frequency of reviews, with 37% of 
respondents reporting that their review was less often than annually. This is 
again in contradiction to the NICE guidelines and Health Improvement Scotland 
standards. The importance of a regular review may increase in the future with 
the potential advent of a new disease modifying therapy for people with Primary 
Progressive MS (PPMS) becoming available on the NHS (European Medicines 
Agency, 2017), as without a review suitable patients for the new disease 
modifying therapy could potentially be overlooked.   
 
6.3 Use of Multiple Sclerosis clinical services  
The most utilised clinical services for the respondents’ MS were an MS Specialist 
Doctor or Nurse (50%), General Practitioner (45%), Physiotherapist (40%) and 
Occupational Therapist (24%). These results were in agreement with the GEMMS 
study conducted by Mynors et al. (2015), which found that the MS nurse was the 
most utilised practitioner. The UK results from a European wide study conducted 
by Kersten et al. (2000) (n=37), found that the most consulted clinicians were 
the same, but were consulted by a greater proportion of their sample: General 
Practitioner (95%), MS specialist (84%), Physiotherapist (62%) and Occupational 
Therapists (62%). The similarity of clinicians consulted but difference in rate of 
utilisation between the study by Kersten et al. (2000) and this present survey 
may indicate that the use of clinical services is similar between those with 
Relapsing Remitting MS (RRMS) and progressive MS but that services used by 
patients may have reduced over the past 17 years. However, the small sample 
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size representing the UK in the study by Kersten et al. (2000) may limit 
comparability between the two studies. 
 
6.4 Disease modifying therapies 
Five percent of this cohort were currently taking DMTs and 24% reported historic 
use of DMTs. This result is in contrast with the survey conducted by the MS 
Society which found that 56% of their cohort were taking a DMTs (MS Society, 
2016c). This difference in results is to be expected, as 57% of their cohort either 
had RRMS or Secondary Progressive MS (SPMS) but were still experiencing 
relapses and were therefore appropriate for DMTs prescription (Scolding et al., 
2015).   
Analysis revealed that current use of DMTs was associated with a better quality 
of life and previous use of DMTs was associated with a worse quality of life and 
worse physical and psychological disease impact. This is, again, as expected as 
respondents who are currently taking DMTs are likely to be in the early stages of 
SPMS and may still be experiencing relapses, and thus, are likely to have a lower 
level of disability and better quality of life (Scolding et al., 2015). Respondents 
not taking DMTs are, by definition, no longer experiencing relapses and thus, 
may experience greater disability and reduced quality of life (Scolding et al., 
2015). This is however, dependent on having access to DMTs which previous 
research has shown to vary across the United Kingdom (MS Society, 2016a, MS 
Society, 2016b). 
 
6.5 Physiotherapy 
6.5.1 Access 
Access to physiotherapy was high (87%) and 32% reported that they were 
currently receiving physiotherapy for their MS. Despite the high rate of access, 
this indicates a lack in service provision of 13%. This percentage of respondents 
without access to physiotherapy was similar to a result reported in the survey by 
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the MS Society which found that 17% did not have access to a physiotherapist (MS 
Society, 2016c). The slightly higher access figures in this present study may be 
due to those who have progressive MS, and likely higher disability, being more 
aware of their services available to them.   
The present survey found that 40% of the cohort received their physiotherapy 
from non-NHS sources, which is a slightly higher result found from the survey by 
the MS Society, which found that 32% of their cohort received their 
physiotherapy from non-NHS sources (MS Society, 2016c). The non-NHS sources 
used by respondents in this present survey were made up of self-funded private 
physiotherapy (20%), physiotherapy provided by a charity (16%), and medical 
insurance funded private physiotherapy (2%). If 16% of all physiotherapy care for 
people with progressive MS is being delivered by the third sector, this could 
indicate that, while these organisations are providing a valuable service to their 
clients, the NHS is not able to deliver the physiotherapy services that people 
with MS need and want. Furthermore, previous research has shown that 
perceptions of physiotherapy service delivery, for people with MS, were 
predominantly negative in the UK (Markwick et al., 2014). If, as was found in this 
present study, people with progressive MS have a high perceived efficacy of 
physiotherapy as a discipline, but a low opinion of the service delivered, they 
may seek out other avenues of physiotherapy delivery, for example private or 
charity-based physiotherapy. Further investigation is warranted to explore this 
further. 
 
6.5.2 Delivery of physiotherapy and waiting times 
Physiotherapy was predominantly delivered in either a clinical or hospital setting 
(46%), at home (25%), or in a charity centre (24%). The survey conducted by the 
MS Society found that 74% of MS care was in a hospital or clinical setting, only 
16% was provided at home and 12% of care was provided in a charity centre (MS 
Society, 2016c). It should be noted however, that the MS Society survey included 
people with all types of MS and the questions that were asked were related to 
MS care in general and not only physiotherapy. Furthermore, as the cohort from 
the current study all had a diagnosis of progressive MS they were more likely to 
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have a higher impairment compared to those with RRMS (Compston and Coles, 
2008). Having a higher level of impairment may lead to care being more likely to 
be received at home and previous research in Australia has shown that an 
increase in domiciliary care can lead to rationing of services and decreased 
volume of individual care (Adams et al., 2015). While this would still mean that 
they had access to these services, the quantity of services provided may be 
reduced and the overall needs of the patient may not be met. 
Ninety percent of this cohort expected to receive a physiotherapy appointment 
within 12 weeks. However, NHS waiting time targets vary across the four 
countries of the UK. In Scotland the target waiting time for an outpatient 
appointment is 12 weeks (Scottish Government, 2011). In Wales and England the 
target waiting time for an outpatient NHS appointment is 18 weeks (NHS 
England, 2016). In Northern Ireland the target for receiving an outpatient 
appointment is more complex. In 2015 they had a target of at least 80% receiving 
an appointment in nine weeks with no patient waiting more than 15 weeks 
(Department of Health, 2015). In 2017 this was revised to 50% of patients should 
be seen in nine weeks and no patient should wait longer than 52 weeks for an 
outpatient appointment (Department of Health, 2017). Initially this would imply 
that the respondents in this survey expected to be seen within the waiting time 
targets in their respective country. However, this study measured expected 
waiting time and not actual waiting times. A report by JJ Consulting (2011) 
summarised waiting times across the UK for physiotherapy appointments and 
found 83% of neurology patients were seen by a neurological physiotherapist in 
the NHS in eight weeks or less (JJ Consulting, 2011). Unfortunately the 
researchers did not have data on individual conditions such as MS, and the 
comparison of the results between the report by JJ Consulting and this present 
study should therefore be treated with caution. 
The positive result of the expected waiting time being less than the NHS targets 
is, however, nuanced as the expected waiting time of the respondent varied 
depending on their provider of physiotherapy. If a respondent received their 
physiotherapy only from non-NHS sources they were more likely to expect a 
shorter waiting time (27% less than a week and 39% expected in 1-2 weeks). This 
is substantially different from those who received their physiotherapy only from 
the NHS as just 2% expected to receive their appointment in less than a week 
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and 22% expected to be seen in 1- 2 weeks. This may explain further, why 
people with MS use charity based and private services.   
 
6.5.3 Desired Delivery 
Half of respondents (52%) reported that they would like more physiotherapy for 
their MS and the most common desired delivery of physiotherapy was: regularly, 
once a week, to be delivered at home, in a one to one setting with sessions 
lasting 30-60 minutes. This is similar to the current model of physiotherapy 
delivery received by respondents. The only difference was that current delivery 
was mainly delivered in a clinical or hospital setting. Similarly a previous survey 
found the majority of all MS care was delivered in a hospital or clinical setting, 
due to this the MS Society called for more home-based care to be delivered from 
the NHS (MS Society, 2016b). The results of this current survey demonstrate that 
the recommendation from the MS Society is aligned with the desires of this 
sample of people with progressive MS. However, delivery of services in this way 
would require increased provision of community-based care, which requires 
further resources to avoid rationing of services which can, as was previously 
stated, result in a decrease in quantity of therapy delivered, especially for those 
living rurally (Adams et al., 2015).   
 
6.5.4 Interventions received 
The most common physiotherapy interventions recently received for the 
respondent’s MS, were exercises to be completed independently (83%), exercises 
with a physiotherapist (71%) and advice or education from a physiotherapist 
(65%). Less frequently prescribed physiotherapy interventions were functional 
electrical stimulation (24%), standing table (17%), acupuncture (10%) and 
Transcutaneous Electrical Nerve Stimulation (TENS) (7%). All of these 
interventions received, apart from acupuncture, advice and TENS, have positive 
evidence for their efficacy in the rehabilitation in people with progressive MS 
(Chapter 3). The systematic review in Chapter 3 found that there was no 
evidence for the use of acupuncture in people with progressive MS (Donnellan 
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and Shanley, 2008). In addition, there is no evidence for the use of advice and 
education in people with progressive MS, although a Cochrane review of ten 
RCTs, found that provision of information increased knowledge of the disease of 
MS (Kopke et al., 2014). However, the results were inconclusive of the effects 
that information provision had on quality of life and on decision making but did 
highlight that there were no negative effects (Kopke et al., 2014). While there 
are no trials investigating the effect of TENS in people with progressive MS there 
is substantial evidence that it is effective in the treatment of pain (Sawant et 
al., 2015) and spasticity in MS (Fernandez-Tenorio et al., 2016). Interestingly 
TENS was the intervention which had the greatest negative perceived efficacy 
from respondents. This is discussed in more detail in section 6.5.5. 
The fact that almost all of the interventions received have positive evidence for 
their use in people with progressive MS, is a reflection of evidence-based 
practice that is implemented by UK physiotherapists. This is a sign of good 
quality care and compliance by UK physiotherapists with the Standards of 
Proficiency laid out by the Health and Care Professions Council (Health & Care 
Professions Council, 2014). 
 
6.5.5 Perceived efficacy 
Physiotherapy was generally perceived positively with 70% of respondents 
perceiving it to be either ‘beneficial’ or ‘very beneficial’ for their MS, and 
contrastingly only 3% felt that it would be harmful. Respondents were more 
likely to think that physiotherapy was ‘very beneficial’ if they were receiving 
physiotherapy and more likely to have an indifferent view if they were not 
receiving physiotherapy (Figure 5-3). These results were in contrast to the study 
conducted by Markwick et al. (2014), exploring opinions of clinical services for 
people with MS in England and Wales; which found that comments made were 
predominantly negative and that physiotherapy received the most negative 
comments out of all disciplines. Differences in results may lie in differences in 
methodology as respondents in the present study were asked about the effect 
they thought physiotherapy would have on them and Markwick et al. (2014) 
asked the opinion of the service delivered not the efficacy of the discipline. 
 122 
 
Studies conducted outwith the UK, produced findings similar to the results of the 
current survey. The three Scandinavian studies (Holmoy et al., 2012, Normann et 
al., 2012, Ytterberg et al., 2008) found that the opinion of physiotherapy was 
predominantly positive, with results ranging from 88% to 100% positive. 
However, all three studies recruited participants from single neurology clinics. 
This will have created sample bias and may not be representative of the MS 
population, or service provision, of their respective countries. 
The most commonly prescribed physiotherapy interventions were also the 
interventions that had the highest perceived efficacy from the respondents 
(section 5.2.2 and Chapter 3).  The intervention that had the largest proportion 
of negative opinions was TENS, with 13% of recipients considering it as ‘harmful’ 
or ‘very harmful’. This opinion is in contrast with two systematic reviews which 
concluded that TENS was both safe and effective in treating pain and spasticity 
in people with MS (Fernandez-Tenorio et al., 2016, Sawant et al., 2015). It was 
however, noted by Sawant et al. (2015), that MS type may affect the efficacy of 
TENS but neither review suggested that it was harmful. Furthermore respondents 
to this survey were not asked for which symptoms the interventions were 
prescribed, and the general opinion of TENS was still positive with 52% 
suggesting that it would be either ‘beneficial’ or ‘very beneficial’ for them. 
 
6.5.6 Barriers to receiving physiotherapy 
The most commonly reported barriers to receiving physiotherapy were mobility, 
fatigue, continence issues, transport issues and needing someone to go with 
them to the appointment. Respondents were then asked to select their three 
most problematic barriers. The outcome of which was the same barriers but also 
included pain. Overall, these barriers can be separated into two categories: 
logistic (transport problems and needing someone to go with them) and 
symptomatic (mobility, fatigue, continence and pain). A previous study 
examining barriers to exercise among people with MS found similar barriers to 
those found in the current survey (Asano et al., 2013). When non-disease specific 
barriers such as lack of time or money were excluded the most commonly 
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reported barriers in Asano et al.’s study were fatigue (87%), impairment (60%), 
needing assistance from someone else (22%) and transport issues (18%). 
The logistic barriers (transport problems and needing someone to go with them) 
could be addressed by an increase in home-based care or provision of volunteer 
drivers for appointments. As already discussed, one of the recommendations 
from the survey conducted by the MS Society (2016b) was an increase in home-
based care for people with MS; and there are some NHS health boards in 
Scotland which already provide volunteer drivers for patients to attend 
appointments (NHS Ayrshire & Arran, 2016). Additionally, steps could be taken 
by service providers to address the symptomatic barriers by establishing the 
needs of the patient from consultation and being pro-active to address them. For 
example, a patient who has identified that they have issues with continence or 
fatigue could have clearly signposted nearby toilets and adjusting timing of their 
appointments to a time of day when their fatigue is at its least debilitating.  
 
6.5.7 Quality of life and disease impact 
There were no differences in disease impact or quality of life scores in those 
who did and did not have access to an MS Specialist.  As this was a cross-
sectional study, it was not possible to draw causality, or lack thereof, between 
these variables. However, those who received more than one clinical service for 
their MS had a poorer quality of life (EQ-5D-3L index), and worse psychological 
and physical disease impact scores (MSIS-29 version 2), compared to respondents 
who only received one clinical service. This may be expected as those who had a 
poorer quality of life and a higher impact of disease would warrant more 
services to manage their symptoms.   
Having access to a physiotherapist or being in receipt of physiotherapy was not 
associated with differences in quality of life or disease impact measures. 
Interestingly those who desired more physiotherapy than they currently received 
for their MS, had a poorer quality of life and higher physical and psychological 
impact of MS, than those who were happy with their current physiotherapy 
provision. This desire for more physiotherapy, when having a poorer quality of 
life, may arise from the high perceived efficacy of physiotherapy held by the 
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respondents. However, even though there is evidence to support the use of 
exercise, which is among the most commonly prescribed interventions in this 
sample, in improving quality of life in people with MS (Dalgas et al., 2010, 
Latimer-Cheung et al., 2013) being in receipt of physiotherapy, as a discipline, is 
not associated with a better quality of life (Yamout et al., 2013). 
While statistically significant differences in quality of life and disease impact 
measures were found, the differences were small and not likely to be clinically 
significant. In MS, the Minimal Clinically Important Difference (MCID) of the EQ-
5D-3L index ranges from 0.065-0.158 when compared to the Patient Determined 
Disease Steps and 0.068-0.098 when compared to the MS Walking Scale-12 (Kohn 
et al., 2014). The largest difference observed in the EQ-5D-3L index between 
any two sub-groups analysed in this present study was 0.063 between those with 
PPMS and SPMS, indicating that a difference in quality of life, while statistically 
significant, was not clinically significant. 
Similarly the MCID of the physical sub-scale of the MSIS-29 version 1 is a 
difference of eight points (Costelloe et al., 2007b) and in the psychological sub-
scale a decrease of six or more is deemed to be clinically significant (Widener 
and Allen, 2014). The largest difference in MSIS-29 physical sub-scale scores was 
between participants with PPMS and SPMS, was three points. While there is no 
MCID data for version 2 of the MSIS-29, this difference while statistically 
significant, may not be clinically significant.  
 
6.6 Complementary and alternative therapies 
In total, 38% of respondents reported that they had used a CAT for their MS in 
the prior three months. This result is lower than that from previous research 
carried out in Germany (67%), the United States of America (58%), and the 
Nordic countries (46-58%) (Apel et al., 2006, Skovgaard et al., 2012, Stoll et al., 
2012). Conversely, CAT use in Turkey was lower, with 26% of people using a CAT 
for their MS (Gedizlioglu et al., 2015). The lower proportion of people using CAT 
in the current study compared with previous research conducted in Germany, 
the United States of America and the Nordic countries, may be due to the 
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majority of participants in other studies having RRMS with time since diagnosis 
between seven and nine years (Apel et al., 2006, Gedizlioglu et al., 2015) 
whereas the current study focussed on people with progressive MS, with a mean 
time since diagnosis of 16 years. It is known that people with MS are more likely 
to try using CAT in the early stages of their disease course (Kochs et al., 2014), 
however the analysis in this present study found that time since diagnosis was 
not a factor in the current use of CAT.  
There were no differences between those who had or had not recently used CAT 
in terms of quality of life, disease impact scores, time since diagnosis, MS type 
or living in a rural or urban location. Use of CAT was however, dependent on 
gender, with recent CAT use higher in women. Previous research examining 
gender and use of CAT is heterogenic. Two previous studies found that CAT use 
was higher amongst women (Skovgaard et al., 2012, Stoll et al., 2012) while one 
study found that CAT use was not dependent on gender (Apel et al., 2006). 
The most commonly used CAT in the current study were massage (41%), 
reflexology (29%), meditation (24%), hyperbaric oxygen therapy (17%), 
acupuncture (14%), chiropractic (11%), herbal medicine or homeopathy (8%) and 
Reiki (7%). Similarities were found between this result and that of previous 
research. Acupuncture was reported amongst the most commonly used CAT in 
the United States, Denmark, Sweden, Finland, Iceland and Norway (Skovgaard et 
al., 2012, Stoll et al., 2012). In the United States, like the United Kingdom, 
massage was the most used CAT (Stoll et al., 2012), and it was the fifth most 
popular in Germany (Apel et al., 2006). However there were also differences 
between the most commonly used CAT by this study’s sample and that of 
samples from other countries. Hyperbaric oxygen therapy was not reported as a 
commonly used CAT in any of the previous research. Reflexology, the second 
most used CAT by this present study’s sample, was only popular in Denmark and 
not any of the other countries previously surveyed. Lastly, CAT use in the Nordic 
countries was dominated by supplements (range of use 58-80%) while in this 
present sample just 2% had recently used a supplement for their MS. 
Differences in CAT used in the present study and the findings from previous 
research may be because the present study focussed only on people with 
progressive MS in the UK, and previous research has included participants with 
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all types of MS. Furthermore, differences in cultural perceptions of CAT may also 
be responsible for differences seen from country to country (Olsen, 2009). 
Lastly, differences in methodology may have been responsible for differences in 
data collection. The Nordic and American studies, like this present study, 
collected data from closed question surveys while the German research used 
semi-structured interviews. 
Exercise was cited as one of the most common CAT in all previous research. In 
this present study, pilates, yoga or Tai Chi were cited 86 times as a CAT used 
recently by the sample in this present study. There is a compelling argument 
that these interventions fall under the umbrella of exercise and physical 
activity, and thus physiotherapy (Lan et al., 2008, Smith et al., 2011, Wells et 
al., 2012).  
 
6.7 Differences between Multiple Sclerosis type 
When compared to the respondents who had SPMS, those who had PPMS were 
older, had a shorter time since diagnosis, a better quality of life and less of a 
psychological and physical impact of MS. Differences in quality of life and 
disease impact are likely explained by the shorter disease duration as time since 
diagnosis is a prognostic factor of impairment and quality of life (Damasceno et 
al., 2013). However, it should be noted, as was explained in section 6.5.7 that 
these differences were not clinically significant. This may explain why there 
were no differences in other variables between those with SPMS and PPMS such 
as access to specialists, access to physiotherapy, receiving physiotherapy or a 
regular review or the use of CAT. 
 
6.8 Limitations 
This survey was limited by its cross-sectional design, meaning that it was not 
possible to draw causality between any variables from results that were found. 
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However, as this is the first study to focus on service access and use in people 
with progressive MS in the UK it lays the foundations for future work. 
Participation in the UK MS Register is voluntary and therefore it has the 
potential for sample bias to those 4,384 members who were active in their use 
of the register. Furthermore it also has the potential to miss those who are very 
severely affected by MS, as they may find completing online questionnaires more 
difficult. One of the other limitations of surveying people through the UK MS 
Register is that currently respondents self-report their diagnosis of MS and 
progressive MS. Thus it is possible, that some respondents did not have 
progressive MS or even MS at all. However, the large sample size of this study 
should attenuate any bias created. In addition, the long term plan of the UK MS 
Register is to form data links with clinical data from the NHS. This should in time 
eliminate this limitation entirely for future studies. 
There was a lack of geographical data available for those living in Northern 
Ireland. This meant that comparison of rural/urban locations was not possible 
for this part of the UK.  Furthermore, respondents from Northern Ireland made 
up just 2% of the cohort.   
Due to the programming of the online survey some respondents did not answer 
all of the questions. The question which respondents most often missed was 
about expected waiting times for a physiotherapy appointment. This question 
was in the first section of the survey. Participants may have missed this question 
due to problems with memory recall, and not due to the length of the survey, as 
questions later in section three had a high number of responses (n=1,248). As 
just 192 participants successfully completed this question, this meant that, 
despite the sample size being 1,298, just these 192 completed the survey in its 
entirety.  
Due to a programming error at the UK MS Register the clinical professions of MS 
Doctor and MS nurse were combined. It was therefore not possible to consider 
each of these professions separately and thus the results were presented 
together. Lastly, due to restraints from ethical approval, it was not possible to 
compare the demographics, quality of life and disease impact measures of those 
on the UK MS Register who did and did not answer the survey. 
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6.9 Recommendations, future work and conclusions 
Despite the high levels of access to physiotherapy and MS Specialists 5% of 
respondents did not have access to an MS Specialist, 26% did not have access to a 
regular review for their MS, and 13% of people with progressive MS did not have 
access to a physiotherapist.  These are short comings when compared to the 
guidelines and standards set in the UK which state that all people with MS should 
have access to these services (Healthcare Improvement Scotland, 2009, NICE, 
2014b). Service providers should make steps towards addressing these gaps. 
Also, some barriers were highlighted in accessing physiotherapy, some of which 
were modifiable and could be addressed.   
Further research should be conducted, to investigate the reasons for people with 
progressive MS seeking out physiotherapy services from non-NHS sources, and if 
the reasons are related to opinions of NHS services. Lastly a second survey may 
be warranted with the same respondents at a later date to examine changes in 
impairment and quality of life over time, potentially draw deeper understanding 
of the cohort as their disease progresses, and to also monitor potential changes 
in progression. 
In conclusion this study was the first to examine access and use of services by 
people with progressive MS in the UK. As such it had the largest sample solely 
made up of people with progressive MS to be surveyed to date. The outcome of 
the survey showed that access to physiotherapy, and MS Specialists was high. 
Whilst this was promising, this does indicate that 5% did not have access.  
Furthermore, a greater lacking was found in the provision and delivery of regular 
reviews, as such, service providers should aim to address this gap. 
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Chapter 7 High intensity interval training in 
people with progressive Multiple Sclerosis  
 
This chapter will present a brief overview of exercise and aerobic fitness in 
Multiple Sclerosis (MS) before discussing the effect exercise has on Brain Derived 
Neurotrophic Factor (BDNF), blood lipids, mental processing speed and fatigue. 
High Intensity Interval Training (HIIT) will then be defined before presenting a 
systematic review of the literature for using HIIT in people with MS, which will 
highlight gaps in the current literature. This systematic review has been 
submitted for publication in Multiple Sclerosis and Related Disorders.  
 
7.1 Exercise and aerobic fitness in Multiple Sclerosis  
Exercise is a safe and feasible intervention for people with MS, is recommended 
for increasing cardiovascular fitness and muscular strength (Latimer-Cheung et 
al., 2013), and evidence suggests that it may have a small effect on fatigue 
(Heine et al., 2015) and quality of life (Motl and Gosney, 2008). Cardiovascular 
fitness in people with MS is lower compared to healthy individuals (Langeskov-
Christensen et al., 2015) and is inversely correlated with disease severity and 
impairment, with fitness and conditioning decreasing as disability and fatigue 
rises (Heine et al., 2014, Heine et al., 2016, Kuspinar et al., 2010, Motl and 
Fernhall, 2012, Marrie and Horwitz, 2010, Valet et al., 2016). Reviews of trials 
evaluating the effects of exercise in people with MS have indicated that exercise 
training is beneficial for reversing deconditioning, and thus increasing 
cardiovascular fitness (Dalgas et al., 2008, Rietberg et al., 2005).   
 
7.2 Brain Derived Neurotrophic Factor 
Brain derived neurotrophic factor is a 252 amino acid protein, coded by the 
BDNF gene, which stimulates growth of new neurons, promotes synaptic 
conductivity and supports the survival of existing neurons in both the central and 
peripheral nervous systems (Johnston, 2009). It has been linked to 
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neuroplasticity and, of all the neurotrophins, is the most responsive to exercise 
(Knaepen et al., 2010).   
Exercise and physical activity can increase the expression of the BDNF gene and 
upregulate BDNF in some brain areas, most notably the hippocampus, which is 
responsible for learning and memory processes (Vaynman and Gomez-Pinilla, 
2005). In rat models, larger BDNF responses are seen with higher levels of 
exercise, and dips in BDNF levels with a decrease in exercise (Neeper et al., 
1995). 
Resting serum concentrations of BDNF can vary in healthy (non-trained) subjects 
with a review of human studies reporting concentrations ranging from 1.5 to 
30.9 ng/ml (Knaepen et al., 2010). Serum BDNF concentrations are altered by a 
number of cardiovascular disease risk factors such as Body Mass Index (BMI) and 
glucose tolerance (Suwa et al., 2006), neurological diseases such as Parkinson’s 
and Alzheimer’s disease (Ventriglia et al., 2013), depression and anxiety (Rabie 
et al., 2014), sex, fitness and lifestyle factors such as binge drinking (Bus et al., 
2011).   
Neurotrophins are either released continuously when they are synthesised to 
maintain a constant concentration or stored in secretory granules and released 
in response to extracellular stimuli (Farhadi et al., 2000). Brain derived 
neurotrophic factor is produced and stored in this latter way and exercise can 
increase the level of the transcriptional regulator cAMP response element 
binding protein, which decreases the impact of downstream effectors on BDNF, 
resulting in increased upregulation of BDNF (Vaynman et al., 2003). Once BDNF 
has been produced in the brain, it is able to cross the blood brain barrier, hence 
its presence in peripheral circulation (Poduslo and Curran, 1996, Pan et al., 
1998). In healthy individuals BDNF serum concentrations increase both during 
and after an acute bout of exercise (Rasmussen et al., 2009, Ferris et al., 2007, 
Seifert et al., 2010). Along with increased levels of BDNF there is also an 
increased absorption rate by tissues and generally, BDNF serum concentrations 
return to baseline levels after 10-60 minutes (Knaepen et al., 2010). 
A recent meta-analysis of 29 studies investigating the response of BDNF levels to 
training in healthy adults found that resting concentrations of BDNF in both 
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plasma and serum were modestly higher after aerobic training programmes but 
not after resistance training programmes (Dinoff et al., 2016). Another meta-
analysis of 29 studies reported an increase in BDNF in response to a single bout 
in healthy individuals and a modest increase in resting concentrations after 
training but also, that training increased the BDNF response to a single bout of 
exercise (Szuhany et al., 2015). The authors did note, however, that even 
though there were increased levels of BDNF in circulation this did not necessarily 
mean that cerebral levels were also raised (Szuhany et al., 2015). This is an 
important point when examining the results of exercise studies as BDNF is 
predominantly measured in peripheral serum.  
 
7.3 Brain Derived Neurotrophic Factor in people with 
Multiple Sclerosis 
To date, there have been seven studies that have investigated the effect of 
aerobic exercise on BDNF concentration levels in people with MS (Bansi et al., 
2013, Briken et al., 2016, Castellano and White, 2008, Gold et al., 2003, Schulz 
et al., 2004, Wens et al., 2016, Zimmer et al., 2017). Four studies investigated 
the effect of both a single bout of exercise and the effect of training on resting 
BDNF levels (Bansi et al., 2013, Briken et al., 2016, Castellano and White, 2008, 
Schulz et al., 2004), two studies investigated just the effect of training on 
resting levels (Wens et al., 2016, Zimmer et al., 2017) and one study 
investigated just the effect of a single bout of exercise (Gold et al., 2003). 
Reported mean resting levels of BDNF ranged from 4.435 ng/ml (Schulz et al., 
2004) to 24.663 ng/ml (Zimmer et al., 2017) (Table 7-1). However, previous 
research has shown that the brand of Enzyme-Linked Immunosorbent Assay 
(ELISA) kit used to measure BDNF concentrations can have an effect on the result 
(Polacchini et al., 2015). Indeed the three lowest concentrations reported were 
within 1 ng/ml of each other and all used the same ELISA kit from Promega-
EmaxTM. All other measurements obtained using different brands of ELISA kit 
were more than double the concentrations of those made with a Promega-
EmaxTM kit (Table 7-1). However, other factors such as lifestyle and BMI may 
have also affected BDNF levels (Suwa et al., 2006) indicating that differences in 
baseline measurements could be multi-factorial. 
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Table 7-1 Evidence table for studies investigating response of brain derived neurotrophic factor to exercise 
Authors, 
Year 
MS type, 
EDSS 
Design Intervention  
  
Time points, 
ELISA kit 
Baseline 
BDNF 
(ng/ml) 
Response to 
single bout 
Response to training 
Bansi et 
al. 
2012  
N=60 
MS type 
NR 
EDSS 1-
6.5  
Mean 4.7 
 
RCT 
Aqua 
cycling 
Vs 
Land cycling 
Aqua: 3 wk, 5 x wk, 30 
min 60% VO2max cycling 
Land: a/a but on land 
Resting,  
0 min post 
test 
 
0 wk, 4 wk 
 
Millipore 
Aqua; 
14.522  
  
Land: 
19.410  
O wk: no changes 
in either group 
3 wk: Aqua: 
increase after 
stress test +4.519 
ng/ml (p=0.002) 
Increase in aqua 
group resting  +3.387  
(p=0.046) 
 
 
Briken et 
al. 
2016 
PP: 11 
SP: 31 
 
EDSS: 4.9 
(0.8) 
RCT 
MS ex vs MS 
no ex 
Ex: 9 wk, 2-3 x wk aerobic 
interval training (intensity 
not given) 
 
C: wait list 
Resting,  
0 min post-
test,  
30 min post-
test 
 
0 wk, 9 wk 
 
Promega 
5.203 (SD 
1.511) 
0 and 9 wk: All 
participants 
increased 
immediately 
(p<0.001), 30 min 
dropped below 
baseline (p<0.05) 
 
No diff between 
groups 
No change in either 
group (p=0.27) 
Castellano 
and White 
2008 
N=22  
 
RR: 11, 
HC: 11 
 
CT 8 wk , cycling, 3 x week, 
30 min, 60% VO2 peak 
BDNF 
resting, 30 
min, 2 hour 
post, and 3 
hour post 
MS: 
~10.000 
(SD 
10.000) 
 
All participants: 
Decrease 2hr and 
3 hr after ex at 
0,4, and 8 wks 
(p<0.001) 
WG MS group 
increase at 4 wks 
(p=0.04) 
 
No change in controls 
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Mean 
EDSS 3.4 
stress test. 
 
0 wk, 4wk, 8 
wk 
 
R&D systems 
HC: 
~20.000 
(SD 
15.000) 
 
(p=0.026) 
 
No difference in 
AUC response 
between wk 
0,and wk4 
(p=0.2) or wk 8 
(p=0.3) 
at 4 wks or 8 wks. 
 
No diff in resting 
concentration BG at 
8 week (p=0.07) (i.e. 
increase in MS group) 
 
Gold et al. 
2003 
N=25 with 
MS 
N=20 
matched 
HC 
MS: RR: 
20, SP: 4, 
PP: 1 
Mean 
EDSS 2.3  
CT 
MS vs HC 
30 min 60% of VO2max Resting 
0 min post 
test 
30 min post 
test 
 
Promega 
MS: 4.435 
(SD 0.533) 
 
HC: 4.717 
(0.492)  
 
(p=0.1) 
0 min: increase 
~1.500 ng/ml 
30 min: returned 
close to baseline  
 
No diff between 
groups (p=0.03) 
n/a 
Schulz et 
al. 
2004 
N=26 
RR: 19 
SP: 5 
PP: 2 
Mean 
EDSS 2.3  
RCT 
MS ex vs MS 
no ex 
Ex: 8 wk, 2 x wk, 30 min 
75% peak power 
 
C: nil 
 
BDNF measured after 30 
min, 60% VO2max stress 
test: pre, immediate post, 
30 min post 
Resting, 
AUC from 
resting, 0 
min, 30 min 
post test 
 
Promega 
EX: 4.353 
(SD 3217)  
 
C: 5.081 
(SD 2312)  
 
(p=0.24) 
AUC Not diff 
between groups. 
(p=0.18) 
 
Resting to 30 min 
post 
concentrations 
not reported 
 
No diff BG resting 
(p=0.17) 
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Wens et 
al. 
2016 
N=41 
MS: 22 
HC: 19 
(comparis
on at 
baseline) 
 
RR: 22 
Mean 
EDSS: 2.6 
RCT  
MS ex vs MS 
no ex 
(both 
compared 
to HC at 
baseline) 
Ex: 24 wk, 5 x 2wk 
Aer+Res  
Aer: start 1 x 6min 
progressing to 3x 10 min 
12-14 Borg RPE 
Res: leg press, curl, 
extension, vertical 
traction, arm curl, chest 
press all 1 x 10 reps, prog 
to 4x 15 reps, Borg RPE: 
12-14 . 
C: no training. 
Resting  
 
0 wk, 24 wk 
 
Meso Scale 
Discovery 
MS: 
11.978 
(SD 0.785)  
 
HC: 
15.200 
(1.124)  
 
(P=0.02) 
n/a 24 wk: BG diff 
(p=0.04) but change 
only sig WG in C 
 
WG:  
C: -10.5% (SD 4.1) 
(p=0.02)  
Ex: +13.9% (SD 8.8) 
(p=0.1) 
 
Zimmer et 
al. 2017 
N= 60 
MS:RR: 
33, SP: 27 
 
EDSS 
range 1.0-
6.5 
Mean 4.37 
RCT 
HIIT vs 
CONT 
HIIT  vs  CONT 
3 wks, HIIT 3 x wk, CONT: 
5 x week 
 
HIIT: 20 min, 5x 3 min 
intervals at 85-90% of 
HRMax, with 1.5 min 
working rest at 50-60% 
HRMax 
CONT: min 70% HRMax 
Resting 
 
0 wk, 3 wk 
 
R&D systems 
HIIT: 
20.965 
(SD 
10.606)  
 
CONT: 
19.286 
(SD 
11.234) 
n/a No change seen in 
HIIT or CONT groups 
 
Final HIIT 
concentration 24.663 
(SD 13.019) 
Abbreviations: EDSS: expanded disability status scale; n: number of participants; NR: not reported: MS: multiple sclerosis; PP: primary progressive; SP: secondary 
progressive; RR: relapsing remitting; HC: healthy controls; RCT: randomised controlled trial; vs: versus; ex: exercise; CT: controlled trial; HIIT: high intensity 
interval training; CONT: continuous moderate intensity training; min: minute; VO2max: maximal oxygen uptake; a/a: as above; wk: week; hr: hour; C: control 
group; BDNF: brain derived neurotrophic factor; aer: aerobic training; Res: resistance training; Borg RPE: borg scale of perceived exertion; AUC: area under curve; 
WG: within group; BG: between group 
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7.3.1 Effect of an acute bout of exercise on levels of Brain 
Derived Neurotrophic Factor in people with Multiple 
Sclerosis 
An increase in BDNF concentrations following an acute bout of exercise was 
found in four of the five studies (Bansi et al., 2013, Briken et al., 2016, Gold et 
al., 2003, Schulz et al., 2004) (Table 7-1). Conversely, Castellano and White 
(2008) reported a decrease in serum BDNF concentrations following their 
exercise stress test. While their exercise test of 30 minutes at 60% of VO2max, 
was similar to that of both Bansi et al. (2013) and Gold et al. (2003), they 
differed in the time points that samples were collected. Castellano and White 
(2008) collected samples 30 minutes after the stress test while all other studies 
collected samples immediately on completion of the test. However, Briken et al. 
(2016) reported an increase in BDNF immediately following the exercise stress 
test which then dropped to below baseline 30 minutes later, and Gold et al. 
(2003) reported that their samples had returned to close to baseline 30 minutes 
after the stress test. This may explain the heterogeneity in the results, but 
neither of these two studies took measurements later than 30 minutes. It has 
been suggested that the 30 minute gap between finishing the exercise test and 
taking samples by Castellano and White (2008) is the reason that an increase was 
not seen (Knaepen et al., 2010). Of note the concentrations of BDNF from 
healthy controls in the study also decreased and was not statistically different 
from the MS participants (Castellano and White, 2008). Indeed the two studies 
which used healthy controls (Castellano and White, 2008, Gold et al., 2003), did 
not find any difference in the changes in BDNF levels between the MS 
participants and healthy controls. This indicates that the response of BDNF 
concentrations to an acute bout of exercise may be similar to that of healthy 
individuals.   
 
7.3.2 Effect of aerobic training on levels of Brain Derived 
Neurotrophic Factor in people with Multiple Sclerosis 
While the evidence for a positive response to BDNF levels to a single bout of 
exercise is strong, the evidence for the effect of training on resting BDNF 
concentrations is inconclusive in people with MS. From the six studies that 
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investigated the effect of training on resting serum levels of BDNF, three found 
an increase after their intervention (Bansi et al., 2013, Castellano and White, 
2008, Wens et al., 2016) and three did not find any changes (Briken et al., 2016, 
Schulz et al., 2004, Zimmer et al., 2017) (Table 7-1). 
Schulz et al. (2004) compared resting BDNF concentrations of a training group 
and a control group of people mildly affected by MS (mean EDSS 2.3), and who 
predominantly had RRMS. The training group received eight weeks of twice 
weekly training sessions of 30 minutes of cycling at 75% of peak power. The 
control group received no training. The researchers found no difference in 
resting BDNF concentrations between the groups at baseline or after the 
exercise intervention. Another study by the same research group, Briken et al. 
(2016), also found no change in resting BDNF concentrations of their intervention 
or control group when they compared 9 weeks of aerobic training (intensity not 
reported), two to three times per week to no training.  Briken et al. (2016) were 
the only research group to recruit people solely with progressive MS and a higher 
disability level (mean EDSS 4.9). The third study not to find a change in BDNF 
levels after training was conducted by Zimmer et al. (2017). These researchers 
compared 3 weeks of thrice weekly HIIT at 85-90% HRMax to continuous 
moderate intensity training 5 times per week at 50-60% of HRMax (Zimmer et al., 
2017). The cohort comprised participants both with RRMS and SPMS who were 
moderately disabled (mean EDSS of 4.4) (Table 7-1). 
Wens et al. (2016) conducted a RCT which compared the effects of exercise to a 
sedentary control group in people with MS, as well as healthy controls. The 
training group received 30 sessions of progressive continuous cardiovascular and 
resistance exercise over 24 weeks. This cohort comprised people with RRMS and 
were mildly affected (mean EDSS of 2.6). The cardiovascular training started at 
1 x 6 minutes per session and progressed to 3 x 10 minutes per session. 
Resistance training started at 1 x 10 reps of each exercise and progressed to 4 x 
15 reps. Intensity for all exercise was between 12 and 14 on the Borg scale of 
perceived exertion and a full list of resistance exercises can be seen in Table 
7-1. The authors reported that the participants with MS had a lower resting BDNF 
concentration compared to the healthy matched controls. The authors also 
reported that, at the end of the training intervention, the exercise group had a 
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higher resting BDNF concentration compared to the sedentary group who 
displayed a decrease in their resting concentration.   
The controlled trial by Castellano and White (2008) compared resting BDNF 
levels of 11 mildly affected (mean EDSS 3.0-4.0) people with RRMS against 
healthy controls after eight weeks of thrice weekly training of 30 minutes at 60% 
of VO2 peak (Table 7-1). The authors found that while the resting BDNF 
concentrations were lower in those with MS at baseline, they were not different 
between the two groups at the end of the intervention indicating a training 
effect in the MS participants but not the healthy controls.   
An RCT by Bansi et al. (2013) compared aquatic cycling to on-land cycling in 
people with MS. This sample was moderately disabled by their MS (mean EDSS 
4.7) but the MS type of participants was not reported. Both groups exercised at 
60% of VO2max five times per week for three weeks. The researchers found an 
increase in resting BDNF concentrations in the aquatic cycling group but not in 
the land-based cycling group.   
The conflicting evidence for the effect of training on resting BDNF levels in 
people with MS indicates that further investigation is warranted in this field.  
While four out the six studies had cohorts that were mildly impaired and two had 
samples that were moderately impaired, level of disability did not appear to 
affect the results. However, the three studies that included people with 
progressive MS, either as a whole cohort (Briken et al., 2016) or within a mixed 
population (Schulz et al., 2004, Zimmer et al., 2017), did not report an increase 
in BDNF concentrations after the training interventions. These three studies 
would suggest that aerobic training did not have an effect on resting BDNF 
concentrations. However, two of these studies did not provide a power 
calculation (Briken et al., 2016, Schulz et al., 2004) and while one did provide a 
power calculation it was for cognitive testing and not BDNF (Zimmer et al., 
2017). Therefore further research, with a fully powered sample, is required to 
deny or confirm the lack of effect of exercise training on resting BDNF levels in 
people with progressive MS.  
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7.4 Effect of exercise on blood lipids in people with 
Multiple Sclerosis 
Lipoproteins carry cholesterol ester and fat in the form of triglyceride around 
the body as these substances are hydrophobic and thus non-soluble in blood 
(McArdle et al., 2006). Lipoproteins fall into two broad categories: High Density 
Lipoproteins (HDL) and Low Density Lipoproteins (LDL). The HDL are smaller and 
less likely to cause atherosclerosis while LDL are exponentially larger and are 
more likely to cause atherosclerosis (Barquera et al., 2015). Low density 
lipoproteins become attached to the endothelium, release cholesterol into the 
arterial wall and become oxidised initiating an inflammatory response (Pryor and 
Ammani Prasad, 2008). This attracts macrophages which ingest the LDL and 
become “foam cells” (McArdle et al., 2006). This in turn encourages production 
of smooth muscle cells which ingest some of the lipid, and also become foam 
cells, before being covered in a fibrous cap which gives the visual appearance of 
a fatty streak (Lu and Daugherty, 2015).   
In early MS, high levels of HDL are associated with lower blood brain barrier 
permeability (Fellows et al., 2015) and low levels of HDL and high levels of total 
cholesterol are associated with inflammation in MS (Mandoj et al., 2015, Tettey 
et al., 2014, Weinstock-Guttman et al., 2011). In people with higher EDSS 
scores, high levels of total cholesterol, low HDL and high LDL levels are 
associated with poor clinical and MRI outcomes (Zhornitsky et al., 2016). 
While LDL levels are considered to be a risk factor for cardiovascular disease, 
NICE guidelines have recommended that non-HDL cholesterol levels should 
instead be used a surrogate marker. This is due to ease of measurement, as LDL 
measurement requires a fasting sample while non-HDL cholesterol does not 
require fasting (NICE, 2014a). The recommended level of total cholesterol is 5 
mmol/l or less. Non-HDL levels should not exceed 4.0 mmol/l, HDL levels should 
be 1.0 mmol or more and non-fasting triglyceride should not exceed 2.3 mmol/l 
(Heartuk.org.uk, 2017). A review by Wens et al. (2013) found that it was unclear 
whether people with MS were at risk of developing cardiovascular disease from 
dyslipidemia because studies measuring cholesterol, triglyceride and HDL levels 
produced conflicting results. An investigation into the effects of eight weeks of 
progressive resistance training in women with an EDSS of 4.0 found no effect on 
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triglyceride, total cholesterol or HDL levels (White et al., 2006). Similarly, even 
though physical activity is associated with lower total cholesterol and HDL levels 
in healthy adults, this is not necessarily true for people with MS, but physical 
activity may have a beneficial effect on fasting triglyceride levels (Slawta et al., 
2002). Finally, a cohort trial by Keytsman et al. (2017), which investigated the 
effects of 12 weeks of HIIT and resistance training in people with RRMS 
(described in detail in section 7.13) did not report any changes in HDL, LDL, 
total cholesterol or fasting triglycerides. Despite these three studies there has 
not been an investigation into the effect of aerobic exercise on lipoprotein and 
cholesterol levels in people with progressive MS.   
 
7.5 Effect of exercise on mental processing speed in 
people with Multiple Sclerosis 
Cognitive disorders in general in MS were discussed in section 2.7.8.  A recent 
systematic review, which included nine studies, reported that the evidence was 
conflicting regarding the effect of exercise training on mental processing speed 
in people with MS (Sandroff et al., 2016). The same review found that although 
evidence was limited, there was an indication for an increase in processing 
speed after an acute bout of exercise in people with MS (Sandroff et al., 2016). 
Since this review has been published an investigation into the effects of HIIT on 
mental processing has been carried out. This RCT by Zimmer et al. (2017) 
(described later in detail in section 7.13) found that both the HIIT and 
continuous training groups improved their mental processing as measured by the 
Symbol Digit Modalities Test (SDMT) but that there was no difference between 
the groups.  
 
7.6 Effect of exercise on fatigue in people with Multiple 
Sclerosis 
Fatigue was discussed in detail in section 2.7.5. In people with MS with mild to 
moderate disability, fatigue is often reported as the most disabling symptom and 
having the largest impact on quality of life (Strupp et al., 2012, Wynia et al., 
2008). A Cochrane review of studies exploring exercise in the management of 
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fatigue in people with MS concluded that while the evidence suggested a positive 
effect, it was weak, and noted the majority of studies did not target those who 
were fatigued or severely fatigued (Heine et al., 2015).    
 
7.7 High Intensity Interval Training 
Traditionally, exercise programmes to increase fitness and reduce cardiovascular 
disease risk factors entail 30-60 minutes of Continuous moderate intensity 
training (CONT) at 40-85% of maximal intensity, with higher intensities producing 
a greater increase in fitness (Pollock et al., 1998). High Intensity Interval 
Training, however, involves short bursts of exercise at higher intensities with 
either a complete or working rest in between bursts. Training sessions typically 
last around 20 minutes, have 4-6 cycles of 80-95% of maximal effort for 1-4 
minutes with a similar time of working recovery at approximately 40% of 
maximal effort (Cassidy et al., 2017, Kessler et al., 2012).   
Aerobic HIIT can be traced back to the 1970s, Sebastian Coe reported in his 
autobiography that his father developed a 200 m training regime, running 200 m 
repeatedly with 30 second rests in between (Coe, 2012). Later Professor Izumi 
Tabata, developed this further comparing CONT to high intensity sprints at 20 
seconds of 170% VO2max, with 10 seconds rests, repeated to exhaustion over 
approximately 8 sprints (Tabata et al., 1996). They found that VO2max increased 
more in the HIIT group.  
Little et al. (2010) proposed a less intensive routine of 8-12 cycles of 60 seconds 
at 95% VO2max with 75 seconds rest. They found that training three times per 
week produced similar effects to 5 times per week of endurance training at 50-
70% VO2max. The same research group developed their protocol further for those 
who had never exercised, consisting of 10 intervals at 60% peak power followed 
by 60 seconds of recovery (Hood et al., 2011). Variations of these training 
programmes are recognised today as HIIT and have become popular in modern 
society (Fleg, 2016). 
Compared to CONT, HIIT is more efficient in improving VO2 max in healthy 
individuals (Milanovic et al., 2015), people with coronary artery disease (Elliott 
et al., 2015), increased cardio-metabolic risk (Weston et al., 2014), chronic 
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heart failure (Haykowsky et al., 2013, Ismail et al., 2013, Smart et al., 2013) and 
in older adults with chronic heart failure (Wisloff et al., 2007). The main 
logistical advantage of HIIT is the shorter time required to achieve similar energy 
expenditure and similar or greater benefits than CONT (Fleg, 2016). These 
benefits include improvements in aerobic fitness and cardiovascular risk factors 
such as body composition, blood pressure, and glucose metabolism. 
 
7.8 Safety of High Intensity Interval Training 
A recent systematic review found HIIT to be safe in people with an elevated 
cardiovascular risk and produced more benefits than CONT (Fleg, 2016). A meta-
analysis involving people with chronic heart failure, from a total of 5877 
participants, found that no deaths could be assigned to either moderate or high 
intensity training (Ismail et al., 2013). In addition, an analysis of participants 
with coronary artery disease found that major complications were one per 
23,182 hours of HIIT and one per 129,456 hours of CONT (Rognmo et al., 2012). 
While there is no evidence to suggest that HIIT is dangerous in people with 
respiratory conditions there is also no evidence, at present, confirming that it is 
safe. 
 
7.9 High intensity interval training in neurological 
disease 
Previous work in people with Parkinsons found that HIIT can increase Brain 
Derived Neurotrophic Factor (BDNF) production and decrease parkinsonian 
rigidity and muscle tone (Marusiak et al., 2015), improve gait parameters (Pohl 
et al., 2003), and improve cognitive performance (Alves et al., 2014). In addition 
there is limited, but positive evidence for using HIIT to improving walking 
endurance in stroke survivors (Boyne et al., 2015, Boyne et al., 2016).   
High Intensity Interval Training has been cited as a possible efficient training 
modality for people with MS as it can allow training at high intensities while 
avoiding thermosensitive reactions (Dalgas et al., 2008). This training modality is 
  142 
however, still under researched in people with MS. In preparation of this thesis a 
systematic review of the literature for using HIIT in people with MS was 
conducted. The following sections (7.10 to 7.15) present this review which has 
been submitted for publication in Multiple Sclerosis and Related Disorders. This 
systematic review differs from the previous systematic review in Chapter 3 as 
this systematic review, of HIIT in MS, included studies with participants with all 
types of MS, while the review in Chapter 3 only included studies that focussed on 
people with progressive MS or separated their data by MS type. 
 
7.10 Systematic review: Abstract 
Background: Aerobic High Intensity Interval Training (HIIT) is safe in the general 
population and more efficient in improving fitness than continuous moderate 
intensity training. The body of literature examining HIIT in Multiple Sclerosis 
(MS) is expanding but to date a systematic review has not been conducted. The 
aim of this review was to investigate the efficacy and safety of HIIT in people 
with MS. 
Methods: A systematic search was carried out in September 2017 in EMBASE, 
MEDline, PEDro, CENTRAL and Web of Science Core collections using appropriate 
keywords and MeSH descriptors. Reference lists of relevant articles were also 
searched. Articles were eligible for inclusion if they were published in English, 
used HIIT, and included participants with MS. Quality was assessed using the 
PEDro scale. The following data were extracted using a standardised form: study 
design and characteristics, outcome measures, significant results, drop-out, and 
adverse events.  
Results: Seven studies (described over 11 articles) were identified: five 
randomised controlled trials and two cohort studies. PEDro scores ranged from 3-
8. Included participants (n=228) were predominantly mildly disabled; one study 
included only people with progressive MS. Six studies used cycle ergometry and 
one used arm ergometry to deliver HIIT. One study reported six adverse events, 
four which could be attributed to the intervention. The other six reported that 
there were no adverse events. Six studies reported improvements in at least one 
outcome measure, however there were 60 different outcome measures in the 
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seven studies. The most commonly measured domain was fitness, which 
improved in five of the six studies measuring aspects of fitness. The only trial 
not to report positive results included people with progressive MS and a more 
severe level of disability (Extended Disability Status Scale 6.0-8.0). 
Conclusions: HIIT appears to be safe and effective in increasing fitness in people 
with MS and low levels of disability. Further research is required to explore the 
effectiveness of HIIT in people with progressive MS and in those with higher 
levels of disability. 
 
7.11 Systematic review: Introduction 
Exercise is a safe and feasible intervention for people with Multiple Sclerosis 
(MS) (Heine et al., 2015) and  is recommended for increasing cardiovascular 
fitness and muscular strength (Latimer-Cheung et al., 2013). Cardiovascular 
fitness in people with MS is lower compared to healthy individuals (Langeskov-
Christensen et al., 2015) and is inversely correlated with disease severity and 
impairment, with fitness and conditioning decreasing as disability and fatigue 
rise (Heine et al., 2014, Heine et al., 2016, Kuspinar et al., 2010, Motl and 
Fernhall, 2012, Marrie and Horwitz, 2010, Valet et al., 2016). Reviews of trials 
evaluating the effects of exercise in people with MS have indicated that exercise 
training is beneficial for reversing deconditioning, and thus increasing 
cardiovascular fitness (Dalgas et al., 2008, Rietberg et al., 2005).   
Traditionally, Continuous moderate intensity training (CONT) programmes, to 
increase fitness and reduce cardiovascular disease risk factors in healthy adults, 
last 30-60 minutes at 40-85% of maximal intensity, with higher intensities 
producing a greater increase in fitness (Pollock et al., 1998). High Intensity 
Interval Training (HIIT), however, involves short bursts of exercise at very high 
intensity with either a complete or working rest in between bursts. Training 
sessions typically last around 20 minutes, have 4-6 cycles of 80-95% of maximal 
effort for 1-4 minutes with a similar time of working recovery or rest (Cassidy et 
al., 2017, Kessler et al., 2012).   
Compared to CONT, HIIT is more efficient in improving VO2 max in healthy 
individuals (Milanovic et al., 2015), people with coronary artery disease (Elliott 
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et al., 2015), increased cardio-metabolic risk (Weston et al., 2014), and heart 
failure (Haykowsky et al., 2013, Ismail et al., 2013, Smart et al., 2013, Wisloff et 
al., 2007). HIIT also produces greater or equal effects, to CONT, in improving 
cardiovascular risk factors such as high blood pressure and altered glucose 
metabolism (Fleg, 2016). The main advantage of HIIT over CONT is the shorter 
time required to achieve similar energy expenditure, and comparable, or greater 
benefits (Fleg, 2016). This is due to an increase in oxygen consumption after 
acute strenuous exercise known as Excess Post-exercise Oxygen Consumption 
(Gaesser and Brooks, 1984). Furthermore, shorter exercise intervals of 2 minutes 
or less have been found to be more enjoyable by participants due to the shorter 
duration of each burst at high intensity (Cassidy et al., 2017).   
Previous work examining the effect of HIIT in people with Parkinson’s found an 
increase in Brain Derived Neurotrophic Factor (BDNF) production, decrease 
parkinsonian rigidity and muscle tone (Marusiak et al., 2015), improved gait 
parameters (Pohl et al., 2003) and cognitive performance (Alves et al., 2014). In 
addition there is limited but positive evidence for using HIIT to improve walking 
endurance in stroke survivors (Boyne et al., 2015, Boyne et al., 2016).    
High intensity interval training has been recommended as a possible effective 
intervention for people with MS as it can allow people to exercise at higher 
intensities while avoiding thermosensitive reactions (Dalgas et al., 2008). Over 
the past several years there has been increasing interest in HIIT in MS and 
several interventional trials published, however no systematic review of HIIT in 
people with MS has been undertaken. Therefore the aim of this review was to 
establish the efficacy and safety of HIIT in people with MS.  
 
7.12 Systematic review: Methods 
An electronic search was undertaken of the following databases in September 
2017: EMBASE, MEDline, PEDro, CENTRAL and Web of Science Core collections.  
The search terms used can be seen in Table 7-2 The Boolean operators ‘AND’ and 
‘OR’ were used to combine searches as appropriate. No limits were placed on 
time of publication. The reference lists of included articles were also searched. 
  145 
Articles were eligible for inclusion if they were clinical trials that consisted of 
aerobic HIIT as an intervention (defined as intervals of exercise of 5 minutes or 
less reaching an intensity of 80% or more of maximal effort in each interval 
(Fleg, 2016)), included participants with MS, or if in a mixed population, data for 
people with MS were presented separately and published in English. Articles 
were excluded if they were non-human studies, case studies, conference 
abstracts or focused solely on resistance, core or balance training. To ensure 
relevant articles were included, if the abstract or title did not provide the 
exercise intensity, the methods of the articles were read.  
Table 7-2. Search strategy 
Database Search terms 
Medline ((exp Multiple Sclerosis/) OR ((Multiple Sclerosis or relapsing 
remitting OR chronic progressive OR secondary progressive OR 
primary progressive).mp.)) AND ((High intensity interval 
training OR interval training OR High intensity interval exercise 
OR interval exercise OR aerobic interval training OR high 
intensity OR high-intensity OR exercise intensity OR HIIT OR 
HIT).mp.) 
Embase ((multiple sclerosis/) OR ((Multiple Sclerosis or relapsing 
remitting OR chronic progressive OR secondary progressive or 
primary progressive).mp.)) AND ((High intensity interval 
training OR interval training OR High intensity interval exercise 
OR interval exercise OR aerobic interval training OR high 
intensity OR high-intensity OR exercise intensity OR HIIT OR 
HIT).mp.) 
Web of Science 
core collections 
(TS=("Multiple sclerosis" OR "MS" OR "relapsing remitting" OR 
"chronic progressive" OR "secondary progressive" OR "primary 
progressive")) AND ( TS=("High intensity interval training" OR 
"Interval training" OR "High intensity interval exercise" OR 
"Interval exercise" OR "Aerobic interval training" OR "High 
intensity" OR “High-intensity” OR "HIIT" OR "HIT")) 
PEDro High intensity multiple sclerosis 
 
CENTRAL (((Multiple Sclerosis) OR (relapsing remitting) OR (chronic 
progressive) or (secondary progressive) OR (primary 
progressive)) OR (MeSH descriptor: [Multiple Sclerosis] explode 
all trees)) AND (((High intensity interval training) OR (interval 
training) or (High intensity interval exercise) OR (interval 
exercise) OR (aerobic interval training) OR (high intensity) OR 
(high-intensity) OR (exercise intensity) or (HIIT) or (HIT))) 
Abbreviations: exp: explode; mp: multi-purpose keyword search; TS: Topic Search  
 
Quality assessment was carried out using the PEDro scale which is valid and 
reliable in methodological rating of studies (de Morton, 2009, Maher et al., 
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2003). The PEDro scale has 11 criteria but produces a score out of ten as no 
point is awarded for listing of exclusion and inclusion criteria. Included articles 
were assessed by at least two reviewers (EC, EHC, LP). Where there was 
disagreement between reviewers this was settled by discussion. Although 
primarily for randomised controlled trials, the PEDro scale can be used for 
cohort studies, with points deducted due to lack of randomisation. This has been 
done in previous systematic reviews of multiple sclerosis interventions (Kjolhede 
et al., 2012). 
The following data were extracted from each article into a standardised form: 
authors, date of publication, study design, sample size, type of MS, disability 
level, number of drop-outs, adverse events, length of intervention, frequency of 
training, type of training, number of intervals per session, target intensity 
ranges, total time spent in high intensity during the intervention, additional 
training modalities employed, outcome measures and results. 
 
7.13 Systematic review: Results 
The electronic search identified 935 potential articles and hand searching of 
relevant reference lists provided an additional article. After the removal of 264 
duplicates, the remaining 671 articles were screened by title and abstract.  
From titles alone, 575 were excluded. Following this, another 58 were excluded 
by abstract. The full text of 38 articles were read for eligibility by at least two 
members of the research team and 27 were subsequently excluded (Figure 7-1). 
Eleven articles, which described seven studies, were included in this review.  
Of the included articles four were Randomised Controlled Trials (RCTs) 
(described by seven articles) (Collett et al., 2011, Farup et al., 2016, Feltham et 
al., 2013, Wens et al., 2015, Wens et al., 2017, Zimmer et al., 2017, Skjerbæk 
et al., 2014, Bansi et al., 2017), one was a randomised crossover trial (Collett et 
al., 2017) and two were cohort studies (Zaenker et al., 2016, Keytsman et al., 
2017).  
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Figure 7-1 Preferred Reporting Items for Systematic Reviews and Meta-
Analyses flowchart of screening and inclusion process for review (Moher et 
al., 2009) 
Abbreviations: n: number, MS: multiple sclerosis 
 
PEDro scores ranged from three to eight out of ten (Table 7-3). Eight articles 
were regarded to be of high quality with a score of seven (Bansi et al., 2017, 
Feltham et al., 2013, Skjerbæk et al., 2014, Wens et al., 2015, Wens et al., 
2017) or eight (Collett et al., 2011, Farup et al., 2016, Zimmer et al., 2017). 
Articles excluded by title 
(n = 575): 
Not MS (n= 348), not 
exercise (n = 168), not a 
trial (n = 51), not human 
study (n = 8) 
 
Articles excluded by 
abstract (n = 58): 
Not MS (n = 10), not 
exercise (n = 7), not a trial 
(n= 14), resistance exercise 
(n = 12), conference 
abstract (n = 7), 
balance/core exercise (n = 
8) 
Full-text articles excluded  
(n = 27): 
Mixed moderate intensity 
circuits (n = 5), steady 
state exercise (n = 17), 
moderate interval training 
(n = 5) 
Articles included in 
review 
(n = 11) 
Articles identified through database searching (n = 935)  
Additional records identified through reference list (n = 1) 
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Points were commonly lost due to a lack of blinding of participants and 
therapists. All articles were included in the review regardless of PEDro score.  
Table 7-3. Quality assessment of articles using the PEDro scale 
Lead author, year C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 Total 
Collet, 2011 Y Y Y Y N N Y Y Y Y Y 8 
Feltham, 2013 Y Y Y Y N N Y N Y Y Y 7 
Collet, 2017 Y N Y Y N N N N N Y Y 4 
Wens, 2015 Y Y Y Y N N N Y Y Y Y 7 
Farup, 2016 Y Y Y Y N N Y Y Y Y Y 8 
Wens, 2017 Y Y Y Y N N N Y Y Y Y 7 
Skjerbaek, 2014 Y Y Y Y N N Y Y N Y Y 7 
Zaenker, 2017 Y N N N N N N Y Y N Y 3 
Zimmer, 2017 Y Y Y Y N N Y Y Y Y Y 8 
Bansi, 2017 N Y Y Y N N N Y Y Y Y 7 
Keytsman, 2017 Y N N N N N N Y Y N Y 3 
C1: specification of inclusion criteria; C2: randomisation of participants; C3: concealment of 
allocation; C4: groups similar at baseline; C5: blinding of subjects; C6: blinding of therapists; C7: 
blinding of assessors; C8: one key outcome measure taken for at least 85% of sample; C9: 
intention to treat analysis if appropriate; C10: between group statistical analysis; C11: point 
measures and measures of variability 
 
Three of the studies, reported by seven articles, provided a power calculation 
and had a sample size large enough to be powered (Collett et al., 2011, Farup et 
al., 2016, Feltham et al., 2013, Wens et al., 2015, Wens et al., 2017, Zimmer et 
al., 2017). The other four studies did not report on power (Skjerbæk et al., 
2014, Collett et al., 2017, Zaenker et al., 2016, Keytsman et al., 2017, Bansi et 
al., 2017). Only one study had a follow up period, which was 12 weeks after 
completion of the intervention (Collett et al., 2011) (Table 7-4). 
Sample sizes ranged from 11 (Skjerbæk et al., 2014) to 61 (Collett et al., 2011) 
with a total number of 249 participants. Five studies included participants that 
were predominantly mildly disabled (EDSS < 4.0) (Collett et al., 2011, Collett et 
al., 2017, Feltham et al., 2013, Keytsman et al., 2017, Farup et al., 2016, Wens 
et al., 2015, Wens et al., 2017, Zaenker et al., 2016) one study recruited a 
predominantly moderately disabled group (EDSS 4.0-6.0) (Zimmer et al., 2017, 
Bansi et al., 2017) and one study recruited participants who were more severely 
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disabled (EDSS 6.0-8.0) (Skjerbæk et al., 2014) (Table 7-4).Five studies included 
participants with both Relapsing Remitting MS (RRMS) and progressive MS (Bansi 
et al., 2017, Collett et al., 2011, Collett et al., 2017, Farup et al., 2016, 
Feltham et al., 2013, Wens et al., 2015, Wens et al., 2017, Zimmer et al., 2017), 
one study only included participants with progressive MS (Skjerbæk et al., 2014), 
and one study did not report on MS type (Keytsman et al., 2017). 
All studies conducted HIIT, in a supervised setting, on a cycle ergometer apart 
from Skjerbæk et al. (2014) who used upper limb ergometry. Four studies (eight 
articles) compared HIIT to a form of continuous training (Bansi et al., 2017, 
Collett et al., 2011, Collett et al., 2017, Farup et al., 2016, Feltham et al., 
2013, Wens et al., 2015, Wens et al., 2017, Zimmer et al., 2017), one study 
compared HIIT and in-patient rehabilitation to just in-patient rehabilitation 
(Skjerbæk et al., 2014), and two studies did not have a comparator group 
(Keytsman et al., 2017, Zaenker et al., 2016) (Table 7-4). 
Four studies (eight articles) combined HIIT with another form of exercise 
training; two with resistance training (Farup et al., 2016, Wens et al., 2015, 
Wens et al., 2017, Keytsman et al., 2017), one with CONT (Collett et al., 2011, 
Feltham et al., 2013), and one with both resistance training and CONT (Zaenker 
et al., 2016) (Table 7-4). 
In terms of exercise dose, the number of training sessions ranged from 1 to 30 
and length of intervention ranged from 3 weeks (Bansi et al., 2017, Zimmer et 
al., 2017) to 12 weeks (Collett et al., 2011, Farup et al., 2016, Feltham et al., 
2013, Wens et al., 2015, Wens et al., 2017, Zaenker et al., 2016, Keytsman et 
al., 2017). Length of exercise interval ranged from 30 seconds (Collett et al., 
2011, Collett et al., 2017, Feltham et al., 2013) to 2 minutes (Farup et al., 2016, 
Keytsman et al., 2017, Wens et al., 2015, Wens et al., 2017). One study had 
intervals of 3 minutes but only 30-60 seconds of each was spent at a high 
intensity (Skjerbæk et al., 2014). Total time spent in high intensity exercise, 
over the whole intervention, ranged from 10 minutes (Collett et al., 2017) to 225 
minutes (Farup et al., 2016, Keytsman et al., 2017, Wens et al., 2015, Wens et 
al., 2017) (Table 7-4). 
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Table 7-4 Summary of evidence of high intensity interval training in people with MS 
Author, 
Year, 
Design 
n,  
Drop-outs,  
Powered 
MS type, 
Disability 
Intervention  
  
Outcome  
Measures, 
Time points 
Statistically significant results* 
Collett et 
al.  
2011 
RCT 3 arm 
 
n=61 
 
Drop out: 6 
 
Pow: Y 
RR: 22 
SP: 25 
PP: 7 
Unknown: 1 
 
Barthel 
index: 19 
Able to walk 
2min with or 
without aid 
 
 
HIIT vs CONT vs COMB 
12 wks, 2/wk 
Total: 24 sessions 
 
CONT (n=20): 45% peak 
power, 20 min 
HIIT (n=18): 90% peak power 
30sec on 30 sec off, 20 min 
COMB (n=17): 10 min CONT 
a/a followed by 10  HIIT a/a 
 
2 min walk 
TUG 
Leg ext power 
Peak power 
 
Barthel Index 
SF36 
FSS 
 
0, 6, 12, 24 
wks 
2 min walk (WG) (p<0.01) 6 wks: HIIT: 
+12.94m (4.71), CONT: +4.71m (4.24), 
COMB: +3.22m (4.60).  Improvements 
maintained at 24 wks 
 
TUG (WG) (p<0.05) 6wks: HIIT: -2.5s (1.8), 
CONT: -3.5s (1.7), COMB: -0.9s (1.9).  
Improvements maintained at 12 wks but 
not 24 
 
Leg power (ALL) (p<0.01) 6 wks: +19.4W 
(4.1), 12 wks: +15.9W (4.1), 24 wks: -
10.9W (3.1) 
 
Peak power (ALL) (p<0.05) 24 wks: -29W 
(5) 
 
SF36: (p<0.05), 12 wks: -4.5 (1.6) 
maintained at 24 wks 
Feltham et 
al.  
2013 
Sub-analysis 
of Collett et 
al.  
RR: 9 
SP: 9 
PP: 3 
CONT a/a n=12 
HIIT a/a n=9 
BP 
RER 
Peak power 
VO2 peak (ALL) (p =0.05): increase from 
med 8.05ml/kg (2.23) to med 9.2ml/kg 
(3.72) 
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RCT 2011 
  
n=21 
 
 
Barthel 
index: 19 
 
Drop out: 0 
VO2 max 
VO2 norm 
HRMax 
 
0, 6, 12 wks 
 
Peak power (ALL) (p =0.05): increase from 
med 112W (58) to med = 113W (55) 
Collett et 
al.  
2017 
RXT 
 
n=23 
14 with MS 
9 HC 
 
Drop out: 4 
(3 MS, 1 
control) 
 
Pow: N 
RR: 5 
SP:5 
PP:1 
 
Barthel 
index: 19 (1) 
Able to use 
ergometer 
safely 
 
CONT1 vs CONT2 vs HIIT 
3 weeks, 1 session/week 
 
Each participant did as single 
CONT1, CONT2 and HIIT 
session  
 
CONT1: 20 min 45% peak 
power  
CONT2: 20 min 60% peak 
power  
HIIT: 20 min 90% peak power 
(30 sec intervals with 30 sec 
rest) 
Recovery of: 
HR, Temp, 
RPEbr, RPEleg, 
MEPs 
 
30 sec post 
session then 
every 2 min 
till 10min, 
then every 5 
min till 45 min 
Return to resting HR: 
CONT1: MS in 15 min vs control 4 min 
CONT2: both groups not down to rest HR 
in 45 min 
HIIT: both MS and control return in 30 min 
 
Recovery to baseline RPEleg 
CONT1: MS 6 min vs control 0.5 min 
CONT2: MS 15 min vs control 6 min 
HIIT: MS 35 min vs control 4 min  
 
RPEbr:  
CONT1: MS 8 min vs control 0.5 min 
CONT2: MS 6 min vs control 2 min 
HIIT: MS 6 min vs control 6 min 
 
MEP: 
Return to baseline levels; 
CONT1: both groups in 15 min 
CONT2: MS 15 min vs control 25 min 
HIIT: MS MEP not significantly decreased 
and control recovered in 4 min 
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Temp: 
CONT1: no change 
CONT2: MS group returned to baseline in 
35 min, no change in control 
HIIT: MS group returned baseline in 25 
min, control in 8 min. 
Wens et al. 
2015 
RCT 3 arm 
 
n=34 
 
Drop out: 0 
 
Pow: Y 
RR: 26 
Progressive: 
8 (type of 
progressive 
NR) 
 
EDSS range 
1.0-6.0 
 
Mean EDSS 
2.7 
 
 
SED vs HIIT+RES vs CONT+RES 
12 wks, 5 session/2 wks 
 
SED, n=11: no intervention 
 
HIIT+RES, n=12: 5 x 1 min 
peak power (80-
90%HRMax)for 6 weeks 
5 x 2 min 100-120% peak 
power (90-100% HRMax) 6 
weeks 
 
CONT+RES, n=11: 6 min at 
80-90% HRMax for first 6 
weeks  
For second 6 weeks 
progressed to 2 x 10 min at 
90-100% HRMax 
 
RES for both ex groups: 
Muscle fibre 
CSA and 
proportion 
 
Isometric 
muscle 
strength 
 
Endurance 
capacity: 
RER 
VO2max 
HRMax 
Test duration 
 
Body 
composition 
 
PA level; 
PASIPD  
BG compared to SED: Mean CSA muscle 
fibres 
HIIT: +21% (7) (p<0.05) 
CONT: +23% (5) (p<0.01) 
 
Muscle fibre type I CSA: 
CONT: +29.8% (5.5) (p=0.003) 
 
Muscle fibre type IIa CSA: 
HIIT: 22.8% (6.2) (p<0.05) 
 
BG compared to SED:  
Strength knee flex + ext weak leg: 
HIIT: range +24% (13) to +44% (20) (p= 
0.01 to  p=0.006) 
CONT: range +19% (9) to 33% (17) (p= 0.01 
to  p=0.006) 
 
Hams strong leg 
HIIT: range +13% (7) to +20% (7) (p=0.006) 
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leg presses, curls, 
extensions, lateral pull 
downs, arm curls, chest 
presses.  Intensity 1 x 10 
reps max load, progressed to 
2 x 20 reps max load 
 
0, 12 wks 
 
BG compared to SED and CONT: 
Peak power +21% (4) (p = 0.0001) 
Time to exhaustion +24% (5) (p=0.00008) 
VO2max +17% (5) (p=0.001) 
 
Lean tissue mass (WG): 
HIIT + 1.4% (0.5)  (p = 0.01) 
Body fat percentage (WG) 
HIIT: -3.9% (2) (p = 0.04) 
CONT: -2.5% (1.2) (p = 0.02) 
 
HRMax (WG) 
CONT: +3.7% SD1.5 
HIIT: +6.2% SD 2.2 
 
PASID (BG vs SED) 
HIIT: 86% (27) (p = 0.004) 
CONT: 73% (19) (p = 0.003) 
Wens et al. 
2017 
Same as 
Wens et al. 
2015 
Same as 
Wens et al. 
2015 
Same as 
Wens et al. 
2015 
Same as Wens et al. 2015 AUC from 
OGTT 
Fasting 
glucose conc 
GLUT4 content  
vastus lateralis 
All WG: 
Fasting glucose conc 
HIIT: -7.3% (6.8) (p< 0.05) 
CONT: - 9.0% (6.2) (p< 0.05) 
 
Glucose clearance (AUC)  
HIIT: -6.9% (6.2)  (p< 0.05) 
CONT: -11.0% (7.7) (p< 0.05) 
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Insulin (AUC) 
CONT: -12.3% (14.7) (p< 0.05) 
 
Muscle GLUT4 content: 
HIIT: +6.6% (4.5) (p< 0.05) 
Farup et al. 
2016 
Same as 
Wens et al. 
2015 
Same as 
Wens et al. 
2015 but no 
SED group 
HC n=18 
 
Pow: Y 
 
MS mixed no 
SED group 
Combined exercise groups as 
Wens et al 2015  
No SED group 
SC/type I fibre 
SC/type II 
fibre,  
SC/ mm2 type 
I and II fibre 
Myonuclei, and 
central nuclei 
analysis 
 
Muscle tissue 
fibrosis and 
lipid content 
MS(WG): 
SC/type II fibre: +165% (68) (p<0.05) 
SC/mm2 type II fibre: +135% (63) (p< 
0.05) 
 
Lipid content BG MS vs HC 
MS: +117% (37) (p < 0.05). 
Zaenker et 
al.  
2017 
Cohort 
study 
 
n=26 
 
Drop out: 0 
 
Pow: N 
MS mix RR 22 
SP 3 
PP 1 
 
EDSS med 2.0 
(0-5) 
HIIT+RES+CONT 
12 wks 
Wks 1-4: 1 x HIIT and 1x RES 
session/wk 
Wks 5-12: a/a + unsupervised 
CONT or RES session 
 
HIIT: 10 min warm up, 5 x 1 
min  90-110% peak power, 3 
VO2 peak 
Peak power 
Peak lactate 
HRMax 
 
Isokinetic 
strength quads 
and hams 
 
ALL WG as cohort study 
VO2peak +13.5% (p<0.0001) 
Peak power +9.4% (p<.0001) 
Peak lactate +31% (p<0.001) 
HRMax +3.73% (p=0.0120) 
 
Inc strength quads and hams at all torques 
(p<0.05) (size of change not provided) 
SEP 59: Improvement in vitality (p= 
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min working rest, 5 min 
warm down 
 
RES: body weight exercises, 
2 x hams + 2 x quads.  Start 4 
x 10 reps prog to 5 x 15 reps 
 
CONT: 30-45 min CONT of pt 
choice such as cycling, 
swimming or walking 
QoL: SEP 59 
 
0, 12 wks 
0.0012), emotional well-being (p= 
0.0378), and general well-being (p= 
0.0052) size of change not reported. 
 
Zimmer et 
al. 
2017 
RCT 
n=57 
 
Dropout: 3 
 
Pow: Y 
MS mix 
RR (30) and 
SP (27) 
 
EDSS range 
1.0-6.5 
Mean 4.37 
HIIT  vs  CONT 
3 Weeks, HIIT 3 x week, 
CONT: 5 x week 
 
HIIT: 20 min, 5x 3 min 
intervals at 85-90% of 
HRMax, with 1.5 min working 
rest at 50-60% HRMax 
CONT: min 70% HRMax 
BICAMS: TMT, 
TAP test 
(errors and 
speed), SDMT, 
VLMT, BVMT 
Serum levels 
of serotonin, 
BDNF, MMP-2, 
MMP-9, 
VO2peak 
 
0, 3 wks 
Time effects 
SDMT 
TMT 
TAP errors 
 
Time x group effect 
Serum MMP-2 in  
HIIT: decreased p=0.009 CI (5.336; 
36.587) 
CONT: no change p=0.305 CI (–22.470; 
7.169) 
 
VO2 peak in both groups 
HIIT: p<0.001 CI (–4.096; –2.002) 
CONT: p=0.006 CI (–2.394; –0.426) 
 
VLMT 
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HIIT: improvement p=0.046 (CI) (–6.319; –
0.51)) 
CONT: no change p=0.316 CI (–1.473; 
4.473)) 
 
TAP errors  
HIIT improved p=0.001 CI (0.508; 1.789) 
CONT: p=0.327 CI (–0.308; 0.908) 
Bansi et al. 
2017 
Same as 
Zimmer et 
al. 2017 
Same as 
Zimmer et al. 
2017 
 
 
Same as 
Zimmer et al. 
2017 
Same as Zimmer et al. 2017 HIIT vs CONT: 
within RRMS 
and SPMS 
5HT,Trp, Kyn, 
Kyn/Trp ratio 
RRMS training groups (no diff between 
HIIT or CONT): 
Reduction in Trp (p=0.02) 
Increase in Trp/Kyn ratio (p=0.002)  
Skjerbaek 
et al.  
2014 
RCT 
n=11 
 
Drop out: 1  
 
Pow: N 
PP (n=3) 
SP (n=8) 
 
EDSS 6.5-8.0  
 
HIIT + in-pt rehab vs in-pt 
rehab 
10 sessions over 4 wks, UL 
ergometer HIIT training 
 
6x 3 min intervals: 2min at 
65-75%VO2max followed by 
30-60 sec sprint of 100% max 
effort 
Pri: VO2 peak, 
HRMax, 
6minWC, 
FSMC, MDI, 
MSIS-29, 9HPT, 
HGT, BBT  
 
0, 4 wks 
Nil 
Keytsman 
et al. 2017 
Cohort 
study 
n=16 
 
Drop out: 0 
 
Pow: N 
MS type: NR 
 
EDSS mean 
2.6  
HIIT+RES 
12 wks, 5 session per 2 wks 
HIIT Wks 1-6: 5 x 1min 85-
90% HRmax, 1 min rest 
Wks 7-12: 5 x 2min 100% 
HRmax, 1 min rest 
RES: leg presses, curls, 
Body 
composition, 
resting HR, BP, 
OGTT, total 
chol, fasting 
glucose, 
All p<0.05 
Resting HR: -6% (bpm) 
2 hr glucose conc: -13% (mmol/l) 
Insulin sensitivity: -24%  
WMax; +25 W (CI -34, -16) 
t to exhaustion: +2 min (CI-3,-1) 
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extensions, lateral pull 
downs, arm curls, chest 
presses. Intensity 1 x 10 reps 
max load, progressed to 2 x 
20 reps max load after 6 wks 
fasting TG, 
HDL, LDL, 
insulin 
sensitivity, 
Wmax, HRMax, 
VO2max, RER, 
peak lactate, t 
to exhaustion, 
VEmax 
Isometric and 
isokinetic 
strength of 
legs ext and 
flex, PASID 
 
VEmax: 15 l/min (CI-23,-7) 
Isometric and isokinetic strength 
increased in both legs 
Peak lactate +2.1 mmol/l 
RER: -0.04  
VO2max: +5.9 ml/min/kg 
Abbreviations: RCT: randomised controlled trial; RXT: randomised crossover trial; n: number of participants; Pow: statistically powered; a/a: as above; HC: healthy 
controls; RR; relapsing remitting; SP: secondary progressive; PP: primary progressive; min: minute; NR: not reported; EDSS: expanded disability status scale; HIIT: 
high intensity interval training; SED: sedentary; med: median; CONT: continuous moderate intensity training; COMB: combination; wk: week; sec: second; RES: 
resistance training; HRMax: maximal heart rate; VO2max: maximal volume oxygen consumed VO2: volume of oxygen consumed; TUG: timed up and go test; ext: 
extension; SF36: short form 36; FSS: fatigue severity scale; BP: blood pressure; RER: respiratory exchange ratio; HR: heart rate; temp: temperature; RPEbr: borg 
scale of perceived exertion breathing; RPEleg: borg scale of perceived exertion legs; MEPs: motor evoked potentials; CSA: cross sectional area; PASIPD; Physical 
Activity Scale for Individuals with Physical Disabilities; OGTT: oral glucose tolerance test; conc: concentration; SC: satellite cells; quads: quadriceps; hams: 
hamstrings; SEP: Sclerose En Plaques-59; BICAMS: brief international cognitive assessment for MS; TMT: trail making test; TAP: Test of Attentional Performance; 
SDMT: symbol digit modalities test; VLMT: California verbal learning memory test; BVMT: Brief visuospatial memory test-revised; BDNF: brain derived neurotrophic 
factor; MMP: matrix metalloproteinases; 6minWC: 6 minute wheelchair test; 5HT: serotonin; Trp; tryptophan; Kyn; kynurenine; FSMC: fatigue scale of motor and 
cognitive function; MDI: major depression inventory; MSIS-29: multiple sclerosis impact scale; 9HPT: 9 hole peg test; HGT: hand grip test; BBT: box and block test; 
HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; chol: cholesterol; VEmax: maximal expiratory volume W: watts; WG: within group 
analysis; BG: between group analysis: CI: confidence interval 
*All values mean (standard deviation) unless otherwise stated. 
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One study reported six adverse events (Collett et al., 2011, Feltham et al., 
2013). Four were knee or leg pain while cycling, which were deemed to be 
possibly related to the intervention. Two of the adverse events were unrelated 
to the intervention (one exacerbation of symptoms and one loss of 
consciousness). The other six studies reported that there were no adverse events 
in either their intervention or control groups (Bansi et al., 2017, Collett et al., 
2017, Farup et al., 2016, Keytsman et al., 2017, Skjerbæk et al., 2014, Wens et 
al., 2015, Wens et al., 2017, Zaenker et al., 2016, Zimmer et al., 2017).  
The retention of participants within the studies was high; one study had a drop 
out of greater than 10% (Collett et al., 2017), two studies less than 10% (Bansi et 
al., 2017, Collett et al., 2011, Feltham et al., 2013, Zimmer et al., 2017), while 
four studies had no drop outs (Farup et al., 2016, Skjerbæk et al., 2014, Wens et 
al., 2015, Wens et al., 2017, Zaenker et al., 2016, Keytsman et al., 2017) (Table 
7-4). 
A total of 60 different outcome measures were used across the seven studies.  
The most common domains assessed were cardiorespiratory fitness which was  
measured in six of the seven studies (Bansi et al., 2017, Collett et al., 2011, 
Farup et al., 2016, Feltham et al., 2013, Keytsman et al., 2017, Skjerbæk et al., 
2014, Wens et al., 2015, Wens et al., 2017, Zaenker et al., 2016, Zimmer et al., 
2017) and strength which was measured in four (Collett et al., 2011, Farup et 
al., 2016, Feltham et al., 2013, Wens et al., 2015, Wens et al., 2017, Zaenker et 
al., 2016, Keytsman et al., 2017) (Table 7-4). Five of the six studies that 
assessed fitness found an improvement however different outcome measures 
were used across the studies. All four studies that measured strength reported 
an improvement. 
Six studies measured either VO2peak or VO2max (Bansi et al., 2017, Collett et 
al., 2011, Farup et al., 2016, Feltham et al., 2013, Keytsman et al., 2017, 
Skjerbæk et al., 2014, Wens et al., 2015, Wens et al., 2017, Zaenker et al., 
2016, Zimmer et al., 2017). One of the RCTs reported an improvement in 
VO2max in their HIIT group (+17% (SD) 5, p<0.01) (Farup et al., 2016, Wens et 
al., 2015, Wens et al., 2017). Two RCTs reported an improvement of VO2peak in 
both their HIIT and CONT groups ((median 8.05 ml/kg - 9.2 ml/kg (Collett et al., 
2011, Feltham et al., 2013)), (HIIT (95% CI (–4.096; –2.002) p<0.001), CONT (95% 
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CI (–2.394; –0.426) p=0.006) (Zimmer et al., 2017, Bansi et al., 2017)). The two 
cohort studies found improvements, one in VO2peak (+13.5% (p<0.0001) (Zaenker 
et al., 2016), and the other in VO2max (+5.9 ml/min/kg (p<0.05 (Keytsman et 
al., 2017)). Conversely, one RCT reported no change in the VO2peak of their HIIT 
group (Skjerbæk et al., 2014) (Table 7-4). 
Two of the five studies which measured HRMax found significant increases in 
their HIIT group; (+3.73%, p=0.012 (Zaenker et al., 2016), +6.2%, p=0.05 (Farup 
et al., 2016, Wens et al., 2015, Wens et al., 2017)). The other three studies 
which measured HRMax did not find changes after their HIIT intervention (Collett 
et al., 2011, Feltham et al., 2013, Skjerbæk et al., 2014, Keytsman et al., 2017) 
(Table 7-4). 
Peak power, was measured in four studies (Collett et al., 2011, Farup et al., 
2016, Feltham et al., 2013, Keytsman et al., 2017, Wens et al., 2015, Wens et 
al., 2017, Zaenker et al., 2016). One RCT reported an increase in peak power 
after the intervention (+21% (SD 4) (p<0.01) (Farup et al., 2016, Wens et al., 
2015, Wens et al., 2017)) and the two cohort studies also reported an increase in 
peak power (+9.4%, p<0.0001, (Zaenker et al., 2016), +25 W (CI -34, -16), p<0.05 
(Keytsman et al., 2017)). The RCT by Collett et al. (2011) initially found no 
differences in peak power post intervention, however, subsequent analysis 
demonstrated that peak power was increased in participants who completed 
more than 8 sessions, (median 112 W to median 113 W, p=0.05) (Feltham et al., 
2013) (Table 7-4). 
Two cohort studies measured peak lactate and found increases after their 
interventions (+31%, p<0.001 (Zaenker et al., 2016), +2.1 mmol/l, p<0.05 
(Keytsman et al., 2017)). One study measured endurance using the 2 min walk 
test and reported improvements in all groups (HIIT, CONT and combined) with 
the largest improvement in the HIIT group (HIIT: +12.94 m (SD 4.71), CONT: 
+4.71 m (SD 4.24), combined: +3.22 m (SD 4.60), p<0.01) and all improvements 
were maintained at 12 week follow up (Collett et al., 2011, Feltham et al., 
2013) (Table 7-4). 
All four studies that examined muscle strength reported improvements following 
the intervention (Collett et al., 2011, Farup et al., 2016, Feltham et al., 2013, 
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Wens et al., 2015, Wens et al., 2017, Zaenker et al., 2016, Keytsman et al., 
2017). Collett et al. (2011) and Feltham et al. (2013) reported improvements in 
isometric leg extension power at the end of the intervention but this was not 
maintained at a 12 week follow up (12 weeks: +15.9W SD 4.1, 24 weeks: -10.9W 
SD 3.1, p<0.01). One study found an increase in isometric hamstring strength in 
the HIIT group only (range +13% Nm, (SE 7) to +20% (SE 7), p=0.006) and between 
group differences in the quadriceps and hamstring of the weak leg in both the 
HIIT (range +24% Nm, SE 13, p=0.01, to +44% Nm, SE 20 p=0.006) and high 
intensity continuous groups (range +19% Nm, SE 9 p= 0.01, to 33% Nm, SE 17 
p=0.006) (Wens et al., 2015). Both cohort studies found improvements in muscle 
strength (Keytsman et al., 2017, Zaenker et al., 2016). Keytsman et al. (2017) 
reported stronger isometric hamstring contractions in the stronger leg at 90 
degrees, in quadriceps at 45 degrees, and both muscle groups in maximal 
isokinetic contractions. In the weaker leg stronger isometric hamstring and 
quadriceps contractions were found at both 45 and 90 degrees along with 
stronger hamstring isokinetic contractions (p<0.05). Zaenker et al. (2016) 
reported increases in the strength of quadriceps and hamstrings of both legs at 
three different torques of 90, 180 and 240 degrees per second (p<0.05) (Table 
7-4). 
In terms of cardiometabolic risk factors, improvements were reported in resting 
heart rate (Keytsman et al., 2017), glucose tolerance, physiological 
characteristics of muscle fibres, and body composition (Farup et al., 2016, Wens 
et al., 2015, Wens et al., 2017). One study observed a decrease in matrix 
metalloproteinase 9 concentrations, improvements in mental processing and 
cognition, and also differences between participants with RRMS and progressive 
forms of MS, but not between HIIT or CONT, in levels of tryptophan and the ratio 
of tryptophan to kynurenine (Zimmer et al., 2017, Bansi et al., 2017).  Finally, 
two studies measured quality of life with conflicting results (Collett et al., 2011, 
Feltham et al., 2013, Zaenker et al., 2016). Full details of these results are 
presented in (Table 7-4). 
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7.14 Systematic review: Discussion 
This was the first systematic review for the use of HIIT in MS. Overall, the seven 
studies included in the review provided positive evidence for the use of HIIT in 
people with MS. All studies except one (Skjerbæk et al., 2014) found 
improvements in multiple outcome measures. Predominantly improvements were 
observed in outcome measures relating to fitness. High intensity interval training 
was well tolerated with adverse events only occurring in one study (Collett et 
al., 2011, Feltham et al., 2013). Previous research has shown that HIIT is safe in 
healthy individuals (Milanovic et al., 2015), people with chronic heart failure 
(Smart et al., 2013), coronary artery disease (Elliott et al., 2015), and increased 
cardio-metabolic risk (Weston et al., 2014). Due to the low incidence of adverse 
events this review suggests that HIIT is also safe in people with MS. 
The evidence in this review is positive for the use of HIIT in increasing 
cardiovascular fitness in people with MS. Five of the six studies that measured 
cardiovascular fitness reported improvements in at least one outcome measure 
(Collett et al., 2011, Farup et al., 2016, Feltham et al., 2013, Wens et al., 2015, 
Wens et al., 2017, Zaenker et al., 2016, Zimmer et al., 2017, Bansi et al., 2017, 
Keytsman et al., 2017). Skjerbæk et al. (2014), who measured both VO2peak and 
HRMax, did not find statistically significant changes, although a trend towards 
statistical significance for VO2peak was reported (p=0.06, data not in Table 7-4). 
This study however differed from the others as the participants had progressive 
MS and were the most disabled and deconditioned. Furthermore, the study was 
underpowered and had one of the lowest time exercising at high intensity over 
the whole intervention (60 minutes). A similar low time at high intensity was 
used by Zaenker et al. (2016), but with the addition of CONT and resistance 
training elements to the intervention.  
Skjerbæk et al. (2014) was also the only study to use arm ergometry, whereas 
the other studies used cycle ergometry. Arm ergometry is a practical modality of 
exercise for those with mobility problems but engages smaller muscles than 
cycle ergometry, resulting in lower energy expenditure and thus creating less 
demand on the cardiorespiratory system. Indeed, a previous study comparing 
arm ergometry, cycling and rowing at a moderate intensity in people with 
progressive MS, found that the cycling group increased their VO2max while no 
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changes were found in the arm ergometry and rowing groups (Briken et al. 
2014). Further research is warranted to investigate the efficacy of using upper 
limb ergometry for delivering HIIT for people with higher levels of 
disability/progressive MS. 
Previous research comparing HIIT to CONT in other conditions has quantified the 
effectiveness via meta-analyses. For example, in healthy individuals HIIT is more 
effective than CONT in increasing VO2max by 4.5 ml/kg/min (Milanovic et al., 
2015) and in people with increased cardiometabolic risk HIIT is more effective in 
increasing VO2peak by 3.03 ml/kg/min (Weston et al., 2014). While the evidence 
for HIIT in people with MS is positive, due to the heterogeneity of outcome 
measures and the lack of control groups in two of the studies, a meta-analysis 
was not possible or appropriate. This makes comparison of the effect of HIIT 
between MS and other conditions difficult.  
The shortest intervention which led to an improvement in fitness was three 
weeks in length (Bansi et al., 2017, Zimmer et al., 2017). This trial trained the 
HIIT group three times per week for three weeks with a total of 135 minutes 
spent exercising at a high intensity. Furthermore this was the only trial to 
compare a HIIT programme to a CONT programme of equal energy expenditure 
by training five times per week. All other protocols included in this review that 
implemented an active comparison group of CONT, due to Excess Post-exercise 
Oxygen Consumption, would have resulted in greater energy expended during 
the HIIT protocol (Collett et al., 2011, Collett et al., 2017, Feltham et al., 
2013). One other study (published over three articles) however, included a high 
intensity continuous group which spent 330 minutes at a high intensity 
(compared to 225 in the HIIT group), but it is unclear if this was to equate 
energy expenditure between the two groups (Farup et al., 2016, Wens et al., 
2015, Wens et al., 2017). Two trials had the shortest work-time at high intensity 
(60 minutes), one of which reported an improvement (Zaenker et al., 2016) and 
one which did not (Skjerbæk et al., 2014). The trial by Zaenker et al. (2016) was 
a cohort study in which the intervention comprised separate sessions of HIIT, 
CONT and resistance training which made it difficult to attribute improvements 
specifically to HIIT. The lack of significant results from Skjerbæk et al. (2014) 
may indicate that more than 60 minutes at high intensity is needed to increase 
fitness in people with MS. The length of the high intensity interval did not 
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appear to have an impact on results as improvements in fitness were observed in 
the trials that used the shortest interval of 30 seconds (Collett et al., 2011, 
Feltham et al., 2013) and the longest interval of three minutes (Bansi et al., 
2017, Zimmer et al., 2017). Therefore this may indicate that improvements in 
fitness in people with MS can be elicited from a lower number and frequency of 
HIIT sessions, compared to CONT, and that this can be achieved in as little as 
three weeks from a total high intensity work-time of 135 minutes. As lack of 
time is a cited barrier for exercise in people with MS (Asano et al., 2013) and 
HIIT is reported to be more enjoyable than CONT (Bartlett et al., 2011) this 
makes HIIT a suitable programme for exercise prescription in people with MS.  
All four studies that measured muscle strength reported improvements (Collett 
et al., 2011, Farup et al., 2016, Feltham et al., 2013, Wens et al., 2015, Wens et 
al., 2017, Zaenker et al., 2016, Keytsman et al., 2017). One of these did not 
specifically include a resistance training element (Collett et al., 2011, Feltham 
et al., 2013), but still reported an increase in isometric muscle strength. This 
may indicate that aerobic HIIT could be effective in increasing leg muscle 
strength however this requires further investigation.  
Only one study (published over two articles) examined the effect of HIIT on 
neurochemicals related to MS, exploring the effects of HIIT on levels of 
serotonin, BDNF, metalloproteinase 2 and 9, and tryptophan metabolism (Bansi 
et al., 2017, Zimmer et al., 2017). The researchers reported, that compared to 
the CONT group, the HIIT group improved their level of matrix metalloproteinase 
2. As the intervention and control undertook an exercise programme of equal 
energy expenditure this suggests that higher intensity of exercise could have a 
more beneficial effect neurological markers. The cohort study by Keytsman et 
al. (2017) measured the effect of HIIT on lipid profiles but did not report any 
significant changes (Keytsman et al. (2017). This trial was however, 
underpowered and had no control group. Both of these areas of research warrant 
further investigation, particularly since a previous review concluded that the 
evidence was inconclusive for the effect of aerobic exercise on BDNF in people 
with neurological conditions (Mackay et al., 2017) and previous work on the 
effect of exercise on blood lipids in people with MS was also inconclusive (Wens 
et al., 2013).  
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7.14.1 Limitations 
The heterogeneity of the outcome measures used across the seven studies 
limited comparison with previous reviews of HIIT in other conditions and 
prevented a meta-analysis. The lack of power calculations in some studies also 
limited the applicability of results in this patient population. 
 
7.15 Systematic review: Conclusions 
The evidence presented in this review suggests that HIIT, via cycle ergometry, is 
a safe and effective way of improving fitness in people with MS and requires 
fewer, shorter training sessions compared to a moderate intensity, continuous 
training mode to gain benefits. Further investigation of HIIT is required in people 
with progressive MS and/or those with a moderate and severe level of disability. 
In addition, future research should examine the possible benefits of HIIT in 
people with MS, beyond cardiovascular fitness and muscle strength. 
 
7.16 Summary of chapter 
In summary the evidence base for using aerobic exercise to increase resting 
BDNF levels in people with MS suggests that there is no effect in people with 
progressive MS, but a lack of statistical power in previous studies limits this 
statement. The evidence base for using exercise to influence mental processing 
speed in people with MS is also inconclusive, as is fatigue. The effect of aerobic 
exercise on blood lipid levels in people with MS has only been examined by one 
study which found no effect but had methodological limitations. Therefore these 
areas warrant further research.  
From the systematic review it was concluded that the evidence for using HIIT in 
people with MS suggests that is safe and has a positive effect on fitness. 
However, there were gaps in the research, namely in lack of studies focussing on 
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people with progressive MS and in people with either a moderate or severe level 
of disability. While the evidence suggests a positive effect on fitness the effect 
on other outcomes is less clear mainly due to the heterogeneity of domains 
assessed and outcome measures used.  
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Chapter 8 High intensity interval training in 
people with progressive Multiple Sclerosis, a 
feasibility trial 
From the systematic review of the literature and of the literature surrounding 
exercise and Multiple Sclerosis (MS), gaps were identified that justified further 
research. These were: 
 No study has focussed on High Intensity Interval Training (HIIT) in people 
with progressive MS and a moderate level of disability (Extended Disability 
Status Scale (EDSS) 4.0-6.0) 
 No study has focussed on people with progressive MS and used cycle 
ergometry to deliver HIIT 
 The effect of aerobic training on Brain Derived Neurotrophic Factor 
(BDNF) levels remains unknown in people with MS and in particular 
progressive MS 
 There is conflicting evidence for the effect of HIIT on quality of life and 
impact of disease in people with MS 
 
This chapter will outline the aims and objectives of a randomised controlled 
feasibility trial before describing the protocol. The results of the trial will be 
presented, discussed and compared to previous HIIT and exercise research in MS. 
The limitations of the trial will then be discussed, before making 
recommendations for future research. 
 
8.1 Aims and objectives 
The aim of this study was to evaluate the feasibility of delivering HIIT to people 
with progressive MS with a moderate level of disability and to evaluate the 
effects of HIIT, compared to Continuous moderate intensity training (CONT), on 
physiological and MS clinical outcomes.  
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The primary objective of this study was to investigate the feasibility of carrying 
out HIIT, twice per week for eight weeks in people with progressive MS and an 
EDSS of 4.0-6.0. The aspects of feasibility that were measured were tolerance to 
protocol, adherence by percentage of training sessions completed, compliance 
rate with protocol, and participant drop-outs (Bowen et al., 2009). 
The secondary objectives were to compare in people with progressive MS, 
objectively measured physiological and clinical outcomes in those who received 
an eight week HIIT intervention and active controls who received a CONT 
intervention.  
 
8.2 Study design and ethical approval  
A Randomised Controlled Trial (RCT) design was used. A feasibility study was 
conducted as it was yet unclear if HIIT could be carried out in people moderately 
disabled by progressive MS, and how well it would be tolerated. Furthermore, 
the outcomes of the feasibility study were to inform a protocol for a larger 
powered RCT. Ethical approval for the study was granted by the West of 
Scotland Research Ethics Committee in January 2017 (Appendix 6) and approved 
by NHS Ayrshire and Arran Research and Development department in February 
2017 (Appendix 7). 
 
8.3 Recruitment 
A convenience sample of people with MS was recruited from the MS Service 
within NHS Ayrshire & Arran. Potential participants were identified from active 
caseloads and discharge lists by members of the MS Service team. Posters were 
placed in waiting areas of the Douglas Grant Rehabilitation Centre (Appendix 8) 
and local MS Society support groups. The PhD student also presented to local 
support groups to raise awareness. Potential participants were given a 
participant information sheet by a member of the NHS Ayrshire & Arran MS team 
(Appendix 9) and were able to opt-in by contacting a member of the research 
  168 
team or, if they gave written consent, their contact details were passed to the 
research team. The recruitment period lasted for 16 weeks. It was expected that 
at least one participant would be recruited per week. Therefore, it was 
expected that between 16 and 20 participants would, in total, be recruited.  
 
8.4 Inclusion and exclusion criteria 
Inclusion criteria for taking part in the study were:  
 Having a progressive form of MS 
 An EDSS score of 4.0-6.0 
 Aged 18 years or older 
 Known to the MS service team of NHS Ayrshire & Arran  
 Able to attend the Douglas Grant Rehabilitation Centre twice a week for 
eight weeks  
 Able to cycle safely, free of assistance on a cycle ergometer  
Previous HIIT studies in MS have included participants with a predominantly low 
level of disability (EDSS<4.0) (section 7.13). Therefore an EDSS range of 4.0-6.0 
was chosen to focus on those with a higher level of disability compared to 
previous research.  
Exclusion criteria were: 
 A relapse of symptoms requiring treatment within the past three months 
 Having commenced, or had a change in, MS disease modifying treatment 
within the past three months 
 A musculoskeletal injury or condition that could be aggravated by cycling 
 A respiratory condition that could be exacerbated by high intensity 
exercise including chronic obstructive pulmonary disorder, uncontrolled or 
poorly controlled asthma.   
 Uncontrolled high blood pressure at screening (>190/100 mmHg) from the 
average of two readings  
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 Cognitive impairment that would impact capacity to consent or ability to 
follow instructions, as noted from the participant’s patient notes 
 Taking part in another interventional trial or any other study that could 
affect their physiological or cardiovascular response to exercise  
 Weighing more than 100 kg  
 A cardiovascular event in the past year including but not limited to: 
transient ischaemic attack, cerebrovascular event and myocardial 
infarction. 
 Condition or medical intervention that precluded taking part in high 
intensity exercise, maximal exertion testing, or could attenuate the 
cardiovascular effect of exercise including: unstable angina, diabetes, 
peripheral vascular disease or intermittent claudication, a pace-maker or 
medicine pump, surgical clips, another neurological condition other than 
MS, and pregnancy. 
 Taking any of the following medication: beta blockers, vasodilators, ACE 
inhibitors, diuretics or any other medication that could cause exercise 
induced hypotension or hypoglycaemic agents including insulin and/or oral 
hypoglycaemic drugs. 
While there is no evidence to suggest that HIIT is unsafe in people with 
cardiorespiratory conditions, such as chronic obstructive pulmonary disorder 
there is, at present, no evidence to say that it is safe. Thus the decision was 
taken to exclude participants with these conditions. Participants were excluded 
if they had uncontrolled high blood pressure because high intensity aerobic 
exercise can increase blood pressure and this would put the participant at 
further risk. For the same reason, participants were excluded if they had a 
serious cardiovascular event in the past year. A weight limit of 100kg was placed 
on participants as this was the weight limit of the cycle ergometer.   
 
8.5 Screening, consent and baseline assessment 
All screening, testing and training sessions were conducted by the PhD student in 
the Douglas Grant Rehabilitation Centre in Irvine, NHS Ayrshire & Arran. At the 
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initial visit, the purpose of the study was explained to the participant and they 
were given an opportunity to ask questions. Participants then underwent 
screening for eligibility (see inclusion and exclusion criteria in previous section) 
and provided written informed consent to participate in the study (Appendix 10) 
and also for their GP to be informed of their participation (Appendix 11). The 
participant and the researcher each kept a signed consent form and one was 
placed in the participant’s medical notes. Participants were informed that they 
were free to withdraw from the study at any point.   
If the participant passed the screening and gave full informed consent the 
following outcome measures were taken, as a baseline assessment, in the 
following order: blood pressure (values taken from screening measurements), 
resting heart rate, timed 25 foot walk test, MSIS-29 version 2, Hospital Anxiety 
and Depression Scale (HADS), Symbol Digit Modalities Test (SDMT), Fatigue Scale 
of Motor and Cognitive functions (FSMC), blood samples for resting serum BDNF 
concentration, resting lactate concentration, resting lactate concentration, 
Maximal Heart Rate (HRMax) from a graded exercise test and peak lactate 
concentration. These outcome measures are described in detail in sections 8.7 
and 8.8. Assistance was provided with scribing if required in the self-report 
outcome measures. All outcome measures were taken again 3 days after the 
final training session in week 9. Where possible, pre and post intervention 
assessments were taken at the same time of day to limit differences in diurnal 
fluctuations. 
 
8.6 Randomisation 
Participants were randomised after baseline assessment. The participant chose 
from an equal number of opaque envelopes containing a piece of paper with 
either “intervention” or “control” written on it. Prior to each randomisation the 
envelopes were shuffled by the researcher. After randomisation the participant 
was given a regular timeslot for their training sessions and asked to return for 
their first training session after abstaining from exercise for at least two days. 
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They were instructed to make sure that they had eaten and drank something 
every morning before each training session. 
 
8.7 Outcome measures 
8.7.1 Primary outcome measure: feasibility of high intensity 
interval training 
Feasibility was measured in terms of acceptability by tolerance to protocol, 
adherence in the percentage of training sessions completed, compliance rate 
with protocol, and the drop-out rate of participants (Bowen et al., 2009). A 
retention rate of 80% and compliance rate of 80% was considered to indicate an 
appropriate level of acceptability (Scottish Intercollegiate Guidelines Network, 
2017). 
Tolerance was measured by monitoring the participant’s MS symptoms over a 48 
hour period after each training session, and in the number of adverse events.  
Prior to each session the participant was given a symptom diary and asked to 
rate their pain, spasms, paraesthesia, fatigue and any other symptom they may 
have on a 10 point visual analogue scale (Appendix 12). After each training 
session the participant was asked to monitor the same symptoms on a visual 
analogue scale in the morning, afternoon and evening for 48 hours. In addition 
any changes to medication were also recorded in the diary. The diary was 
reviewed by the researcher and discussed with the participant at the next 
training session. If symptoms returned to baseline within the 48 hour time 
period, this was regarded as well tolerated. If symptoms had not returned to 
baseline after the 48 hour period this was discussed with the participant to see if 
the fluctuation in symptoms was a normal occurrence for them or not. If this was 
not normal for the participant and it repeatedly happened this was discussed 
with the participant, and the exercise protocol was adjusted for the next two 
sessions. If the exercise training was still producing an adverse effect on the 
participant’s symptoms, withdrawal was considered. 
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8.8 Secondary outcome measures 
8.8.1 Blood pressure and resting heart rate 
During the exercise sessions, blood pressure and resting heart rate were 
measured using an Omron 7051T blood pressure and heart rate monitor. After 
the participant had been sitting for 10 minutes, two readings were taken 30 
seconds apart and the mean of the readings was recorded. Readings were taken 
with the participant in a sitting position with their arm resting on a table with 
their palm facing up.   
 
8.8.2 Timed 25 foot walk test  
The participant was asked to walk 25 feet on a marked floor as quickly, but 
safely, as possible, using their usual walking aids or assistive devices. A stop 
watch was started when the participant began from a standing start and was 
stopped when they crossed the finish line. The test was repeated twice with no 
rest period between tests and the average of both times calculated. A maximum 
time of 180 seconds was placed on both trials as per the protocol set out by 
Cutter et al. (1999). If the participant did not manage the first trial in this time 
then they were not required to do the second trial.   
The timed 25 foot walk test was found to be reliable in people in MS (Learmonth 
et al., 2012). Studies have found the timed 25 foot walk test correlated with the 
EDSS across all levels (Kalkers et al., 2000) but was less sensitive at lower levels 
of disability (Bethoux and Bennett, 2011). The Minimal Clinically Important 
Difference (MCID) for the timed 25 foot walk test in people with MS is a decrease 
of 20% in time (Kaufman et al., 2000). 
 
8.8.3 Multiple Sclerosis Impact Scale - 29 version 2  
The MSIS-29 version 2 self-report measure was described in Chapter 4 (section 
4.9.3). The MSIS-29 is valid and sensitive to change in disability in people with 
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MS (Gray et al., 2009, McGuigan and Hutchinson, 2004). While the MCID  for 
version 1 of the MSIS-29 is 8 points in the physical sub-scale (Costelloe et al., 
2007a) and 6 in the psychological sub-scale (Widener and Allen, 2014) there is no 
available MCID for the sub-scales in MSIS-29 version 2. The MSIS-29 version 2 
takes approximately 10 minutes to complete. 
 
8.8.4 Hospital Anxiety and Depression Scale  
The HADS is a self-report measure of depression and anxiety (Zigmond and 
Snaith, 1983). It consists of 14 items: 7 for depression and 7 for anxiety. The 
participant is asked to recall the past week and choose 1 of 4 possible options 
for each statement each scoring 0-3. Both depression and anxiety subscales are 
scored out of 21. A total score of 0-7 is considered normal, 8-10 borderline, and 
11-21 indicates clinical symptoms and warrants further referral if the participant 
is not already receiving treatment (Zigmond and Snaith, 1983). The HADS has 
been found to be valid for identifying anxiety and depression in people with MS 
(Patten et al., 2015, Watson et al., 2014). The HADS takes approximately five 
minutes to complete.   
 
8.8.5 Symbol Digit Modalities Test  
The SDMT assesses mental processing speed by asking the participant to 
substitute as many numbers in a list of symbols in 90 seconds with the aid of a 
symbol key (Smith, 1982). There are two ways to administer the test: in a 
written or oral format (Benedict et al., 2008). The oral format was chosen as it 
was more suitable for people with MS due to potential deficits in fine motor 
control slowing down the participant’s answer rate.   
The participant was presented with a sheet containing a series of nine different 
symbols. At the top of the page was a key linking each of the symbols with the 
numbers one to nine (Appendix 13). The participant was asked to say the 
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corresponding number for each symbol of the series in order as quickly as they 
could in 90 seconds. The total number of correct answers was recorded.  
The SDMT has been shown to be valid and reliable in detecting impaired mental 
processing speed in people in MS (Walker et al., 2016). The SDMT is also more 
valid than the paced auditory serial addition test, easier to administer (Drake et 
al., 2010) and is preferred by people with MS (Walker et al., 2012). A cut-off 
score of 40 or below indicates cognitive impairment, not just mental processing 
speed, in people with MS (Van Schependom et al., 2014). Changes in the SDMT 
are deemed to be likely to be clinically significant if they are of 8 or more and 
convincing if 12 or more (Benedict et al., 2012). 
 
8.8.6 Fatigue Scale for Motor and Cognitive functions  
The FSMC is a 20 item self-report measure which assesses the severity of fatigue 
on both motor and cognitive functions (Penner et al., 2009). Each question has 
the options ‘Does not apply at all’, ‘Does not apply much’, Slightly applies’, 
‘Applies a lot’ and ‘Applies completely’. Each option scores 5, 4, 3, 2 and 1 
respectively. The scores for all questions in each category are summed to give a 
score which can range from 10 to 50. The FSMC has defined cut-off scores to 
classify mildly, moderately and severely fatigued patients. Mild, moderate and 
severe cut off points are 22, 27 and 32 for the physical domain; 22, 28 and 34 for 
the cognitive domain; and 43, 53 and 63 for the total score (Penner et al., 
2009). Both the motor and cognitive sub-scales have been shown to be valid in 
people with MS (Penner et al., 2009). The FSMC takes approximately 5 minutes 
to complete and the participant is asked to answer the questions in relation to 
their general day to day life.   
 
8.8.7 Resting serum concentrations of brain derived neurotrophic 
factor 
To test for BDNF, blood samples were collected before the HRMax test at the 
baseline assessment (week 0) and again at the post intervention assessment 
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(week 9). Blood was drawn into a serum vacutainer via venepuncture of the 
cubital fossa and left for 30 min to coagulate and then centrifuged at 3000 
Revolutions Per Minute (RPM) for 20 minutes. When immediate centrifugation 
was not possible samples were stored at < 5oC and for a maximum of 8 hours 
before centrifugation. Samples were then aliquoted and frozen at -80oC. 
Samples were thawed in batches and analysed using a QuantikineTM ELISA kit 
(R&D systems, catalogue number DBNT00). 
 
8.8.8 Plasma concentrations of cholesterol, triglyceride and high 
density lipoprotein  
To test for non-fasting triglycerides, and blood lipids, blood was drawn into an 
EDTA vacutainer and stored at < 5oC. Plasma was separated with swing out 
centrifugation and frozen as described above (section 8.9.7). Samples were 
thawed in batches and concentrations of total cholesterol, triglyceride and High 
Density Lipoprotein (HDL) were obtained via Spectrophotometry using a Roche 
CobasTM 311 Clinical Chemistry Analyser. 
 
8.8.9 Whole blood lactate (resting and peak concentrations) 
Whole blood lactate was measured using an ArkrayTM Lactate Pro 2 handheld 
lactate analyser both before and after the HRMax test. A disposable pin prick 
lancet was used to obtain a droplet of blood (as low as 0.3 microlitres) from a 
sterilised forefinger or thumb pad of the participant. This droplet was drawn 
into a capillary sensor and test strip and after 5 seconds a concentration in 
mmol/l was provided. As per the ACSM definitions of maximal exertion, a post 
exercise reading of 8.0 mmol/l or above was considered to indicate maximal 
exertion (Thompson et al., 2000). 
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8.8.10 Maximal heart rate test 
While the gold standard for measuring cardiovascular fitness is maximal oxygen 
consumption (VO2 max), which gives a measure of ventilation of oxygen in 
ml/kg/min, the equipment for conducting VO2 max testing was not available.    
Instead HRMax was selected as heart rate positively correlates with VO2 
consumption and the correlation becomes stronger as intensity rises (Gastinger 
et al., 2010). Uth et al. (2004) have shown that the HRMax and resting heart rate 
can be used to estimate VO2 max with a strong correlation (r=0.87) using the 
following equation: VO2max = 15 x (HRMax/ resting heart rate). The use of 
HRMax as a proxy measure for a work rate of %VO2max is commonplace in 
exercise studies and was implemented in three of the six HIIT studies identified 
in the systematic review (Skjerbæk et al., 2014, Wens et al., 2015, Zimmer et 
al., 2017).   
Maximal heart rate was measured using a graded exercise test on a Roger Black 
GoldTM cycle ergometer and a PolarTM heart rate monitor. Participants were 
asked, for the day of the test, to abstain from consuming caffeine prior to the 
test and to make sure that they had eaten before coming to the session. The 
ergometer seat height was adjusted accordingly to the ergonomics of the 
participant so that when the pedal was at its lowest point the participant’s knee 
was flexed to approximately 25 degrees (Peveler et al., 2007). A PolarTM heart 
rate monitor chest sensor strap was moistened and attached to the participant’s 
chest. The participant had a three minute warm up of unloaded pedalling at 
their own chosen cadence. The testing phase then began at resistance one (of 
eight) and a target speed of 30 km/h, which was an approximate cadence of 60 
RPM. Resistance was then increased by one level every minute until resistance 
level eight was reached. The 10 point Borg Scale of Perceived Exertion was in 
front of the ergometer in view of the participant (described in section 8.9). The 
participant was given verbal encouragement throughout and asked to state their 
exertion from the 10 point Borg Scale of Perceived Exertion once a minute. If 
the participant was able to cycle at 30km/h at resistance level eight, the speed 
was increased by 5 km/h each minute thereafter. The researcher recorded the 
highest heart rate reached. Testing was stopped when one of the following 
occurred indicating volitional exhaustion: 
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 Unable to consistently sustain a cadence greater than 40 RPM 
 Felt that they could not continue  
At this point the warm down phase began where the participant pedalled at a 
nominal resistance and chosen low cadence for three minutes, or longer if the 
participant desired, or until their heart rate decreased to below 70% of the 
highest heart rate recorded. 
The highest heart rate recorded was used to calculate training intensities for the 
HIIT and CONT sessions. The test generally lasted between 8-12 minutes. A fan 
was set up to keep the participant cool and two therapists were present for the 
entire test to the ensure safety of the participant and to help the participant on 
and off the cycle ergometer if required.   
After the test the participant rested on a plinth for as long as needed but for a 
minimum of 10 minutes, as lower limb symptoms may be temporarily 
exacerbated by exercise. The participant was provided with water before and 
after the test to ensure they remained hydrated.   
Maximal exertion during a cardiorespiratory test can be characterised by any one 
of the following (Midgley et al., 2007, Thompson et al., 2000): 
 A perceived exertion of >18 on the Borg Scale of perceived exertion or >10 
on the 10 point Borg Scale 
 Heart rate plateau with increased workload 
 Post-test lactate level > 8.0 mmol/l 
 VO2 consumption plateau with rising workload 
 Respiratory exchange ratio of CO2: O2 of 1.10 or more  
Due to the lack of available equipment, indicators of maximal exertion used 
were the criteria involving the Borg scale, a heart rate plateau and post-test 
lactate levels. 
For safety reasons the HRMax test was also halted if any of the following 
occurred: 
 Participant felt unwell 
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 Participant did not want to carry on 
 Participant was unsteady/ felt dizzy or faint/ was sick/ became 
incoherent 
 Participant was unable to control the exercise intensity and repeatedly 
exceeded target heart rate  
 Participant had angina symptoms  
 Participant displayed signs of poor perfusion: cyanosis, pallor, clammy or 
cold skin 
 
8.9 10 point Borg scale of perceived exertion 
The 10 point Borg scale of perceived exertion measures perceived physical 
exertion during physical activity. The scale ranges from ‘0 nothing at all’ to ‘10 
very, very strong (maximal)’ (Appendix 14). The 10 point Borg scale of perceived 
exertion has been shown to be reliable and valid in people with MS and a mild to 
moderate disability whilst undertaking cycling exercise (Cleland et al., 2016). 
Furthermore, compared to the original Borg scale of rated perceived exertion 
which ranged from 6-20, the 10 point Borg scale was found to be more suitable 
for graded tests lasting more than four minutes (Borg and Kaijser, 2006). 
 
8.10 Training protocols 
The intervention and active control groups both received an eight week exercise 
programme. The participants attended the Douglas Grant Rehabilitation Centre 
in Ayrshire Central Hospital, Irvine, twice a week for supervised training 
sessions, with sessions separated by at least two days to allow for recovery. 
Participants received individual training sessions. A physiotherapist (the PhD 
student) was present for all training sessions. A PolarTM heart rate monitor chest 
sensor strap was moistened and attached to the participant’s chest with the 
heart rate monitor placed on the handle bars so the participant could see their 
own heart rate. The seat height of the bicycle ergometer was adjusted in a 
similar way as the assessments (described above). A fan was set up to keep the 
participant cool. The 10 point Borg Scale of Perceived Exertion was placed in 
front of the cycle ergometer within the participant’s view (Appendix 14). Safety 
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criteria for halting a training session were the same as those used for halting the 
HRMax test (8.8.10).  
 
 
Figure 8-1 Participant position for exercise session 
 
8.10.1 High intensity interval training protocol 
The HIIT protocol consisted of a 2 minute warm up, 6 x 90 second bursts at 80-
95% of HRMax with 90 second working rests in between, followed by a 3 minute 
warm down. The participant was informed of their 80-95% HRMax range and 
advised not to exceed this range during their exercise session. If the HRMax 
recorded during HRMax test was greater than the age predicted HRMax (220- age 
in years) then, for safety reasons, the range prescribed was 80-95% of age 
predicted HRMax.  
The participant warmed up for 2 minutes by cycling at their self-selected light 
resistance and a cadence of <60 RPM to increase their heart rate to a minimum 
of 50% HRMax. If during the warm up the participant’s heart rate did not 
increase to 50%, the resistance was increased manually by the researcher to 
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increase workload and thus heart rate. After the 2 minute warm up period the 
resistance of the ergometer was increased to 70% of maximal resistance 
recorded during HRMax test and the participant was asked to pedal at >60 RPM 
for 1.5 minutes to increase heart rate to 80-95% of HRMax. After the 1.5 minute 
training interval was complete the resistance was reduced to the participant’s 
self-selected light resistance and the participant pedalled at <60 RPM for 1.5 
minutes to bring their heart rate down to 60-70% HRMax. The 1.5 minute high 
intensity interval and 1.5 minute working rest were repeated another five times 
to give a total of six high intensity intervals and six working rest intervals. The 
participant then pedalled at <60 RPM with nominal resistance for three minutes 
as a warm down. Total time on the ergometer was 23 minutes and total working 
time at a high intensity was nine minutes per session.  
Similar intensities were used in a previous HIIT study that equated 90% of HRMax 
to approximately 80% VO2max and 70% of HRMax to approximately 65% VO2max 
(Zimmer et al., 2017). Interval lengths of 1.5 minutes were selected as previous 
research has found that intervals of 2 minutes or shorter are more enjoyable 
(Cassidy et al., 2017). Even though the previous study to investigate HIIT in 
people with progressive MS used intervals of 3 minutes only 30-60 seconds of 
each interval was spent at a high intensity (Skjerbæk et al., 2014). 
If the participant did not reach >80% HRMax in the first interval then for 
subsequent intervals the participant was encouraged to pedal faster and 
resistance was manually increased by the researcher. If the participant’s heart 
rate exceeded 95% HRMax the participant was advised to decrease their RPM and 
the researcher manually decreased resistance. If during the first resting interval 
of the first training session the participant’s heart rate did not decrease to less 
than 70% HRMax in 1.5 minutes, the resting interval was increased by 30 second 
increments up to 3.5 minutes and this increased duration was used for all 
following resting intervals for that session and sessions two to four. On the fifth 
session the resting interval was decreased by 30 seconds and then another 30 
seconds every 4 sessions thereafter until it was 1.5 minutes. 
The participant was given verbal encouragement and reassurance throughout.  
After the training session the participant was able to rest on a plinth for as long 
as needed as lower limb symptoms and fatigue may sometimes be temporarily 
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exacerbated. If the participant experienced pain, spasms, paraesthesia, fatigue 
or any other MS related symptom such as visual disturbances or dizziness these 
were recorded, the severity and the length of time for the symptoms to subside 
were also recorded and then monitored in subsequent sessions.   
 
8.11 Active control protocol 
The active control group received an eight week, CONT programme. The 
participants visited the Douglas Grant Rehabilitation Centre twice weekly for 
training sessions separated by at least two days to allow for recovery.  
Participants received individual supervised training sessions. An active control of 
CONT was used as the effectiveness of HIIT in producing increases in fitness has 
always been compared to CONT as this is the traditional endurance training 
method to improve fitness. Thus it was appropriate to compare these two 
training modalities in people with progressive MS. 
 
8.11.1 Continuous moderate intensity session protocol 
The participant was informed of their 60-70% HRMax range and told not to 
exceed this during the session. After a 2 minute warm up, cycling at a nominal 
resistance and <60 RPM the resistance was increased to 50% of maximal 
resistance recorded during the HRMax test and the participant cycled at ~60 RPM 
for 30 minutes, during which they were asked to keep their heart rate in the 60-
70% HRMax range. If the participant exceeded 70% HRMax they were asked to 
decrease their RPM or the researcher manually decreased the resistance to 
decrease the workload. Conversely, if the participant did not reach 60% HRMax 
then they were asked to increase their RPM or the researcher manually 
increased the resistance to increase the workload. After the 30 minutes was 
complete the participant cycled for 3 minutes at a nominal resistance as a warm 
down. Total work time in the continuous moderate intensity training session was 
30 minutes at 60-70% of HRMax. Participants in CONT group were also given the 
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opportunity to rest afterwards and any increase in the severity of symptoms and 
length of time to subside were recorded.  
 
8.11.2 Comparison of the two training protocols  
Energy cost of VO2 is 20.5 kJ/l. Assuming a weight of 75kg, a VO2 peak of 25.5 ml 
O2/kg/min, and equating 70% HRMax to 60% VO2Max (Langeskov-Christensen et 
al., 2015) this would equate to a consumption of 34.4 l O2 per CONT session, or 
705.2 kJ. A similar calculation for the HIIT protocol, assuming 90% HRMax 
equates to 80% VO2max, totals at 13.8 l O2, or 282.9 kJ. Despite this difference 
in workload with the HIIT group apparently burning less energy during training, 
previous research, using similar protocols in healthy individuals, has shown that 
due to Excess Post-exercise Oxygen Consumption, the total energy expenditure 
or VO2 consumed both in working intervals, rests during the HIIT session and 
afterwards, is similar or greater that the CONT session (Tremblay et al., 1994, 
Gaesser and Brooks, 1984). A comparison of the two training protocols can be 
seen in Figure 8-2.  
 
Figure 8-2 Exercise intensity for high intensity interval training and 
continuous training sessions 
Abbreviations: HIIT: high intensity interval training; CONT: continuous moderate intensity 
interval training; HRMax: maximal heart rate 
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8.12 Statistical analysis and handling of data 
  
All data analysis was conducted using IBM SPSS Statistics version 22. Continuous 
variables were assessed for normality using Kolmogorov-Smirnov tests and means 
with standard deviations (SD), or medians with ranges, were reported as 
appropriate. Baseline continuous variables were compared between training 
groups using independent sample t tests, or Mann Whitney U tests when the data 
were not normally distributed. Categorical variables were compared using chi 
square tests.   
The difference between pre and post intervention measures was calculated for 
each participant and the means of these differences were compared between 
the two training groups using independent sample t tests and Mann Whitney U 
tests where appropriate. Effect sizes of all statistically significant results were 
calculated using Cohen’s d analysis. Effect sizes were defined as weak (d<0.5), 
moderate (0.5<d<0.8) or strong (d>0.8) (Cohen, 1988). Statistical significance 
was set at p<0.05 and all analysis was conducted per protocol. 
Adherence was calculated as a percentage of sessions attended and compliance 
was calculated as the percentage of training sessions where protocol was 
followed successfully.  
 
8.13 Participants 
Twenty four people with progressive MS expressed an interest in taking part in 
the study. Twelve were excluded for the following reasons: non progressive MS 
(n=3), failed to respond to telephone messages after expressing an interest 
(n=2), EDSS<4.0 (n=1),  myocardial infarction less than a year ago and was taking 
a beta blocker (n=1), taking a beta blocker (n=1), uncontrolled high blood 
pressure at screening (n=1), chronic obstructive pulmonary disorder (n=1), 
participating in another intervention study for their MS (n=1) and unable to 
commit to the timeframe (n=1).   
Twelve people were then included in the study, underwent screening and 
baseline measurements, before being randomised. One participant withdrew 
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from the HIIT group due to new personal time constraints and one participant 
withdrew from the CONT group because they did not enjoy cycling. See Figure 
8-3 for a CONSORT diagram describing the flow of participants through the 
study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-3 CONSORT diagram of flow of participants through the study 
Abbreviations: n: number; EDSS: extended disability status scale; COPD: chronic obstructive 
pulmonary disorder; HIIT: high intensity interval training; CONT: continuous moderate intensity 
interval training 
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8.14 Restarting of five participants 
During the study period the PhD student became ill and was unable to carry out 
the intervention for four weeks. At that point, six participants (participants 7-
12) were still receiving the intervention and six had already completed their 
final assessment. Of the six participants who were still receiving the 
intervention, two were in the CONT group and four were in the HIIT group. As 
the intervention was eight weeks in length the decision was taken to restart 
these participants, collect new baseline data and start a new eight week training 
programme. It was at this point one of the participants (number 12) decided to 
withdraw as he did not enjoy cycling. For participants 7-11, the baseline data 
reported in this chapter is the second set of measurements collected. For these 
five participants statistical analysis revealed no difference between the two sets 
of baseline measurements (p>0.05). A comparison of the two sets of baseline 
data can be seen in Appendix 15. 
 
8.15 Demographics 
The cohort comprised eight males and four females, eight had SPMS and four had 
PPMS. The mean age was 54 years (SD 8) and mean time since diagnosis was 15 
years (SD 12). The median EDSS score was 6.0 (range 4.0–6.0) (Table 8-1). One 
participant used an ankle foot orthosis and one participant used functional 
electrical stimulation (Table 8-2). The mean Body Mass Index (BMI) across the 
sample was 26.4 (SD 3.2) kg/m2 (Table 8-1). Three participants were a healthy 
weight (BMI <25 kg/m2), six were overweight (BMI 25-30 kg/m2) and three 
participants were obese (BMI >30 kg/m2) (NICE, 2014c) (Table 8-2). Only one 
participant was working full time and one part time, all the other participants 
were either retired, or unemployed (Table 8-2). 
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Table 8-1 Demographics of the cohort 
 Whole sample HIIT  CONT   
  Mean SD Mean SD Mean SD P 
Age (years) 54 8 54 8 54 9 0.973 
TSD (years) 15 12 13 11 18 12 0.463 
Height (m) 1.72 0.15 1.72 0.16 1.72 0.14 0.982 
Weight (kg) 80.2 10.2 82.7 14.3 77.8 3.2 0.443 
BMI (kg/m2) 26.4 3.2 27.4 2.9 25.9 3.3 0.489 
EDSS* 6.0 4.5-6.0 6.0 4.0-6.0 6.0 4.0-6.0 0.574^ 
Gender:  Male 8  4  4   
(n)         Female 4  2  2   
MS type†: PPMS 4  3  1   
(n)          SPMS 8  3  5   
Abbreviations: TSD: time since diagnosis, BMI: body mass index; EDSS: expanded disability status 
scale; PPMS: primary progressive MS; SPMS: secondary progressive MS HIIT: high intensity interval 
training: CONT: continuous moderate intensity training SD: standard deviation 
*EDSS expressed as median and range 
^All tests compared HIIT and CONT groups and were independent samples t tests, apart from 
EDSS which was Chi-Square test 
 
 
There was an equal distribution of males and females across the HIIT and CONT 
groups with four males and two females in each. There were three people with 
PPMS and three people with SPMS in the HIIT group and five people with SPMS 
and one person with PPMS in the CONT group (Table 8-1). There were no 
differences between the two groups in terms of age, time since diagnosis, 
height, weight or EDSS (Table 8-1). 
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Table 8-2 Demographics of participants 
Pt Group Age 
(yrs) 
Gender MS  
Type 
TSD TSR Indoor 
WA  
Outdoor 
WA 
WC 
Use 
Working Height 
(m) 
Weight 
(kg) 
BMI 
(kg/m2) 
EDSS 
1 HIIT 45 M SPMS 12 >2 yrs 1 ws 1 ws weekly Ret 1.82 89.7 27.1 6 
2 HIIT 57 F SPMS 30 1-2 yrs 1 ws 1 ws occ UE 1.53 75.3 32.2 6 
3 CONT 52 F SPMS 5 >2 yrs 1 ws 1 ws occ Ret 1.57 73.6 29.9 6 
4 CONT 46 M SPMS 8 >2 yrs none none never Ret 1.78 75.6 23.9 4 
5 CONT 65 M SPMS 29 unknown 1 ws 1 ws never Ret 1.91 82 22.5 6 
6 CONT 43 M PPMS 11 none 1 ws 1 ws occ FT 1.75 77.2 25.2 6 
7 HIIT 64 M PPMS 20 none 1 ws 1 ws never Ret 1.74 79.5 26.3 6 
8 HIIT 49 M PPMS 1 none none none never Ret 1.78 97 30.7 4.5 
9 HIIT 62 M PPMS 10 none 1 ws 1 ws never Ret 1.91 95.2 26.1 6 
10 CONT 62 F SPMS 36 3/12-1 yr 1 ws 1 ws occ UE 1.55 77.1 32.1 6 
11 HIIT 49 F SPMS 2 3/12-1 yr none none never PT 1.52 59.4 25.7 4 
12 CONT 57 M SPMS 17 1-2 yrs none 1 ws occ Ret 1.75 81 26.4 6 
Abbreviations: Pt: participant number; HIIT: high intensity interval training; CONT: continuous moderate intensity training; M; male; F: female; SPMS: secondary 
progressive MS; PPMS: primary progressive MS; TSD: time since diagnosis; TSR: time since last relapse; 3/12: 3 months; yrs: years; WA: walking aid; ws: walking 
stick; AFO: ankle foot orthosis; FES: functional electrical stimulation; WC: wheelchair; occ: occasional; Ret: retired; UE: unemployed; FT: full time; PT: part time; 
BMI: body mass index; EDSS: expanded disability status scale 
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8.16 Baseline data 
8.16.1 Cardiovascular related outcome measures 
As a cohort the participants had a HRMax lower than that of their age predicted 
HRMax, suggesting they were deconditioned. The mean age was 54 years and 
thus the mean age predicted HRMax was 166 bpm (220-54) (Table 8-3).  
Table 8-3 Baseline measurements of cardiovascular related outcome 
measures for each participant 
Pt  Group Weight 
(kg) 
Resting 
HR 
(bpm) 
Systolic 
(mm/Hg) 
Diastolic 
(mm/Hg) 
HRMax  
(bpm) 
3 CONT 73.6 87 144 77 174 
4 CONT 75.6 69 120 70 180 
5 CONT 82 73 117 72 136 
6 CONT 77.2 72 126 84 170 
10 CONT 77.1 93 125 76 124 
12 CONT 81 83 129 85 116 
1 HIIT 89.7 70 126 78 137 
2 HIIT 75.3 63 142 74 110 
7 HIIT 79.5 66 108 64 135 
8 HIIT 97 59 123 80 137 
9 HIIT 95.2 82 128 97 138 
11 HIIT 59.4 75 126 74 137 
All Mean 80.2 74 126 78 141 
 SD 10.2 10 10 8 22 
CONT Mean 77.8 80 127 77 150 
 SD 3.2 1 10 6 28 
HIIT Mean 82.7 69 126 78 132 
 SD 14.3 8 11 22 11 
 P 0.443* 0.075* 0.825* 0.924* 0.519^ 
Abbreviations: Pt: participant number; CONT: continuous moderate intensity training; HIIT: high 
intensity interval training; SD: standard deviation; HR: heart rate; HRMax: maximal heart rate 
*Result from independent t test between HIIT and CONT groups. 
^Result from Mann Whitney U test between HIIT and CONT groups. 
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The mean HRMax of the sample was 141 (SD 22) bpm. This indicated that as a 
cohort their HRMax was approximately that of a 79 year old. The cohort had a 
healthy resting HR of 74 (SD 10) bpm but the large standard deviation reflected 
that four participants had a high resting HR of 80 bpm or above (Table 8-3). 
Diastolic and systolic blood pressures were in normal ranges across the whole 
cohort. This was expected as uncontrolled high blood pressure was an exclusion 
criterion. There were no differences between the groups at baseline in terms of 
weight (p=0.443), resting HR (p=0.075), systolic (p=0.825) or diastolic blood 
pressure (p=0.924), or HRMax (p=0.519) (Table 8-3). 
 
8.16.2 Multiple Sclerosis clinical outcome measures 
Mean time to complete the timed 25 foot walk test was 10.9 (SD 7.9) seconds 
(Table 8-4). The large standard deviation highlights the large range of results 
across the 12 participants (5.2 – 23.5 seconds). Participants with the slowest 
times had an EDSS of 6.0 and used a walking stick both indoors and outdoors. 
Results from the HADS suggested that the cohort were not anxious or depressed 
with mean scores of 7 (SD 3.9) and 6 (SD 3.2) respectively (Table 8-4). However, 
one participant had a depression score of 11, and three participants had anxiety 
scores of 11 or more indicating potential high levels of depression and anxiety. 
As a cohort the mean physical impact score from the MSIS-29 was 53 (SD 13.8) 
from a maximal score of 80, indicating a moderate amount of physical impact. 
The mean psychological impact score from the MSIS-29 was 22 (SD 8) from a 
maximal score of 36 also indicating a moderate psychological impact of MS.   
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Table 8-4 Baseline measurements of gait speed, impact of disease and 
anxiety and depression scores for each participant 
Pt  Group T25FW 
(sec) 
MSIS29 
Phys 
MSIS29 
Psych 
HADS 
Anx 
HADS 
Dep 
3 CONT 18.1 68 23 15 11 
4 CONT 5.4 48 19 7 7 
5 CONT 5.2 36 15 2 7 
6 CONT 10.2 31 11 6 2 
10 CONT 23.5 51 34 3 5 
12 CONT 11.9 76 36 9 9 
1 HIIT 6.8 55 21 7 4 
2 HIIT 22.7 74 27 11 8 
7 HIIT 8.7 53 17 6 5 
8 HIIT 5.3 50 19 8 0 
9 HIIT 7 48 11 3 5 
11 HIIT 6.2 45 25 12 10 
All Mean 10.9 53 22 7 6 
 SD 7.9 14 8 4 3 
CONT Mean 12.4 52 23 7 7 
 SD 7.2 18 10 5 3 
HIIT Mean 9.5 54 20 8 5 
 SD 6.6 10 6 3 3 
 p 0.522^ 0.770* 0.543* 0.730* 0.448* 
Abbreviations: Pt: participant number; CONT: continuous moderate intensity training; HIIT: high 
intensity interval training; SD: standard deviation; T25FW: timed 25 foot walk test; MSIS-29: 
multiple sclerosis impact scale; Phys: physical sub-scale; Psych: psychological sub-scale; HADS: 
hospital anxiety and depression scale; Anx: anxiety; Dep: depression 
*Result from independent t test between HIIT and CONT groups. 
^Result from Mann Whitney test between HIIT and CONT groups. 
 
The mean fatigue score measured by the total score from the FSMC, for all 
participants was 73 (SD 22.4) indicating that the cohort as a whole was severely 
fatigued (cut off score of 63, n=8). Mean scores of 38 (SD 9.8) for motor fatigue 
also meant that the sample was severely fatigued in this domain (cut off 34, 
n=8) and a mean score of 35 (SD 12.7) indicated the same for the domain of 
cognitive fatigue (cut off 32, n=8) (Penner et al., 2009) (Table 8-5).  
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Table 8-5 Baseline measurements of fatigue and mental processing speed for 
each participant 
Pt  Group FSMC 
Total 
FSMC 
Mot 
FSMC 
Cog 
SDMT 
3 CONT 100 50 50 47 
4 CONT 70 37 33 46 
5 CONT 42 25 17 30 
6 CONT 34 23 11 57 
10 CONT 92 48 44 15 
12 CONT 100 50 50 15 
1 HIIT 74 36 38 57 
2 HIIT 88 44 44 33 
7 HIIT 87 45 42 34 
8 HIIT 83 42 41 28 
9 HIIT 50 26 24 43 
11 HIIT 61 33 28 48 
All Mean 73 38 35 38 
 SD 22 10 13 14 
CONT Mean 73 39 34 35 
 SD 30 12 17 18 
HIIT Mean 74 38 36 41 
 SD 15 7 8 11 
 p 0.952* 0.848* 0.800* 0.532* 
Abbreviations: Pt: participant number; CONT: continuous moderate intensity training; HIIT: high 
intensity interval training; SD: standard deviation; FSMC: fatigue scale for motor and cognitive 
function; Mot: motor; Cog: cognitive; SDMT: symbol digit modalities test 
*Result from independent t test between HIIT and CONT groups. 
 
When metal processing speed was measured using the SDMT, the scores across 
the cohort ranged from 15 to 57 with a mean of 38 (SD 14.3). A score below 40 
indicates cognitive impairment in people with MS (Van Schependom et al., 
2014), indicating that this cohort as a whole had impaired mental processing 
speed. However, six of the twelve participants had scores over 40 meaning only 
half of the participants were cognitively impaired (Table 8-5). 
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There were no differences between the HIIT and CONT groups at baseline in the 
timed 25 foot walk test (p=0.522), MSIS-29 physical (p=0.77) and psychological 
sub-scale scores (p=0.543), HADS anxiety (p=0.73) or depression scores (p=0.448) 
(Table 8-4), SDMT scores (p=0.532), total FSMC scores (p=0.952), motor FSMC 
scores (p=0.848), or cognitive FSMC scores (p=0.800) (Table 8-5). 
 
8.16.3 Physiological outcomes 
Non-fasting levels of triglyceride across the whole cohort, were low with a mean 
concentration of 1.8 (SD 0.9) mmol/l, indicating healthy levels of circulating 
triglyceride with only three participants displaying non-fasting triglyceride levels 
over the healthy limit of 2.3 mmol/l. Total cholesterol concentrations were 
slightly above the healthy range (5.0 mmol/l), with a mean concentration of 5.8 
(SD 0.9) mmol/l. Two participants, had total cholesterol levels over 7.0 mmol/l, 
indicating that while they would warrant an intervention to lower their 
cholesterol, their levels were not high enough to warrant further investigation 
(>7.5 mmol/l) (NICE, 2014a) (Table 8-6). However, none of the participants were 
taking a statin or similar cholesterol lowering medication.  
Concentrations of HDL varied across the cohort with a mean concentration of 1.3 
(SD 0.4) mmol/l indicating, as a cohort, they were on the limit of the healthy 
range (1.0 mmol/l). Three participants had HDL concentrations below 1.0 
mmol/l and two of these had high levels of non-HDL cholesterol.  
The mean BDNF concentration for this sample was 36.40 (SD 7.8) ng/ml 
indicating that baseline serum BDNF concentrations were within the average 
expected range of 8-46 ng/ml for healthy individuals (Polacchini et al., 2015) 
(Table 8-6).  
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Table 8-6 Baseline physiological measurements for each participant 
Pt Group TG 
 
Total  
chol 
 
HDL 
 
Non  
HDL  
chol 
Resting  
lactate 
 
Peak  
lactate 
 
BDNF 
 
3 CONT 1.5 7.2 0.9 6.2 5.6 7.8 50.18 
4 CONT 1.5 4.7 1.6 3.1 4.5 18.5 31.74 
5 CONT 1.5 5.2 1.5 3.7 4.8 6 37.99 
6 CONT 3.5 5.9 0.8 5.1 2.1 8.1 36.12 
10 CONT 2.9 5.9 1.1 4.8 2.5 4.3 33.33 
12 CONT 1.3 6.2 1.3 4.9 2.1 3.8 40.83 
1 HIIT 0.9 5.1 1.8 3.3 0.6 6.2 19.60 
2 HIIT 0.6 5.1 1.9 3.2 0.8 4.6 41.03 
7 HIIT 2.3 6.8 1.3 5.6 5.4 11.6 36.14 
8 HIIT 1.6 4.5 0.9 3.6 1 15.5 34.81 
9 HIIT 1.4 7.0 1.6 5.4 1.5 12.4 44.91 
11 HIIT 2.5 5.7 1.2 4.5 1.7 4.4 29.68 
All Mean 1.8 5.8 1.3 4.7 2.7 8.6 36.36 
 SD 0.9 0.9 0.4 1.1 1.8 4.8 7.79 
CONT Mean 2.0 5.8 1.2 4.6 3.6 8.1 38.40 
 SD 0.9 0.8 0.3 1.2 1.6 5.4 6.60 
HIIT Mean 1.5 5.7 1.5 4.2 1.8 9.1 34.34 
 SD 0.8 1.0 0.4 1.2 1.8 4.7 8.90 
 p 0.350* 0.801* 0.225* 0.527* 0.037^ 0.730* 0.399* 
Abbreviations: pt: participant number; CONT: continuous moderate intensity training; HIIT: high 
intensity interval training; SD: standard deviation; TG: triglyceride; chol: cholesterol; HDL: high 
density lipoprotein; BDNF: brain derived neurotrophic factor 
*Result from independent t test between HIIT and CONT groups. 
^Result from Mann Whitney test between HIIT and CONT groups. 
All values are in mmol/l apart from BDNF concentrations which are ng/ml. 
 
Peak lactate at baseline assessment across the whole cohort was 8.6 (SD 4.84) 
mmol/l indicating, according the 8.0 mmol/l cut-off (Thompson et al., 2000, 
Midgley et al., 2007), that they reached maximal exertion during their exercise 
test (Table 8-6). However, only five of the 12 participants were above the cut-
off of 8.0 mmol/l and one participant (participant 4), who was an ex-naval 
serviceman and previously experienced in maximal exertion testing, produced a 
peak lactate of 18.5 mmol/l (Table 8-6). The two participants with the highest 
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peak lactate at baseline also had the lowest EDSS scores of 4.0 and 4.5 (Table 
8-2).   
There were no differences between the groups at baseline in terms 
concentrations of triglyceride (p=0.35), total cholesterol (p=0.801), HDL 
(p=0.225), non-HDL cholesterol (p=0.527) BDNF (p=0.399) or peak lactate 
(p=0.73). There was a statistically significant difference between the HIIT and 
CONT groups in resting lactate (p=0.037). The CONT group had a higher resting 
lactate; mean of 3.6 mmol/l compared to 1.8 mmol/l in the HIIT group (Table 
8-6).   
 
 
8.17 Post intervention results: primary outcome measure 
of feasibility  
8.17.1 Adherence and drop-out rate 
Adherence in both groups was equally high with 98.8% attendance at exercise 
sessions. All participants apart from two, one in each group, attended all their 
training sessions. One participant dropped out from each group. The participant 
who dropped out of the HIIT group did so because of new personal time 
constraints which meant that she was unable to continue attending. The 
participant who dropped out of the CONT group did so because he did not enjoy 
cycling. The baseline data for these participants was included in the statistical 
analysis comparing the HIIT and CONT groups at baseline and is presented for 
each outcome for comparison. The subsequent analysis was conducted on a per 
protocol basis.  
 
8.17.2 Tolerance 
Both the HIIT and CONT protocols were well tolerated. No participants reported 
any fluctuation in their MS symptoms, that could be attributed to the 
intervention, and that did not return to baseline within the 48 hour monitoring 
period.   
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There were no adverse events in the HIIT group. There were, however, three 
adverse events in the CONT group. One participant (participant 5) stopped two 
of his training sessions prematurely complaining of a headache and dizziness. He 
later informed the PhD student that on both occasions that he had not been 
feeling well prior to the training session and had not eaten or drunk anything on 
either morning. He was advised on both occasions that he should be hydrated 
and eat before exercising. Another participant (participant 10) stopped one of 
her training sessions due to pain in her right knee while cycling. The pain 
resolved immediately after stopping the session and after adjusting the height of 
the seat at subsequent sessions she did not experience any further pain. Up until 
this point the participant’s seat had been, at the participant’s request, lower 
than described in the protocol. 
 
8.17.3 Compliance with protocol 
The compliance rate with the whole protocol was 89.6%. From a total of 164 
sessions, across both groups, two were stopped early due to participant 5 not 
feeling well and one was stopped early due to participant 10 experiencing knee 
pain while cycling. Furthermore, for all of her 15 training sessions, participant 
10 trained at a percentage of her HRMax which was higher than her protocol due 
to her deconditioned baseline measurements (discussed in more detail in section 
8.18). This therefore equated to a total of 17 sessions where the protocol was 
not complied with. However all instances of non-compliance were in the CONT 
group meaning compliance rate with the CONT protocol was 79.3% and 
compliance with the HIIT protocol was 100%. 
The contingency plan described in the HIIT protocol to increase the length of 
working rest intervals if a participant’s heart rate did not drop back down to 
below 70% of the HRMax during their working rest (section 8.10.1) was never 
implemented as it was not necessary.  
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8.18 Results from one participant  
Participant 10 had an exercise profile different to the other participants in the 
study. In the participant’s baseline exercise test she reached a maximal 
resistance of 2, was on the exercise bike for 4 minutes 38 seconds before 
starting the warm down, and reached a HRMax of 124 bpm. After randomisation 
she was allocated to the CONT group, however due to such a low HRMax, when 
she trained at nominal resistance, her heart rate was always above 70% of her 
HRMax. In her initial training session she was able to cycle for 9 min 37 seconds 
before having to stop due to being fatigued. Over the next seven sessions her 
time on the cycle ergometer steadily progressed, apart from one session where 
she had to stop due to knee pain, so that on her eighth session she was able to 
cycle for the full 30 minutes. For the rest of the sessions she managed the full 30 
minutes (with warm up and cool down). Her working heart rate was calculated 
by noting her heart rate every five minutes and taking an average. This working 
heart rate dropped from 88% of her HRMax in her first training session to 78% in 
her final session, indicating an improvement in working heart rate and thus 
fitness (Table 8-7). This meant that the participant’s average working heart rate 
was 85% HRMax. This was higher that the training zone of 60-70% of HRMax 
prescribed by the protocol for the CONT group. It should be noted that 
throughout all the training sessions the resistance was on the lowest level and 
the workload was never increased as her HRMax was never within, or below, her 
training zone of 60-70% of HRMax.   
When the participant completed her post intervention HRMax test she reached a 
maximal resistance of 5, was on the exercise bike for 7 minutes 16 seconds 
before starting the warm down, but only reached a HRMax of 105 bpm with a 
peak lactate that was 0.4 mmol/l lower than her baseline measurement. This 
HRMax value, which was lower than baseline and previous working heart rates 
during training, was an unexpected result and was treated as an outlier. Due to 
this participant being an outlier, and the fact that the participant trained at a 
continuous steady state of 85% HRMax, statistical tests were run both including 
and excluding this participant’s data.  
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Table 8-7 Participant 10’s progression of working heart rate and length of 
session over the 16 training sessions 
Training session 
number 
HR average  
(bpm) 
% HRMax Time 
(min) 
1 110 89 8.37 
2 112 90 13.06 
3 110 89 18.03 
4 113 91 20.01 
5 113 91 26.35 
6 110 89 28.00 
7 106 85 12.29* 
8 109 88 30.00 
9 107 86 30.00 
10 101 81 30.00 
11 106 85 30.00 
12^  -   -  -  
13 98 79 30.00 
14 97 78 30.00 
15 98 79 30.00 
16 97 78 30.00 
Abbreviations: HR: heart rate; HRMax: maximal heart rate 
*Session stopped early due to knee pain. 
^The participant missed session 12 due to transport issues. 
 
 
8.19 Post intervention results: trends in secondary 
outcome measures 
 
8.19.1 Cardiovascular related outcome measures  
In the HIIT group all participants improved their HRMax (range 12-19 bpm). In 
the CONT group three participants improved (range 2-5 bpm) and two 
participants decreased their HRMax by 8 and 19 bpm (Table 8-8). These trends 
were confirmed as the mean differences between the two groups was 
statistically significantly different post intervention (p=0.013). This may indicate 
that HIIT had a positive effect on HRMax while CONT did not have an effect. 
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There was no trend displayed in resting HR in either the HIIT or the CONT group 
and there were no difference between the changes in either group. This may 
indicate that neither HIIT nor CONT had an effect on resting HR (p=0.605) (Table 
8-8). 
Table 8-8 Baseline, post-trial and difference between the measurements of 
resting heart rate, and maximal heart rate for each participant 
  Rest HR (bpm) HRMax (bpm) 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 70 74  4 137 156  19 
2 HIIT 63 60 -3 110 126  16 
7 HIIT 66 62 -4 135 150  15 
8 HIIT 59 67  8 137 149  12 
9 HIIT 82 67 -15 138 154  16 
11* HIIT 75   137   
 Mean 69 66 -2 132 147  16 
 SD 8 5  9 11 12  3 
3 CONT 87 65 -22 174 178  4 
4 CONT 69 67 -2 180 182  2 
5 CONT 73 75  2 136 124 -8 
6 CONT 72 74  2 170 175  5 
10 CONT 93 87 -6 124 105 -19 
12* CONT 83   116   
 Mean 80 74 -5 150 153 -3 
 SD 10 9  10 28 36  10 
 p  0.605  0.013 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; SD: standard deviation; base: baseline; post: post intervention; diff: 
difference between baseline and post-trial; HRMax: maximal heart rate 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
 
In the HIIT group there was a trend towards an increase in systolic blood 
pressure as four of the participants displayed an increase (range -2 – 30 mmHg) 
while there was no notable trend in the changes of systolic blood pressure in the 
CONT group. There was, however, no difference between the changes of the two 
groups (p=0.089) (Table 8-9).  
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There were no noticeable trends in changes of diastolic blood pressure in either 
training group and there was no difference between the changes of the two 
training groups (p=0.649) (Table 8-9). These results may suggest that neither 
HIIT nor CONT had an effect on blood pressure levels. 
Table 8-9 Baseline, post-trial and difference between the measurements of 
blood pressure rate for each participant 
  Rest systolic  (mm/Hg) Rest Diastolic (mm/Hg) 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 126 132  6 78 72 -6 
2 HIIT 142 140 -2 74 72 -2 
7 HIIT 108 138  30 64 72  8 
8 HIIT 123 152  29 80 90  10 
9 HIIT 128 154  26 97 106  9 
11* HIIT 126   74   
 Mean 126 143  18 78 82  4 
 SD 11 9  15 11 15  7 
3 CONT 144 157  13 77 91  14 
4 CONT 120 115 -5 70 71  1 
5 CONT 117 124  7 72 73  1 
6 CONT 126 130  4 84 81 -3 
10 CONT 125 119 -6 76 71 -5 
12* CONT 129   85   
 Mean 127 129  3 77 77  2 
 SD 9 17  8 6 9  7 
 p  0.089  0.649 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; SD: standard deviation; base: baseline; post: post intervention; diff: 
difference between baseline and post-trial; HRMax: maximal heart rate 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
 
8.19.2 Multiple Sclerosis clinical outcome measures 
There was no trend in changes in timed 25 foot walk test in either training group 
and there was no difference between the changes of the groups (p=1.000) (Table 
8-10). There were however, two participants who improved more than the 20% 
MCID for people with MS (Kaufman et al., 2000). One of these was in the CONT 
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group (participant 6: 20%) and one in the HIIT group (participant 2: 38%). Both of 
these participants reported that subjectively the intervention had a large 
positive impact on them. 
 
Table 8-10 Baseline, post-trial and difference between the measurements of 
the timed 25 foot walk test for each participant 
  T25FWT (sec) 
Pt  Group Base Post Diff 
1 HIIT 6.8 6.3 -0.5 
2 HIIT 22.7 14.1 -8.6 
7 HIIT 8.7 9.0  0.3 
8 HIIT 5.3 6.4  0.9 
9 HIIT 7.0 6.2 -0.8 
11* HIIT 6.2   
 Mean 9.5 8.4 -1.7 
 SD 6.6 3.4  3.9 
3 CONT 18.1 14.9 -3.2 
4 CONT 5.4 5.1 -0.3 
5 CONT 5.2 5.5  0.3 
6 CONT 10.2 8.2 -2.0 
10 CONT 23.5 23.9  0.4 
12* CONT 11.9   
 Mean 12.4 11.5 -1.0 
 SD 7.2 8.0  1.6 
 p   1.000 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; T25FW: timed 25 foot walk test; base: baseline; post: post –trial; 
diff: difference between baseline and post-trial 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
 
In the HIIT group there were no noticeable trends in total fatigue, motor fatigue 
or cognitive fatigue when measured by the FSMC, and this was also the case for 
the CONT group. There was also no difference between the two training groups 
in changes in total fatigue (p=0.621), motor fatigue (p=0.695), or cognitive 
fatigue scores (p=0.474) (Table 8-11). One participant (participant 3) reported a 
large decrease in their overall score, of 25 points, and (decreases of 13 and 12 
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points in the motor and cognitive scores respectively). However, despite the 
large decrease this patient remained in the severely fatigued category (cut-off 
of 63), as her baseline score was 100/100 (Table 8-11). Subjectively, the 
intervention had a profound effect on this participant. At the beginning she 
reported fatigue to be her most disabling symptom, commenting while 
completing the FSMC, “I feel like this is describing me”. Prior to the study, she 
was a non-exerciser and reported that at least once a week she would be 
bedridden by fatigue for an entire day. After starting the intervention, this 
happened just once, in the first week, after a long day of travelling. 
Table 8-11 Baseline, post-trial and difference between the measurements of 
the total, motor and cognitive scores of the fatigue scale of motor and 
cognitive function for each participant 
  FSMC total FSMC motor FSMC Cognitive 
Pt  Group Base Post Diff Base Post Diff Base Post Diff 
1 HIIT 74 74  0 36 37  1 38 37 -1 
2 HIIT 88 94  6 44 45  1 44 49  5 
7 HIIT 87 83 -4 45 40 -5 42 43  1 
8 HIIT 83 82 -1 42 39 -3 41 43  2 
9 HIIT 50 33 -17 26 20 -6 24 13 -9 
11* HIIT 61   33   28   
 Mean 74 72 -3 38 36 -2 36 37  0 
 SD 15 23  9 7 10  3 8 14  5 
3 CONT 100 75 -25 50 37 -13 50 38 -12 
4 CONT 70 54 -16 37 28 -9 33 25 -8 
5 CONT 42 48  6 25 28  3 17 20  3 
6 CONT 34 35  1 23 23  0 11 12  1 
10 CONT 92 92  0 48 48  0 44 44  0 
12* CONT 100   50   50   
 Mean 73 61 -7 39 33 -4 34 28 -3 
 SD 29 23  13 12 10  7 17 13  6 
 p    0.621   0.695   0.474 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; FSMC: fatigue scale of motor and cognitive function; base: baseline; 
post: post –trial; diff: difference between baseline and post-trial 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
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In the HIIT group four of the participants decreased their MSIS-29 physical sub-
scale score and one remained the same (range -7 - 0). There was no trend in 
changes in the CONT group in this variable. However, there was no difference 
between the changes of the two training groups (p=0.845) (Table 8-12).  
Table 8-12 Baseline, post-trial and difference between the measurements of 
the physical and psychological sub-scales of the multiple sclerosis impact 
scale for each participant 
  Physical Psychological 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 55 49 -6 21 15 -4 
2 HIIT 74 68 -6 27 29  2 
7 HIIT 53 46 -7 17 16 -1 
8 HIIT 50 50  0 19 17 -2 
9 HIIT 48 46 -2 11 9 -2 
11* HIIT 45   25   
 Mean 54 52 -4 20 17 -1 
 SD 10 9  3 6 17  2 
3 CONT 68 28 -40 23 11 -12 
4 CONT 48 43 -5 19 20  1 
5 CONT 36 40  4 15 16  1 
6 CONT 31 32  1 11 10 -1 
10 CONT 51 61  10 34 32 -2 
12* CONT 76   36   
 Mean 52 41 -6 23 18 -3 
 SD 18 13  20 10 9  5 
 p    0.845   0.658 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; base: baseline; post: post –trial; diff: difference between baseline 
and post-trial 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
There were no noticeable trends in the changes of the MSIS-29 psychological sub-
scale scores in either training groups and there was no difference between the 
changes of the two groups (p=0.658). Participant 3 however, displayed large 
changes in both their physical and psychological impact scores; with a decrease 
of 40 in physical impact, and 12 in psychological impact. This was also the 
participant who had the largest decrease in their fatigue scores and a clinically 
significant improvement in their timed 25 foot walk test.  
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There was no trend in changes in anxiety scores observed in either training group 
and there was no difference between the changes in either group (p=0.683). This 
lack of trend and lack of difference was also observed when depression scores 
were examined (p=0.916) (Table 8-13). Participant 3, who reported the largest 
decreases in both their anxiety and depression scores, had abnormal scores at 
baseline and subsequently at post intervention was below the abnormal cut-off 
(<11 points) following the CONT intervention. This was also the participant who 
reported the large decrease in fatigue and MSIS-29 scores. 
Table 8-13 Baseline, post-trial and difference between the measurements of 
the anxiety and depression sub-scales of the hospital and anxiety depression 
scale and the symbol digit modalities test for each participant 
  Anxiety Depression SDMT  
Pt  Group Base Post Base Post Diff Diff Base Post Diff 
1 HIIT 7 9  2 4 4  0 57 59  2 
2 HIIT 11 9 -2 8 11  3 33 39  6 
7 HIIT 6 6  0 5 6  1 34 37  3 
8 HIIT 8 4 -4 0 6  6 28 29  1 
9 HIIT 3 1 -2 5 3 -2 43 48  5 
11* HIIT 12   10   48   
 Mean 8 6 -1 5 6  2 41 42  3 
 SD 3 3  2 3 3  3 11 11  2 
3 CONT 15 6 -9 11 5 -6 47 36 -11 
4 CONT 7 6 -1 7 9  2 46 47  1 
5 CONT 2 4  2 7 11  4 30 28 -2 
6 CONT 6 1 -5 2 4  2 57 56 -1 
10 CONT 3 5  2 5 7  2 15 25  10 
12* CONT 9   9   15   
 Mean 7 4 -2 7 7  1 35 38 -1 
 SD 5 2  5 3 3  4 18 13  8 
 p   0.683   0.916   0.284 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; base: baseline; SDMT: symbol digit modalities test; post: post –trial; 
diff: difference between baseline and post-trial 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
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In the HIIT group all participants increased their SDMT score post intervention 
(range 1 - 6) (Table 8-13) but only two people in the CONT group had increased 
scores (range -11 to 10). There was no difference between the changes in the 
two groups (p= 0.284). However, when participant 10 was removed from the 
analysis, the difference was significant (p=0.036) (result not in table). This may 
indicate that HIIT had a positive effect on mental processing speed and that 
CONT did not have an effect. However, previous research has reported that 
changes in the SDMT are only likely to be clinically significant if they are of 8 or 
more and convincing if 12 or more (Benedict et al., 2012). Therefore despite this 
increase in mental processing speed across the HIIT group it was unlikely to be 
clinically significant.   
 
8.19.3 Physiological outcomes 
There was no noticeable trend in the changes of resting levels of BDNF in the 
HIIT group, but there was a trend towards an increase in the CONT group as four 
participants increased their levels (range -2.69 - 14.08 ng/ml) (Table 8-14). 
There were however, no differences in the changes between the two training 
groups (p=0.761). 
There were no noticeable trends in non-fasting triglyceride levels or total 
cholesterol in either the HIIT or the CONT group. There were also no differences 
in changes between the two training groups in either non-fasting triglyceride 
levels (p=0.754), or total cholesterol (p=0.745) (Table 8-15). Most participants 
however, already had healthy baseline measurements. One participant did 
display a large increase in their non-fasting triglyceride levels of an increase of 
2.4 mmol/l but this participant also had a high baseline non-fasting triglyceride 
level over 3.0 mmol/l at baseline (Table 8-15).   
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Table 8-14 Baseline, post-trial and difference between the measurements of 
concentrations of brain derived neurotrophic factor for each participant 
  BDNF concentration (ng/ml) 
Pt  Group Base Post Diff 
1 HIIT 19.6 44.11  24.51 
2 HIIT 41.03 38.34 -2.69 
7 HIIT 36.14 40.09  3.95 
8 HIIT 34.81 22.55 -12.26 
9 HIIT 44.91 46.24  1.33 
11* HIIT 29.68   
 Mean 34.36 38.27  2.97 
 SD 8.93 9.33  13.52 
3 CONT 50.18 53.45  3.27 
4 CONT 31.74 45.82  14.08 
5 CONT 37.99 47.97  9.98 
6 CONT 36.12 37.00  0.88 
10 CONT 33.33 30.64 -2.69 
12* CONT 40.83   
 Mean 38.37 42.98  5.10 
 SD 6.64 9.09  6.82 
 p    0.761 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; BDNF: brain derived neurotrophic factor; base: baseline; post: post –
trial; diff: difference between baseline and post-trial. 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
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Table 8-15 Baseline, post-trial and difference between the measurements of 
concentrations of triglyceride, and total cholesterol for each participant 
  Triglyceride Total cholesterol 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 0.9 1.3  0.5 5.1 6.0  0.9 
2 HIIT 0.6 0.7  0.1 5.1 5.2  0.1 
7 HIIT 2.3 2.1 -0.2 6.8 6.4 -0.4 
8 HIIT 1.6 1.5 -0.1 4.5 4.8  0.2 
9 HIIT 1.4 1.5  0.1 7.0 7.1  0.1 
11* HIIT 2.5   5.7   
 Mean 1.5 1.4  0.1  5.7 5.9  0.2 
 SD 0.7 0.5  0.3 1.0 0.9  0.5 
3 CONT 1.5 1.8  0.9 7.2 7.8  0.6 
4 CONT 1.5 0.7 -0.8 4.7 4.5 -0.2 
5 CONT 1.5 2.0  0.5 5.2 5.2  0.0 
6 CONT 3.5 5.9  2.4 5.9 6.0  0.1 
10 CONT 2.9 2.5 -0.4 5.9 6.7  0.8 
12* CONT 1.3   6.2   
 Mean 2.0 2.6  0.4 5.8 6.0  0.3 
 SD 0.9 2.0  1.3 0.8 1.3  0.5 
 p    0.754   0.745 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; SD: standard deviation; base: baseline; post: post –trial; diff: 
difference between baseline and post-trial; HDL: high density lipoprotein 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
All measurements are in mmol/l. 
 
There was no trend observed in the changes of HDL concentrations in either the 
HIIT or the CONT groups and there was no difference between the changes of 
the two training groups (p=0.383) (Table 8-16). These results indicate that 
neither HIIT nor CONT had an effect on HDL concentrations.    
There was a trend towards an increase in non-HDL cholesterol levels in both the 
HIIT and the CONT groups as in both groups four out five participants displayed 
an increase. However, as with the other lipoprotein measurements, there was no 
difference between the changes of the two training groups (p=0.712) (Table 
8-16). 
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Table 8-16 Baseline, post-trial and difference between the measurements of 
concentrations of high density lipoprotein and non-high density lipoprotein 
cholesterol for each participant 
  HDL   Non-HDL cholesterol 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 1.8 2.0  0.2 3.3 4.1  0.8 
2 HIIT 1.9 1.6 -0.3 3.2 3.6  0.4 
7 HIIT 1.3 1.2 -0.1 5.6 5.1 -0.5 
8 HIIT 0.9 1.1  0.2 3.6 3.7  0.1 
9 HIIT 1.6 1.5 -0.1 5.4 5.6  0.2 
11* HIIT 1.2   4.5   
 Mean 1.5 1.5 -0.05 4.2 4.4  0.2 
 SD 0.4 0.3  0.2 1.2 0.9  0.5 
3 CONT 0.9 0.8  0.1 6.2 7  0.8 
4 CONT 1.6 1.7  0.1 3.1 2.8 -0.3 
5 CONT 1.5 1.5  0.0 3.7 3.7  0.0 
6 CONT 0.8 0.7 -0.1 5.1 5.3  0.2 
10 CONT 1.1 1.1  0.0 4.8 5.7  0.9 
12* CONT 1.3   4.9   
 Mean 1.2 1.2  0.04 4.6 4.9  0.3 
 SD 0.3 0.4  0.1 1.2 1.7  0.5 
 p   0.373   0.712 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; SD: standard deviation; base: baseline; post: post –trial; diff: 
difference between baseline and post-trial; HDL: high density lipoprotein 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
All measurements are in mmol/l. 
 
 
There was no noticeable trend in changes in resting lactate concentrations of 
either the HIIT or the CONT groups and no difference between the changes of 
either training group (p=0.465) (Table 8-17). Similarly, there was no trend in 
changes in peak lactate in either the HIIT or the CONT groups and there was no 
difference between the changes of the training groups (p=0.309) (Table 8-17). 
However, the number of participants who reached a peak lactate greater than 
8.0 mmol/l, indicating maximal exertion (Midgley et al., 2007, Thompson et al., 
2000), rose from two (pre-intervention) to three (post-intervention) in the CONT 
group and three to four in the HIIT group. This may indicate that 8 weeks of 
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aerobic training, regardless of whether it is HIIT or CONT can increase the 
likelihood of reaching maximal exertion during testing. 
Table 8-17 Baseline, post-trial and difference between the measurements of 
concentrations of resting and peak lactate for each participant 
  Resting lactate Peak lactate 
Pt  Group Base Post Diff Base Post Diff 
1 HIIT 0.6 0.8  0.2 6.2 6.3  0.1 
2 HIIT 0.8 1.7  0.9 4.6 9.8  5.2 
7 HIIT 5.4 1.2 -4.2 11.6 9.5 -2.1 
8 HIIT 1.0 2.2  1.2 15.5 13.4 -2.1 
9 HIIT 1.5 2.2  0.7 12.4 11.0 -1.4 
11* HIIT 1.7   4.4   
 Mean 1.8 1.6 -0.2 9.1 10.0  0.8 
 SD 1.8 0.6  2.2 4.7 2.6  3.0 
3 CONT 5.6 1.1 -4.5 7.8 9.0  1.2 
4 CONT 4.5 6.9  2.4 18.5 12.4 -6.1 
5 CONT 4.8 2.4 -2.4 6.0 3.4 -2.6 
6 CONT 2.1 1.3 -0.8 8.1 9.3  1.2 
10 CONT 2.5 3.1  0.6 4.3 3.9 -0.4 
12* CONT 2.1   3.8   
 Mean 3.6 3.0 -0.9 8.1 7.6 -1.6 
 SD 1.6 2.4  2.7 5.4 3.9  3.5 
 p   0.465   0.309 
Abbreviations: pt: participant number; HIIT: high intensity interval training; CONT: continuous 
moderate intensity training; SD: standard deviation base: baseline; post: post –trial; diff: 
difference between baseline and post-trial 
*No post intervention measurements for participants 11 or 12 as both dropped out. 
 
8.20 Effect sizes of significant results  
There were only two instances of statistically significant differences in changes 
between the two groups. These were in HRMax (p=0.013) (Table 8-18) and in 
SDMT scores when participant 10 was removed as an outlier (p=0.036) (Table 
8-19). There were no other statistically significant differences in changes 
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between the two groups both when participant 10 was included and excluded 
(Table 8-18, Table 8-19). 
After the intervention, the HIIT group increased their HRMax by a mean of 16 
bpm (SD 3), with a large effect size (Cohen’s d=1.67) and the CONT group 
decreased their HRMax by 3 bpm (SD10) with a weak effect size (Cohen’s d=-
0.13). This indicates that HIIT had a beneficial effect on the group’s HRMax 
while there was no difference in the CONT group. 
After the intervention the HIIT group increased their SDMT score by a mean 3 
points (SD 2), with a moderate effect size (Cohen’s d= 0.67), while the CONT 
group worsened their score by a mean of -1 point (SD 8) with a weak effect size 
(Cohen’s d= -0.09). These changes were however, small and below the threshold 
of a likely clinically significant change of 8 or more (Benedict et al., 2012).   
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Table 8-18 Baseline, post intervention and difference from baseline measurements of cardiovascular risk factors and physiological 
outcomes for both training groups 
  HIIT     CONT         
  Pre  Post Diff Pre Post Diff p (n=10) p (n=9) 
Resting HR (bpm) 69 (8) 66 (5) -2 (9) 80 (10) 74 (9) -5 (10) 0.605 0.67 
Systolic (mm/Hg) 126 (11) 143 (9)  18 (15) 127 (9) 129 (17)  3 (8) 0.089 0.135 
Diastolic (mm/Hg) 78 (11) 82 (15)  4 (7) 77 (6) 77 (9)  2 (7) 0.649 0.914 
Resting Lactate (mmol/l) 1.83 (1.80) 1.62 (0.62) -0.24 (2.24) 3.60 (1.55) 2.96 (2.35) -0.94 (2.66) 0.465 0.462 
HRMax (bpm) 132 (11) 147 (12)  16 (3) 150 (28) 153 (36) -3 (10) 0.013* 0.001* 
Peak lactate (mmol/l) 9.1 (4.7) 10.0 (2.6)  0.8 (3.0) 8.1 (5.4) 7.6 (3.9) -1.6 (3.5) 0.309 0.309 
TG (mmol/l) 1.5 (0.7) 1.4 (0.5)  0.1 (0.3) 2.0 (0.9) 2.6 (2.0)  0.4 (1.3) 0.754 0.327 
Chol (mmol/l) 5.7 (1.0) 5.9 (0.9)  0.2 (0.5) 5.8 (0.8) 6.0 (1.3)  0.3 (0.5) 0.745 0.899 
HDL (mmol/l) 1.5 (0.4) 1.5 (0.3) -0.05 (0.2) 1.2 (0.3) 1.2 (0.4)  0.04 (0.1) 0.373 0.383 
Non-HDL chol (mmol/l) 4.2 (1.2) 4.4 (0.9)  0.2 (0.5) 4.6 (1.2) 4.9 (1.7)  0.3 (0.5) 0.712 0.939 
BDNF (ng/ml) 34.36 (8.93) 38.27 (9.33)  2.97 (13.52) 38.37 (6.64) 42.98 (9.09)  5.1 (6.82) 0.761 0.596 
Abbreviations: HR: heart rate; HRMax: maximal heart rate; TG: triglyceride; chol: cholesterol; HDL: high density lipoprotein; BDNF: brain derived neurotrophic 
factor; HIIT: high intensity interval training; CONT: continuous moderate intensity training; base: baseline; post: post –trial; diff: difference between baseline and 
post-trial 
All figures are mean (standard deviation).  All difference values are post-intervention value minus pre-intervention value. All tests were independent t tests 
between the means of the difference between pre and post intervention apart from the testing of resting lactate and TG which were Mann-Whitney tests due to 
non-normal distribution. 
* Statistically significant <0.05 
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Table 8-19  Baseline, post intervention and difference from baseline measurements of multiple sclerosis clinical outcome 
measures for both training groups 
 HIIT   CONT     
 Pre Post Diff Pre Post Diff p (n=10) p (n=9) 
T25FW 9.5 (6.6) 8.4 (3.4) -1.7 (3.9) 12.4 (7.2) 11.5 (8.0) -1.0 (1.6) 1.000 0.712 
MSIS-29 Phys 54 (10) 52 (9) -4 (3) 52 (18) 41 (13) -6 (20) 0.845 0.61 
MSIS-29 Psych 20 (6) 17 (17) -1 (2) 23 (10) 18 (9) -3 (5) 0.658 0.662 
HADS Anxiety 8 (3) 6 (3) -1 (2) 7 (5) 4 (2) -2 (5) 0.683 0.421 
HADS Depress 5 (3) 6 (3)  2 (3) 7 (3) 7 (3)  1 (4) 0.916 1.000 
FSMC Total 74 (15) 72 (23) -3 (9) 73 (29) 61 (23) -7 (13) 0.621 0.513 
FSMC Motor 38 (7) 36 (10) -2 (3) 39 (12) 33 (10) -4 (7) 0.695 0.591 
FSMC Cog 36 (8) 37 (14)  0 (5) 34 (17) 28 (13) -3 (6) 0.474 0.412 
SDMT 41 (11) 42 (11)  3 (2) 35 (18) 38 (13) -1 (8) 0.284 0.036* 
Abbreviations: T25FW: timed 25 foot walk test; MSIS-29: multiple sclerosis impact scale; n: number; Phys: physical sub-scale; Psych: psychological sub-scale; HADS: 
hospital anxiety and depression scale; FSMC: fatigue scale for motor and cognitive function; Cog: cognitive; SDMT: symbol digit modalities test; HIIT: high intensity 
interval training; CONT: continuous moderate intensity training; base: baseline; post: post –trial; diff: difference between baseline and post-trial 
All values are mean (standard deviation).  All testing was independent t tests of differences in baseline and post intervention values apart from timed 25 foot walk 
test and the HADS depression sub-scale which were Mann-Whitney due to non-normal distribution. 
* Statistically significant at p<0.05 
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8.21 Summary of results 
In summary, these results demonstrate that HIIT was well tolerated in people 
with progressive MS and is a feasible intervention to use in the rehabilitation of 
this patient group. Adherence to, and compliance with, the protocol was high, 
and participants in the HIIT group experienced no adverse events while there 
were three adverse events in the CONT group. In addition both HIIT and CONT 
were well tolerated as there was no adverse impact on the participants’ MS 
symptoms. 
The small sample of completing participants (n=10) and large standard 
deviations in the outcomes meant although there were some trends in the 
results, with two exceptions, there were no statistically significant differences 
between the changes of the two groups pre and post intervention. 
The participants who received the HIIT intervention demonstrated a significant 
improvement in their HRMax compared to the CONT group. In both groups there 
was a higher number of participants reaching maximal exertion, as measured by 
peak lactate. This may indicate a learning effect because prior to the 
intervention just one participant had experience in maximal exertion tests. 
A statistically significant difference was also found between the HIIT and CONT 
groups in mental processing speed (SDMT). However, this difference is likely due 
to an outlier who had poorer scores after the intervention in the CONT group and 
differences were not clinically significant.  
 
8.22 Discussion 
Overall this study showed that the implementation of HIIT is feasible in people 
moderately affected by progressive MS as adherence was high at 98.8%, overall 
compliance with the protocol was high at 89.6% and was 100% with the HIIT 
protocol, there were only two participants who dropped out, and there were 
only three adverse events which were all in the CONT group. Furthermore when 
compared to CONT, participants who received HIIT, increased their HRMax and 
their mental processing speed. The high rate of adherence and compliance add 
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to the case of HIIT being an appropriate modality for training people with MS. It 
has previously been stated that HIIT may be an appropriate modality because of 
the high energy expenditure in a short period of time and that the rest periods 
decrease the chance of thermosensitive symptoms in people with MS (Dalgas et 
al., 2008).  
This HIIT study was only the second to solely include people with progressive MS, 
and the first to use cycle ergometry in a sample only with progressive forms of 
the disease. Similar to previous studies in this area the control group was a form 
of continuous moderate intensity exercise  (Collett et al., 2011, Collett et al., 
2017, Farup et al., 2016, Feltham et al., 2013, Wens et al., 2015, Wens et al., 
2017, Zimmer et al., 2017). The HIIT protocol of 6 x 90 seconds at 80-95% HRMax 
produced a total time of 144 minutes spent at a high intensity workload over the 
whole intervention. This is higher than three of the previous HIIT studies (Collett 
et al., 2011, Feltham et al., 2013, Zaenker et al., 2016, Skjerbæk et al., 2014), 
one of which found an improvement in VO2peak (median 8.05 - 9.2ml/kg, 
p=0.05) (Collett et al., 2011, Feltham et al., 2013) and one in VO2peak (+13.5%, 
p<0.0001) and HRMax (+3.73%, p=0.0120) (Zaenker et al., 2016).  
It is interesting that the only other study to investigate HIIT in people with 
progressive MS did not find improvements (Skjerbæk et al., 2014). However, 
Skjerbæk et al. (2014), used arm ergometry, had a lower total high intensity 
worktime of 60 minutes, and included participants with a higher level of 
disability (EDSS 6.0-8.0). It is unclear whether any of these three differences of 
using arm ergometry, higher disability level and lower total worktime are the 
reason that improvements were not found in the sample of Skjerbæk et al. 
(2014). However, it should be noted that both this present study and the study 
by Skjerbæk et al. (2014) were not sufficiently powered meaning that any lack 
of result should be treated with caution. 
 
8.22.1 The effect of high intensity interval training on 
maximal heart rate 
An increase in HRMax was observed in the HIIT group and not in the CONT group. 
Five out of the six previous studies which investigated the effects of HIIT on 
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fitness, in people with MS, reported increases in a related outcome (Collett et 
al., 2011, Farup et al., 2016, Feltham et al., 2013, Wens et al., 2015, Wens et 
al., 2017, Zaenker et al., 2016, Zimmer et al., 2017, Bansi et al., 2017, 
Keytsman et al., 2017). Two of these were in HRMax (Farup et al., 2016, Wens et 
al., 2015, Wens et al., 2017, Zaenker et al., 2016) and two were VO2max (Collett 
et al., 2011, Feltham et al., 2013, Zimmer et al., 2017, Bansi et al., 2017). The 
only other study to investigate HIIT just in people with progressive MS did not 
find an increase in either HRMax or VO2max (Skjerbæk et al., 2014). The 
differences in methodology between this present study and the study by 
Skjerbæk et al. (2014) have already been discussed above.  
It was interesting that the CONT group did not show any improvement in their 
HRMax as a recent meta-analysis found that exercise had a moderate effect on 
fitness related outcomes in people with MS (Platta et al., 2016). The authors did 
note however, that intensities in the 20 studies included varied greatly or were 
poorly described. The lack of improvements in this study by the CONT group may 
have been due to the general deconditioning in the group which meant that two 
participant’s resting HR was in their 60-70% HRMax training zone and one 
participant had a resting HR within 8 bpm of their training zone. Indeed, higher 
intensity training is linked to greater improvements in fitness in healthy 
individuals (Fleg, 2016).  
Improvements in HRMax of HIIT group could have been generated by the higher 
level of energy expended due to Excess Post-exercise Oxygen Consumption 
(Tremblay et al., 1994, Gaesser and Brooks, 1984). This latter theory is 
strengthened by the study by Zimmer et al. (2017) and Bansi et al. (2017), who 
compared HIIT to CONT of an equal energy output and found that both groups 
increased their fitness when measured by VO2max. 
 
8.22.2 The effect of high intensity interval training on mental 
processing speed 
When the outlier participant 10, was removed, there was a difference between 
the changes of HIIT and CONT groups in mental processing speed as measured by 
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the SDMT. The improvements noted were however, overall quite small (mean +3 
points SD 2) and unlikely to be clinically significant as the Brief International 
Cognitive Assessment for MS committee stated that an increase of 8 points or 
more was likely to be clinically significant (Benedict et al., 2012). The only other 
study investigating the effect of HIIT on mental processing speed found that 
there was a time effect on SDMT scores but no time x group effects (Zimmer et 
al., 2017, Bansi et al., 2017). A systematic review examining the effect of 
exercise on cognition in people with MS found the evidence to be inconclusive 
(Sandroff et al., 2016). The authors reported that just one of the studies 
reviewed showed improvements in mental processing speed after 8 weeks of 
thrice weekly, 60 minute sessions of aerobic, balance and flexibility exercises 
(Sangelaji et al., 2015). Indeed an RCT by Coote et al. (2017), compared group 
exercise and education to group exercise and social cognitive therapy, and found 
increases in mental processing speed only in the social cognitive therapy group 
indicating that the effect was not from the exercise component. The fact that 
the present trial and previous HIIT research (Bansi et al., 2017, Zimmer et al., 
2017) found positive effects on mental processing may indicate that beneficial 
effects can be produced using exercise of a higher intensity. Furthermore it may 
indicate that benefits can be elicited as good as or more than CONT. Further 
investigation by fully powered RCTs is warranted to confirm or deny this. 
 
8.22.3 The effect of high intensity interval training on resting 
heart rate and blood pressure 
This was only the second HIIT study to use resting HR an outcome measure, but 
found no effect from either HIIT or CONT. The cohort trial by Keytsman et al. 
(2017) found a decrease in resting HR after 12 weeks of combined HIIT, CONT 
and resistance training. Differences in results may have been due to the trial by 
Keytsman et al. (2017) having a longer intervention and also incorporating a 
resistance training element. Furthermore all participants in the present study 
had progressive MS and were moderately affected by their MS, while Keytsman 
et al. (2017) included participants who were mildly affected (EDSS<3.0) and did 
not report on MS type. Further investigation is warranted with a powered sample 
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size to establish if these variables are factors in the lack of effect found in this 
present study.   
Two previous studies investigated the effects of HIIT on blood pressure in people 
with MS (Collett et al., 2011, Feltham et al., 2013, Keytsman et al., 2017). Like 
this present study no effect was observed. This lack of effect may have been 
because all three samples had blood pressures within a healthy range (Collett et 
al., 2011, Feltham et al., 2013, Keytsman et al., 2017). Uncontrolled high blood 
pressure was an exclusion criterion from taking part in this study, and while it 
was not in the other two previous studies. This may indicate that neither HIIT 
nor CONT have an effect on blood pressure, in people with MS, when it is in a 
healthy range. Further research should however investigate the effect of HIIT on 
blood pressure when it is in an unhealthy range. 
 
8.22.4 The effect of high intensity interval training on brain 
derived neurotrophic factor  
This study found that there was no effect of training on resting serum BDNF 
levels in either the HIIT or the CONT group. As was discussed in section 7.3.2 the 
evidence for using aerobic training to increase resting BDNF levels, in people 
with MS, is inconclusive. Of note all studies that included people with 
progressive MS, including the current study, did not report an increase in resting 
BDNF levels after receiving a training intervention. Also, this cohort’s baseline 
concentration of BDNF was higher than the baseline concentrations reported in 
the previous studies investigating the effects of exercise on BDNF levels in 
people with MS as the highest concentration reported was 24.70 ng/ml SD 13 
(Zimmer et al., 2017). There are however, a number of factors that could have 
affected this, including influences from disease and lifestyle (Bus et al., 2011) 
and also the ELISA kit used to measure the concentration (Polacchini et al., 
2015). While the effect of training on BDNF levels is well established in healthy 
individuals (Dinoff et al., 2016), the evidence for the effect of exercise training 
on resting levels of BDNF remains inconclusive in people with MS but there is an 
indication that it may not have an effect on people with progressive MS. 
However, no studies to date have included a power calculation specifically for 
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BDNF. Further investigation should be carried out with suitably powered samples 
to establish if aerobic training does or does not have an effect on resting BDNF 
levels in people with progressive MS. 
 
8.22.5 The effect of high intensity interval training on lipids 
This was the first RCT, and second interventional study, to examine the effect of 
aerobic exercise on lipid profiles in people with MS and no effect was observed 
on levels of non-fasting triglyceride, HDL, total cholesterol and non-HDL 
cholesterol. The results of this trial were similar to that of Keytsman et al. 
(2017) who, after 12 weeks of HIIT and resistance training, also did not observe 
any changes in the lipid profiles of their participants. A review by Wens et al. 
(2013) concluded that it was unclear whether people with MS were at risk of 
developing cardiovascular disease from dyslipidemia because evidence was 
conflicting. A study by White et al. (2006) found that eight weeks of progressive 
resistance training, in moderately disabled people with MS, had no effect on 
triglyceride, HDL or total cholesterol. A cohort study investigating the links 
between physical activity and cholesterol and triglyceride levels found that 
triglyceride levels were lower in people that exercised but there was no 
association with cholesterol levels (Slawta et al., 2002). However, similar to the 
sample included by Keytsman et al. (2017), most of the participants in this 
present sample were not in dyslipidemia at baseline. Similar to the effects of 
blood pressure and resting heart rate, further investigation is warranted in 
people with MS, who are in dyslipidemia, to establish if HIIT has a beneficial 
effect.   
 
8.22.6 The effect of high intensity interval training on gait 
speed 
There were no changes in walking speed in either the HIIT or the CONT groups, 
although there were some clinically significant changes at individual levels. Only 
one previous HIIT study examined walking in the form of the 2 min walk test 
(Collett et al., 2011, Feltham et al., 2013). The results of this test, which 
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technically examines sub-maximal endurance, found an increase in both the HIIT 
and CONT groups. These improvements were also maintained at the 12 week 
follow up period after the intervention had finished. This may indicate that an 
exercise programme, regardless of it is CONT or HIIT could have a beneficial 
effect on walking endurance, but not gait speed.  
A recent meta-analysis of studies which examined the effect of exercise on 
walking in all people with MS found an overall positive effect (Pearson et al., 
2015). Analysis by the authors found that although there was a positive response 
to walking speed from aerobic, resistance training and yoga when delivered 
individually, but the greatest benefits were found in interventions which 
combined both aerobic and resistance training (Pearson et al., 2015). This may 
explain the lack of results in this study as only one type of training was 
employed.  
 
8.22.7 The effect of high intensity interval training on fatigue 
This study found no impact from either training protocol on the fatigue of 
participants. This is in line with two previous HIIT studies which measured 
fatigue that similarly found no differences between their intervention and 
control groups (Collett et al., 2011, Feltham et al., 2013, Skjerbæk et al., 
2014). As was stated in the systematic review (section 7.13) one study used the 
Fatigue Severity Scale (Collett et al., 2011, Feltham et al., 2013) which has 
limitations in people with MS and one study used a sample that was not severely 
fatigued (Skjerbæk et al., 2014). In general the evidence for using exercise to 
improve fatigue in people with MS is positive, but weak (Heine et al., 2015). This 
2015 Cochrane review called for more exercise studies involving participants 
who were severely fatigued. As measured by the FSMC, the participants in the 
present study were severely fatigued, and while improvements were noted in 
some individuals, there was not a change across the training groups. Further 
research on the effects of HIIT on fatigue in people with MS is needed.  
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8.22.8 The effect of high intensity interval training on impact 
of disease 
The present study found no improvement in disease impact measures. The two 
previous studies that have examined the effect of HIIT on quality of life in 
people with MS found conflicting results. One measured an improvement 
(Zaenker et al., 2016) and one measured a deterioration (Collett et al., 2011, 
Feltham et al., 2013). The study which reported an improvement also had a 
resistance and CONT element in their protocol making it difficult to attribute 
any changes to the HIIT element. Other research examining the effect of 
exercise on quality of life in people with progressive MS, found that a 12 week 
training protocol of aerobic training three times a week, of either body weight 
supported treadmill training or recumbent stepping produced improvements 
when measured by the Multiple Sclerosis Quality of Life – 54 questionnaire 
(Pilutti et al., 2016). Furthermore, two RCTs investigating resistance training in 
people with MS both found improvements in quality of life (Dalgas et al., 2010, 
Dodd et al., 2011). However, only one of these studies found that their 
improvements were maintained at a three month follow up period (Dalgas et al., 
2010). These, conflicting results in the literature and the results from the 
current study highlight that further research is needed. The study by Pilutti et 
al. (2016) involved people with progressive MS with severe disability, while 
Dalgas et al. (2010) and Dodd et al. (2011) involved people with RRMS and 
moderate disability. Similarly the studies by Zaenker et al. (2016), Collett et al. 
(2011) and Feltham et al. (2013) included moderately disabled patients who did 
not have progressive forms of the disease. The limited evidence to date would 
indicate that neither disability nor type of MS is a factor affecting the effect of 
exercise on quality of life in people with MS.  
 
8.22.9 The effect of high intensity interval training on anxiety 
and depression 
There was no effect on anxiety or depression in either training group. To date 
there has been only one other HIIT study in MS that measured depression as an 
outcome measure (Skjerbæk et al., 2014) and none that measured anxiety. 
Skjerbæk et al. (2014) also found that there was no effect of HIIT on depression 
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when measured using the Major Depression Inventory. This may indicate that the 
use of HIIT may not be effective in reducing anxiety or depression in people with 
progressive MS.  However, neither the study by Skjerbæk et al. (2014) nor the 
present study, were sufficiently powered. 
In the general population exercise has been shown to have a positive effect on 
both depression and anxiety but the effect size was higher in depression (Wegner 
et al., 2014). However, previous research investigating the effect of exercise on 
anxiety and depression in people with MS is conflicting. The study by Coote et 
al. (2017) which compared the effects of 10 weeks of group exercise combined 
with education relating to physical activity and group exercise combined with 
social cognitive theory, in people with MS, only found improvements in 
depression in the social cognitive theory group. While Aydin et al. (2014) 
reported that a 12 week programme of hospital based calisthenics, five times a 
week, improved anxiety but not depression. Conversely the RCT by Dalgas et al. 
(2010) found improvements in depression scores following a 12 week resistance 
training programme. However, all three of these studies used moderately 
disabled people with RRMS. The lack of significant results from this study and 
conflicting results from previous studies, create the need for further 
investigation especially in people with progressive MS. 
 
8.22.10 The effect of high intensity interval training on lactate 
levels 
There were no differences in changes in resting or peak lactate concentrations 
after the intervention. This was an unexpected result as overall HRMax rose in 
the HIIT group indicating an increase in fitness and work rate during the maximal 
exertion test. However, even though there was no difference at a group level, 
the number of participants with results above the 8.0 mmol/l threshold, 
indicating maximal exertion, increased from two to three in the CONT group and 
three to four in the HIIT group. The two participants with the highest peak 
lactate at baseline also had the lowest EDSS scores of 4.0 and 4.5. This was 
expected, as previous research has shown that as EDSS scores rise, the likelihood 
of reaching maximal aerobic capacity decreases, and patients are more likely to 
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stop due to symptomatic reasons such as muscle fatigue in affected limbs 
(Romberg et al., 2004). However, the measurement of exertion by lactate in 
people with MS has been criticised, as people with MS have higher 
concentrations of resting lactate and this is particularly more prevalent in 
people with progressive forms of the disease (Amorini et al., 2014). Indeed the 
resting lactate level of this sample was 2.7 (SD 1.8) mmol/l at baseline which 
puts the resting concentrations above that of normal reported levels in 
untrained healthy individuals of 0.8-1.5 mmol/l (McArdle et al., 2006). This 
higher resting lactate may provide false positives for reaching maximal aerobic 
capacity as the work rate to reach 8.0 mmol/l could be less than if a participant 
had a lower resting lactate level.   
 
8.22.11 Participant 10 
In addition to receiving higher intensity than the protocol stated, participant 10 
did not respond as expected during the post intervention measurements of her 
HRMax. This participant was very deconditioned at baseline, only being able to 
cycle for less than 5 minutes. Her HRMax at baseline was 124 bpm and over the 8 
weeks she improved her endurance and was able to cycle for the full 30 minutes. 
During this time her average working HR dropped from 88% to 78% of HRMax. 
Post intervention she cycled for longer than baseline, reached a higher 
resistance, but had a lower HRMax (124 to 105 bpm), lower peak lactate (4.3 to 
3.9 mmol/l) and lower difference in lactate (1.8 to 0.8 mmol/l). There are a 
number of possible reasons for this spurious result. Firstly, that her heart, for 
some reason, did not respond to the increased workload and oxygen demands 
placed on it. Secondly there was a malfunction with the HR monitor, which had 
happened occasionally during the intervention. Thirdly, there was human error 
in the delivery of the test. However, as both physiological measures of the 
HRMax and lactate response indicate that this participant did not work as hard 
during her post intervention maximal test, this would indicate human error. 
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8.22.12 Limitations 
Originally, it had been planned to use a repeated two way measure analysis of 
variance to explore differences between the two training groups. However, due 
to recruitment issues, the total completed sample of just five participants in 
each group meant that this form of analysis was not appropriate. Furthermore 
while a matched pair randomisation design controlling for fatigue, gender, age, 
EDSS level and baseline fitness was highly desirable, this was not appropriate 
with the small sample obtained. The small sample size and lack of power may be 
why some of the outcome measures utilised did not reach statistical significance 
despite an indication of a trend of change. Lastly there was no blinding of the 
assessor, which could have potentially led to bias of results.  
   
8.22.13 Recommendations for future research 
Recommendations for research have already been identified. A fully powered 
RCT in a similar sample of people with progressive MS is warranted to strengthen 
the results found in this study. Furthermore, future research should also 
investigate if it is feasible to use arm ergometry to improve fitness in people 
with MS. As this study and all others before which used a progressive sample, did 
not find a positive result, a comparison of the effects of exercise on BDNF, 
resting heart rate, blood pressure, blood lipids, fatigue, anxiety and depression 
levels, by MS type should be carried out to explore the potential effect of this 
variable. 
 
8.22.14 Relevance for clinicians and people with Multiple 
Sclerosis 
Due to small numbers recruited, the generalisability of the results from this 
study remain limited. However, when the results of this trial are combined with 
the rest of the literature, presented in sections 7.13-7.14, this trial adds to this 
body of evidence, reaffirming the positive results found that HIIT is both a safe 
and feasible intervention that can be used for aerobic training in people with MS 
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who are mildly, moderately or severely disabled. Clinicians should consider the 
use of HIIT in their management of their patients, and people with MS should 
approach HIIT with confidence that it is safe and a more efficient training 
method than traditional continuous aerobic training. 
 
8.22.15 Conclusions 
Overall, this study indicates that HIIT is a feasible intervention to use in people 
with progressive MS and an EDSS range of 4.0-6.0. Furthermore, improvements 
were observed in the HIIT group in HRMax and mental processing speed 
indicating that HIIT may be a more appropriate intervention to elicit 
improvements in these areas. Further investigation through a fully powered RCT 
is warranted in this patient group. 
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Chapter 9 Final conclusions and 
recommendations 
The overall aim of this research was to investigate the use of physiotherapy for 
people with progressive MS by evaluating the current literature, surveying the 
patient population in regard to their use of services, and assess the feasibility of 
High Intensity Exercise Training (HIIT) which was not previously investigated in 
moderately disabled people with progressive MS. This aim was formulated to 
address gaps in the literature and was driven by calls for investigation and 
further research into the benefits of physiotherapy in people with progressive MS 
(Fox et al., 2012, MS Society, 2014).  
 
9.1 Original contribution of studies 
All three studies make an original contribution to knowledge in the field of 
rehabilitation of people with progressive MS. The systematic review reported in 
Chapter 3 was the first to assess the available literature for the efficacy of using 
physiotherapy in the rehabilitation of people with progressive MS. The online 
survey conducted included the largest sample only of people with progressive 
MS, and was the first to assess the level of access and use of clinical services at 
a national level in the United Kingdom. The feasibility study was the first to 
explore the use of HIIT in people moderately affected by progressive MS. It was 
also the first to explore the use of cycle ergometry as the mode for delivering 
HIIT in a sample solely of people with progressive MS.  
 
9.2 Overall conclusions and recommendations 
The aim of the systematic review was to assess the efficacy of using 
physiotherapy in the rehabilitation of people with progressive MS. The outcome 
of the review demonstrated positive, but weak, evidence for the use of 
physiotherapy in the rehabilitation of people with progressive MS. It highlighted 
that, to improve the evidence base, studies with more robust methodologies 
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were required in this area, specifically fully powered randomised controlled 
trials.  
The aim of the online survey was to investigate the level of access to, delivery 
of, barriers to access, and opinion of physiotherapy services by people with 
progressive MS in the UK, along with the level of access to MS Specialists, a 
regular review, use of clinical services and the use of complementary and 
alternative therapies. The results of the survey revealed a high rate of access to 
MS Specialists across the United Kingdom, but almost a quarter were not 
receiving a regular review. It is recommended that service providers should aim 
to address this gap. Access to physiotherapy was also high and as a discipline, 
was well perceived among respondents with 70% reporting it had a positive 
effect on their MS. The most commonly prescribed interventions were supervised 
and unsupervised exercise. Delivery of physiotherapy closely matched desired 
delivery however there was a desire for more home-based care. Although it is 
recognised that home based care is more expensive than out-patient care it is 
recommended that service providers should investigate the feasibility of 
providing home-based care for those in need. This was also a recommendation of 
the UK MS Society (MS Society, 2016b).  
The aim of the intervention study was to explore the feasibility of using HIIT in 
moderately disabled people with progressive MS. Furthermore this study also 
explored the effects of HIIT, compared to continuous moderate intensity 
training, on physiological and MS clinical outcomes in people with progressive 
MS. High Intensity Interval Training was found to be a feasible modality of 
aerobic training for people with progressive MS. As an intervention, HIIT was 
found to be very well tolerated and acceptable with a high adherence and 
compliance rate and no adverse in the HIIT group. Furthermore, participants 
receiving HIIT improved their maximal heart rate and mental processing speed 
while no significant improvements were found in the group receiving continuous 
training. As HIIT takes less time than continuous training and allows for working 
at high intensities while avoiding thermosensitive reactions, this suggests that 
HIIT may be a practical and effective intervention in eliciting health benefits in 
people with progressive MS. However, a fully powered trial is required to 
confirm or deny this result.  
 
 
 226 
In conclusion while each of the three studies produced positive results, overall 
further research is required to strengthen or confirm the findings. As such, the 
work contained within this thesis should be viewed as the groundwork to be built 
upon for further research or service improvement. As was stated in Chapter 1, 
the three studies in this thesis may be of interest to different audiences and 
therefore the recommendations for further research or service implementation 
from each study (sections 3.5.2, 6.9 and 8.22.13) may be more applicable for 
these specific audiences. However, despite the need for further work this body 
of research has shown that physiotherapy has the potential to be beneficial for 
people with progressive MS, that people with progressive MS in the UK are 
engaging with physiotherapy as a discipline, and that new interventions such as 
HIIT hold promising results for improving health of this patient group. 
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Appendices 
Appendix 1 – Physiotherapy rehabilitation for people with 
progressive Multiple Sclerosis: a systematic review 
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Appendix 2 – Access delivery and perceived efficacy of 
physiotherapy and use of complementary and 
alternative therapies by people with progressive 
multiple sclerosis in the United Kingdom: An online 
survey  
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Appendix 3 – Access to and use of clinical services and 
disease-modifying therapies by people with 
progressive multiple sclerosis in the United Kingdom 
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Appendix 4 – Full online survey 
Below is a copy of the online survey used to collect data for chapters 4 – 6.  It 
comprises an introduction and then three sections of questions.  The text in 
italics next to questions is the instructions for logical progression that were 
given to the UK MS Register. 
 
 
Introduction  
You have been invited to take part in this study by answering a questionnaire 
regarding your experiences of physiotherapy.  You have been selected because 
you have a progressive form of MS and are registered on the UK MS Register.  It 
is up to you to decide whether or not to take part.  There are no risks involved 
in taking part and you will remain anonymous.  If you decide to start the 
questionnaire you are free to stop at any point.  Filling in the questionnaire 
completely or in part indicates consent to take part in this study.  If you have 
problems using a computer it is appropriate for someone to fill in the answers 
for you as long as the answers are your own. 
The purpose of this questionnaire is to find out if you receive physiotherapy as a 
treatment for your MS, if physiotherapy is available to you, what you think of 
physiotherapy, how you would like your physiotherapy delivered and what other 
therapies you receive for your MS. 
Physiotherapy can mean different things to different people.  There are many 
different treatments that are classed as physiotherapy.  In this questionnaire, 
physiotherapy means any treatment that is carried out by a physiotherapist or a 
physiotherapy assistant.   
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Section 1. This section is about the physiotherapy you receive and what you 
think of it. 
 
Q1.1 Do you receive physiotherapy at the moment? (Please tick the most 
appropriate box) 
 Yes   if yes go to Q 1.3.a 
 No    if No go to Q 1.2 
 
Q1.2 Could you get physiotherapy if you wanted it? (Please tick the most 
appropriate box) 
 Yes  if yes go to Q1.3.b 
 No   if no go to Q1.5b 
 
Q1.3.a Who refers you to the physiotherapist? (Please tick all that apply) 
 MS specialist Doctor/Neurologist 
 GP 
 I self-refer  
 MS specialist nurse 
 Other (please state) __________ 
 Don’t know   go to question 1.4 
 
Q1.3.b If you wanted to see a physiotherapist, what would you do? (Please tick 
all that apply) 
 Ask the MS specialist Doctor/Neurologist 
 Ask your GP 
 Self-refer 
 Ask MS specialist nurse 
 Other (please state) __________ 
 Don’t know   go to question 1.4 
 
Q1.4 To the best of your knowledge what type of organisation provides your 
physiotherapy at the moment? (Please tick all that apply) 
 NHS (National Health Service) 
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 Private (self-funded) 
 Private (insurance company, or equivalent, funded) 
 Charity 
 Other (please state) _________   if answered yes to Q1.1 go to Q 
1.5.a. all other options go to Q1.5.b 
Q1.5a Please describe the effect you think physiotherapy has on you at the 
moment. (Please tick the most appropriate box) 
Likert scale:  
very beneficial, beneficial, neither harmful nor beneficial, harmful, very harmful  
 go to Q1.6 
 
Q1.5b Please describe the effect you think physiotherapy would have on you at 
the moment? (Please tick the most appropriate box) 
Likert scale:  
very beneficial, beneficial, neither harmful nor beneficial, harmful, very harmful  
if “very harmful”, “harmful” or “neither harmful nor beneficial” chosen go to Q 
3.1, all other answers go to Section Q2.1. 
 
Q1.6 Please think about the physiotherapy that you received in the past 3 
months.  There are different types of physiotherapy treatment.  From the list 
tick all that you have had in the past 3 months. 
 Exercises to do on my own that were given to me by a physiotherapist 
 Exercises with a physiotherapist 
 FES (functional electrical stimulation)  
 TENS (transcutaneous electrical stimulation) 
 Standing frame or tilt table 
 Acupuncture 
 Advice or education from a physiotherapist 
 other (Please state) ______________    all options go to Q1.7 
 
Q1.7 Now please describe the effect you think the different types of 
physiotherapy that you have received in the past 3 months have had on you. 
(Please tick the most appropriate box)   
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A list of interventions will be generated from the ticked boxes in question 6.  
Rate each with Likert scale.   
very beneficial     beneficial  neither harmful nor beneficial        harmful       
very harmful  
all options go to Q1.8 
 
Q1.8 Do you receive physiotherapy sessions regularly or does the frequency of 
your physiotherapy sessions depend on your symptoms? (Please tick the most 
appropriate box)   
 I receive physiotherapy sessions regularly   go to Q 1.10 
 How often I receive physiotherapy varies depending on my symptoms
 go to Q 1.9 
 
Q1.9 How long would you expect to wait for your physiotherapy appointment 
after asking/ being referred? (Please tick the most appropriate box)   
 Less than a week 
 1 to 2 weeks 
 2 or more weeks but less than 4 weeks 
 4 or more weeks but less than 6 weeks 
 6 or more weeks but less than 12 weeks 
 12 or more weeks    all options go to Q1.11 
 
Q1.10 How often do you receive physiotherapy at the moment?  This means that 
you had contact with the physiotherapist and received one of the treatments 
that you listed earlier. (Please tick the most appropriate box)  
 once or more a week  
 once a fortnight 
 once every 1 to 3 months 
 twice a year 
 once a year or less     all options go to Q1.11 
 
Q1.11 How long do your physiotherapy sessions usually last? (Please tick the 
most appropriate box)   
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 up to half an hour 
 between half an hour and an hour 
 more than an hour     all options go to Q1.12 
 
Q1.12 There are different ways of receiving physiotherapy.  Which of the 
following best describes the contact you have with your physiotherapist: (Please 
tick all that apply)    
 Just the therapist and me 
 In a small group of 2-4 people  
 In a larger group of 5 or more people  
 I receive my physiotherapy by the telephone or internet  all options go 
to Q1.13 
 
Q1.13 Where do you usually receive physiotherapy? (Please tick all that apply)   
 At home  
 In a hospital or clinic 
 In a community centre 
 In a charity centre 
 Other (please state) ____________   all options go to Q2.1 
 
Section 2.  This section is about how you would like to receive physiotherapy 
and factors that may restrict your ability to receive physiotherapy? 
Q2.1 Do you think you need more physiotherapy than you receive at the 
moment? (Please tick the most appropriate box) 
 Yes 
 No 
 Don’t know       all options go to Q2.2 
 
Q2.2 Given the choice; would you prefer to receive physiotherapy regularly or 
for it to vary as you need it depending on your symptoms? 
 Regularly       if regularly go to Q2.3 
 To vary  depending on my symptoms   if to vary go to Q2.4 
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Q2.3 Given the choice; how often would you like to receive physiotherapy? 
(Please tick the most appropriate box) 
 once or more a week  
 once a fortnight 
 once every 1 to 3 months  
 twice a year 
 once a year or less      all options go to Q2.4 
 
Q2.4 Given the choice; how long would you like your physiotherapy sessions to 
last? (Please tick the most appropriate box) 
 up to half an hour 
 between half an hour and an hour 
 more than an hour      all options go to Q2.5 
 
Q2.5 Given the choice; where would you like to receive physiotherapy? (Please 
tick the most appropriate box) 
 At home  
 In a hospital or clinic 
 In a community centre 
 In a charity centre 
 Other (please state) ____________    all options go to 
Q2.6 
 
Q2.6 Given the choice; which of the following best describes how you would like 
your usual contact with your physiotherapist to be? (Please tick the most 
appropriate box)  
 Just the therapist and me 
 In a small group of 2-4 people  
 In a larger group of 5 or more people  
 I would like to receive my physiotherapy by the telephone or internet 
 all options go to Q2.7 
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Q2.7 Sometimes it is difficult for people with MS to receive physiotherapy 
treatment.  From the following list  tick all that restrict your ability to receive 
physiotherapy at the moment:  
 pain 
 fear of falling 
 bladder or bowels problems 
 fatigue  
 depression 
 anxiety/panic attacks 
 difficulty with walking  
 difficulty with wheelchair transfers 
 transport problems 
 distance to travel 
 lack of suitable parking 
 lack of time 
 family commitments 
 work commitments  
 cost  
 need someone to come with me 
 personal issues with physiotherapist 
 problems being referred to physiotherapy 
 physiotherapy is not available 
 physiotherapy will not be beneficial for me 
 there is nothing that makes it difficult for me to receive physiotherapy 
 other (please state) ____________    go to Q2.8 unless 
“there is nothing that makes it difficult for me to receive physiotherapy” 
is only one ticked in which case go to Q3.1 
 
Q2.8 From the list above order the 3 things, from 1 to 3, that restrict your 
ability for you to get physiotherapy the most (number 1 being the most 
restrictive).   
List generated from Q2.7.   
List vertically  number 1 number 2  number 3    
   all options go to Q3.1 
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Section 3.  This section is about other healthcare services that you receive for 
your MS. 
Q3.1 Do you have access to an MS specialist service? 
 Yes     go to Q3.2 
 No     go to Q3.3b 
Q3.2 Are you able to be referred or self-refer to this service if your symptoms or 
needs change? 
 Yes  
 No     all options got to Q3.3a 
Q3.3a What other health care professionals have you seen for your MS in the past 
3 months?  Please tick all that apply:  
 Occupational therapist 
 Social worker 
 MS specialist nurse 
 Continence nurse 
 Nurse: other (please state) __________ 
 Psychologist 
 GP 
 MS specialist Doctor/Neurologist 
 Doctor: other (please state) ___________ 
 Speech and language therapist 
 Dietician 
 Orthotist 
 Other _________     all options go to Q3.4 
 
Q3.3b What other health care professionals would you be able to see for your MS 
if you wanted to? Please tick all that apply:  
 Occupational therapist  
 Social worker 
 MS specialist nurse 
 Continence nurse 
 Nurse: other (please state) __________ 
 Psychologist 
 
 
 284 
 GP 
 MS specialist Doctor/Neurologist 
 Doctor: other (please state) ___________ 
 Speech and language therapist 
 Dietician 
 Orthotist 
 Other _________     all options go to Q3.3c 
Q3.3c From the list please tick all that you have seen in the past 3 months. 
List generated from Q3.3b with “I have not seen any of these in the past 3 
months” as the last option.  All options go to Q3.4 
Q3.4 Are you offered a regular review for you MS? (This is an appointment to 
check to see how you are and if you have any unaddressed needs) (Please tick 
the most appropriate box for you) 
 Yes      if yes go  to Q3.5 
 No       if no go to Q3.8 
 Don’t know      if don’t know go to Q3.8 
Q3.5 On average; how often is your review? (Please tick the most appropriate 
box) 
 Twice a year 
 Once a year 
 Less than once a year 
 Don’t know      all options go to Q3.6 
Q3.6 Who usually undertakes your review? (Please tick the most appropriate box) 
 MS specialist Doctor/Neurologist 
 GP 
 Nurse 
 Physiotherapist 
 Occupational therapist 
 The person who does my review can vary 
 Other (please state) ______________   all options go to Q3.7 
Q3.7 Where does your review normally take place? (Please tick the most 
appropriate box) 
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 At home  
 In a hospital or clinic 
 In a community centre 
 GP surgery 
 Other (please state) ______________   all options go to Q3.8 
Q3.8 Which of the following medications have you ever taken? The original name 
of the drug is written first and then the brand name/names are written in 
brackets. (Please tick all that apply) 
 Beta-interferon  (Rebif, Avonex, Betaferon) 
 Glatiramer acetate (Copaxone) 
 Dimethyl fumarate (Tecfidera) 
 Teriflunomide (Aubagio) 
 Natalizumab (Tysabri, Antigren)    
 Fingolimod (Gilenya, Novartis) 
 Mitoxantrone (novantrone) 
 Alemtuzumab (Lemtrada)    all options go to Q3.9 apart from 
“I have never” 
 I have never taken any of these medications  which goes to Q3.10 
Q 3.9 Which of the following medications do you currently take? The original 
name of the drug is written first and then the brand name/names are written in 
brackets. (Please tick all that apply) 
 Beta-interferon  (Rebif, Avonex, Betaferon) 
 Glatiramer acetate (Copaxone) 
 Dimethyl fumarate (Tecfidera) 
 Teriflunomide (Aubagio) 
 Natalizumab (Tysabri, Antigren) 
 Fingolimod (Gilenya, Novartis) 
 Mitoxantrone (novantrone) 
 Alemtuzumab (Lemtrada)     
 I do not currently take any of these medications  all options go to 
Q3.10 
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Q 3.10 Complimentary therapies are forms of treatment that are not classed as 
medical but are often used in the treatment of MS.  Which of the following 
complimentary therapies have you used/had for your MS in the past 3 months? 
(Please tick all that apply) 
 Massage 
 Reflexology 
 Osteopathy or chiropractic 
 Magnet field therapy 
 The Alexander technique 
 Acupuncture or acupressure 
 Hyperbaric oxygen therapy 
 Reiki 
 Aromatherapy 
 Relaxation or meditation 
 Homeopathy or herbal medicine 
 Other  _____________    all options go to Q3.11 
 
 
 
 
Thank you very much for taking the time to complete this questionnaire.   
 
Survey ends 
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Appendix 5 – Research questions that required more 
than one answer from the survey to be completed. 
Research questions and the relevant questions from the survey  
Research Question Questions used from survey 
What proportion of 
respondents have access to 
an MS Specialist? 
3.1 Do you have access to an MS specialist 
service? 
3.3b What other health care professionals 
would you be able to see for your MS if you 
wanted to? 
What proportion of 
respondents use their MS 
Specialist? 
3.3a What other health care professionals have 
you seen for your MS in the past 3 months?   
3.3c What other health care professionals 
would you be able to see for your MS if you 
wanted to?  
Which clinical services are 
used for their MS? 
1.1 Do you receive physiotherapy at the 
moment? 
3.3a What other health care professionals have 
you seen for your MS in the past 3 months?   
3.3c What other health care professionals 
would you be able to see for your MS if you 
wanted to? 
Multiple or single services 
used for MS? 
1.1 Do you receive physiotherapy at the 
moment? 
3.3a What other health care professionals have 
you seen for your MS in the past 3 months?   
3.3c What other health care professionals 
would you be able to see for your MS if you 
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wanted to?  
What proportion of 
respondents have taken 
DMTs? 
3.8 Which of the following medications have 
you ever taken? The original name of the drug 
is written first and then the brand name/names 
are written in brackets. 
What proportion of 
respondents are currently 
taking DMTs? 
3.9 Which of the following medications do you 
currently take? The original name of the drug is 
written first and then the brand name/names 
are written in brackets. 
What proportion of 
respondents have access to 
physiotherapy? 
1.1 Do you receive physiotherapy at the 
moment?  
1.2 Could you get physiotherapy if you wanted 
it? 
How do respondents get 
referred to physiotherapy? 
1.3a Who refers you to the physiotherapist? 
1.3b If you wanted to see a physiotherapist, 
what would you do? 
What is the respondents’ 
perceived efficacy of 
physiotherapy? 
1.5a Please describe the effect you think 
physiotherapy has on you at the moment. 
1.5b Please describe the effect you think 
physiotherapy would have on you at the 
moment? 
Only the question is supplied, the possible answers to each question are not 
listed.  These can be seen in full survey in Appendix 4 
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Appendix 6 – Ethics committee approval letter 
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Appendix 7 – Research and development approval letter 
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Appendix 8 – Poster to raised awareness for exercise 
trial 
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Appendix 9 – Participant information sheet 
 
 
 
 
 
Participant information sheet 
Exercise training for people with progressive Multiple 
Sclerosis 
Improving fitness in people with progressive Multiple Sclerosis 
using either continuous or interval exercise. 
 
This study is being carried out by the University of Glasgow and NHS Ayrshire & 
Arran.  Before you decide whether or not you wish to take part is important that 
you understand what the study will involve and why we are doing the research.  
Please read the following carefully and if you have any questions please do not 
hesitate to ask us if something is not clear. 
 
What is the purpose of the study? 
We are carrying out this study to see if we can improve fitness of people with 
progressive Multiple Sclerosis (MS).  We will do this by using high intensity interval 
training (described below) on an exercise bike, twice a week, for eight weeks.  We 
will then compare these results to the results of people who have undertaken a 
similar exercise programme but at lower exercise intensity and without breaks. 
 
Why is this important? 
Having poor fitness is linked to risk factors for many diseases such as heart 
disease and diabetes.  Previous research has shown that people with MS have 
poorer fitness than those without MS.  This puts people with MS at a higher risk of 
developing these diseases. 
 
Why have I been chosen? 
You have been chosen because you are a person with progressive Multiple 
Sclerosis and are able to pedal on an exercise bike. 
 
Do I have to take part? 
No, it is entirely up to you whether or not you choose to take part.  Also if you start 
and then decide that you don’t want to continue you are free to stop at any point.   
 
What will happen to me if I take part? 
If you choose to take part we will send a letter to your GP to tell them that you are 
taking part.  You will then be invited to attend Douglas Grant Rehabilitation Centre 
in Irvine.  Once there we will explain the study in detail and then take your blood 
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pressure and ask you some questions about your past medical history to make 
sure that it is suitable and safe for you to take part. 
If you are suitable to take part in the study we will then do the heart rate test that 
was described above, ask you to fill out some questionnaires, measure your 
walking speed and take some blood samples.  We will take blood from a vein in 
your arm we will only take 10 mls (2 teaspoons) of blood.  The blood samples are 
to examine the levels of a hormone which is important in brain health, your 
cholesterol, and how much exercise waste materials (lactate) you have in your 
blood. 
At this point you will be asked to pick an envelope.  Inside will be a piece of paper 
which will tell you if you are in the interval training group or the continuous training 
group. 
 
What happens if I’m in the interval training group? 
Interval training means short bursts of high effort followed by short periods of low 
effort.  In our interval training program you will spend a total 20 minutes on an 
exercise bike.  After a 2 minute warm up you will pedal hard for 90 seconds and 
then pedal lightly for 90 seconds.  The hard pedalling followed by light pedalling 
will be repeated another 5 times.  After this you will then have a 3 minute cool 
down.  This means that over the 23 minutes you only do a total of 9 minutes hard 
work! 
In the week before the start of the study we will ask you to attend an appointment 
with us. At this appointment you will cycle as hard as you can on the exercise bike 
and we will monitor how high your heart rate goes.  This will take about 10 
minutes.  We will use your highest heart rate to calculate a target heart rate for the 
hard pedalling intervals during the study.  We will repeat this test again after the 
study has finished to see if your highest heart rate has changed. 
If you are in the intervention group you will do the interval training programme.  
This means that you will attend the Douglas Grant rehabilitation Centre twice a 
week for 8 weeks. Each appointment will last approximately 1 hour. Even though 
the training only takes 23 minutes you will rest afterwards.  It is common for your 
legs to be tired and to have a temporary increase in your leg symptoms but these 
will usually pass within 30 minutes. 
At the end of the study we will ask you attend one more time to do the same heart 
rate test, questionnaires that we did before you started and take some more blood. 
   
What happens if I’m in the continuous training group? 
Continuous exercise means exercising at a constant intensity for a set period of 
time.  In our continuous training program you will spend a total of 35 minutes on 
the exercise bike.  After a 2 minute warm up you will pedal at a medium intensity 
for 30 minutes and then have a 3 minute cool down. 
If you are in the continuous training group you will do the continuous exercise 
program.  This means that you will attend the Douglas Grant rehabilitation Centre 
twice a week for 8 weeks.  Each appointment will last approximately 1 hour to 
allow time for you to rest afterwards. 
At the end of the study we will ask you attend one more time to complete the same 
heart rate test, questionnaires that we did before you started and take some more 
blood samples.  
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Are there any disadvantages or risks of taking part?  
All exercise carries some risk of injury and this can never be fully eliminated.  
However, during this trial you will be exercising in a controlled environment and a 
physiotherapist will be with you at all times.  There will also be medical staff on 
hand if they are ever needed. 
After doing strenuous leg exercise it is common for people with MS to feel an 
increase in their leg symptoms (such as pins and needles) but these usually pass 
quickly and resolve in about 30 minutes.  In addition it is common for everybody 
who exercises to feel little muscle soreness and tiredness both during and after 
they exercise.  This is also normal and temporary. However, there will always be a 
physiotherapist and their assistant present throughout all of your training who will 
make sure you are safe. 
You may feel some discomfort when the blood samples are being taken.  This will 
be similar to receiving an injection at the doctor’s. 
 
What are the possible benefits of taking part? 
You may find that after completing the exercise programme (both the interval and 
continuous training groups) that your fitness improves.  This means that your heart 
and lungs are working more efficiently.  You may also find that your leg muscles 
become stronger and have more stamina.  You will also find out about your 
measurements such as blood pressure and how these have changed over the 8 
weeks. 
 
Will I have to pay for my travel? 
No, we will cover you travel expenses for all of your visits to Douglas Grant 
Rehabilitation Centre.  Just make sure you keep your receipts for any taxi or bus 
journeys and we can reimburse you. 
 
What happens when the research study stops? 
When the study stops we will give you a summary of all of your individual 
measurements as well as a summary of the findings of the study. 
 
Will my taking part in this study be kept confidential? 
Yes.  All of your details will be made anonymous.  If any of your measurements 
are used for publications or presentations there will be no information displayed 
that could identify you. 
 
What happens if new information becomes available? 
If new information becomes available we will discuss this with you. 
 
What will happen if I don’t want to continue in the study? 
If you want to stop taking part in the study this is fine.  You are free to stop at any 
point. 
 
What happens to the results of the research study? 
The results will be used as part of Evan Campbell’s PhD and may also be used to 
write an article for a medical journal. 
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Who is organising and funding the study?  
The study has been organised by the academic staff from the University of 
Glasgow.  The study is funded by the Bevan Scholarship which is funding Evan 
Campbell’s PhD and came from NHS Ayrshire & Arran. 
 
Who has reviewed this study? 
 
This study has been reviewed and approved by the West of Scotland Research 
Ethics Service. 
 
Participation, further information and contact details. 
If you are interested in taking part, have any questions about whether or not you 
should take part in the study please contact:  
 
Evan Campbell 
University of Glasgow 
Tel: 0141 330 7154  
Email: e.campbell.4@research.gla.ac.uk. 
 
Alternatively if you would like to talk to someone who has an understanding of the 
research but is not directly involved in the study please contact: 
Dr Aleksandra Dybus  
University of Glasgow 
Tel: 0141 330 5536. 
 
Thank you for taking the time to read this information sheet 
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Exercise training for people with progressive Multiple 
Sclerosis 
Improving fitness in people with progressive Multiple Sclerosis 
using either continuous or interval exercise. 
I _________________________   give my consent for my contact details to be 
given to Evan Campbell so they can contact me about participation in the above 
study. 
Signed: ______________________________________________ 
(Participant copy) 
 
 
 
 
(Please cut/tear along line)
 
 
 
Exercise training for people with progressive Multiple 
Sclerosis 
Improving fitness in people with progressive Multiple Sclerosis 
using either continuous or interval exercise. 
I _________________________   give my consent for my contact details to be 
given to Evan Campbell so he can contact me about participation in the above 
study. 
Signed: ______________________________________________ 
(Researcher’s copy, please give to Evan Campbell) 
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Appendix 10 – Consent form 
  
 
 
Participant Identification Number for this study:  
 
STUDY CONSENT FORM 
 
Title of Project: The effect of high intensity interval training on 
cardiovascular fitness in people with progressive Multiple Sclerosis. 
 
Lay title: Exercise training for people with progressive Multiple Sclerosis 
 
Name of Researchers: Mr Evan Campbell, Dr Lorna Paul, Dr Elaine Coulter 
 
         Please initial boxes 
 
1. I confirm that I have read and understand the participant information  
      sheet (ver 2 dated 20/01/2017) for the above study and have had the  
      opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to    
      withdraw at any time, without giving any reason. All data (personalised  
      and study data) collected up to the point of withdrawal from the study  
      will be retained until the end of the study. 
 
 3.  I understand that information collected about me may be looked at  
      by authorised individuals from the study sponsor, NHS Ayrshire &       
      Arran or from the regulatory authorities to ensure that the study has 
      been performed to the appropriate standards. 
 
3. I give permission for the researchers to contact my GP to inform them 
of my participation. 
 
4. I agree to my GP will be informed of any abnormal results that may  
  arise during assessment or screening. 
 
 5.  I give permission for my blood sample to be stored at The University  
   of Glasgow until the end of the study. 
 
 7. I agree to take part in the above study. 
 
 
           
Name of Participant           Date       Signature 
 
   
Researcher            Date        Signature 
*1 copy for participant , 1 copy for researcher and 1 copy for participant’s notes   
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Appendix 11 – Letter to general practitioner 
 
Date: 
 
Re: 
 
Dear Doctor 
 
Re: Improving fitness in people with progressive Multiple Sclerosis using either continuous or 
interval exercise. 
 
I am writing to inform you that the patient named above has expressed interest in taking part in this 
study which is being conducted by staff at the University of Glasgow and is funded by NHS 
Ayrshire & Arran. The study has two groups and the patient will be randomly allocated to the 
either receive an interval training program or a continuous training program (both described 
below).    
 
The overall aims are to increase fitness in people with progressive MS using high intensity interval 
training and compare this to continuous training at a moderate intensity.  People with MS are at a 
higher risk of developing cardiovascular co-morbidities and this is partly due to the decreased 
fitness seen in this population.  We hope by participating in this study that the participants will 
increase their fitness and thus decrease their risk factors of developing such co-morbidities.  Both 
training programs will be on an exercise bike, twice weekly for 8 weeks and will be carried out in 
the Douglas Grant Rehabilitation Centre, Ayrshire Central Hospital. 
 
The interval training group will perform 6x 90 second exercise bouts at 80-95% of their heart rate 
max interspersed with 90 second intervals of active rest to bring their heart rate down to 60-70% of 
heart rate max.  After the last working rest there will be a 3 minute cool down.  The continuous 
training group will cycle for 30 minutes at 60-70% of their heart rate max and then have a 3 minute 
cool down.  After the cool down participants in both groups will be given the opportunity to rest for 
up to one hour. 
 
I have attached a patient information sheet for your information. If you require any further 
information or have any questions please do not hesitate to contact me. 
 
Yours sincerely,  
 
 
 
Evan Campbell  
Research Physiotherapist and PhD Candidate 
School of Medicine 
The University of Glasgow 
59 Oakfield Avenue 
Glasgow 
G12 8LL            Tel: 0141 330 7154    email: e.campbell.4@research.gla.ac.uk 
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Appendix 12 – Symptom diary 
Symptom Diary 
Please rate all of your symptoms on the following scale out of 10.  10 is the worst 
and 0 is the best.  
         
              No symptom             Worst symptom 
 
Answer before your training session.  How is your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
In the afternoon of                      how was your (do not answer if your training 
session was in the afternoon) 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
In the evening of                      how was your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
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In the morning of                      how was your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
 
 
In the afternoon of                      how was your  
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
In the evening of                      how was your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
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In the morning of                      how was your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
In the afternoon of                       how was your  
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
In the evening of                       how was your 
Fatigue      
Pain     
Spasms    
Pins and needles/ numbness 
Other _____________ 
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Appendix 13 – Symbol Digit Modalities Test 
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Appendix 14 – 10 point Borg scale of perceived exertion 
0 Nothing at all 
0.5 Very, very slightly (just 
noticeable) 
1 very slightly 
2 Slight (light) 
3 moderate 
4 Somewhat strong 
5 Strong (heavy) 
6  
7 Very Strong 
8  
9  
10 Very, very strong (maximal) 
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Appendix 15 – Baseline data from five participants who restarted exercise trial 
           
Participant  7  8  9  10  11   
 B1 B2 B1 B2 B1 B2 B1 B2 B1 B2 p 
Weight (kg) 80.7 79.5 96.3 97 94.1 95.2 77.2 77.1 58.3 59.4 0.506 
Resting HR (bpm) 75 66 62 59 74 82 91 93 65 75 0.671 
Systolic BP (mm/Hg) 149 108 124 123 158 128 119 125 130 126 0.199 
Diastolic BP (mm/Hg) 66 64 83 80 99 97 70 76 70 74 0.760 
T25FW (s) 8.1 8.7 5.2 5.3 7.2 7 23.3 23.5 5.5 6.2 0.166 
MSIS- 29 Phys 47 53 48 50 48 48 60 51 45 45 0.939 
MSIS-29 Psych 17 17 22 19 13 11 31 34 24 25 0.861 
HADS Anx 2 6 11 8 3 3 3 3 11 12 0.740 
HADS Dep 4 5 8 0 6 5 9 5 8 10 0.333 
FSMC Total 87 87 75 83 59 50 93 92 71 61 0.507 
FSMC Motor 45 45 39 42 33 26 49 48 37 33 0.353 
FSMC Cog 42 42 36 41 26 24 44 44 34 28 0.753 
SDMT 33 34 28 28 47 43 14 15 41 48 0.600 
Resting Lact (mmol/l) 1.0 5.4 0.5 1 2.8 1.5 3.9 2.5 5.3 1.7 0.845 
HRMax (bpm) 148 135 132 137 146 138 111 124 148 137 0.608 
Peak  Lact (mmol/l) 12.0 11.6 6.6 15.5 12 12.4 3.6 4.3 6.1 4.4 0.447 
Abbreviations: HR: heart rate; BP: blood pressure; T25FW: timed 25 foot walk test; MSIS-29: multiple sclerosis impact scale; Phys: physical sub-scale; Psych: 
psychological sub-scale; HADS: hospital anxiety and depression scale; Anx: anxiety; Dep: depression; FSMC: fatigue scale for motor and cognitive function; Mot: 
motor; Cog: cognitive; SDMT: symbol digit modalities test; lact: lactate; HRMax; maximal heart rate; B1: first baseline measurement; B2: second baseline 
measurement 
All testing paired sampled t tests. 
 
